

Transcript of the Testimony of **M. Jayne Lawrence**

Date: September 4, 2015

Case: Senju Pharmaceutical Co., LTD., et al. v. Lupin, LTD., and Lupin
Pharmaceutical, Inc.,



Ace-Federal Reporters, Inc.
Phone: 202-347-3700
Fax: 202-737-3638
Email: info@acefederal.com
Internet: www.acefederal.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

-----X
SENJU PHARMACEUTICAL CO.,
LTD., BAUSCH & LOMB
INCORPORATED, and BAUSCH
& LOMB PHARMA HOLDINGS CORP.,

Civil Action Nos.:
1:14-cv-00667-JBS-KMW
1:14-cv-04149-JBS-KMW
1:14-cv-05144-JBS-KMW
1:15-cv-00335-JBS-KMW

Plaintiffs,
-vs-
LUPIN, LTD., and LUPIN
PHARMACEUTICALS, INC.,
Defendants.

INNOPHARMA LICENSING, INC.,
INNOPHARMA LICENSING, LLC,
INNOPHARMA, INC., INNOPHARMA,
LLC, MYLAN PHARMACEUTICALS,
INC., and MYLAN INC.,
Defendants.

Civil Action Nos.:
1:14-cv-06893-JBS-KMW
1:15-cv-03240-JBS-KMW

----- X

Deposition of:

M. JAYNE LAWRENCE, Ph.D.

September 4, 2015
New York, New York

Page 2

1 VIDEOTAPED DEPOSITION of M. JAYNE LAWRENCE,
 2 Ph.D., taken pursuant to Notice, held at the law
 3 offices of GOODWIN PROCTER, LLP, 620 Eighth Avenue,
 4 26th Floor, New York, New York, 10018-1405, on
 5 Friday, September 4, 2015, at 8:00 a.m. before
 6 JEANNETTE MCCORMICK, a-Certified Shorthand Reporter,
 7 and a Notary Public.
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22

Page 3

1 APPEARANCES:
 2 FINNEGAN, HENDERSON, FARABOW, GARRETT
 3 & DUNNER, LLP
 4 Attorneys for Plaintiffs
 5 901 New York Avenue, NW
 6 Washington, D.C. 20001-4413
 7 BY: JUSTIN J. HASFORD, ESQ.
 8 BRYAN C. DINER, ESQ.
 9 (202) 408-4000 (Telephone)
 10 (202) 408-4400 (Fax)
 11 justin.hasford@finnegan.com
 12 bryan.diner@finnegan.com
 13
 14 GODWIN PROCTER, LLP
 15 Attorneys for Defendant Lupin
 16 The New York Times Building
 17 620 Eighth Avenue
 18 New York, New York 10018-1405
 19 BY: DANIEL P. MARGOLIS, ESQ.
 20 (212) 813-8800 (Telephone)
 21 (212) 355-3333 (Fax)
 22 dmargolis@goodwinprocter.com

Page 4

1 APPERANCES (CONTINUED):
 2
 3 ALSTON & BIRD, LLP
 4 Attorneys for Defendant Innopharma
 5 333 South Hope Street, 16th Floor
 6 Los Angeles, California 90071
 7 BY: H. JAMES ABE, ESQ.
 8 (213) 576-1000 (Telephone)
 9 (213) 576-1100 (Fax)
 10 james.abe@alston.com
 11
 12
 13
 14 Also Present:
 15 Thomas Del Vecchio (Videographer)
 16
 17
 18
 19
 20
 21
 22

Page 5

1 INDEX
 2 WITNESS EXAMINATION BY PAGE
 3 M. JAYNE LAWRENCE, Ph.D.
 4 MR. HASFORD 17
 5
 6 EXHIBITS
 7 LAWRENCE
 8 NUMBER DESCRIPTION PAGE
 9
 10 Exhibit 1 Declaration of M. Jayne
 11 Lawrence, Ph.D. and
 12 Appendices and Exhibits 18
 13
 14 Exhibit 2 "Models for Intestinal Drug
 15 Absorption", Wood & Lawrence
 16 (1991) Journal of Biopharmaceutical
 17 Sciences (pgs. 147-172)
 18 (Publication No. 5 on CV) 206
 19
 20
 21
 22

Page 6				Page 8			
1	EXHIBITS			1	EXHIBITS		
2	LAWRENCE			2	LAWRENCE		
3	NUMBER	DESCRIPTION	PAGE	3	NUMBER	DESCRIPTION	PAGE
4				4	Exhibit 9	"Recent Advances in	
5	Exhibit 3	"Effect of diclofenac sodium		5		Microemulsions as Drug	
6		and disodium		6		Delivery Vehicles" in	
7		ethylenediaminetetraacetate on		7		"Nanoparticulates as Drug	
8		electrical parameters of the		8		Carriers," (pgs. 125-171)	
9		mucosal membrane and their		9		(Book Chapters No. 14 on CV)	262
10		relation to the permeability		10	Exhibit 10	"Drug Delivery Systems:	
11		enhancing effects in the rat		11		Neutron Scattering Studies" in	
12		jejunum" by Yamashita, et al,		12		"Encyclopedia of Pharmaceutical	
13		in the J. Pharm. Pharmacol.		13		Technology," (pgs. 1049-1070)	
14		1987, volume 39, pages 621 to 626	208	14		(Book Chapters No. 15 on CV)	265
15				15	Exhibit 11	"New Medicines, Better	
16	Exhibit 4	U.S. Patent No. 8,192,755 B2	232	16		Medicines, Better Use of	
17	Exhibit 5	U.S. Patent Application		17		Medicines," (120 pgs.)	
18		Publication No. 2013/0210878 A1	237	18		(Other Outputs No. 12 on CV)	267
19				19			
20				20			
21				21			
22				22			

Page 7				Page 9			
1	EXHIBITS			1	EXHIBITS		
2	LAWRENCE			2	LAWRENCE		
3	NUMBER	DESCRIPTION	PAGE	3	NUMBER	DESCRIPTION	PAGE
4	Exhibit 6	"Structural Investigations of		4	Exhibit 12	"Association Characteristics	
5		the Monolayers and Vesicular		5		of Synthetic Non-ionic	
6		Bilayers Formed by a Novel Class		6		Surfactants in Aqueous Solution"	
7		of Nonionic Surfactant" in the		7		in "Physical Chemistry in	
8		"Chemical Aspects of Drug		8		Condensed Phases," (pgs. 1903-1910)	
9		Delivery System," (pgs. 65-76)		9		(Articles in Academic Journals	
10		(Book Chapters No. 6 on CV)	240	10		No. 1 on CV)	279
11				11			
12	Exhibit 7	"Neutron Scattering in		12	Exhibit 13	"Effect of Structural	
13		Pharmaceutical Sciences" in		13		Variations of Non-ionic	
14		"Applications of Neutron		14		Surfactants on Micellar	
15		Scattering to Soft Condensed		15		Properties and Solubilization:	
16		Matter," (pgs. 325-356)		16		Surfactants with Semi-Polar	
17		(Book Chapters No. 7 on CV)	257	17		Hydrophobes" in "Journal of	
18	Exhibit 8	"Molecular Modelling of		18		Pharmacy & Pharmacology,"	
19		Surfactant Vesicles" in		19		(pgs. 585-589) (Articles in	
20		"Synthetic Surfactant		20		Academic Journals No. 2 on CV)	281
21		Vesicles," (pgs. 9-23)		21			
22		(Book Chapters No. 8 on CV)	259	22			

Page 10	<p>1 EXHIBITS</p> <p>2 LAWRENCE</p> <p>3 NUMBER DESCRIPTION PAGE</p> <p>4 Exhibit 14 "Analysis and Modelling of the</p> <p>5 Structures of Beta-Cyclodextrin</p> <p>6 Complexes" in "BBA, Biochimica</p> <p>7 et Biophysica Acta, (pgs. 27-36)</p> <p>8 (Articles in Academic Journals</p> <p>9 No. 8 on CV) 283</p> <p>10</p> <p>11 Exhibit 15 "Surfactant Systems: Their</p> <p>12 Use in Drug Delivery" in</p> <p>13 "Chemical Society Reviews,"</p> <p>14 (pgs. 417-424) (Articles in</p> <p>15 Academic Journals No. 9 on CV) 285</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>	Page 12
Page 11	<p>1 EXHIBITS</p> <p>2 LAWRENCE</p> <p>3 NUMBER DESCRIPTION PAGE</p> <p>4 Exhibit 16 "Surfactant Systems:</p> <p>5 Microemulsions and Vesicles as</p> <p>6 Vehicles for Drug Delivery" in</p> <p>7 "European Journal of Drug</p> <p>8 Metabolism & Pharmacokinetics,</p> <p>9 1994, No. 3, (pgs. 257-269)</p> <p>10 (Articles in Academic Journals</p> <p>11 No. 12 on CV) 288</p> <p>12</p> <p>13 Exhibit 17 "The Formation, Characterization</p> <p>14 & Stability of Non-Ionic</p> <p>15 Surfactant Vesicles" in "STP</p> <p>16 Pharma Sciences." (Pgs. 49-60)</p> <p>17 (Articles in Academic Journals</p> <p>18 No. 16 on CV) 292</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>	Page 13
Page 10	<p>1 EXHIBITS</p> <p>2 LAWRENCE</p> <p>3 NUMBER DESCRIPTION PAGE</p> <p>4 Exhibit 18 "Microemulsions as Drug Delivery</p> <p>5 Vehicles" in "Current Opinion in</p> <p>6 Colloid & Interface Science,"</p> <p>7 (pgs. 826-832) (Articles in</p> <p>8 Academic Journals No. 18 on CV) 295</p> <p>9 Exhibit 19 "Aggregation & Surface Properties</p> <p>10 of Synthetic Double-Chain Non-Ionic</p> <p>11 Surfactants in Aqueous Solution in</p> <p>12 "Journal of Pharma & Pharmacology,</p> <p>13 Volume 49, May 1997 (pgs. 594-600)</p> <p>14 (Articles in Academic Journals</p> <p>15 No. 20 on CV) 297</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>	Page 13

Page 14	<p>1 EXHIBITS</p> <p>2 LAWRENCE</p> <p>3 NUMBER DESCRIPTION PAGE</p> <p>4 Exhibit 22 "Formulation of Electrically</p> <p>5 Conducting Microemulsion-Based</p> <p>6 Organogels" in "International</p> <p>7 Journal of Pharmaceutics"</p> <p>8 (pgs. 65-83 (Articles in Academic</p> <p>9 Journals No. 49 on CV) 305</p> <p>10 Exhibit 23 "Molecular Dynamics Simulations</p> <p>11 of the Interfacial & Structural</p> <p>12 Properties of</p> <p>13 Dimethyldodecylamine-N-Oxide</p> <p>14 Micelles" in "Langmuir, The ACS</p> <p>15 Journal of Surfaces & Colloids"</p> <p>16 (pgs. 546-553 (Articles in Academic</p> <p>17 Journals No. 87 on CV) 308</p> <p>18 Exhibit 24 "Microemulsion-Based Media as</p> <p>19 Novel Drug Delivery Systems" in</p> <p>20 "Advanced Drug Delivery Reviews"</p> <p>21 (pgs. 175-193 (Articles in</p> <p>22 Academic Journals No. 102 on CV) 312</p>	Page 16	<p>1 The court reporter today is Jeannette 08:11:53</p> <p>2 McCormick with the firm of Ace-Federal 08:11:57</p> <p>3 Reporters. My name is Thomas Del Vecchio. I 08:12:00</p> <p>4 am the legal video specialist representing 08:12:04</p> <p>5 Ace-Federal Reporters, 1625 I Street, 08:12:06</p> <p>6 Northwest, Washington, D.C., 20006. 08:12:12</p> <p>7 Will counsel identify themselves and who 08:12:17</p> <p>8 they represent. 08:12:19</p> <p>9 MR. HASFORD: Justin Hasford of Finnegan 08:12:20</p> <p>10 on behalf of plaintiffs Senju and Bausch & 08:12:21</p> <p>11 Lomb. 08:12:21</p> <p>12 MR. DINER: Bryan Diner of Finnegan, 08:12:25</p> <p>13 also on behalf of plaintiffs Senju and Bausch 08:12:27</p> <p>14 & Lomb. 08:12:31</p> <p>15 MR. MARGOLIS: Dan Margolis from Goodwin 08:12:31</p> <p>16 Procter for the Lupin defendants. 08:12:33</p> <p>17 MR. ABE: James Abe of Alston & Bird for 08:12:36</p> <p>18 the Innopharma defendants. 08:12:38</p> <p>19 THE VIDEOGRAPHER: Thank you. Now, will 08:12:42</p> <p>20 the court reporter please swear in or affirm 08:12:43</p> <p>21 the witness. 08:12:45</p> <p>22 M. JAYNE LAWRENCE, Ph.D.,</p>
Page 15	<p>1 PROCEEDINGS</p> <p>2 THE VIDEOGRAPHER: Good morning. We are 08:10:15</p> <p>3 now going on the record. Please note that 08:10:16</p> <p>4 microphones are sensitive and may pick up 08:10:20</p> <p>5 whispering and private conversations. Please 08:10:22</p> <p>6 turn off all telephones or place them away 08:10:25</p> <p>7 from the microphones as they can interfere 08:10:29</p> <p>8 with the video deposition audio. 08:10:32</p> <p>9 Recording will continue until parties 08:10:34</p> <p>10 agree to go off the record. 08:10:36</p> <p>11 The deponent today is Dr. Jayne Lawrence 08:10:38</p> <p>12 in the matter of Senju Pharmaceutical 08:10:42</p> <p>13 Company, Ltd, et al, plaintiffs, versus 08:10:48</p> <p>14 Lupin, Ltd, et al, defendants, Civil Action 08:10:52</p> <p>15 Number 1:14-CV-00667, in the United States 08:11:00</p> <p>16 District Court for the District of New 08:11:13</p> <p>17 Jersey. 08:11:23</p> <p>18 This deposition is being taken at the 08:11:23</p> <p>19 office of Goodwin Procter, the New York Times 08:11:25</p> <p>20 Building, 620 Eighth Avenue, New York, New 08:11:30</p> <p>21 York, 10018. The time is approximately 8:12 08:11:33</p> <p>22 a.m. Today is Friday, September 4, 2015. 08:11:44</p>	Page 17	<p>1 having been first duly sworn</p> <p>2 testified as follows:</p> <p>3 EXAMINATION</p> <p>4 BY MR. HASFORD: 08:12:57</p> <p>5 Q. Good morning, Dr. Lawrence. 08:12:57</p> <p>6 A. Good morning. 08:13:01</p> <p>7 Q. Would you please state your name and address 08:13:02</p> <p>8 for the record. 08:13:04</p> <p>9 A. Yes. Dr. Margaret Jayne Lawrence of 62 08:13:04</p> <p>10 Wellington Road, Ashford, Middlesex, UK. 08:13:08</p> <p>11 Q. How many times have you been deposed before? 08:13:11</p> <p>12 A. This is my first time. 08:13:14</p> <p>13 Q. Let me tell you how today's deposition will 08:13:16</p> <p>14 proceed. I represent the plaintiffs in this case. 08:13:18</p> <p>15 Today I will ask you a series of questions, and I 08:13:20</p> <p>16 would ask that you answer my questions truthfully 08:13:23</p> <p>17 and accurately. 08:13:25</p> <p>18 If you need a break, just let me know, but if 08:13:26</p> <p>19 I have asked a question I would ask that you first 08:13:29</p> <p>20 answer the question and then we can take a break. 08:13:31</p> <p>21 If for any reason you do not understand a 08:13:34</p> <p>22 question that I ask, please let me know. If you 08:13:36</p>

Page 18	<p>1 answer a question, I will assume that you understood 08:13:38</p> <p>2 the question. Is that okay? 08:13:40</p> <p>3 A. Yes. 08:13:42</p> <p>4 Q. Is there any reason why you cannot testify 08:13:42</p> <p>5 truthfully and accurately today? 08:13:45</p> <p>6 A. No. 08:13:46</p> <p>7 MR. HASFORD: I'm handing the court 08:13:49</p> <p>8 reporter what I've asked to be marked as 08:13:50</p> <p>9 Lawrence Exhibit I. 08:13:52</p> <p>10 For the record, Lawrence Exhibit I is 08:13:53</p> <p>11 the Declaration of Jayne Lawrence, Ph.D., and 08:13:55</p> <p>12 Appendices and Exhibits. 08:13:59</p> <p>13 (Whereupon, Plaintiff's Deposition 08:14:30</p> <p>14 Exhibit No. Lawrence I was marked for 08:14:31</p> <p>15 Identification.) 08:14:33</p> <p>16 Q. Is Lawrence Exhibit I your claim construction 08:14:33</p> <p>17 declaration, appendices and exhibits in this case? 08:14:37</p> <p>18 A. Yes. 08:14:45</p> <p>19 Q. Please turn to page 25. Does your signature 08:14:46</p> <p>20 appear on page 25 of your claim construction 08:14:54</p> <p>21 declaration for this case? 08:14:57</p> <p>22 A. It does. 08:14:58</p>	Page 20	<p>1 question again? 08:15:44</p> <p>2 Q. Certainly. In what areas do you consider 08:15:44</p> <p>3 yourself an expert? 08:15:46</p> <p>4 MR. MARGOLIS: Same objection. 08:15:47</p> <p>5 THE WITNESS: In terms of scientific 08:15:49</p> <p>6 activities? In terms of professional 08:15:54</p> <p>7 activities? Could you please clarify a bit 08:15:56</p> <p>8 more? 08:15:58</p> <p>9 Q. In what areas do you hold yourself out as an 08:15:58</p> <p>10 expert? 08:16:01</p> <p>11 MR. MARGOLIS: Objection. Vague. 08:16:01</p> <p>12 THE WITNESS: It depends what -- I find 08:16:06</p> <p>13 that a very difficult question to answer 08:16:10</p> <p>14 because you could be expert in lots of areas 08:16:12</p> <p>15 and that's why I ask for clarification. 08:16:15</p> <p>16 Q. In what scientific areas do you consider 08:16:17</p> <p>17 yourself an expert? 08:16:19</p> <p>18 A. Okay. I -- 08:16:20</p> <p>19 MR. MARGOLIS: Objection. Vague. 08:16:20</p> <p>20 Q. You may answer. 08:16:21</p> <p>21 A. Do you mean an expert in the context of this 08:16:23</p> <p>22 particular case? 08:16:35</p>
Page 19	<p>1 Q. Who prepared your claim construction 08:14:58</p> <p>2 declaration for this case? 08:15:00</p> <p>3 A. I did. 08:15:02</p> <p>4 Q. Take a look, if you would, at Appendix A. Is 08:15:03</p> <p>5 Appendix A to your claim construction declaration a 08:15:13</p> <p>6 copy of your curriculum vitae? 08:15:16</p> <p>7 A. It is. 08:15:18</p> <p>8 Q. Does your curriculum vitae list your relevant 08:15:19</p> <p>9 professional experience? 08:15:22</p> <p>10 A. It does. 08:15:23</p> <p>11 Q. In what areas do you consider yourself an 08:15:24</p> <p>12 expert? 08:15:26</p> <p>13 MR. MARGOLIS: Objection. Vague. 08:15:27</p> <p>14 BY MR. HASFORD: 08:15:30</p> <p>15 Q. You may answer. 08:15:30</p> <p>16 MR. ABE: Counsel, will we agree that if 08:15:32</p> <p>17 counsel for Lupin objects it will apply for 08:15:35</p> <p>18 Innopharma as well? 08:15:39</p> <p>19 MR. HASFORD: Sure. We can agree to 08:15:40</p> <p>20 that. 08:15:41</p> <p>21 MR. ABE: Thank you. Please proceed. 08:15:42</p> <p>22 THE WITNESS: Could you just repeat the 08:15:43</p>	Page 21	<p>1 Q. What's your understanding of an expert, 08:16:36</p> <p>2 Doctor? 08:16:44</p> <p>3 A. An expert is a person who has knowledge in a 08:16:44</p> <p>4 particular area. 08:16:48</p> <p>5 Q. Okay. And I'm asking the question based on 08:16:49</p> <p>6 your understanding. So I will ask it again. In 08:16:51</p> <p>7 what areas do you consider yourself an expert? 08:16:53</p> <p>8 MR. MARGOLIS: Objection. Vague. 08:16:56</p> <p>9 THE WITNESS: I think to answer that 08:17:06</p> <p>10 question I'm going to have to qualify the 08:17:08</p> <p>11 particular areas I'm talking about because I 08:17:12</p> <p>12 have expertise in several areas. 08:17:15</p> <p>13 Q. What areas? 08:17:17</p> <p>14 A. I have expertise in respect to professional 08:17:19</p> <p>15 activities where I'm chair of -- I'm sorry -- where 08:17:27</p> <p>16 I'm Chief Scientist for Royal Pharmaceutical 08:17:30</p> <p>17 Society, and so I have expertise, and surrounding my 08:17:36</p> <p>18 activities as a chief scientist in that context. I 08:17:43</p> <p>19 obviously have expertise surrounding my activities 08:17:47</p> <p>20 as an academic in King's College, London. 08:17:50</p> <p>21 Q. Are you an expert in any other areas? 08:17:56</p> <p>22 MR. MARGOLIS: Objection. Vague. 08:18:00</p>

Page 22	<p>1 Q. You may answer. 08:18:02</p> <p>2 A. I do find that really, really hard to answer. 08:18:06</p> <p>3 I can give you an expertise if you tell me what 08:18:09</p> <p>4 particular areas you are referring to. 08:18:11</p> <p>5 Q. I'm asking you for your understanding. In 08:18:13</p> <p>6 what other areas do you hold yourself out as an 08:18:17</p> <p>7 expert? 08:18:20</p> <p>8 MR. MARGOLIS: Objection. Vague. 08:18:20</p> <p>9 THE WITNESS: Well, I'm going to answer 08:18:36</p> <p>10 it this way. I have expertise in a number of 08:18:38</p> <p>11 scientific disciplines. I have expertise in 08:18:42</p> <p>12 respect to my professional activities 08:18:47</p> <p>13 regarding my work at Pharmaceutical Society. 08:18:54</p> <p>14 I think my main -- my main two areas of 08:18:56</p> <p>15 expertise. 08:19:01</p> <p>16 Q. Take a look at paragraph 5 of your 08:19:02</p> <p>17 declaration on page two. 08:19:05</p> <p>18 A. Which is headed? 08:19:11</p> <p>19 Q. It's going to be page 2 of your declaration. 08:19:13</p> <p>20 A. Yes. 08:19:13</p> <p>21 Q. Paragraph 5 under Qualifications. I don't 08:19:16</p> <p>22 think you're on the right page. 08:19:19</p>	Page 24	<p>1 Q. What other areas? 08:20:04</p> <p>2 A. Getting -- that's incredibly vague and 08:20:06</p> <p>3 probably not relevant to this particular case. For 08:20:12</p> <p>4 example, I'm an expert on neutron scattering, but 08:20:15</p> <p>5 it's probably irrelevant for this particular case. 08:20:20</p> <p>6 Q. Well, I'm asking you the question and, you 08:20:24</p> <p>7 know, I'm not asking you to try to determine what's 08:20:27</p> <p>8 relevant or not relevant for the case. 08:20:31</p> <p>9 Are you an expert in any other areas? 08:20:33</p> <p>10 A. I consider I have expertise in a number of 08:20:59</p> <p>11 other areas, yes. For example, I'm a recognized 08:21:02</p> <p>12 expert on neutron scattering. 08:21:09</p> <p>13 Q. And you just said that. What other areas 08:21:12</p> <p>14 besides neutron scattering? 08:21:15</p> <p>15 A. I think I'm expert in promoting of 08:21:18</p> <p>16 pharmaceutical science. 08:21:23</p> <p>17 Q. Any other areas? 08:21:25</p> <p>18 A. I'll qualify that, promoting to the public 08:21:27</p> <p>19 and other scientists. Can I look at my CV? 08:21:32</p> <p>20 Q. Oh, please. 08:21:40</p> <p>21 A. I consider I'm an expert teacher with respect 08:21:48</p> <p>22 to pharmaceutical science. I've been given awards 08:21:54</p>
Page 23	<p>1 A. I'm sorry. 08:19:20</p> <p>2 Q. It's your declaration. 08:19:21</p> <p>3 A. Sorry. Paragraph 5? 08:19:22</p> <p>4 Q. So, I still don't believe you're on the right 08:19:26</p> <p>5 page. It's your declaration, not your curriculum 08:19:28</p> <p>6 vitae. 08:19:31</p> <p>7 A. I'm sorry. Five did you say? Page 5? 08:19:31</p> <p>8 Q. Page 2, paragraph 5. 08:19:37</p> <p>9 A. Page 2. Okay. 08:19:39</p> <p>10 Q. It says, "I am an expert in the field of 08:19:40</p> <p>11 formulation and drug delivery, specifically 08:19:42</p> <p>12 pharmaceutical formulation for oral and parenteral 08:19:44</p> <p>13 use (i.e., non-oral, including intravenous 08:19:48</p> <p>14 intramuscular, nasal, respiratory and ophthalmic), 08:19:52</p> <p>15 including aqueous liquid preparations." 08:19:57</p> <p>16 Do you see that? 08:19:58</p> <p>17 A. Yes. 08:19:59</p> <p>18 Q. Do you hold yourself out to the public as an 08:19:59</p> <p>19 expert in any other areas? 08:20:01</p> <p>20 A. In other areas? 08:20:02</p> <p>21 Q. Correct. 08:20:03</p> <p>22 A. Yes. 08:20:04</p>	Page 25	<p>1 for that activity. 08:22:00</p> <p>2 I consider I'm an expert researcher, which 08:22:02</p> <p>3 includes an expert in the areas you highlighted. 08:22:06</p> <p>4 Q. Any other areas? 08:22:10</p> <p>5 A. Archaeology. Hobby. 08:22:14</p> <p>6 Q. Anything else? 08:22:22</p> <p>7 A. It's very hard to answer when asked are you 08:22:37</p> <p>8 an expert in, not knowing what the point of the 08:22:40</p> <p>9 question is. 08:22:44</p> <p>10 Q. Well, let me ask it this way. Are you an 08:22:45</p> <p>11 expert in the field of pharmacy? 08:22:47</p> <p>12 A. Yes. 08:22:48</p> <p>13 Q. Have you ever practiced pharmacy? 08:22:49</p> <p>14 A. Yes. 08:22:51</p> <p>15 Q. When did you last practice pharmacy? 08:22:51</p> <p>16 A. I'm a practicing pharmacist. 08:22:53</p> <p>17 Q. When did you last dispense a medication to a 08:22:55</p> <p>18 patient? 08:22:58</p> <p>19 A. Dispense medication? Probably 20 years ago. 08:22:58</p> <p>20 Q. Are you an expert in pharmacology? 08:23:10</p> <p>21 A. No. 08:23:12</p> <p>22 Q. Are you an expert in pharmacokinetics? 08:23:12</p>

Page 26	Page 28
1 MR. MARGOLIS: Objection. Vague. 08:23:18	1 A. As a pharmacist in the UK, that is not your 08:25:17
2 Q. You may answer. 08:23:19	2 role. 08:25:21
3 A. I have -- I have a good level of expertise in 08:23:23	3 Q. Is that a "no"? 08:25:22
4 that. 08:23:28	4 A. In the UK, that would not be the role of a 08:25:24
5 Q. Have you ever held yourself out to the public 08:23:29	5 pharmacist. 08:25:26
6 as an expert in pharmacokinetics? 08:23:31	6 Q. Have you ever dispensed any bromfenac product 08:25:27
7 A. No. 08:23:33	7 to a patient? 08:25:30
8 Q. Have you ever held yourself out to the public 08:23:33	8 A. No. 08:25:32
9 as an expert in pharmacodynamics? 08:23:36	9 Q. Have you ever dispensed any product 08:25:33
10 MR. MARGOLIS: Objection. Vague. 08:23:40	10 containing tyloxapol to a patient? 08:25:35
11 Q. You may answer. 08:23:41	11 A. Yes. 08:25:38
12 A. I have not. 08:23:44	12 Q. What product? 08:25:39
13 Q. Are you an expert in ophthalmology? 08:23:45	13 A. Exosurf. 08:25:40
14 MR. MARGOLIS: Objection. Vague. 08:23:52	14 Q. You may have to spell that for the reporter. 08:25:42
15 Q. You may answer. 08:23:54	15 A. E-X-O-S-U-R-F. 08:25:45
16 A. I'm an expert in parenteral formulations of 08:23:57	16 Q. What is Exosurf? 08:25:50
17 which ophthalmology -- ophthalmic formulations as 08:24:01	17 A. It's a product for respiratory distress 08:25:52
18 well. 08:24:06	18 syndrome in pre-term infants. 08:25:59
19 Q. Have you ever held yourself out to the public 08:24:06	19 Q. Is that an ophthalmic product? 08:26:03
20 as an expert in ophthalmology? 08:24:09	20 A. It's not an ophthalmic product. I have 08:26:06
21 MR. MARGOLIS: Objection. Vague. 08:24:11	21 dispensed many ophthalmic products. 08:26:08
22 THE WITNESS: No. 08:24:12	22 Q. Have you ever dispensed an ophthalmic product 08:26:11
Page 27	Page 29
1 Q. Are you an expert in any field of medicine? 08:24:13	1 containing tyloxapol to a patient? 08:26:16
2 MR. MARGOLIS: Objection. Vague. 08:24:17	2 A. Undoubtedly. 08:26:16
3 THE WITNESS: Medicine is a huge area. 08:24:19	3 Q. Which one? 08:26:17
4 And what are you covering? Are you covering 08:24:25	4 A. Many products contain tyloxapol. As a 08:26:19
5 pharmaceutical medicine? 08:24:27	5 pharmacist, I have dispensed most ophthalmic 08:26:28
6 Q. Have you ever held yourself out to the public 08:24:29	6 preparations. 08:26:32
7 as an expert in any field of medicine? 08:24:31	7 Q. What ophthalmic product containing tyloxapol 08:26:32
8 MR. MARGOLIS: Objection. Vague. 08:24:34	8 have you dispensed to a patient? 08:26:36
9 THE WITNESS: I am a Registered 08:24:37	9 A. As a pharmacist, it is not normal you read 08:26:37
10 Practicing Pharmacist in the UK. 08:24:39	10 the list of excipients. 08:26:40
11 Q. Have you ever -- 08:24:42	11 Q. Sitting here today, can you name any 08:26:41
12 A. So, I am not a medic. 08:24:43	12 ophthalmic product containing tyloxapol that you 08:26:43
13 Q. Well, when you say -- 08:24:47	13 have dispensed to a patient? 08:26:46
14 A. So, I would not claim to practice medicine. 08:24:48	14 A. No. 08:26:52
15 Q. Have you ever prescribed medication to a 08:24:53	15 Q. Are you aware that the acronym EDTA stands 08:26:53
16 patient? 08:24:56	16 for ethylenediaminetetraacetic acid? 08:26:59
17 A. No. 08:24:58	17 A. I am. 08:27:02
18 Q. Have you ever treated an inflammatory disease 08:24:59	18 Q. Have you ever administered any product 08:27:02
19 of the eye? 08:25:02	19 containing EDTA or any salt or anion of EDTA to a 08:27:04
20 A. No. 08:25:06	20 patient? 08:27:11
21 Q. Have you ever administered any bromfenac 08:25:06	21 A. Undoubtedly, yes. 08:27:12
22 product to a patient? 08:25:11	22 Q. Which product? 08:27:14

Page 30			Page 32		
1	A. Eye drops that contain it.	08:27:15	1	Q. Have you ever conducted any research on any	08:29:37
2	Q. Which eye drops?	08:27:17	2	product containing EDTA or any salt or anion of	08:29:40
3	A. I don't recall.	08:27:19	3	EDTA?	08:29:45
4	Q. Have you ever conducted any research on any	08:27:21	4	A. Yes.	08:29:45
5	bromfenac product?	08:27:25	5	Q. What product?	08:29:45
6	MR. MARGOLIS: Objection. Vague.	08:27:27	6	A. It's frequently -- it's a compound that is	08:29:48
7	Q. You may answer.	08:27:28	7	frequently used in academic research for a variety	08:29:53
8	A. On a bromfenac product, no.	08:27:38	8	of purposes.	08:29:58
9	Q. Have you ever conducted any research on any	08:27:40	9	Q. When did you last use EDTA in your academic	08:29:58
10	product containing tyloxapol?	08:27:42	10	research?	08:30:02
11	A. Yes.	08:27:45	11	A. Personally, a while ago. My research group,	08:30:03
12	Q. What product?	08:27:45	12	all the time. So, I don't know how that answers	08:30:08
13	A. Exosurf, for example.	08:27:47	13	your question.	08:30:14
14	Q. Any others?	08:27:52	14	Q. No. Thank you for clarifying.	08:30:14
15	A. Formulations I have undertaken research in my	08:27:55	15	When personally did you last use EDTA in your	08:30:16
16	own laboratory.	08:27:59	16	academic research?	08:30:19
17	Q. Which formulations?	08:28:00	17	A. Probably about five years ago.	08:30:22
18	A. That I have made up in my own laboratory.	08:28:01	18	Q. When personally did you last use tyloxapol in	08:30:37
19	Q. How did you make a formulation in your	08:28:04	19	your academic research?	08:30:39
20	laboratory containing tyloxapol?	08:28:07	20	A. Very recently.	08:30:42
21	A. That is a very vague question. I have used	08:28:11	21	Q. Do you remember how recently?	08:30:45
22	tyloxapol much in my research.	08:28:16	22	A. Probably last year or so.	08:30:47
Page 31			Page 33		
1	Q. What did you use it for?	08:28:18	1	Q. Is bromfenac a water-soluble hydrophilic	08:30:52
2	A. To make a variety of formulations, of types	08:28:20	2	drug?	08:31:00
3	of formulations.	08:28:24	3	MR. MARGOLIS: Objection. Vague.	08:31:00
4	Q. Why did you use tyloxapol in the formulations	08:28:25	4	THE WITNESS: Can I ask you to clarify	08:31:02
5	that you made in your laboratory?	08:28:28	5	that? Do you mean the free acid or do you	08:31:02
6	MR. MARGOLIS: Objection. Vague.	08:28:30	6	mean the salt?	08:31:04
7	Compound.	08:28:31	7	Q. Well, let me ask it this way. Is the sodium	08:31:05
8	Q. You may answer.	08:28:32	8	salt of bromfenac a water-soluble hydrophilic drug?	08:31:07
9	A. I used it for several reasons. For example,	08:28:35	9	A. It is.	08:31:12
10	it is accepted pharmaceutically.	08:28:40	10	Q. Would a solution containing tyloxapol in	08:31:13
11	Q. What other reasons?	08:28:42	11	water be considered a water-based surfactant system?	08:31:16
12	A. It's a non-ionic surfactant.	08:28:45	12	MR. MARGOLIS: Objection. Vague.	08:31:19
13	Q. What other reasons?	08:28:51	13	THE WITNESS: Sorry. Repeat the	08:31:23
14	A. It is well-known to solubilize drugs. To	08:28:53	14	question?	08:31:25
15	solubilize, S-O-L-U-B-I-L-I-S-E, or Z-E.	08:29:05	15	Q. Certainly. I will repeat the question.	08:31:25
16	Q. Any other reasons?	08:29:07	16	Would a solution containing tyloxapol in	08:31:27
17	A. It's -- it stabilizes many formulations.	08:29:09	17	water be considered a water-based surfactant system?	08:31:30
18	Q. What do you mean by "it stabilizes many	08:29:26	18	MR. MARGOLIS: Objection. Vague.	08:31:34
19	formulations"?	08:29:29	19	THE WITNESS: It is vague because you	08:31:37
20	A. It depends on the formulation you're looking	08:29:29	20	don't give enough information as to regards	08:31:43
21	at, how it acts, but it is used to formulate many	08:29:31	21	to how much tyloxapol or what else is in	08:31:45
22	preparations.	08:29:35	22	there. So it's very -- it's difficult to	08:31:49

Page 34	<p>1 answer. 08:31:52</p> <p>2 Q. How would you make a water-based surfactant 08:31:52</p> <p>3 system with tyloxapol? 08:31:56</p> <p>4 A. Can I ask for clarification? 08:31:57</p> <p>5 Q. Sure. 08:31:59</p> <p>6 A. What do you mean by water-based? 08:32:00</p> <p>7 Q. What's your understanding of water-based? 08:32:01</p> <p>8 A. I don't know. I'm asking for clarification. 08:32:03</p> <p>9 Q. Have you ever used the term water-based? 08:32:06</p> <p>10 A. It's not a frequently used term -- a term I 08:32:09</p> <p>11 frequently use, no. 08:32:12</p> <p>12 Q. Have you ever used it in any of your 08:32:13</p> <p>13 publications? 08:32:15</p> <p>14 A. I don't know. I don't remember every single 08:32:17</p> <p>15 publication I've had. 08:32:24</p> <p>16 Q. Would a solution containing tyloxapol in 08:32:25</p> <p>17 water be considered an aqueous surfactant system? 08:32:28</p> <p>18 MR. MARGOLIS: Objection. Vague. 08:32:31</p> <p>19 THE WITNESS: Again, you need to tell me 08:32:32</p> <p>20 how much water and tyloxapol there are to 08:32:34</p> <p>21 answer that question. I'm sorry. 08:32:37</p> <p>22 Q. Why does it matter how much water and 08:32:37</p>	Page 36	<p>1 concentration, that would depend on what you would 08:33:48</p> <p>2 do next. 08:33:50</p> <p>3 Q. Would that be considered a water-based 08:33:51</p> <p>4 surfactant system? 08:33:53</p> <p>5 MR. MARGOLIS: Objection. Vague. 08:33:55</p> <p>6 THE WITNESS: Again, it depends on what 08:34:00</p> <p>7 the definition of based is. 08:34:04</p> <p>8 Q. Would that be considered an aqueous 08:34:06</p> <p>9 surfactant system? 08:34:09</p> <p>10 MR. MARGOLIS: Objection. Vague. 08:34:11</p> <p>11 THE WITNESS: It would depend on the 08:34:13</p> <p>12 relative -- depending on the relative 08:34:15</p> <p>13 proportions of surfactant and water. 08:34:16</p> <p>14 Q. If the water is in the greater proportion, 08:34:18</p> <p>15 would that be an aqueous surfactant system? 08:34:21</p> <p>16 A. Yes. 08:34:24</p> <p>17 Q. Are you an expert in clinical testing? 08:34:26</p> <p>18 A. No. I would consider myself somebody of 08:34:33</p> <p>19 ordinary skill in the art. 08:34:35</p> <p>20 Q. Have you ever conducted any clinical testing 08:34:36</p> <p>21 with a pharmaceutical product? 08:34:39</p> <p>22 A. When you mean conduct, again, that's very 08:34:47</p>
Page 35	<p>1 tyloxapol are there? 08:32:39</p> <p>2 A. Because you still haven't answered really 08:32:42</p> <p>3 what based is. So, when you say water-based, if you 08:32:45</p> <p>4 can clarify that, please? 08:32:49</p> <p>5 Q. No. I asked a different question. I 08:32:51</p> <p>6 asked -- 08:32:53</p> <p>7 A. I can't answer if you're talking about 08:32:53</p> <p>8 water-based and it's not clarified. So I can't 08:32:56</p> <p>9 answer. Sorry. 08:32:58</p> <p>10 Q. Okay. How would you make an aqueous 08:33:00</p> <p>11 surfactant system using tyloxapol? 08:33:03</p> <p>12 MR. MARGOLIS: Objection. Vague. 08:33:06</p> <p>13 Q. You may answer. 08:33:09</p> <p>14 A. The only way I can answer that is to make 08:33:12</p> <p>15 some assumptions. 08:33:15</p> <p>16 Q. Please do. 08:33:16</p> <p>17 A. Assuming you want a predominantly 08:33:17</p> <p>18 water-based -- water to be there in the biggest 08:33:25</p> <p>19 amount, largest amount, which I assume is what you 08:33:28</p> <p>20 are trying to say by based, you would add water, a 08:33:31</p> <p>21 known amount of water, to a pre-weighed amount of 08:33:42</p> <p>22 tyloxapol, and depending upon the particular 08:33:45</p>	Page 37	<p>1 vague because have I led a clinical trial, have I 08:34:54</p> <p>2 designed a clinical trial, have I analyzed a 08:34:58</p> <p>3 clinical trial? That's not -- 08:35:00</p> <p>4 Q. Have you ever led any clinical testing on a 08:35:02</p> <p>5 pharmaceutical product? 08:35:05</p> <p>6 A. No. 08:35:06</p> <p>7 Q. Have you ever designed any clinical testing 08:35:06</p> <p>8 on a pharmaceutical product? 08:35:09</p> <p>9 A. No. 08:35:10</p> <p>10 Q. Are you an expert in statistics or 08:35:10</p> <p>11 biostatistics? 08:35:12</p> <p>12 MR. MARGOLIS: Objection. Vague. 08:35:15</p> <p>13 THE WITNESS: I have a good 08:35:21</p> <p>14 understanding of statistics. 08:35:23</p> <p>15 Q. Do you hold yourself to the public as an 08:35:24</p> <p>16 expert in statistics or biostatistics? 08:35:26</p> <p>17 A. No, I would not. 08:35:30</p> <p>18 Q. Are you an expert in the U.S. Pharmacopeia 08:35:31</p> <p>19 criteria for antimicrobial effectiveness? 08:35:35</p> <p>20 MR. MARGOLIS: Objection. Vague. 08:35:39</p> <p>21 THE WITNESS: I'm very aware of what the 08:35:42</p> <p>22 criteria are. 08:35:48</p>

Page 38		Page 40			
1	Q. Do you hold yourself as an expert in the U.S.	08:35:49	1	question to answer that because I'm still	08:37:54
2	Pharmacopeia criteria for antimicrobial	08:35:52	2	uncertain -- I believe that expertise falls	08:38:00
3	effectiveness?	08:35:56	3	under my experience and expertise in	08:38:06
4	MR. MARGOLIS: Objection. Vague.	08:35:57	4	formulation.	08:38:09
5	THE WITNESS: I am unclear what an	08:35:58	5	Q. Have you ever told anyone that you were an	08:38:10
6	expert would need to do under those --	08:35:59	6	expert in the stability testing on aqueous liquid	08:38:12
7	somebody would need to do under those	08:36:02	7	preparations?	08:38:15
8	circumstances to be an expert.	08:36:05	8	A. Who would I need to have told?	08:38:18
9	Q. Have you ever conducted any tests measuring	08:36:06	9	Q. Is that a "no"?	08:38:20
10	antimicrobial effectiveness according to the U.S.	08:36:09	10	A. I don't know who you mean. I'm considered to	08:38:22
11	Pharmacopeia criteria?	08:36:13	11	be an expert in drug and gene delivery and all that	08:38:26
12	A. Yes.	08:36:15	12	entails. So that would be an integral part of that.	08:38:32
13	Q. What test did you conduct?	08:36:16	13	Q. Have you ever told anyone that you're an	08:38:35
14	A. A long time ago with some products that were	08:36:19	14	expert in stability testing on aqueous liquid	08:38:37
15	being prepared in the laboratory.	08:36:23	15	preparations?	08:38:40
16	Q. When did you last conduct a test measuring	08:36:25	16	MR. MARGOLIS: Objection. Asked and	08:38:44
17	antimicrobial effectiveness according to the U.S.	08:36:28	17	answered.	08:38:45
18	Pharmacopeia criteria?	08:36:31	18	THE WITNESS: I repeat again that is an	08:38:50
19	A. I can't recall.	08:36:34	19	integral part of my expertise in drug	08:38:53
20	Q. Are you an expert in the European	08:36:38	20	delivery.	08:39:01
21	Pharmacopeia criteria B standards?	08:36:42	21	Q. Have you ever conducted stability testing on	08:39:06
22	MR. MARGOLIS: Objection. Vague.	08:36:44	22	aqueous liquid preparations?	08:39:11
Page 39		Page 41			
1	THE WITNESS: Again, I am obviously	08:36:48	1	A. I have.	08:39:20
2	aware of those, being a pharmacist and a	08:36:51	2	Q. Why did you conduct stability testing on	08:39:22
3	researcher. I'm unclear what would be an	08:36:54	3	aqueous liquid preparations?	08:39:25
4	expert in that area.	08:36:58	4	A. Stability testing is a very large field and	08:39:28
5	Q. Have you ever held yourself out to the public	08:36:59	5	it would depend upon -- the tests you performed	08:39:39
6	as an expert in the European Pharmacopeia criteria B	08:37:02	6	would depend upon formulation and its ultimate	08:39:42
7	standards?	08:37:07	7	intended use.	08:39:47
8	A. No.	08:37:07	8	Q. How did you conduct stability testing on	08:39:48
9	MR. MARGOLIS: Objection. Vague.	08:37:08	9	aqueous liquid preparations?	08:39:50
10	Q. Are you an expert in stability testing of	08:37:09	10	MR. MARGOLIS: Objection. Vague.	08:39:52
11	aqueous liquid preparations?	08:37:12	11	THE WITNESS: I repeat my answer.	08:39:56
12	A. I believe I have a --	08:37:17	12	Stability testing is a very large area. The	08:39:58
13	MR. MARGOLIS: Objection. Vague.	08:37:17	13	tests you performed and how I perform them	08:40:04
14	THE WITNESS: I believe I have a very	08:37:18	14	would depend upon the formulation I was	08:40:07
15	good understanding of a large number of	08:37:21	15	looking at and the purpose, the intended	08:40:10
16	stability tests that would be appropriate for	08:37:26	16	purpose.	08:40:13
17	that.	08:37:28	17	Q. When did you last conduct stability testing	08:40:13
18	Q. Have you ever held yourself out to the public	08:37:28	18	on aqueous liquid preparations?	08:40:15
19	as an expert in stability testing of aqueous liquid	08:37:31	19	A. It's conducted all the time in my laboratory.	08:40:19
20	preparations?	08:37:34	20	Q. When did you last do it?	08:40:23
21	MR. MARGOLIS: Objection. Vague.	08:37:38	21	A. I conducted tests personally within the last	08:40:33
22	THE WITNESS: That's a really difficult	08:37:52	22	few weeks.	08:40:36

Page 42	<p>1 Q. How did you conduct those tests? 08:40:37</p> <p>2 A. This is a really impossible question to 08:40:43</p> <p>3 answer. It's like how long is a piece of string. 08:40:51</p> <p>4 Q. You've told me that you just conducted those 08:40:54</p> <p>5 tests and -- 08:40:56</p> <p>6 A. I conducted some tests, yes. 08:40:56</p> <p>7 Q. How did you conduct them? 08:40:58</p> <p>8 A. Those particular tests? Okay. In this 08:40:59</p> <p>9 particular case, these tests were looking at 08:41:06</p> <p>10 stability of drug in micelle formulations. 08:41:09</p> <p>11 Formulations were prepared to standard criteria in 08:41:18</p> <p>12 my laboratory, and they were assayed over time using 08:41:22</p> <p>13 a variety of techniques which were appropriate 08:41:26</p> <p>14 ranging from spectroscopic through to size stability 08:41:30</p> <p>15 through to neutron scattering. 08:41:36</p> <p>16 Q. Why did you conduct those particular tests? 08:41:40</p> <p>17 A. If you're working in drug delivery, gene 08:41:44</p> <p>18 delivery, formulation stability is a prerequisite. 08:41:48</p> <p>19 Q. Why is formulation stability a prerequisite 08:41:53</p> <p>20 for drug delivery? 08:41:56</p> <p>21 A. A patient doesn't want an unstable 08:41:59</p> <p>22 formulation that's not going to behave in the 08:42:02</p>	Page 44	<p>1 the concept of solubility with respect to aqueous 08:43:32</p> <p>2 liquid preparations? 08:43:37</p> <p>3 MR. MARGOLIS: Objection. Vague. 08:43:39</p> <p>4 THE WITNESS: They are not synonymous at 08:43:41</p> <p>5 all. 08:43:49</p> <p>6 Q. Why are they not synonymous at all? 08:43:49</p> <p>7 A. Solubility is assessing the amount of the 08:43:51</p> <p>8 material of interest that is molecularly dispersed 08:43:57</p> <p>9 in solution. Stability always has to be defined. 08:44:03</p> <p>10 There are different types of stability, and 08:44:12</p> <p>11 that's -- and you want to ensure that your 08:44:17</p> <p>12 formulation is unchanged in its use -- in use. 08:44:24</p> <p>13 Q. Are you an expert in chemistry? 08:44:34</p> <p>14 MR. MARGOLIS: Objection. Vague. 08:44:37</p> <p>15 Q. You may answer. 08:44:38</p> <p>16 A. I'm going to ask you what you mean by 08:44:41</p> <p>17 chemistry. 08:44:43</p> <p>18 Q. Well, what's your understanding of chemistry? 08:44:43</p> <p>19 A. Chemistry is a huge subject. That's my 08:44:47</p> <p>20 understanding of chemistry. 08:44:50</p> <p>21 Q. Have you ever held yourself out to the public 08:44:52</p> <p>22 as an expert in the field of chemistry? 08:44:54</p>
Page 43	<p>1 appropriate way. 08:42:04</p> <p>2 Q. Why is it important for a patient to have a 08:42:06</p> <p>3 stable formulation that will behave in an 08:42:09</p> <p>4 appropriate way? 08:42:12</p> <p>5 MR. MARGOLIS: Objection. Lacks 08:42:14</p> <p>6 foundation. 08:42:16</p> <p>7 Q. You may answer. 08:42:17</p> <p>8 A. There are a number of reasons. For example, 08:42:20</p> <p>9 to ensure the drug hasn't degraded into toxic 08:42:24</p> <p>10 impurities. 08:42:29</p> <p>11 Q. What other reasons? 08:42:31</p> <p>12 A. To ensure that the formulation hasn't changed 08:42:33</p> <p>13 its state. 08:42:39</p> <p>14 Q. Any other reasons? 08:42:42</p> <p>15 A. To ensure that the formulation is likely to 08:42:44</p> <p>16 be stable under the condition of use of the patient, 08:42:47</p> <p>17 to ensure the container you're putting the 08:42:53</p> <p>18 formulation in is appropriate for end use, ensure 08:42:59</p> <p>19 there's sufficient shelf-life, to ensure it's not 08:43:05</p> <p>20 contaminated with microbial contamination, to ensure 08:43:14</p> <p>21 it's not affected by light. I could go on. 08:43:20</p> <p>22 Q. How does the concept of stability differ from 08:43:30</p>	Page 45	<p>1 MR. MARGOLIS: Objection. Vague. 08:44:57</p> <p>2 THE WITNESS: I have a known expertise 08:45:00</p> <p>3 in physical chemistry. I have a good 08:45:02</p> <p>4 understanding of organic chemistry. 08:45:06</p> <p>5 Q. Have you ever published anything in The 08:45:13</p> <p>6 Journal of the American Chemical Society? 08:45:15</p> <p>7 A. No. 08:45:18</p> <p>8 Q. Have you ever been qualified by any court as 08:45:18</p> <p>9 an expert in chemistry? 08:45:21</p> <p>10 A. Having only done two court cases prior, no. 08:45:28</p> <p>11 Q. Are you an expert in patent law? 08:45:33</p> <p>12 A. No. 08:45:37</p> <p>13 Q. Are you a named inventor on any U.S. patents? 08:45:37</p> <p>14 A. Not U.S., no. 08:45:42</p> <p>15 Q. Are you a named inventor on any U.S. patent 08:45:44</p> <p>16 applications? 08:45:47</p> <p>17 A. No. 08:45:48</p> <p>18 Q. Prior to this case, have you ever provided 08:45:49</p> <p>19 any opinion regarding the interpretation of the 08:45:52</p> <p>20 phrases sodium edetate or EDTA sodium salt in a 08:45:55</p> <p>21 patent claim? 08:46:00</p> <p>22 MR. MARGOLIS: Objection. Vague. 08:46:06</p>

Page 46	<p>1 THE WITNESS: I can't recall. I may 08:46:19</p> <p>2 have, but I can't recall definitely. 08:46:21</p> <p>3 Q. Prior to this case, have you provided any 08:46:23</p> <p>4 opinion regarding the interpretation of the term 08:46:28</p> <p>5 stable or any phrase concerning the term stabilized 08:46:30</p> <p>6 in a patent claim? 08:46:34</p> <p>7 A. I have. 08:46:35</p> <p>8 MR. MARGOLIS: Objection. Vague. 08:46:36</p> <p>9 Q. And what case was that? 08:46:36</p> <p>10 A. Novartis versus Ivax. Novartis versus Dixel. 08:46:44</p> <p>11 Q. What was your opinion? 08:46:49</p> <p>12 A. Very vague, that question. It was related to 08:46:52</p> <p>13 the particular formulation in the case. 08:46:55</p> <p>14 Q. Did the court accept your opinion? 08:46:58</p> <p>15 A. Yes. 08:47:00</p> <p>16 Q. Prior to this case, have you ever provided 08:47:02</p> <p>17 any opinion regarding the interpretation of any 08:47:05</p> <p>18 phrase dealing with preservative efficacy in a 08:47:08</p> <p>19 patent claim? 08:47:11</p> <p>20 MR. MARGOLIS: Objection. Vague. 08:47:13</p> <p>21 THE WITNESS: I may have, but I can't 08:47:22</p> <p>22 definitely recall. 08:47:24</p>	Page 48	<p>1 containing EDTA or any salt or anion of EDTA? 08:48:34</p> <p>2 A. I've used formulations in my laboratory with 08:48:39</p> <p>3 EDTA and the salts, yes. 08:48:43</p> <p>4 Q. Have you ever actually formulated any 08:48:45</p> <p>5 products containing EDTA? 08:48:47</p> <p>6 A. Can you explain what you mean by formulate? 08:48:48</p> <p>7 Q. Well, what's your understanding of 08:48:51</p> <p>8 formulation? 08:48:52</p> <p>9 A. A formulate is make up a preparation. 08:48:52</p> <p>10 Q. Okay. Well, I'm asking based on your 08:48:56</p> <p>11 understanding. 08:48:58</p> <p>12 Have you ever formulated any product 08:48:58</p> <p>13 containing EDTA or any salt or anion of EDTA? 08:49:00</p> <p>14 A. Okay. What do you mean by product? 08:49:04</p> <p>15 Q. Well, what's your understanding of a product? 08:49:06</p> <p>16 A. Do you mean something that got on to market? 08:49:09</p> <p>17 Q. I'm asking you more generally than that. Any 08:49:14</p> <p>18 formulation? 08:49:17</p> <p>19 A. I have made formulations in my laboratory 08:49:19</p> <p>20 using EDTA and its salts, yes. 08:49:23</p> <p>21 Q. And you mentioned the market -- excuse me. 08:49:26</p> <p>22 Have you ever formulated any marketed drug product? 08:49:29</p>
Page 47	<p>1 Q. Back to the Novartis case you mentioned, for 08:47:25</p> <p>2 which party in that case did you provide your 08:47:29</p> <p>3 opinion? 08:47:32</p> <p>4 A. Novartis. 08:47:33</p> <p>5 Q. In what court was that? 08:47:34</p> <p>6 A. The UK High Court. 08:47:37</p> <p>7 Q. Did you provide public testimony at trial in 08:47:40</p> <p>8 that case? 08:47:49</p> <p>9 A. Yes. 08:47:49</p> <p>10 Q. Did you provide testimony at a deposition in 08:47:50</p> <p>11 that case? 08:47:53</p> <p>12 A. They don't do deposition in the UK. 08:47:54</p> <p>13 Q. Have you ever formulated any bromfenac 08:47:57</p> <p>14 product? 08:48:02</p> <p>15 A. No, but formulated closely related molecules. 08:48:08</p> <p>16 Q. Have you ever formulated any product 08:48:14</p> <p>17 containing tyloxapol? 08:48:21</p> <p>18 A. I have formulated products in my laboratory, 08:48:23</p> <p>19 yes. 08:48:29</p> <p>20 Q. Containing tyloxapol? 08:48:29</p> <p>21 A. Yes. 08:48:31</p> <p>22 Q. Have you ever formulated any products 08:48:31</p>	Page 49	<p>1 A. Not as lead formulator, no. 08:49:33</p> <p>2 Q. Have you ever formulated any product for 08:49:37</p> <p>3 treating an inflammatory disease of the eye? 08:49:39</p> <p>4 A. No, not that's got to market. 08:49:43</p> <p>5 Q. Have you ever formulated any product 08:49:47</p> <p>6 containing multiple active ingredients? 08:49:49</p> <p>7 A. Yes. 08:49:51</p> <p>8 Q. What product? 08:49:52</p> <p>9 A. It's a combination formulation consisting of 08:49:53</p> <p>10 another particle and microemulsion. 08:50:01</p> <p>11 Q. How does the addition of a second active 08:50:03</p> <p>12 ingredient to a pharmaceutical formulation affect 08:50:06</p> <p>13 the physical and chemical properties of the 08:50:10</p> <p>14 formulation? 08:50:12</p> <p>15 MR. MARGOLIS: Objection. Lacks 08:50:13</p> <p>16 foundation. 08:50:14</p> <p>17 THE WITNESS: Again, that very much 08:50:16</p> <p>18 depends upon the two drugs and the 08:50:18</p> <p>19 formulation. 08:50:22</p> <p>20 Q. What else does it depend on? 08:50:23</p> <p>21 A. A huge amount of things. It would depend 08:50:25</p> <p>22 upon the two drugs. It would depend upon how the 08:50:32</p>

Page 50	<p>1 two drugs were formulated, relative amounts of the 08:50:38</p> <p>2 two drugs, the pH, the temperature of use, the 08:50:46</p> <p>3 presence of excipients. You would have to test to 08:50:55</p> <p>4 ensure whether or not it worked. 08:51:00</p> <p>5 Q. Is it fair to say that that's a complicated 08:51:04</p> <p>6 process? 08:51:07</p> <p>7 MR. MARGOLIS: Objection. Vague. 08:51:11</p> <p>8 THE WITNESS: It would depend upon the 08:51:15</p> <p>9 products you were interested in. 08:51:18</p> <p>10 Q. How so? 08:51:20</p> <p>11 A. I gave a potential landscape of problems that 08:51:32</p> <p>12 you would need to consider -- of considerations you 08:51:48</p> <p>13 would need to make when designing your study. 08:51:49</p> <p>14 Depending upon the two systems you're interested in, 08:51:53</p> <p>15 you may or may not have to do all of those, and I 08:51:58</p> <p>16 can't say without that knowledge. 08:52:01</p> <p>17 Q. Have you authored any papers dealing with the 08:52:04</p> <p>18 formulation of aqueous liquid preparations 08:52:07</p> <p>19 containing multiple active ingredients? 08:52:10</p> <p>20 A. Yes. 08:52:13</p> <p>21 Q. Have you authored or edited any book chapters 08:52:13</p> <p>22 dealing with formulation of aqueous liquid 08:52:16</p>	Page 52	<p>1 A. No. 08:53:13</p> <p>2 Q. Aside from your work in this case, have you 08:53:14</p> <p>3 ever consulted for any party concerning any 08:53:16</p> <p>4 bromfenac product? 08:53:21</p> <p>5 MR. MARGOLIS: Objection. Vague. 08:53:24</p> <p>6 THE WITNESS: I would like to state that 08:53:25</p> <p>7 I actually have written monographs in The 08:53:27</p> <p>8 Handbook for Pharmaceutical Excipients. 08:53:30</p> <p>9 Q. Did you write any monographs regarding 08:53:33</p> <p>10 bromfenac in the Handbook of Pharmaceutical -- 08:53:36</p> <p>11 A. No. It was on surfactants. 08:53:36</p> <p>12 Q. Did you write any monographs in The Handbook 08:53:40</p> <p>13 of Pharmaceutical Excipients regarding bromfenac? 08:53:42</p> <p>14 A. No. The Handbook of Excipients, and 08:53:46</p> <p>15 bromfenac is not an excipient, so I've written them 08:53:52</p> <p>16 on surfactants. 08:53:56</p> <p>17 Q. Aside from your work in this case, have you 08:53:57</p> <p>18 ever consulted for any party regarding any bromfenac 08:53:59</p> <p>19 product? 08:54:03</p> <p>20 MR. MARGOLIS: Objection. Vague. 08:54:04</p> <p>21 Q. You may answer. 08:54:06</p> <p>22 A. No. 08:54:10</p>
Page 51	<p>1 preparations containing multiple active ingredients? 08:52:18</p> <p>2 A. Have I edited a book or did I -- 08:52:22</p> <p>3 Q. Or authored any book chapter, correct. 08:52:30</p> <p>4 A. A book chapter, yes. I have, yes. 08:52:33</p> <p>5 Q. Have you ever contributed to the content of 08:52:35</p> <p>6 any edition of the European Pharmacopeia? 08:52:39</p> <p>7 A. No. 08:52:42</p> <p>8 Q. Have you ever contributed to the content of 08:52:43</p> <p>9 any edition of the United States Pharmacopeia? 08:52:45</p> <p>10 A. No. 08:52:49</p> <p>11 Q. Are you aware that the United States 08:52:49</p> <p>12 Pharmacopeia is a publication of the National 08:52:51</p> <p>13 Formulary? 08:52:54</p> <p>14 A. I am. 08:52:55</p> <p>15 Q. And have you ever consulted for the National 08:52:56</p> <p>16 Formulary? 08:52:59</p> <p>17 A. I have not. 08:52:59</p> <p>18 Q. Have you ever contributed to the content of 08:53:00</p> <p>19 any edition of the Japanese Pharmacopeia? 08:53:02</p> <p>20 A. I have not. 08:53:06</p> <p>21 Q. Have you ever contributed to the content of 08:53:08</p> <p>22 any edition of the Merck Index? 08:53:10</p>	Page 53	<p>1 Q. Aside from your work in this case, have you 08:54:11</p> <p>2 ever consulted for any party regarding any product 08:54:13</p> <p>3 containing tyloxapol? 08:54:16</p> <p>4 A. Yes. 08:54:20</p> <p>5 Q. In what context did you do that? 08:54:23</p> <p>6 A. I acted as an expert for a pharmaceutical 08:54:26</p> <p>7 company. 08:54:28</p> <p>8 Q. And what company was that? 08:54:28</p> <p>9 A. It's confidential. 08:54:30</p> <p>10 Q. Did you serve in that capacity in a court 08:54:31</p> <p>11 case? 08:54:37</p> <p>12 A. No. 08:54:37</p> <p>13 Q. Aside from your work in this case, have you 08:54:40</p> <p>14 ever consulted for any party regarding any product 08:54:42</p> <p>15 containing EDTA or a salt or anion of EDTA? 08:54:45</p> <p>16 MR. MARGOLIS: Objection. Vague. 08:54:50</p> <p>17 THE WITNESS: EDTA and its salts are 08:54:55</p> <p>18 excipients, so may be an integral part of a 08:54:59</p> <p>19 large number of formulations. It is unlikely 08:55:04</p> <p>20 you would be called upon to advise only on 08:55:08</p> <p>21 that particular ingredient. 08:55:11</p> <p>22 Q. Aside from your work in this case, have you 08:55:13</p>

Senju Pharmaceutical Co., LTD., et al. v. Lupin, LTD., and Lupin Pharmaceutical, Inc.,

Page 54	<p>1 ever consulted for any party regarding EDTA in 08:55:15</p> <p>2 particular or any salt or anion of EDTA? 08:55:19</p> <p>3 MR. MARGOLIS: Objection. Vague. 08:55:26</p> <p>4 THE WITNESS: EDTA is a common excipient 08:55:32</p> <p>5 in lots of formulations. I have consulted a 08:55:34</p> <p>6 lot on formulations for companies. So it's 08:55:38</p> <p>7 highly likely EDTA has been a component of 08:55:42</p> <p>8 those. 08:55:46</p> <p>9 Q. Have you ever consulted on the chemistry of 08:55:46</p> <p>10 EDTA? 08:55:49</p> <p>11 MR. MARGOLIS: Objection. Vague. 08:55:52</p> <p>12 THE WITNESS: Again, I think it would be 08:55:57</p> <p>13 unlikely anybody would be asked to consult 08:56:01</p> <p>14 only on the chemistry of EDTA. That might be 08:56:05</p> <p>15 part of a formulation package. 08:56:08</p> <p>16 Q. Have you ever consulted for the FDA? 08:56:11</p> <p>17 A. No. 08:56:13</p> <p>18 Q. Take a look at your curriculum vitae, please. 08:56:14</p> <p>19 A. I have consulted for the EMA though. 08:56:19</p> <p>20 Q. I'd like to direct your attention to page one 08:56:23</p> <p>21 under Previous Appointments. 08:56:27</p> <p>22 A. Yes. 08:56:33</p>	Page 56	<p>1 funded by industry. So I have -- I could go on. I 08:57:45</p> <p>2 have a lot more connections with industry. 08:57:49</p> <p>3 Q. When was the last time you actually worked at 08:57:51</p> <p>4 a pharmaceutical company? 08:57:53</p> <p>5 A. About -- I was working as a consultant about 08:58:01</p> <p>6 a year ago in the company. 08:58:11</p> <p>7 Q. Have you ever been hired for a permanent 08:58:14</p> <p>8 position at a pharmaceutical company? 08:58:17</p> <p>9 A. I have been offered lots of jobs. 08:58:19</p> <p>10 Q. Were you ever hired for one? 08:58:21</p> <p>11 A. I never accepted them. 08:58:23</p> <p>12 Q. When was the last time you were offered a 08:58:24</p> <p>13 permanent position at a pharmaceutical company? 08:58:26</p> <p>14 A. Okay. Gosh. I can't remember now. I have 08:58:29</p> <p>15 to think on that one. I'm sorry. Let me just look. 08:58:50</p> <p>16 I believe it was just prior to me taking up 08:59:14</p> <p>17 the role as Chief Scientist, Royal Pharmaceutical 08:59:17</p> <p>18 Society. I haven't been offered a job since then. 08:59:22</p> <p>19 Q. What year was that? 08:59:26</p> <p>20 A. 2007. 08:59:28</p> <p>21 Q. Have you ever worked in a full-time position 08:59:30</p> <p>22 at a pharmaceutical company? 08:59:35</p>
Page 55	<p>1 Q. And toward the bottom of that entry it says, 08:56:34</p> <p>2 "6 months (total) sabbatical leave." 08:56:38</p> <p>3 Do you see that? 08:56:40</p> <p>4 A. Yes. 08:56:41</p> <p>5 Q. Did you take six months of sabbatical leave 08:56:41</p> <p>6 from academia in 1993 to work in the Inhalation 08:56:44</p> <p>7 Research Group at Glaxo? 08:56:48</p> <p>8 A. Yes. 08:56:51</p> <p>9 Q. Aside from your six months of sabbatical 08:56:51</p> <p>10 leave from academia in 1993, have you ever worked at 08:56:53</p> <p>11 a pharmaceutical company? 08:56:57</p> <p>12 A. Yes. 08:56:58</p> <p>13 Q. When was that? 08:56:58</p> <p>14 A. I've worked -- well, while a student, in my 08:57:01</p> <p>15 summer vacations I've worked with Richardson and 08:57:06</p> <p>16 Vicks. I spent six months working as a 08:57:10</p> <p>17 pre-registration pharmacist in Richardson and Vicks, 08:57:15</p> <p>18 which is under my Previous Appointments, and I have 08:57:18</p> <p>19 spent time in industry consulting with industrial 08:57:22</p> <p>20 colleagues, running joint projects in my research 08:57:32</p> <p>21 laboratory, Ph.D. projects, post-doctoral projects. 08:57:36</p> <p>22 I have several students in my laboratory currently 08:57:42</p>	Page 57	<p>1 A. Explain full-time. 08:59:38</p> <p>2 Q. Well, you currently work in a full-time 08:59:51</p> <p>3 position at King's College, correct? 08:59:54</p> <p>4 A. Okay. No. They've always been fixed 08:59:56</p> <p>5 contracts. 08:59:58</p> <p>6 Q. Have you ever founded or co-founded a 09:00:00</p> <p>7 pharmaceutical services company? 09:00:02</p> <p>8 A. No. 09:00:04</p> <p>9 Q. Have you ever formulated an ophthalmic 09:00:05</p> <p>10 product at a pharmaceutical company? 09:00:09</p> <p>11 MR. MARGOLIS: Objection. Vague. 09:00:11</p> <p>12 THE WITNESS: That is vague. I have -- 09:00:14</p> <p>13 again, please define product. 09:00:23</p> <p>14 Q. Well, let me ask it this way. Were you ever 09:00:24</p> <p>15 responsible for formulating any ophthalmic product 09:00:27</p> <p>16 at a pharmaceutical company? 09:00:30</p> <p>17 MR. MARGOLIS: Objection. Vague. 09:00:32</p> <p>18 THE WITNESS: We worked on, when I was 09:00:35</p> <p>19 in GSK on my sabbatical, we also looked at 09:00:38</p> <p>20 using the same platform for ophthalmic 09:00:44</p> <p>21 preparations. 09:00:47</p> <p>22 Q. Have you ever formulated a marketed 09:00:47</p>

Page 58	Page 60
1 ophthalmic product -- 09:00:49	1 A. Yes. 09:02:55
2 A. No. 09:00:49	2 Q. Which grant did you receive for that? 09:02:56
3 Q. -- at a pharmaceutical company? 09:00:50	3 A. In the last ten years? Okay. So, the 09:02:58
4 A. No. 09:00:51	4 question was a non-ionic surfactant in a -- 09:03:04
5 Q. Take a look, if you would, at pages 9 through 09:00:52	5 Q. Pharmaceutical formulation? 09:03:08
6 10 of your CV. Let me direct your attention to the 09:00:57	6 A. -- pharmaceutical formulation? 09:03:09
7 section entitled Research Grants. 09:01:01	7 Q. Correct. 09:03:11
8 Do pages 9 through 10 of your curriculum 09:01:07	8 A. Okay. The novel microemulsion formulations. 09:03:12
9 vitae describe your research grants? 09:01:10	9 Q. That's the one for 17,000 pounds? 09:03:31
10 A. Not all of them, no. A selection. 09:01:11	10 A. Yes. The novel colloidal formulations, 09:03:34
11 Q. Okay. Which ones are not described here? 09:01:14	11 that's actually for more money, but we only get 09:03:38
12 A. Well, if you read the text, I have nothing 09:01:20	12 credited with the GSK side of the money. That's for 09:03:42
13 listed before, that started before 2005. And there 09:01:24	13 100,000. And there's been some other contracts and 09:03:45
14 will be some that are not listed if they are 09:01:30	14 there's been other projects. If you go to my -- let 09:03:49
15 confidential contracts as well. 09:01:32	15 me just find it -- current research students. 09:03:56
16 Q. Over the past ten years, what has been the 09:01:33	16 Q. What page is that? 09:04:03
17 focus of your scientific research? 09:01:36	17 A. Sorry. Page 11. 09:04:04
18 MR. MARGOLIS: Objection. Vague. 09:01:39	18 Q. Okay. 09:04:04
19 Q. You may answer. 09:01:41	19 A. And 12. 09:04:07
20 A. My focus of my scientific research has been 09:01:49	20 Q. Um-mm. 09:04:07
21 preparation of gene and drug delivery systems 09:01:53	21 A. And if you look at that one, two, three, four 09:04:08
22 intended for parenteral use in the correct way 09:01:58	22 of those students that are not on those grants you 09:04:13
Page 59	Page 61
1 formulations. That's the focus. 09:02:02	1 just mentioned are using novel or using surfactants 09:04:17
2 Q. Has your scientific research focused on 09:02:04	2 for formulations. 09:04:21
3 studying various systems or formulating drugs for 09:02:07	3 Q. Have you ever received a research grant for 09:04:23
4 administration? 09:02:10	4 the use of tyloxapol in a pharmaceutical 09:04:25
5 MR. MARGOLIS: Objection. Vague. 09:02:15	5 formulation? 09:04:28
6 THE WITNESS: Repeat the question? 09:02:19	6 MR. MARGOLIS: Objection. Vague. 09:04:30
7 Q. Sure. Has your scientific research focused 09:02:20	7 THE WITNESS: Tyloxapol -- you receive 09:04:33
8 on the studying of various systems or formulating 09:02:22	8 grants for looking at non-ionic surfactants, 09:04:39
9 drugs for administration? 09:02:27	9 of which tyloxapol is a standard non-ionic 09:04:43
10 MR. MARGOLIS: Objection. 09:02:29	10 surfactant to use under these circumstances. 09:04:46
11 THE WITNESS: They are all part in the 09:02:30	11 Q. Have you ever received a research grant 09:04:48
12 same thing. 09:02:32	12 specifically to use tyloxapol in a pharmaceutical 09:04:50
13 Q. Well, which does your research focus more? 09:02:32	13 formulation? 09:04:54
14 A. No. No. No. No. That's part of the same 09:02:35	14 A. You would not get a grant in the UK to use 09:04:54
15 story. 09:02:37	15 tyloxapol because that's not how the grant system 09:04:57
16 Q. How so? 09:02:37	16 works in the UK. But have I used tyloxapol in my 09:05:00
17 A. Because if you're looking at systems, you 09:02:38	17 research? Yes, extensively. 09:05:04
18 obviously might want to know if they're appropriate 09:02:41	18 Q. Have you ever received a research grant for 09:05:06
19 for drugs. So they go together hand-in-hand. 09:02:43	19 the use of EDTA in a pharmaceutical formulation? 09:05:08
20 Q. In the past ten years, have you received a 09:02:47	20 A. The same comment would stand, you don't get 09:05:13
21 research grant for the use of a non-ionic surfactant 09:02:50	21 grants in the UK for that type of thing. I have 09:05:21
22 in a pharmaceutical formulation? 09:02:54	22 used EDTA in a product. So to say no is 09:05:26

Page 62		Page 64	
1	meaningless. 09:05:31	1	A. Yes. 09:08:20
2	Q. Have you ever received a research grant for 09:05:32	2	Q. Have you published a book chapter since 2002 09:08:21
3	formulating a stable aqueous liquid preparation? 09:05:34	3	dealing with non-ionic surfactants? 09:08:25
4	MR. MARGOLIS: Objection. Vague. 09:05:39	4	MR. MARGOLIS: Objection. Vague. 09:08:28
5	THE WITNESS: Yes. 09:05:39	5	THE WITNESS: It is vague, but 17 09:08:31
6	Q. What research grant did you receive for 09:05:40	6	includes non-ionic surfactants. 09:08:34
7	formulating a stable aqueous liquid preparation? 09:05:42	7	Q. Have you published a book chapter since 2008 09:08:36
8	A. Okay. For example, the novel microemulsion 09:05:51	8	dealing with non-ionic surfactants? 09:08:40
9	formulations. 09:05:58	9	A. I would have to check my records. 09:08:43
10	Q. That is on page 10 of your CV? 09:05:59	10	Q. Have you ever published a book chapter 09:08:45
11	A. That's on page 10 of the CV. And I've had a 09:06:02	11	dealing with the use of tyloxapol in a 09:08:48
12	large number of grants from Pharma, sometimes 09:06:05	12	pharmaceutical formulation? 09:08:50
13	confidential, sometimes not, looking at formulating 09:06:13	13	MR. MARGOLIS: Objection. Vague. 09:08:52
14	aqueous surfactant solutions. I think it is, 09:06:18	14	THE WITNESS: I would have to go and 09:08:59
15	without doubt, I'm acknowledged as an expert in the 09:06:23	15	check some of the references whether it was 09:09:00
16	use of surfactants for formulation in aqueous 09:06:27	16	mentioned in there. 09:09:02
17	systems. 09:06:31	17	Q. Have you ever published a book chapter 09:09:03
18	Q. Take a look, if you would, at pages 19 09:06:32	18	dealing with the use of EDTA in a pharmaceutical 09:09:06
19	through 20 of your CV. 09:06:35	19	formulation? 09:09:09
20	A. Yes. 09:06:36	20	MR. MARGOLIS: Objection. Vague. 09:09:10
21	Q. And let me direct your attention to the 09:06:39	21	THE WITNESS: I would have to look at 09:09:12
22	section entitled Chapters in Books. 09:06:46	22	the contents to see if there was any mention 09:09:19
Page 63		Page 65	
1	Do you see that? 09:06:47	1	of it. 09:09:21
2	A. I do. 09:06:48	2	Q. Have you ever published a book chapter 09:09:21
3	Q. Do pages 19 through 20 of your curriculum 09:06:48	3	dealing with formulating a stable aqueous liquid 09:09:23
4	vitae list all of your published book chapters? 09:06:51	4	preparation? 09:09:26
5	A. I would say most, not all. 09:07:01	5	MR. MARGOLIS: Objection. Vague. 09:09:27
6	Q. Which one or ones is or are missing? 09:07:06	6	THE WITNESS: It is very vague, but all 09:09:29
7	A. If I am honest, book chapters are not highly 09:07:27	7	of those chapters I believe contain work on 09:09:39
8	rated in the British academic system, so my 09:07:31	8	formulating aqueous-based, if that is the 09:09:46
9	recordkeeping of that is less good than my 09:07:34	9	word, a phrase, aqueous continuous phase 09:09:52
10	recordkeeping of academic journals. I have 09:07:36	10	systems. 09:09:56
11	certainly got something recently about neutron 09:07:40	11	Q. All 17 of your book chapters -- 09:09:57
12	scattering. 09:07:49	12	A. I -- just -- I believe set 15 does include 09:09:59
13	Q. Take a look at item 17 on page 20. That was 09:07:51	13	some -- set 5 doesn't because it's microemulsions. 09:10:02
14	published in 2008, correct? 09:07:55	14	But everything else I believe -- so, 5 is not -- is 09:10:07
15	A. Yes. 09:07:57	15	triglycerides. 9 is triglycerides. 10 is 09:10:15
16	Q. Have you published a book chapter since 2008? 09:07:57	16	surfactants. 11 is surfactants. But everything 09:10:19
17	A. I really can't remember. As I explained, 09:08:05	17	else is formulation of systems that have, at least 09:10:22
18	they're not particularly well-rated in the British 09:08:08	18	as part of the chapter, aqueous continuous phase. 09:10:27
19	academic system. You don't get credit for those. 09:08:10	19	Q. Take a look at pages 20 through 28 of your 09:10:30
20	You get credit for full academic papers. So I 09:08:12	20	curriculum vitae, the section entitled Articles in 09:10:35
21	really have not kept good records. 09:08:16	21	Academic Journals. 09:10:40
22	Q. Take a look at item number 12, if you would. 09:08:17	22	Do you see that? 09:10:42

Page 66		Page 68	
1	A. Yes. 09:10:43	1	preparation? 09:13:57
2	Q. Do pages 20 through 28 of your curriculum vitae list all of your published articles in academic journals? 09:10:46	2	MR. MARGOLIS: Objection. Vague. 09:13:59
3	09:10:48	3	THE WITNESS: I am looking at formulating for pharmaceutical use, so a goal of all the work is to try and make something that is stable. However, it may not report the whole range of stability tests that you would need for pharmaceutical formulation. 09:14:05
4	09:10:48	4	09:14:07
5	A. I believe so, yes. 09:10:49	5	09:14:11
6	Q. Take a look, if you would, at item number 73. Have you published a journal article since 2008 dealing with non-ionic surfactants? 09:10:50	6	09:14:14
7	09:10:58	7	09:14:18
8	09:11:01	8	09:14:20
9	A. Yes. 09:11:04	9	Q. Take a look, if you would, at page 28 of your curriculum vitae. 09:14:26
10	Q. Which one? 09:11:05	10	09:14:33
11	A. 108. 09:11:31	11	A. Yes. 09:14:35
12	Q. Any others? 09:11:33	12	Q. Does page 28 of your curriculum vitae list your only two patent applications? 09:14:40
13	A. I'm just looking. 102 is the -- it's a strange one. That's -- that's almost a citation classic that one. 93, 89, 84, 83, 82 has got something in it, I believe. I would have to check, but I believe it has. And the vast majority of the other ones are either cationic surfactants or lipids which are lipid molecules which behave in an analogous way to lot of non-ionic surfactants. 09:11:35	13	09:14:42
14	09:11:43	14	A. It does. 09:14:44
15	09:11:48	15	Q. Did either of your two patent applications issue as a patent? 09:14:45
16	09:12:23	16	09:14:47
17	09:12:25	17	A. The second one, no. The first one was taken over by a pharmaceutical company because they funded the work and I don't know. 09:14:49
18	09:12:30	18	09:14:54
19	09:12:35	19	09:14:57
20	09:12:39	20	Q. Do either of your two patent applications deal with non-ionic surfactants -- 09:14:59
21	09:12:42	21	09:15:03
22	09:12:45	22	A. Both do. 09:15:05
Page 67		Page 69	
1	is your last publication dealing with non-ionic surfactants? 09:12:48	1	Q. Okay. Have you ever filed a patent application dealing with the use of tyloxapol in a pharmaceutical formulation? 09:15:06
2	09:12:51	2	09:15:07
3	MR. MARGOLIS: Objection. Vague. 09:12:59	3	09:15:10
4	THE WITNESS: No. There are others. 117 deals with non-ionic surfactants. And they are all -- all the papers are related to each other. They all deal with lipids -- all deal with amphiphilic molecules or polymers. 09:13:01	4	A. No. 09:15:14
5	09:13:10	5	Q. Have you ever filed a patent application dealing with the use of EDTA in a pharmaceutical formulation? 09:15:15
6	09:13:14	6	09:15:17
7	09:13:17	7	09:15:20
8	09:13:20	8	A. No. 09:15:21
9	Q. Have you ever published a journal article dealing with the use of tyloxapol in a pharmaceutical formulation? 09:13:23	9	Q. Have you ever filed a patent application dealing with formulating a stable aqueous liquid preparation? 09:15:22
10	09:13:26	10	09:15:24
11	09:13:28	11	09:15:28
12	A. No, because that's normally been confidential information for the company. 09:13:29	12	A. Interestingly, no. The second patent application was to make those particles unstable. 09:15:35
13	09:13:31	13	09:15:38
14	Q. Have you ever published a journal article dealing with the use of EDTA in a pharmaceutical formulation? 09:13:33	14	Q. I understand. 09:15:42
15	09:13:38	15	Take a look, if you would, back to your declaration. Let me direct your attention to page 2, paragraph 4. It says, "I have not testified in any case in the previous four years." 09:15:45
16	09:13:41	16	09:15:48
17	MR. MARGOLIS: Objection. Vague. 09:13:45	17	09:15:59
18	THE WITNESS: I would have to look at the references, but EDTA will be in some of those papers definitely. 09:13:47	18	09:16:07
19	09:13:48	19	Do you see that? 09:16:09
20	09:13:51	20	A. Yes. 09:16:10
21	Q. Have you ever published a journal article dealing with formulating a stable aqueous liquid 09:13:52	21	Q. When was the case in which you testified in the UK? 09:16:11
22	09:13:54	22	09:16:15

Page 70			Page 72		
1	A. That went to court 2006 and 2009.	09:16:17	1	Q. Did you provide opinions that the patent	09:18:34
2	Q. Have you testified as an expert in any case	09:16:22	2	should or should not be invalidated?	09:18:36
3	since 2009?	09:16:26	3	A. I said it shouldn't be invalidated.	09:18:39
4	A. I've been consulted as an expert, but none	09:16:29	4	Q. Should not? Why was it your opinion that the	09:18:42
5	have gone to court.	09:16:32	5	patent in that case should not be invalidated?	09:18:44
6	Q. Have you ever been qualified by a court as an	09:16:33	6	MR. MARGOLIS: Objection. Vague.	09:18:47
7	expert in any previous patent infringement case?	09:16:36	7	THE WITNESS: It was a very novel, very	09:18:50
8	A. I don't understand the question.	09:16:40	8	effective formulation.	09:18:54
9	Q. What don't you understand about it?	09:16:42	9	Q. Was it a formulation containing a non-ionic	09:18:56
10	A. I don't know how you get qualified as an	09:16:45	10	surfactant?	09:19:00
11	expert.	09:16:49	11	A. It was microemulsion formulation containing a	09:19:00
12	Q. So, do you understand that a court qualifies	09:16:50	12	non-ionic surfactant.	09:19:04
13	a particular --	09:16:53	13	Q. What was the active pharmaceutical ingredient	09:19:06
14	A. I have been an expert in a court case, yes.	09:16:53	14	in the formulation?	09:19:08
15	Q. In --	09:16:57	15	A. Cyclosporin.	09:19:08
16	A. As the main expert in those two -- in two	09:16:57	16	Q. What other excipients were in the	09:19:10
17	court cases.	09:16:59	17	formulation?	09:19:12
18	Q. Okay. In two court cases.	09:17:00	18	A. I would have to consult my notes. Sorry.	09:19:13
19	A. Novartis against Dexel, and Novartis against	09:17:02	19	Q. What non-ionic surfactant was in the	09:19:15
20	Ivax.	09:17:11	20	formulation?	09:19:20
21	Q. In those cases, in what field did the court	09:17:14	21	A. I'd have to consult my notes.	09:19:20
22	qualify you as an expert?	09:17:19	22	Q. Why was it your opinion in that case that the	09:19:22
Page 71			Page 73		
1	MR. MARGOLIS: Objection. Vague.	09:17:24	1	patent at issue was valid?	09:19:30
2	THE WITNESS: I was the main expert in	09:17:27	2	MR. MARGOLIS: Objection. Vague.	09:19:33
3	the case that was concerned with a novel	09:17:33	3	THE WITNESS: I was consulted as an	09:19:36
4	non-ionic surfactant-based microemulsion	09:17:38	4	expert in preparing microemulsions for	09:19:39
5	formulation.	09:17:41	5	pharmaceutical use, and the patent was	09:19:45
6	Q. And what were your opinions, generally	09:17:42	6	concerned with a microemulsion formulation.	09:19:51
7	speaking, in that case?	09:17:43	7	So I was very expert in the area -- I was	09:19:58
8	MR. MARGOLIS: Objection. Vague.	09:17:49	8	able to make a judgment, and the patent was	09:20:01
9	THE WITNESS: What do you mean opinions?	09:17:50	9	upheld.	09:20:04
10	Q. Well, what opinions did you provide in that	09:17:52	10	Q. Why was it your opinion in that case that the	09:20:05
11	case to the court?	09:17:54	11	patent dealing with a pharmaceutical formulation	09:20:08
12	MR. MARGOLIS: Objection. Vague.	09:17:56	12	containing a non-ionic surfactant was valid?	09:20:13
13	THE WITNESS: I was the main expert	09:17:58	13	A. It was the first time anybody had prepared a	09:20:18
14	talking about -- it was a patent formulation,	09:18:01	14	microemulsion formulation to deliver a drug and it	09:20:25
15	a formulation -- yes, a patent -- a	09:18:06	15	showed distinct improvements over the existing	09:20:31
16	formulation patent, and I was the sole expert	09:18:09	16	formulation.	09:20:39
17	in the first case to defend -- well, it's an	09:18:14	17	Q. What type of distinct improvements?	09:20:40
18	infringement case, and the defendees came	09:18:18	18	A. Reproducibility of dose and total	09:20:45
19	back and tried to invalidate the patent. So	09:18:24	19	bioavailability, ease of use for the patients.	09:20:51
20	I was the expert for that. So, I dealt with	09:18:27	20	Q. Anything else?	09:20:57
21	the whole of the -- the opinions on the whole	09:18:30	21	A. Probably, but I can't remember.	09:20:58
22	of the patent.	09:18:34	22	Q. Take a look, if you would, at paragraph 6 of	09:21:04

Page 74		Page 76	
1	your declaration.	09:21:08	
2	A. Yes.	09:21:10	
3	Q. And in the second sentence you use the phrase	09:21:10	
4	"physic-chemical characterization" -- sorry. Are	09:21:15	
5	you there?	09:21:19	
6	A. Yes.	09:21:19	
7	Q. Okay. You use the phrase "physic-chemical	09:21:19	
8	characterization of novel, non-ionic surfactants."	09:21:24	
9	Do you see that?	09:21:26	
10	A. Yes.	09:21:26	
11	Q. What do you mean by "physic-chemical	09:21:27	
12	characterization"?	09:21:29	
13	A. Well, there should be an O after the C, but	09:21:30	
14	using standard physicochemical techniques, light	09:21:34	
15	scattering, viscosity, surface tension, behavior,	09:21:38	
16	characterization of the surfactants. Yep.	09:21:44	
17	Q. And you use the term novel non-ionic	09:21:51	
18	surfactants.	09:21:55	
19	Do you see that?	09:21:56	
20	A. Yes. I synthesis them.	09:21:56	
21	Q. What is a novel non-ionic surfactant?	09:21:58	
22	A. I designed and synthesized the surfactant.	09:22:00	
Page 75		Page 77	
1	Q. How many different non-ionic surfactants are	09:22:03	
2	known to exist?	09:22:06	
3	A. Sorry. As many as you want in your brain.	09:22:09	
4	Q. You used the term "physic" and you meant to	09:22:15	
5	say physicochemical --	09:22:21	
6	A. Yes.	09:22:21	
7	Q. -- characterization, correct?	09:22:21	
8	A. Yes.	09:22:22	
9	Q. What are some of the different physical and	09:22:23	
10	chemical properties that different non-ionic	09:22:25	
11	surfactants possess?	09:22:27	
12	A. It would depend in what state you were	09:22:31	
13	looking at them, whether you were looking at, the	09:22:37	
14	surfactant on its own, the surfactant with oil and	09:22:41	
15	water, et cetera.	09:22:45	
16	Q. Let me -- let me rephrase the question then.	09:22:46	
17	What are some of the different physical and chemical	09:22:53	
18	properties that different non-ionic surfactants	09:22:55	
19	possess in aqueous liquid preparations?	09:22:59	
20	MR. MARGOLIS: Objection. Vague.	09:23:05	
21	THE WITNESS: That would depend upon the	09:23:07	
22	structure of the surfactant you were looking	09:23:09	
1	at.	09:23:12	
2	Q. How would it depend on the structure of the	09:23:12	
3	surfactant?	09:23:15	
4	A. It would depend upon what the hydrophobic	09:23:22	
5	moiety was. It would depend upon what the head	09:23:30	
6	group was, for example.	09:23:35	
7	Q. Anything else?	09:23:37	
8	A. The way in which, the concentration in which	09:23:42	
9	it was present and its state of dispersal.	09:23:46	
10	Q. Anything else?	09:23:51	
11	A. pH, temperature, presence of excipients,	09:23:55	
12	other excipients, presence of salts.	09:24:05	
13	Q. Anything else?	09:24:10	
14	A. I can't think of all the ones I've	09:24:15	
15	listed already. Presence of -- if you're using as a	09:24:17	
16	formulation, presence of drug.	09:24:22	
17	Q. Anything else?	09:24:27	
18	A. I think I might have listed excipients, pH,	09:24:35	
19	temperature, electrolytes, drug, concentration --	09:24:39	
20	they're the main ones.	09:24:48	
21	Q. Why do different non-ionic surfactants have	09:24:49	
22	different chemical and physical properties?	09:24:53	
1	MR. MARGOLIS: Objection. Vague.	09:24:56	
2	Compound. Lack of foundation.	09:24:59	
3	Q. You may answer.	09:25:02	
4	A. Because the structure of the surfactants can	09:25:06	
5	vary, so the balance between the hydrophobic and the	09:25:14	
6	hydrophilic can vary.	09:25:20	
7	Q. Can the physical and chemical properties of a	09:25:20	
8	non-ionic surfactant be predicted from the physical	09:25:22	
9	and chemical properties of a different non-ionic	09:25:26	
10	surfactant with a different chemical structure?	09:25:30	
11	MR. MARGOLIS: Objection. Vague.	09:25:33	
12	THE WITNESS: That's very vague. The	09:25:34	
13	best answer I can give you is in a	09:25:37	
14	structurally related series or a closely	09:25:41	
15	related series of molecules. You can have a	09:25:44	
16	good estimate, yes.	09:25:52	
17	Q. Have you ever accurately predicted the	09:25:54	
18	physical and chemical properties of a non-ionic	09:25:57	
19	surfactant based on the physical and chemical	09:25:59	
20	properties of a different non-ionic surfactant with	09:26:02	
21	a different chemical structure?	09:26:05	
22	MR. MARGOLIS: Objection. Vague.	09:26:07	

Page 78		Page 80		
1	THE WITNESS: That's vague. I'm unclear	09:26:09	1 expect the same amount of two different non-ionic	09:29:13
2	when you say accurately what you mean, what	09:26:23	2 surfactants having different chemical structures to	09:29:18
3	level of accuracy you're talking about?	09:26:28	3 have the same stabilizing effect or different	09:29:21
4	Q. Have you ever with any level of accuracy	09:26:32	4 stabilizing effects in an aqueous liquid preparation	09:29:24
5	predicted the physical and chemical properties of a	09:26:34	5 of a nonsteroidal anti-inflammatory drug?	09:29:27
6	non-ionic surfactant based on the physical and	09:26:37	6 MR. MARGOLIS: Objection. Vague.	09:29:31
7	chemical properties of a different non-ionic	09:26:40	7 THE WITNESS: You couldn't -- I couldn't	09:29:32
8	surfactant with a different chemical structure?	09:26:43	8 answer that on the vagueness of the question.	09:29:34
9	MR. MARGOLIS: Objection. Vague.	09:26:47	9 You would have to do tests under those	09:29:38
10	Compound.	09:26:48	10 circumstances.	09:29:41
11	THE WITNESS: A different	09:26:48	11 Q. Take a look, if you would, at page 3 of your	09:29:42
12	chemical structure. I explained that if	09:26:51	12 declaration.	09:29:47
13	there is, for example, a relationship between	09:26:53	13 MR. HASFORD: Oh, you know what? That	09:29:49
14	the head group used and -- yes, you can	09:26:59	14 might actually be a good time for a break	09:29:50
15	predict with reasonable accuracy.	09:27:04	15 because we need to do a tape change.	09:29:53
16	Q. Have you ever done that?	09:27:07	16 THE VIDEOGRAPHER: The time is	09:29:57
17	A. Yes.	09:27:09	17 approximately 9:31 a.m., Friday, September 4,	09:29:59
18	Q. Did you publish your findings?	09:27:09	18 2015. This is the end of tape number one of	09:30:09
19	A. I don't know. I would have to -- sorry. I	09:27:13	19 the videotaped deposition of Dr. Jayne	09:30:12
20	would have to look. I don't know.	09:27:16	20 Lawrence. We are off the record.	09:30:15
21	No. I have got students in laboratory doing	09:27:58	21 (Recess from 9:31 to 9:46.)	09:30:18
22	that at the moment.	09:28:00	22 THE VIDEOGRAPHER: The time is	09:45:18
Page 79		Page 81		
1	Q. Is it fair to say that the physical and	09:28:01	1 approximately 9:46 a.m., Friday, September 4,	09:45:33
2	chemical properties of a non-ionic surfactant cannot	09:28:05	2 2015. This is tape number two of the	09:45:45
3	be predicted from the physical and chemical	09:28:08	3 videotaped deposition of Dr. Jayne Lawrence.	09:45:48
4	properties of a different non-ionic surfactant with	09:28:10	4 We are back on the record.	09:45:50
5	a different chemical structure?	09:28:13	5 BY MR. HASFORD:	09:45:52
6	MR. MARGOLIS: Objection. Vague.	09:28:16	6 Q. Doctor, could you please turn to page 3,	09:45:52
7	Compound.	09:28:18	7 paragraph 10 of your declaration, and take a look at	09:45:55
8	THE WITNESS: Yes. It depends how	09:28:18	8 the second sentence, if you would.	09:46:00
9	different they were.	09:28:21	9 And do you see where it says, "Novel,	09:46:05
10	Q. How does it depend how different they are?	09:28:22	10 non-ionic and zwitterionic surfactants"?	09:46:09
11	A. Again, that's very vague. There is quite a	09:28:26	11 A. Oh, yes.	09:46:11
12	lot of understanding available, for example, in the	09:28:30	12 Q. What novel non-ionic surfactants have you	09:46:13
13	literature about the relationship between the	09:28:33	13 synthesized and characterized?	09:46:17
14	hydrophobic chain and the relationship if it -- the	09:28:38	14 A. Quite a few. Some of them -- do you want me	09:46:27
15	non-ionic, if it's a -- yeah, if it's a -- if it's a	09:28:44	15 to describe them or --	09:46:32
16	straight chain, or a single chain I should say,	09:28:49	16 Q. Sure. Please.	09:46:33
17	hydrophobic group -- actually, there's quite a lot	09:28:53	17 A. Some of them have different head groups, not	09:46:35
18	of information about the effect of the head group,	09:28:59	18 having polyethylene oxide head groups that have	09:46:39
19	and the head group often dominates. So it would	09:29:02	19 alternative polymers. Some have been used for	09:46:44
20	really depend on the structure how differently in	09:29:07	20 production of vesicles. They've got two chains.	09:46:49
21	order to be able to say that.	09:29:09	21 Some have been used to solubilize drug in micelles.	09:47:00
22	Q. Would a person of ordinary skill in the art	09:29:11	22 Q. How have you characterized the physical and	09:47:07

Page 82	<p>1 chemical properties of the new non-ionic surfactants 09:47:09</p> <p>2 that you've synthesized? 09:47:13</p> <p>3 MR. MARGOLIS: Objection. Vague. Lacks 09:47:16</p> <p>4 foundation. 09:47:21</p> <p>5 THE WITNESS: Well, the first -- the 09:47:25</p> <p>6 first thing to say is how you characterize 09:47:29</p> <p>7 them is partially dependent upon what they 09:47:32</p> <p>8 are going to be used for. So that would 09:47:36</p> <p>9 vary. Micelle-forming surfactants we'd 09:47:42</p> <p>10 characterize analytically the surfactants, 09:47:46</p> <p>11 checking it's the structure we think it is. 09:47:50</p> <p>12 We would then typically put it through a 09:47:54</p> <p>13 whole battery of studies, looking at surface 09:47:58</p> <p>14 tension, viscosity, aggregation using light 09:48:04</p> <p>15 and neutron scattering, solubilization 09:48:10</p> <p>16 capacity, and then further studies depending 09:48:15</p> <p>17 on how they're going to -- how you're going 09:48:18</p> <p>18 to use them. 09:48:22</p> <p>19 Q. How do the physical and chemical properties 09:48:24</p> <p>20 of the new non-ionic surfactants you have 09:48:27</p> <p>21 synthesized differ from the physical and chemical 09:48:31</p> <p>22 properties of other non-ionic surfactants in the 09:48:34</p>	Page 84	<p>1 depends in what way you mean complex. 09:49:56</p> <p>2 Q. How do you view it? 09:49:59</p> <p>3 MR. MARGOLIS: Objection. Vague. 09:50:04</p> <p>4 THE WITNESS: We have been concerned 09:50:08</p> <p>5 with trying to design surfactants with 09:50:10</p> <p>6 improved properties for particular uses. 09:50:13</p> <p>7 It's not that complicated because we 09:50:20</p> <p>8 rationally design them. So, by understanding 09:50:22</p> <p>9 rules, we've managed to design them. 09:50:26</p> <p>10 Q. Why would a person of ordinary skill in the 09:50:29</p> <p>11 art want to synthesize a new non-ionic surfactant? 09:50:32</p> <p>12 A. It didn't say that they would. 09:50:37</p> <p>13 MR. MARGOLIS: Objection. Calls for 09:50:37</p> <p>14 speculation. 09:50:39</p> <p>15 THE COURT REPORTER: I didn't get your 09:50:39</p> <p>16 answer. 09:50:39</p> <p>17 THE WITNESS: No, I don't -- I don't -- 09:50:43</p> <p>18 I'm unsure why somebody ordinary skilled in 09:50:50</p> <p>19 the art would necessarily want to do what I 09:50:56</p> <p>20 have been doing, designing new surfactants. 09:51:00</p> <p>21 Q. Well, let me ask it this way. Under what 09:51:03</p> <p>22 circumstances would a person of ordinary skill in 09:51:05</p>
Page 83	<p>1 art? 09:48:39</p> <p>2 MR. MARGOLIS: Objection. Vague. Lack 09:48:39</p> <p>3 of foundation. 09:48:42</p> <p>4 THE WITNESS: It's quite a complicated 09:48:44</p> <p>5 story, if you want me to tell you the story? 09:48:46</p> <p>6 Q. Please do. 09:48:48</p> <p>7 A. One way to improve drug solubilization would 09:48:51</p> <p>8 be to make larger micelles. In brief, the 09:49:01</p> <p>9 non-ionic -- the PEG head group is not good at 09:49:09</p> <p>10 making huge -- I'm talking about very large micelles 09:49:14</p> <p>11 here. These are not things that are commercially 09:49:18</p> <p>12 available. And that's because PEG mixes with a 09:49:21</p> <p>13 hydrocarbon chain and destroys the capacity of 09:49:25</p> <p>14 micelle to solubilize the drug. We use a different 09:49:29</p> <p>15 polymer to overcome that property. So we have 09:49:33</p> <p>16 rationally designed. I could go on and give you 09:49:35</p> <p>17 other examples, but it's a rationale design of the 09:49:38</p> <p>18 surfactant for a particular purpose. 09:49:41</p> <p>19 Q. Is it fair to say that this is a complex 09:49:43</p> <p>20 field? 09:49:45</p> <p>21 MR. MARGOLIS: Objection. Vague. 09:49:46</p> <p>22 THE WITNESS: It depends how -- it 09:49:51</p>	Page 85	<p>1 the art want to synthesize a new non-ionic 09:51:07</p> <p>2 surfactant? 09:51:11</p> <p>3 A. Again -- 09:51:21</p> <p>4 MR. MARGOLIS: Objection. Lack of 09:51:21</p> <p>5 foundation. 09:51:22</p> <p>6 THE WITNESS: That's vague. A vague 09:51:22</p> <p>7 answer would be if there isn't a surfactant 09:51:26</p> <p>8 available to do what they want. 09:51:29</p> <p>9 Q. Why would a person of ordinary skill in the 09:51:31</p> <p>10 art want to characterize the physical and chemical 09:51:34</p> <p>11 properties of a new non-ionic surfactant that he or 09:51:37</p> <p>12 she has synthesized? 09:51:41</p> <p>13 MR. MARGOLIS: Objection. Lack of 09:51:43</p> <p>14 foundation. Vague. 09:51:45</p> <p>15 THE WITNESS: Anybody receiving a novel 09:51:56</p> <p>16 excipient for use in formulation would want 09:51:58</p> <p>17 to understand the properties. So they would 09:52:02</p> <p>18 do some basic characterization that was 09:52:06</p> <p>19 appropriate for their use. 09:52:08</p> <p>20 Q. What characterization would they do? 09:52:11</p> <p>21 A. Again, that would be dependent on how they 09:52:14</p> <p>22 wanted to use the surfactant. 09:52:17</p>

Page 86	<p>1 Q. What if they wanted to use it in a stable 09:52:21 2 aqueous liquid preparation, what characterization 09:52:24 3 would they do? 09:52:26 4 MR. MARGOLIS: Objection. Vague. 09:52:28 5 THE WITNESS: There's a plethora of 09:52:29 6 stable -- of surfactants in water. So it 09:52:32 7 would depend upon the aggregation state, the 09:52:38 8 formulation state. 09:52:42 9 Q. What else would it depend on? 09:52:44 10 A. The tests the person would do with any 09:52:49 11 unfamiliar or novel excipients, or non-ionic 09:52:56 12 surfactant here, would depend on their ultimate use. 09:53:00 13 Q. How so? 09:53:07 14 A. If you wanted to make a water continuous 09:53:09 15 semi-solid formulation would be characterized using 09:53:22 16 rheology, for example. If you were using it -- if 09:53:33 17 you wanted to inject your aqueous formulation, you 09:53:42 18 would want it to be low viscosity. You would use 09:53:46 19 viscometric techniques. So, it's impossible to say 09:53:50 20 unless you are much more specific. 09:53:54 21 Q. What if a person of ordinary skill in the art 09:53:57 22 wanted to formulate a stable aqueous liquid 09:54:00</p>	Page 88	<p>1 MR. MARGOLIS: Objection. Vague. 09:55:25 2 THE WITNESS: There's a lot of 09:55:29 3 conditions you would have to put on to that 09:55:31 4 statement. So, could somebody who is 09:55:34 5 ordinary skilled in the art with the same 09:55:44 6 formulation but just different amounts of 09:55:46 7 surfactant be able to form a stability -- an 09:55:49 8 assessment on stability? 09:55:53 9 Q. A different type of surfactant. So let me 09:55:54 10 ask it -- 09:55:56 11 A. Yes. 09:55:56 12 Q. -- again just to be clear. 09:55:57 13 A. Yeah. No. In hypothetical, yes, of course. 09:55:57 14 Q. Could a person of ordinary skill in the art 09:56:00 15 conduct an experiment comparing the stability of two 09:56:02 16 different aqueous liquid preparations with identical 09:56:05 17 compositions where only the amount of surfactant was 09:56:09 18 varied? 09:56:13 19 MR. MARGOLIS: Objection. Vague. 09:56:15 20 THE WITNESS: Hypothetically, yes. 09:56:19 21 Q. Take a look, if you would, at page 4 of your 09:56:23 22 declaration, paragraph 12. 09:56:27</p>
Page 87	<p>1 preparation for ophthalmic use, how would that 09:54:04 2 person characterize the physical and chemical 09:54:09 3 properties of the formulation? 09:54:11 4 MR. MARGOLIS: Objection. Vague. Lacks 09:54:14 5 foundation. Calls for speculation. 09:54:15 6 THE WITNESS: It would depend upon the 09:54:21 7 drug you're using and the drug dose, and that 09:54:24 8 may determine the formulation type you would 09:54:28 9 prepare. 09:54:32 10 Q. Could a person of ordinary skill in the art 09:54:32 11 conduct an experiment comparing the stability of two 09:54:54 12 different aqueous liquid preparations with identical 09:54:58 13 compositions where only the type of surfactant is 09:55:01 14 varied? 09:55:04 15 MR. MARGOLIS: Objection. Vague. 09:55:09 16 THE WITNESS: Can you repeat the 09:55:10 17 question? 09:55:11 18 Q. Certainly. Could a person of ordinary skill 09:55:12 19 in the art conduct an experiment comparing the 09:55:13 20 stability of two different aqueous liquid 09:55:16 21 preparations with identical compositions where only 09:55:19 22 the type of surfactant is varied? 09:55:22</p>	Page 89	<p>1 A. Yes. 09:56:31 2 Q. And in the first sentence it says, "As listed 09:56:32 3 in my curriculum vitae, I have also received 09:56:36 4 numerous awards pertaining to my research and 09:56:38 5 teaching." 09:56:41 6 Do you see that? 09:56:41 7 A. Yes. 09:56:42 8 Q. Do you currently teach pharmaceuticals classes 09:56:42 9 at King's College? 09:56:45 10 A. I teach some pharmaceuticals, yes. 09:56:46 11 Q. Have you ever taught your students that the 09:56:48 12 phrases EDTA sodium salt and sodium edetate are 09:56:50 13 limited to the tetrasodium salt of EDTA? 09:56:55 14 A. I don't recall. 09:57:02 15 Q. Have you ever taught your students the term 09:57:03 16 stable in the context of pharmaceutical formulations 09:57:06 17 is indefinite? 09:57:08 18 A. I have told them -- I have -- I lecture on 09:57:11 19 stability, so I explain to my students what 09:57:16 20 stability is and the need to define stability. 09:57:20 21 Q. Have you ever actually taught your students 09:57:22 22 the term stable in the context of pharmaceutical 09:57:25</p>

Page 90	<p>1 formulations as indefinite? 09:57:28</p> <p>2 A. No. I haven't used the word indefinite, no. 09:57:30</p> <p>3 Q. Take a look, if you would, at your 09:57:35</p> <p>4 declaration back at page 1, paragraph 2. And it 09:57:37</p> <p>5 says, "I have been asked to provide my opinion on 09:57:46</p> <p>6 the meaning of several claim terms in U.S. Patents," 09:57:48</p> <p>7 and then you list the patents-in-suit. 09:57:53</p> <p>8 Do you see that? 09:57:55</p> <p>9 A. Yes. 09:57:55</p> <p>10 Q. Let me just go through each of them, if 09:57:56</p> <p>11 that's okay with you. Did you review U.S. Patent 09:58:01</p> <p>12 No. 8,129,431 in connection with your declaration in 09:58:04</p> <p>13 this case? 09:58:08</p> <p>14 A. I did. 09:58:08</p> <p>15 Q. If I refer to U.S. Patent No. 8,129,431 as 09:58:09</p> <p>16 the '431 patent, will you understand what I mean? 09:58:13</p> <p>17 A. Yes. 09:58:16</p> <p>18 Q. Did you also review U.S. Patent No. 8,669,290 09:58:16</p> <p>19 in connection with your declaration in this case? 09:58:21</p> <p>20 A. I did. 09:58:23</p> <p>21 Q. If I refer to U.S. Patent No. 8,669,290 as 09:58:24</p> <p>22 the '290 patent, will you understand what I mean? 09:58:29</p>	Page 92	<p>1 will you understand what I mean? 09:59:36</p> <p>2 A. Yes. 09:59:37</p> <p>3 Q. Did you review the patents-in-suit in 09:59:38</p> <p>4 connection with your opinions in this case? 09:59:40</p> <p>5 A. I did. 09:59:42</p> <p>6 Q. And you state in paragraph 2 that you have 09:59:43</p> <p>7 been asked to provide your opinion on the meaning of 09:59:45</p> <p>8 several claim terms in the patents-in-suit. 09:59:48</p> <p>9 Do you see that? 09:59:50</p> <p>10 A. Yes. 09:59:51</p> <p>11 Q. Did you consider the entirety of the claims 09:59:51</p> <p>12 of the patents-in-suit or did you focus on certain 09:59:54</p> <p>13 terms? 09:59:57</p> <p>14 MR. MARGOLIS: Objection. Vague. 09:59:58</p> <p>15 THE WITNESS: I read -- when I was 10:00:06</p> <p>16 preparing this document, I read the whole 10:00:08</p> <p>17 patents very carefully -- all the patents 10:00:12</p> <p>18 very carefully, but -- 10:00:15</p> <p>19 Q. And my question -- 10:00:16</p> <p>20 A. -- I took it in whole. 10:00:16</p> <p>21 Q. Okay. My question is slightly different. 10:00:18</p> <p>22 Did you consider the entirety of the claims 10:00:20</p>
Page 91	<p>1 A. Yes. 09:58:32</p> <p>2 Q. Did you also review U.S. Patent No. 8,754,131 09:58:32</p> <p>3 in connection with your declaration in this case? 09:58:38</p> <p>4 A. I did. 09:58:40</p> <p>5 Q. If I refer to U.S. Patent No. 8,754,131 as 09:58:41</p> <p>6 the '131 patent, will you understand what I mean? 09:58:46</p> <p>7 A. Yes. 09:58:49</p> <p>8 Q. Did you also review U.S. Patent No. 8,871,813 09:58:50</p> <p>9 in connection with your declaration in this case? 09:58:55</p> <p>10 A. I did. 09:58:57</p> <p>11 Q. If I refer to U.S. Patent No. 8,871,813 as 09:58:58</p> <p>12 the '813 patent, will you understand what I mean? 09:59:03</p> <p>13 A. Yes. 09:59:07</p> <p>14 Q. And did you also review U.S. Patent No. 09:59:07</p> <p>15 8,927,606 in connection with your declaration in 09:59:09</p> <p>16 this case? 09:59:14</p> <p>17 A. I did. 09:59:15</p> <p>18 Q. If I refer to U.S. Patent No. 8,927,606 as 09:59:15</p> <p>19 the '606 patent, will you understand what I mean? 09:59:21</p> <p>20 A. Yes. 09:59:24</p> <p>21 Q. If I refer to the '431, '290, '131, '813 and 09:59:25</p> <p>22 '606 patents collectively as the patents-in-suit, 09:59:32</p>	Page 93	<p>1 of the patents-in-suit or did you focus on certain 10:00:22</p> <p>2 terms in those claims? 10:00:24</p> <p>3 MR. MARGOLIS: Objection. Asked and 10:00:27</p> <p>4 answered. 10:00:28</p> <p>5 Q. You may answer. 10:00:29</p> <p>6 A. Can you repeat the specific wording of the 10:00:33</p> <p>7 question you asked me? 10:00:36</p> <p>8 Q. Certainly. Did you consider the entirety of 10:00:37</p> <p>9 the claims of the patents-in-suit or did you focus 10:00:39</p> <p>10 on certain terms in the claims? 10:00:43</p> <p>11 A. Okay. 10:00:45</p> <p>12 MR. MARGOLIS: Objection. Vague. 10:00:47</p> <p>13 THE WITNESS: Perhaps you can explain 10:00:48</p> <p>14 what you mean by the entirety of the claims? 10:00:52</p> <p>15 Q. Do you understand what the claims of the 10:00:55</p> <p>16 patents-in-suit are? 10:00:56</p> <p>17 A. Yes. 10:00:58</p> <p>18 Q. Okay. Did you consider the entirety of the 10:00:58</p> <p>19 claims of the patents-in-suit or did you focus on 10:01:01</p> <p>20 certain terms in those claims? 10:01:04</p> <p>21 MR. MARGOLIS: Objection. Vague. 10:01:06</p> <p>22 THE WITNESS: I'm assuming entirety is 10:01:09</p>

Page 94	<p>1 not a legal word in this context? No? Is 10:01:12</p> <p>2 it? 10:01:16</p> <p>3 Q. I'm not using any particular legal meaning. 10:01:16</p> <p>4 A. No. So, did I -- 10:01:19</p> <p>5 Q. Let me just -- 10:01:22</p> <p>6 A. I read the whole -- I considered the whole 10:01:23</p> <p>7 patent, all the patents, the whole -- all the 10:01:26</p> <p>8 claims, yes. 10:01:29</p> <p>9 Q. Okay. Did you focus on certain terms in 10:01:29</p> <p>10 those claims? 10:01:31</p> <p>11 MR. MARGOLIS: Objection. Vague. 10:01:33</p> <p>12 THE WITNESS: My report focuses on 10:01:38</p> <p>13 several terms, but they were made in 10:01:40</p> <p>14 relationship to reading the whole entirety of 10:01:44</p> <p>15 the patent. 10:01:47</p> <p>16 Q. In your opinion, would a person with a Ph.D. 10:01:48</p> <p>17 and several years of experience in pharmaceutical 10:01:53</p> <p>18 sciences be considered an expert in the field of the 10:01:55</p> <p>19 patents-in-suit? 10:01:58</p> <p>20 A. I believe I have defined that as somebody -- 10:02:00</p> <p>21 just let me turn to the -- as somebody of ordinary 10:02:05</p> <p>22 skill. 10:02:09</p>	Page 96	<p>1 engineering in this country is more related to what 10:03:16</p> <p>2 I would term industrial pharmacy. 10:03:21</p> <p>3 Is that your understanding before I answer? 10:03:25</p> <p>4 Q. Well, so, I'm asking based on your 10:03:28</p> <p>5 understanding, but I will ask the question both ways 10:03:30</p> <p>6 just to be clear. 10:03:32</p> <p>7 Do the patents-in-suit relate to chemical 10:03:33</p> <p>8 engineering as you use the term? 10:03:35</p> <p>9 A. No. 10:03:36</p> <p>10 MR. MARGOLIS: Objection. Objection. 10:03:37</p> <p>11 Vague. 10:03:39</p> <p>12 Q. Do the patents-in-suit relate to gene 10:03:39</p> <p>13 formulation? 10:03:43</p> <p>14 A. No. 10:03:46</p> <p>15 Q. Take a look, if you would, at page 8 of your 10:03:47</p> <p>16 declaration. Skip ahead a bit, and I want to direct 10:03:55</p> <p>17 your attention to footnote 2. Just read that to 10:03:58</p> <p>18 yourself and let me know when you're ready. 10:04:04</p> <p>19 A. Okay. 10:04:18</p> <p>20 Q. Is it your understanding that the 10:04:18</p> <p>21 patents-in-suit all have essentially the same 10:04:20</p> <p>22 specification? 10:04:22</p>
Page 95	<p>1 Q. Would you consider that person an expert in 10:02:09</p> <p>2 the field of the patents-in-suit? 10:02:11</p> <p>3 MR. MARGOLIS: Objection. Vague. 10:02:13</p> <p>4 THE WITNESS: Unlikely. 10:02:23</p> <p>5 Q. Do the patents-in-suit relate to gene 10:02:25</p> <p>6 delivery? 10:02:28</p> <p>7 A. No. 10:02:30</p> <p>8 Q. Do the patents-in-suit relate to gene 10:02:30</p> <p>9 formulation? 10:02:33</p> <p>10 A. They have learnings that would be useful for 10:02:42</p> <p>11 gene delivery. 10:02:47</p> <p>12 Q. Do the patents-in-suit relate to chemical 10:02:47</p> <p>13 engineering? 10:02:50</p> <p>14 MR. MARGOLIS: Objection. Vague. 10:02:52</p> <p>15 THE WITNESS: I have probably a 10:02:54</p> <p>16 different definition of chemical engineering 10:02:56</p> <p>17 than you. 10:02:58</p> <p>18 Q. What is your definition? 10:02:59</p> <p>19 A. The British definition. 10:03:00</p> <p>20 Q. Okay. Please. 10:03:02</p> <p>21 A. Which is much more focused on engineering in 10:03:03</p> <p>22 a sort of industrial context. I understand chemical 10:03:10</p>	Page 97	<p>1 A. They have very similar claims, yes. 10:04:28</p> <p>2 Q. And so that -- my question is slightly 10:04:31</p> <p>3 different. I want to focus on the specification as 10:04:34</p> <p>4 opposed to the claims. 10:04:36</p> <p>5 Is it your understanding that the 10:04:37</p> <p>6 patents-in-suit all have essentially the same 10:04:38</p> <p>7 specification? 10:04:41</p> <p>8 A. Broadly, yes. 10:04:45</p> <p>9 Q. Turn, if you would, to the '606 patent. It's 10:04:47</p> <p>10 going to be I believe Exhibit 16 to your 10:04:51</p> <p>11 declaration. 10:04:56</p> <p>12 A. There are obviously some differences between 10:04:58</p> <p>13 the patents, which is what I say there. 10:05:00</p> <p>14 Q. Take a look, if you would, at column 11, 10:05:06</p> <p>15 claim 1 of the '606 patent. 10:05:11</p> <p>16 Did you consider claim 1 of the '606 patent 10:05:22</p> <p>17 in connection with your opinions in this case? 10:05:25</p> <p>18 MR. MARGOLIS: Objection. Vague. 10:05:27</p> <p>19 THE WITNESS: As far as I understand 10:05:43</p> <p>20 what you mean by consider, yes. 10:05:45</p> <p>21 Q. How would a person of ordinary skill in the 10:05:46</p> <p>22 art carry out the method of claim 1 of the '606 10:05:48</p>

Page 98			Page 100		
1	patent?	10:05:52	1	Q. What other information do you think they	10:08:50
2	MR. MARGOLIS: Objection. Vague.	10:05:56	2	would need?	10:08:53
3	THE WITNESS: It's vague. There really	10:05:56	3	A. They would need to know the range of	10:08:55
4	isn't a method.	10:05:59	4	materials of the ingredients that they could be	10:09:03
5	Q. Please turn now to the '431 patent, if you	10:06:01	5	used. They ideally should be told whether there's	10:09:09
6	would?	10:06:24	6	any specific order of mixing of the materials. This	10:09:14
7	A. Yes.	10:06:24	7	also includes no water, as far as I can see, but	10:09:27
8	Q. And let me direct your attention to column 13	10:06:25	8	it's supposed to be an aqueous formulation. They	10:09:32
9	and in particular claim 18. Did you consider claim	10:06:29	9	couldn't make it just on that information alone.	10:09:38
10	18 of the '431 patent in connection with your	10:06:34	10	Q. How would a person of ordinary skill in the	10:09:41
11	opinions in this case?	10:06:38	11	art use the aqueous liquid preparation of claim 18	10:09:43
12	MR. MARGOLIS: Objection. Vague.	10:06:42	12	of the '431 patent?	10:09:46
13	THE WITNESS: I will say again, as far	10:06:45	13	MR. MARGOLIS: Objection. Vague.	10:09:49
14	as I understand what you mean by consider, of	10:06:48	14	THE WITNESS: Use under what	10:09:50
15	course.	10:06:51	15	circumstances?	10:09:52
16	Q. How would a person of ordinary skill in the	10:06:51	16	Q. Use in an ophthalmic product or use as an	10:09:52
17	art make the aqueous liquid preparation of claim 18	10:06:54	17	ophthalmic product. Actually, let me rephrase the	10:10:00
18	of the '431 patent?	10:06:57	18	question so it's clear.	10:10:04
19	MR. MARGOLIS: Objection. Vague. Calls	10:07:01	19	How would a person of ordinary skill in the	10:10:05
20	for speculation.	10:07:02	20	art use the aqueous liquid preparation of claim 18	10:10:07
21	THE WITNESS: There isn't a	10:07:10	21	of the '431 patent as an ophthalmic product?	10:10:10
22	formulation -- there isn't a formulation as	10:07:14	22	MR. MARGOLIS: Objection. Vague.	10:10:28
Page 99			Page 101		
1	such. It's just a list of ingredients. It	10:07:18	1	THE WITNESS: I am struggling here to	10:10:28
2	wouldn't give anybody who is skilled in the	10:07:21	2	understand that. That on its own doesn't	10:10:30
3	art based on that list how to make it.	10:07:24	3	give somebody enough information to be able	10:10:36
4	Q. Do you have an understanding as to how a	10:07:28	4	to formulate the preparation.	10:10:38
5	person of ordinary skill in the art would make the	10:07:30	5	Q. In interpreting claim 18 of the '431 patent,	10:10:44
6	aqueous liquid preparation of claim 18 of the '431	10:07:32	6	would a person of ordinary skill in the art look to	10:10:47
7	patent?	10:07:36	7	the specification of the patent for guidance?	10:10:50
8	A. Please explain to me why it's a preparation	10:07:43	8	A. They would, yes.	10:10:52
9	because there is no formulation there.	10:07:46	9	Q. Based on the teachings of the '431 patent,	10:10:53
10	Q. Do you see the words "an aqueous liquid	10:07:49	10	how would a person of ordinary skill in the art use	10:10:59
11	preparation"?	10:07:51	11	the aqueous liquid preparation of claim 18 of the	10:11:01
12	A. Yes.	10:07:52	12	'431 patent?	10:11:04
13	Q. All right. So, my question is do you	10:07:52	13	A. Sorry. Say that again? I'm sorry.	10:11:07
14	understand how a person of ordinary skill in the art	10:07:56	14	Q. Based on the teachings of the '431 patent,	10:11:09
15	would make the aqueous liquid preparation specified	10:07:58	15	how would a person of ordinary skill in the art use	10:11:12
16	in claim 18 of the '431 patent?	10:08:02	16	the aqueous liquid preparation of claim 18 of the	10:11:14
17	MR. MARGOLIS: Objection. Vague.	10:08:30	17	'431 patent?	10:11:18
18	THE WITNESS: I don't believe anybody of	10:08:34	18	A. Based on this -- based on the teaching in the	10:11:22
19	or the skill could make a liquid -- easily	10:08:38	19	patent, they would be able to get some indication of	10:11:30
20	make or rationally make a liquid preparation	10:08:44	20	the amounts of material that are needed to make the	10:11:39
21	based on that particular formula. They would	10:08:47	21	preparation.	10:11:43
22	need other information.	10:08:49	22	Q. Based on the teachings of the '431 patent,	10:11:43

Page 102	<p>1 how would a person of ordinary skill in the art make 10:11:46</p> <p>2 then aqueous liquid preparation of claim 18 of the 10:11:50</p> <p>3 '431 patent? 10:11:53</p> <p>4 A. Well, as far as I can remember, there's no 10:11:55</p> <p>5 specific instructions about how you actually make 10:12:00</p> <p>6 it. 10:12:06</p> <p>7 Q. Based on the general teachings of the '431 10:12:07</p> <p>8 patent, how would a person of ordinary skill in the 10:12:10</p> <p>9 art make the aqueous liquid preparation of claim 18 10:12:12</p> <p>10 of the '431 patent? 10:12:15</p> <p>11 A. I assume they would take an example and try 10:12:23</p> <p>12 adding the ingredients in the order in which they 10:12:31</p> <p>13 are listed on an example. 10:12:34</p> <p>14 Q. Does the plain language of claim 18 of the 10:12:36</p> <p>15 '431 patent restrict the phrase EDTA sodium salt to 10:12:39</p> <p>16 the tetrasodium form? 10:12:44</p> <p>17 MR. MARGOLIS: Objection. Vague. 10:12:46</p> <p>18 THE WITNESS: But it doesn't say -- 10:12:56</p> <p>19 sodium edetate has a strict meaning, just 10:12:58</p> <p>20 like polyvinylpyrrolidone has. 10:13:02</p> <p>21 Q. I'm just asking based on the plain language 10:13:05</p> <p>22 of the claim. Let me ask it again. 10:13:05</p>	Page 104	<p>1 '431 patent restrict the phrase sodium edetate to 10:14:15</p> <p>2 the tetrasodium form? 10:14:18</p> <p>3 MR. MARGOLIS: Objection. Vague. Asked 10:14:21</p> <p>4 and answered. 10:14:23</p> <p>5 Q. You may answer. 10:14:23</p> <p>6 A. All I can say -- again, I'm really, really 10:14:27</p> <p>7 sorry -- my understanding of what sodium edetate is 10:14:29</p> <p>8 is quite clear. So, I don't understand the question 10:14:33</p> <p>9 why somebody would consider it might refer to 10:14:36</p> <p>10 something else. 10:14:42</p> <p>11 Q. Do you understand the plain language of the 10:14:42</p> <p>12 claims of the patents-in-suit? 10:14:44</p> <p>13 A. I believe I do. 10:14:51</p> <p>14 Q. Does the plain language of any claim of the 10:14:52</p> <p>15 patent-in-suit, or the patents-in-suit rather -- 10:14:54</p> <p>16 strike that and try again. 10:14:57</p> <p>17 Does the plain language of any claim of the 10:14:59</p> <p>18 patents-in-suit restrict the phrase sodium edetate 10:15:01</p> <p>19 to the tetrasodium form? 10:15:04</p> <p>20 A. I believe the way it's written, yes. 10:15:06</p> <p>21 Q. Did you review the specification of the 10:15:09</p> <p>22 patents-in-suit in connection with your opinions in 10:15:11</p>
Page 103	<p>1 Does the plain language of claim 18 of the 10:13:08</p> <p>2 '431 patent restrict the phrase EDTA sodium salt to 10:13:11</p> <p>3 the tetrasodium form? 10:13:14</p> <p>4 A. I believe it does. It's telling you only 10:13:16</p> <p>5 that you're using sodium edetate. 10:13:19</p> <p>6 Q. Take a look, if you would, at claim 8 of the 10:13:22</p> <p>7 '431 patent. 10:13:26</p> <p>8 A. Okay. 10:13:29</p> <p>9 Q. Does the plain language of claim 8 of the 10:13:30</p> <p>10 '431 patent restrict the phrase sodium edetate to 10:13:33</p> <p>11 the tetrasodium form? 10:13:37</p> <p>12 MR. MARGOLIS: Objection. Vague. 10:13:40</p> <p>13 THE WITNESS: I'm struggling here 10:13:43</p> <p>14 because sodium edetate has a strict meaning. 10:13:45</p> <p>15 So it would be like saying, I don't know, 10:13:49</p> <p>16 does sodium hydroxide -- does this patent 10:13:57</p> <p>17 restrict sodium hydroxide -- does it include 10:14:02</p> <p>18 calcium hydroxide. It's not applicable in my 10:14:05</p> <p>19 understanding. 10:14:08</p> <p>20 Q. I'm just asking about the plain language of 10:14:09</p> <p>21 the claim for the time being. 10:14:11</p> <p>22 Does the plain language of claim 8 of the 10:14:12</p>	Page 105	<p>1 this case? 10:15:13</p> <p>2 A. Yes. 10:15:14</p> <p>3 Q. Does the specification of the patents-in-suit 10:15:15</p> <p>4 in any place limit the phrases sodium edetate or 10:15:18</p> <p>5 EDTA sodium salt to the tetrasodium form? 10:15:22</p> <p>6 MR. MARGOLIS: Objection. Vague. 10:15:26</p> <p>7 THE WITNESS: I'm really struggling with 10:15:31</p> <p>8 this because there was no reason to because 10:15:35</p> <p>9 it's a known specific compound. You wouldn't 10:15:38</p> <p>10 say, you know, E. coli becomes some other 10:15:42</p> <p>11 gram negative bacteria. To me, it's very, 10:15:45</p> <p>12 very clear what they're telling you is sodium 10:15:49</p> <p>13 edetate. 10:15:51</p> <p>14 Q. Does the specification of the patents-in-suit 10:15:52</p> <p>15 in any place refer to edetic acid, tetrasodium salt 10:15:54</p> <p>16 or tetrasodium edetate? 10:16:00</p> <p>17 A. Sorry. Does? 10:16:02</p> <p>18 Q. Sure. Does the specification -- 10:16:04</p> <p>19 A. Yes. 10:16:04</p> <p>20 Q. -- of the patents-in-suit in any place refer 10:16:06</p> <p>21 to edetic acid, tetrasodium salt or tetrasodium 10:16:09</p> <p>22 edetate? 10:16:14</p>

Page 106	<p>1 A. I would have to read to check that. 10:16:15</p> <p>2 Q. Sitting here today, do you know that? 10:16:17</p> <p>3 A. I don't know whether it says it in my -- I 10:16:20</p> <p>4 can look at my declaration or my -- I'm sorry. I 10:16:32</p> <p>5 would have to re-read them to answer you 10:16:44</p> <p>6 categorically. 10:16:46</p> <p>7 Q. Please turn -- actually, please turn back to 10:16:48</p> <p>8 the '606 patent. I want to direct your attention 10:16:52</p> <p>9 again to claim 1. 10:16:56</p> <p>10 A. '606? 10:17:03</p> <p>11 Q. Yes, '606. Are you there? 10:17:04</p> <p>12 A. Yes. 10:17:10</p> <p>13 Q. Based on the teachings of the '606 patent, 10:17:11</p> <p>14 how would a person of ordinary skill in the art 10:17:14</p> <p>15 carry out the method of claim 1 of the '606 patent? 10:17:16</p> <p>16 MR. MARGOLIS: Objection. Vague. 10:17:21</p> <p>17 THE WITNESS: The same way we discussed 10:17:52</p> <p>18 before. You turn to an example that's taught 10:17:54</p> <p>19 and use that to try and make it up. 10:18:00</p> <p>20 Q. Take a look, if you would, now at the '290 10:18:05</p> <p>21 patent. I believe it's Exhibit 13 in your binder. 10:18:10</p> <p>22 A. Thank you. 10:18:15</p>	Page 108	<p>1 1 of the '290 patent for ophthalmic administration? 10:19:24</p> <p>2 A. In a patient -- they would -- I guess, take 10:19:30</p> <p>3 the example which they felt was of interest or more 10:19:38</p> <p>4 likely take a range of formulations, prepare them, 10:19:42</p> <p>5 and then have to test them appropriately for 10:19:54</p> <p>6 stability. 10:20:00</p> <p>7 Q. Take a look, if you would, at column 14 of 10:20:00</p> <p>8 the '290 patent and let me direct your attention to 10:20:05</p> <p>9 claim 26. 10:20:09</p> <p>10 Did you consider claim 26 of the '290 patent 10:20:13</p> <p>11 in connection with your opinions in this case? 10:20:15</p> <p>12 A. I certainly did, yes. 10:20:17</p> <p>13 Q. Okay. Based on the teachings of the '290 10:20:18</p> <p>14 patent, how would a person of ordinary skill in the 10:20:20</p> <p>15 art make the aqueous liquid preparation of claim 26 10:20:23</p> <p>16 of the '290 patent? 10:20:26</p> <p>17 A. I don't know if "make" is the word I would 10:20:32</p> <p>18 use. I believe that is a test. Once they have made 10:20:34</p> <p>19 the preparation, they would have to, according to 10:20:38</p> <p>20 this, make a preparation for claim 1. We've 10:20:43</p> <p>21 discussed that. And then check that that 10:20:47</p> <p>22 preparation fulfills the EP, criteria B of the 10:20:50</p>
Page 107	<p>1 Q. Let me direct your attention to column 12, 10:18:15</p> <p>2 claim 1. Did you consider claim 1 of the '290 10:18:18</p> <p>3 patent in connection with your opinions in this 10:18:25</p> <p>4 case? 10:18:28</p> <p>5 A. I read all the claims, yes. 10:18:28</p> <p>6 Q. Based on the teachings of the '290 patent, 10:18:30</p> <p>7 how would a person of ordinary skill in the art make 10:18:33</p> <p>8 the aqueous liquid preparation of claim 1 of the 10:18:35</p> <p>9 '290 patent? 10:18:39</p> <p>10 MR. MARGOLIS: Objection. Vague. 10:18:40</p> <p>11 THE WITNESS: They would have to turn to 10:18:48</p> <p>12 the teachings in the patent and use that as a 10:18:49</p> <p>13 starting point. 10:18:53</p> <p>14 Q. Based on the teachings of the '290 patent, 10:18:53</p> <p>15 how would a person of ordinary skill in the art use 10:18:56</p> <p>16 the aqueous liquid preparation of claim 1 of the 10:18:59</p> <p>17 '290 patent? 10:19:02</p> <p>18 MR. MARGOLIS: Objection. Vague. 10:19:05</p> <p>19 THE WITNESS: Used in what context? 10:19:13</p> <p>20 Q. I apologize. Based on the teachings of the 10:19:15</p> <p>21 '290 patent, how would a person of ordinary skill in 10:19:18</p> <p>22 the art use the aqueous liquid preparation of claim 10:19:21</p>	Page 109	<p>1 European Pharmacopeia. 10:21:02</p> <p>2 Q. Would that be a fairly straightforward test? 10:21:08</p> <p>3 MR. MARGOLIS: Objection. Vague. 10:21:11</p> <p>4 THE WITNESS: I don't know what a fairly 10:21:15</p> <p>5 straightforward test is. It's a standard 10:21:17</p> <p>6 test. 10:21:20</p> <p>7 Q. Would it be a fairly straightforward or 10:21:20</p> <p>8 standard test based on the teachings of the 10:21:22</p> <p>9 patents-in-suit? 10:21:24</p> <p>10 A. Well, somebody ordinary skilled in the art 10:21:25</p> <p>11 would obviously go to the European Pharmacopeia and 10:21:30</p> <p>12 check the criteria, because that would obviously be 10:21:36</p> <p>13 their responsibility, and follow the protocol that's 10:21:40</p> <p>14 there, the more detailed protocol. This is only an 10:21:46</p> <p>15 abstract of the protocol. 10:21:49</p> <p>16 Q. Based on the teachings of the '290 patent, 10:21:51</p> <p>17 how would a person of ordinary skill in the art use 10:21:54</p> <p>18 the aqueous liquid preparation of claim 26 of the 10:21:56</p> <p>19 '290 patent as an ophthalmic formulation? 10:22:00</p> <p>20 MR. MARGOLIS: Objection. Vague. Lacks 10:22:06</p> <p>21 foundation. 10:22:09</p> <p>22 THE WITNESS: I don't believe anybody 10:22:10</p>

Page 110			Page 112		
1	would use that formulation in isolation of	10:22:26	1	MR. MARGOLIS: Objection. Vague.	10:25:04
2	just doing that test. They would have to do	10:22:29	2	THE WITNESS: I think somebody who is	10:25:21
3	a test to satisfy themselves that it is	10:22:33	3	ordinary skilled in the art would be	10:25:23
4	suitable for ophthalmic use.	10:22:35	4	concerned that the formulation doesn't have	10:25:29
5	Q. And what test would they do?	10:22:38	5	the full raft of stability tests that you	10:25:32
6	A. We've already discussed a little bit about	10:22:42	6	would need to ensure something was suitable	10:25:39
7	the necessary range of stability tests that they	10:22:47	7	for ophthalmic use.	10:25:42
8	would have to do. This preservative test would	10:22:52	8	Q. Based on the specification of the '131	10:25:45
9	complement the whole raft of stability tests that	10:22:58	9	patent, how would a person of ordinary skill in the	10:25:48
10	would be needed.	10:23:01	10	art make the aqueous liquid preparation of claim 25	10:25:51
11	Q. Take a look, if you would, at the '131 patent	10:23:01	11	of the '131 patent?	10:25:53
12	now. It should be the next exhibit in your binder.	10:23:05	12	MR. MARGOLIS: Objection. Vague.	10:25:57
13	Let me direct your attention to column 14, claim 25.	10:23:10	13	THE WITNESS: I thought I answered this.	10:26:05
14	A. Okay.	10:23:19	14	They would go to claim 1, make some	10:26:07
15	Q. How would a person of ordinary skill in the	10:23:20	15	formulations which falls within the	10:26:11
16	art make the aqueous liquid preparation of claim 25	10:23:23	16	specification that they were interested in.	10:26:15
17	of the '131 patent?	10:23:26	17	Assuming some of those formulations looked	10:26:20
18	MR. MARGOLIS: Objection. Vague.	10:23:30	18	promising from the initial screen, they would	10:26:23
19	THE WITNESS: Well, the answer -- if	10:23:36	19	do a more detailed screening and do some	10:26:25
20	somebody was using this patent, they would go	10:23:39	20	stability tests which would include the	10:26:28
21	to the examples, produce a variety of	10:23:41	21	preservative tests.	10:26:31
22	formulations to their preferred	10:23:46	22	Q. So, could you turn back to the '290 patent	10:26:38
Page 111			Page 113		
1	specification. If they looked promising,	10:23:50	1	please?	10:26:42
2	they would then start to test those	10:23:52	2	A. Yes.	10:26:43
3	formulations with respect to stability which	10:23:54	3	Q. Let me direct your attention to column 7 and	10:26:56
4	would include, but not totally be,	10:23:57	4	Experimental Example 1. Did you review Experimental	10:27:0
5	preservative stability. And they would go to	10:24:02	5	Example 1 in connection with your opinions in this	10:27:10
6	the European -- uh, the U.S. Pharmacopeia and	10:24:05	6	case?	10:27:12
7	get the full detailed methods for -- because	10:24:10	7	A. I did.	10:27:12
8	these are not detailed methods. These are	10:24:16	8	Q. Under Table 1, the paragraph reads, "The	10:27:13
9	incomplete. And then they would realize	10:24:18	9	remaining rate percent in the above Table 1	10:27:17
10	there was some discrepancy here.	10:24:21	10	indicates values obtained by correcting moisture	10:27:21
11	Q. How would a person of ordinary skill in the	10:24:23	11	vaporization from the container. As is apparent	10:27:24
12	art use the aqueous liquid preparation of claim 25	10:24:25	12	from Table 1, stability test was carried out under	10:27:27
13	of the '131 patent as an ophthalmic formulation?	10:24:29	13	the conditions of pH 7.0 at 60 degrees Celsius for	10:27:31
14	MR. MARGOLIS: Objection. Vague.	10:24:34	14	four weeks, and sodium 2-amino-3-(4-bromobenzoyl)	10:27:36
15	THE WITNESS: They wouldn't use it	10:24:39	15	phenylacetate in each eye drop was stable in the	10:27:45
16	unless they performed a whole raft of other	10:24:44	16	order of tyloxapol-containing preparation greater	10:27:47
17	tests to ensure that it is suitable for	10:24:47	17	than polyoxyl 40 stearate-containing preparation	10:27:51
18	ophthalmic use.	10:24:50	18	greater than polysorbate 80-containing preparation."	10:27:56
19	Q. Based on the teachings of the '131 patent,	10:24:52	19	Do you see that?	10:27:59
20	how would a person of ordinary skill in the art use	10:24:56	20	A. I do.	10:28:00
21	the aqueous liquid preparation of claim 25 of the	10:24:58	21	Q. Does Experimental Example 1 of the '290	10:28:01
22	'131 patent?	10:25:01	22	patent teach that formulation A-03 was stable within	10:28:04

Page 114	<p>1 the meaning of the claims? 10:28:07</p> <p>2 A. It's my understanding from the claims, no, 10:28:12</p> <p>3 because they're quite -- it's difficult to follow. 10:28:18</p> <p>4 Just let me turn to my -- so, as I've said in my 10:28:23</p> <p>5 report, it discusses an order of stability, but it 10:28:40</p> <p>6 doesn't discuss an absolute stability. It doesn't 10:28:44</p> <p>7 say in the -- in this patent here, it doesn't say 10:28:53</p> <p>8 what remaining rate is required for stability. 10:28:57</p> <p>9 Q. Let me direct your attention then to claim 8 10:29:01</p> <p>10 of the '290 patent. Do you see that claim 8 of the 10:29:05</p> <p>11 '290 patent has a clause that says, "Wherein the 10:29:11</p> <p>12 stable aqueous liquid preparation is characterized 10:29:14</p> <p>13 in that greater than about 90 percent of the 10:29:17</p> <p>14 original amount of the first component remains in 10:29:20</p> <p>15 the preparation after storage at about 60 degrees 10:29:23</p> <p>16 Celsius for four weeks"? 10:29:27</p> <p>17 A. Okay. 10:29:28</p> <p>18 Q. Do you see that? 10:29:29</p> <p>19 A. Yes. 10:29:31</p> <p>20 Q. Does Experimental Example 1 of the '290 10:29:31</p> <p>21 patent teach that formulation A-03 was a stable 10:29:35</p> <p>22 within the meaning of claim 8 of the '290 patent? 10:29:38</p>	Page 116	<p>1 Q. Well, let's take a look at Table 2 in 10:32:06</p> <p>2 Experimental Example 2 and formulation A-04. 10:32:11</p> <p>3 Does Experimental Example 2 of the '290 10:32:16</p> <p>4 patent teach that formulation A-04 was stable within 10:32:19</p> <p>5 the meaning of claim 8 of the '290 patent? 10:32:23</p> <p>6 A. I believe it does. 10:32:34</p> <p>7 Q. Is the concept of stability in the 10:32:36</p> <p>8 patents-in-suit directed to the physical stability 10:32:39</p> <p>9 or the chemical stability of the claimed aqueous 10:32:41</p> <p>10 liquid preparations? 10:32:45</p> <p>11 A. It's quite vague because it does -- just let 10:32:51</p> <p>12 me find something. I'm sorry. 10:32:58</p> <p>13 Q. Tell me when you're ready. I'll be happy to 10:33:27</p> <p>14 reask the question. 10:33:29</p> <p>15 A. Sorry. 10:33:30</p> <p>16 Q. That's all right. 10:33:31</p> <p>17 A. I can't find in this patent the bit I'm 10:33:32</p> <p>18 looking for. I'm sorry. 10:33:36</p> <p>19 Q. Take your time. Tell me when you're ready. 10:33:37</p> <p>20 A. I think this patent is vague with respect to 10:34:11</p> <p>21 stability. I don't think it's explicit in what it 10:34:15</p> <p>22 teaches because part of the goal was to ensure that 10:34:20</p>
Page 115	<p>1 MR. MARGOLIS: Objection. Vague. 10:29:43</p> <p>2 THE WITNESS: I'm really, really sorry. 10:29:46</p> <p>3 You were too quick for me then. 10:29:48</p> <p>4 Q. Okay. 10:29:48</p> <p>5 A. Can you say it again? 10:29:50</p> <p>6 Q. I can repeat. 10:29:50</p> <p>7 A. Thank you. 10:29:51</p> <p>8 Q. Certainly. Does Experimental Example 1 of 10:29:52</p> <p>9 the '290 patent teach that formulation A-03 was 10:29:54</p> <p>10 stable within the meaning of claim 8 of the '290 10:29:59</p> <p>11 patent? 10:30:03</p> <p>12 MR. MARGOLIS: Objection. Vague. 10:30:09</p> <p>13 THE WITNESS: Okay. So, ask me the 10:31:23</p> <p>14 question again? Sorry. 10:31:24</p> <p>15 Q. Sure. Does Experimental Example 1 of the 10:31:26</p> <p>16 '290 patent teach that formulation A-03 was stable 10:31:29</p> <p>17 within the meaning of claim 8 of the '290 patent? 10:31:33</p> <p>18 MR. MARGOLIS: Objection. Vague. 10:31:38</p> <p>19 THE WITNESS: A-03, you said? Yes. I 10:31:43</p> <p>20 thought you said example one before. I'm 10:31:51</p> <p>21 sorry. Okay. It is vague, the lower limit, 10:31:52</p> <p>22 but I would say that probably. 10:31:59</p>	Page 117	<p>1 the preservative kept its -- its intended, or 10:34:26</p> <p>2 disclosure was that they found the preservative kept 10:34:31</p> <p>3 its effect. And there was no precipitate, which is 10:34:35</p> <p>4 possibly chemical, possibly physical stability. 10:34:40</p> <p>5 There is some indication of chemical stability here, 10:34:44</p> <p>6 but it doesn't define properly under what conditions 10:34:48</p> <p>7 you're looking at it. I think it's vague. 10:34:53</p> <p>8 Q. Do Experimental Examples 1 and -- sorry -- 10:34:56</p> <p>9 let me strike that and try again. 10:34:59</p> <p>10 Do Experimental Example 1 and Experimental 10:35:01</p> <p>11 Example 2 in the patents-in-suit deal with physical 10:35:05</p> <p>12 or chemical stability? 10:35:07</p> <p>13 A. Sorry. This is Experimental -- this is on 10:35:15</p> <p>14 page 7 -- column 7? 10:35:18</p> <p>15 Q. Correct. Columns 7 and 8. 10:35:20</p> <p>16 A. Okay. That deals with chemical stability, 10:35:24</p> <p>17 but only as far as it does also indicate there's 10:35:48</p> <p>18 some physical component to it because it's 10:35:54</p> <p>19 correcting for moisture vaporization from the 10:36:03</p> <p>20 container. 10:36:08</p> <p>21 Q. Aside from the correction for moisture 10:36:09</p> <p>22 vaporization from the container, do Experimental 10:36:12</p>

Page 118	Page 120
<p>1 Example 1 and Experimental Example 2 in the 10:36:17</p> <p>2 patents-in-suit deal with chemical stability? 10:36:19</p> <p>3 A. I guess so, yes. 10:36:37</p> <p>4 Q. Do you know how the aqueous liquid 10:36:38</p> <p>5 preparations disclosed and claimed in the 10:36:41</p> <p>6 patents-in-suit regulate the dose of drug to the 10:36:43</p> <p>7 patient? 10:36:46</p> <p>8 MR. MARGOLIS: Objection. Vague. 10:36:47</p> <p>9 THE WITNESS: I don't understand that 10:36:53</p> <p>10 question anyway. 10:36:54</p> <p>11 Q. What don't you understand about it? 10:36:55</p> <p>12 A. How can the formulation -- how can the 10:36:59</p> <p>13 formulation that is regulate the dose. I don't 10:37:03</p> <p>14 understand. I'm sorry. 10:37:06</p> <p>15 Q. Take a look at the first sentences above 10:37:07</p> <p>16 Tables 1 and 2 of the '290 patent. 10:37:17</p> <p>17 A. Um-mm. 10:37:20</p> <p>18 Q. And it says, "Four eye drops of sodium 10:37:21</p> <p>19 2-amino-3-(4-bromobenzoyl) phenylacetate comprising 10:37:24</p> <p>20 the components as shown in Table 1 were prepared, 10:37:29</p> <p>21 filled respectively into a polypropylene container 10:37:32</p> <p>22 and subjected to stability test at 60 degrees 10:37:35</p>	<p>1 obviously. It's a type of plastic. It would be 10:38:42</p> <p>2 normal for eye drops to be in a -- if they're in a 10:38:47</p> <p>3 plastic container, normally in one that you could 10:38:52</p> <p>4 use to squeeze -- to drop out the eye drops. I 10:38:54</p> <p>5 don't know. It doesn't say what type of 10:38:58</p> <p>6 polypropylene. I don't know what plasticizers are 10:38:59</p> <p>7 there or anything. 10:39:01</p> <p>8 Q. Would a person of ordinary skill in the art 10:39:01</p> <p>9 readily understand how to use a polypropylene 10:39:04</p> <p>10 container to carry out Experimental Examples 1 and 10:39:06</p> <p>11 2? 10:39:11</p> <p>12 MR. MARGOLIS: Objection. Vague. 10:39:16</p> <p>13 THE WITNESS: These are not standard 10:39:19</p> <p>14 tests. They're not standard stability tests. 10:39:20</p> <p>15 A standard ICH stability test or regulatory 10:39:26</p> <p>16 test would have a very prescribed way of 10:39:32</p> <p>17 doing a stability test. There was no mention 10:39:36</p> <p>18 here about controlling external humidity, how 10:39:40</p> <p>19 you heat them up or anything. So, it is 10:39:45</p> <p>20 vague. 10:39:49</p> <p>21 Q. Well, my question is a little simpler -- 10:39:49</p> <p>22 A. Yeah. 10:39:49</p>
Page 119	Page 121
<p>1 Celsius." 10:37:35</p> <p>2 And then the sentence above Table 2 says, 10:37:39</p> <p>3 "Five eye drops of sodium 2-amino-3-(4- 10:37:43</p> <p>4 bromobenzoyl) phenylacetate comprising the 10:37:46</p> <p>5 components as shown in Table 2 were prepared, filled 10:37:50</p> <p>6 respectively into a polypropylene container and 10:37:54</p> <p>7 preserved at 60 degrees Celsius for four weeks, and 10:37:57</p> <p>8 then the content of 2-amino-3-(4-bromobenzoyl) 10:38:01</p> <p>9 phenylacetic acid and the pH in each eye drop were 10:38:07</p> <p>10 measured." 10:38:09</p> <p>11 Do you see those sentences? 10:38:10</p> <p>12 A. Yes. 10:38:12</p> <p>13 Q. Do the -- does -- sorry. Let me strike that 10:38:12</p> <p>14 and try again. 10:38:14</p> <p>15 Does the specification of the patents-in-suit 10:38:14</p> <p>16 state that Experimental Examples 1 and 2 were 10:38:17</p> <p>17 carried out using polypropylene containers? 10:38:21</p> <p>18 A. Yes. 10:38:24</p> <p>19 Q. What are polypropylene containers? 10:38:25</p> <p>20 A. They're effectively a plastic container. I 10:38:29</p> <p>21 assume -- there are different types of 10:38:36</p> <p>22 polypropylene, so you would need more information 10:38:38</p>	<p>1 Q. -- actually. 10:39:51</p> <p>2 Would a person of ordinary skill in the art 10:39:51</p> <p>3 readily understand how to use a polypropylene 10:39:53</p> <p>4 container to carry out Experimental Examples 1 and 10:39:56</p> <p>5 2? 10:40:00</p> <p>6 MR. MARGOLIS: Objection. Vague. 10:40:00</p> <p>7 THE WITNESS: I thought I answered that. 10:40:01</p> <p>8 Sorry. There's no specification on the 10:40:05</p> <p>9 polypropylene bottle, so that would be 10:40:14</p> <p>10 initial concern. There's no discussion when 10:40:20</p> <p>11 you make these formulations as to whether you 10:40:28</p> <p>12 sterilize them before you put them in the 10:40:31</p> <p>13 bottle or -- so, there are things that are 10:40:33</p> <p>14 not available so you could not be a hundred 10:40:40</p> <p>15 percent certain that you were completely 10:40:42</p> <p>16 using the same protocol. 10:40:47</p> <p>17 Q. Would a person of ordinary skill in the art 10:40:48</p> <p>18 with several years of experience know how to find 10:40:50</p> <p>19 the information necessary to use a polypropylene 10:40:54</p> <p>20 container to carry out Experimental Examples 1 and 10:40:57</p> <p>21 2? 10:41:01</p> <p>22 MR. MARGOLIS: Objection. Vague. Lack 10:41:01</p>

Page 122		Page 124	
1	of foundation. 10:41:03	1	paragraph under "Disclosure of the Invention" that 10:43:19
2	THE WITNESS: I'm struggling with your 10:41:06	2	goes from line 16 through line 23? 10:43:22
3	use of the word use. I'm sorry. How would 10:41:09	3	A. I do. 10:43:25
4	they use as in -- would they just put it into 10:41:13	4	Q. Could you just read that to yourself and let 10:43:25
5	an -- I don't know. Is that what you mean by 10:41:19	5	me know when you're ready. 10:43:31
6	use? 10:41:22	6	A. Okay. 10:43:42
7	Q. Well, let me ask it this way. Would a person 10:41:23	7	Q. And you understand that the chemical name 10:43:43
8	of ordinary skill in the art readily understand how 10:41:25	8	2-amino-3-(4-bromobenzoyl) phenylacetic acid is the 10:43:45
9	to obtain a polypropylene container to carry out 10:41:27	9	chemical name for bromfenac, correct? 10:43:52
10	Experimental Examples 1 and 2? 10:41:31	10	A. Correct. 10:43:55
11	A. Yes. There are, of course, the 10:41:36	11	Q. Okay. I'll refer to it as bromfenac because 10:43:55
12	manufacturers. 10:41:39	12	that chemical name is a bit of a mouthful. 10:43:57
13	Q. Okay. What size polypropylene container 10:41:40	13	Does the specification of the patents-in-suit 10:43:59
14	would a person of ordinary skill in the art want to 10:41:42	14	state that it is an object of the present invention 10:44:01
15	select when carrying out Experimental Examples 1 and 10:41:44	15	to provide an aqueous liquid preparation comprising 10:44:04
16	2? 10:41:48	16	bromfenac or a pharmacologically acceptable salt 10:44:07
17	A. It would suggest a hundred mil, but that 10:41:49	17	thereof or a hydrate thereof, which is stable within 10:44:11
18	would seem ridiculous for an eye drop formulation. 10:41:52	18	a pH range giving no irritation to eyes and in 10:44:13
19	Q. Why would it seem ridiculous for an eye drop 10:41:58	19	which, when a preservative such as benzalkonium 10:44:17
20	formulation? 10:42:03	20	chloride is incorporated therein, preservative 10:44:21
21	A. As you only administer one or two drops into 10:42:03	21	effect of the preservative does not substantially 10:44:23
22	the eye possibly twice a day, you would not need a 10:42:06	22	deteriorate? 10:44:26
Page 123		Page 125	
1	hundred mil. You would obviously want to do this on 10:42:09	1	A. Yes. 10:44:27
2	a much smaller scale. 10:42:11	2	Q. Take a look, if you would, now down at column 10:44:27
3	Q. Why do Experimental Examples 1 and 2 suggest 10:42:14	3	6, lines 38 through 40. So, over to column 6, it's 10:44:32
4	using a one hundred milliliter polypropylene 10:42:17	4	going to be the sentence that starts "The pH"? 10:44:37
5	container to carry out those examples? 10:42:20	5	A. Yes. 10:44:41
6	MR. MARGOLIS: Objection. 10:42:23	6	Q. Can you read that to yourself and let me know 10:44:42
7	Mischaracterizes her testimony. 10:42:24	7	when you're ready? 10:44:44
8	Q. You may answer. 10:42:27	8	A. Yes. 10:44:47
9	A. It doesn't say anything else. I mean, it 10:42:29	9	Q. Does the specification of the patents-in-suit 10:44:48
10	doesn't even say polypropylene dropper bottle, which 10:42:32	10	state that the pH of the aqueous liquid preparation 10:44:52
11	is what I -- or container, which is what I would 10:42:35	11	of the present invention can be adjusted to about 6 10:44:55
12	normally expect. 10:42:38	12	to 9, preferably about 7 to 9, especially about 7.5 10:44:59
13	Q. What shape polypropylene container would a 10:42:39	13	to 8.5? 10:45:04
14	person of ordinary skill in the art want to select 10:42:42	14	A. Yes. 10:45:05
15	when carrying out Experimental Examples 1 and 2? 10:42:44	15	Q. Based on the specification of the 10:45:06
16	MR. MARGOLIS: Objection. Lacks 10:42:50	16	patents-in-suit, would a person of ordinary skill in 10:45:07
17	foundation. 10:42:51	17	the art expect that the claimed aqueous liquid 10:45:10
18	THE WITNESS: Something that is the same 10:42:52	18	preparations are stable within the especially 10:45:13
19	shape as a normal eye drop bottle. 10:42:57	19	preferred pH range of about 7.5 to 8.5? 10:45:15
20	Q. Take a look, if you would, at the '290 10:42:59	20	MR. MARGOLIS: Objection. Vague. 10:45:20
21	patent, column 2, line 16. And I want to read to 10:43:03	21	THE WITNESS: Ask the question again? 10:45:24
22	you the paragraph-- well, actually, do you see the 10:43:18	22	Sorry. 10:45:26

Page 126	<p>1 Q. Sure. Based on the specification of the 10:45:26</p> <p>2 patents-in-suit, would a person of ordinary skill in 10:45:28</p> <p>3 the art expect that the claimed aqueous liquid 10:45:30</p> <p>4 preparations are stable within the especially 10:45:33</p> <p>5 preferred pH range of about 7.5 to 8.5? 10:45:36</p> <p>6 MR. MARGOLIS: Objection. Vague. Calls 10:45:41</p> <p>7 for speculation. Compound. 10:45:43</p> <p>8 THE WITNESS: Not necessarily, no. 10:45:55</p> <p>9 Q. Take a look, if you would, at the Abstract. 10:45:58</p> <p>10 And if you would just read the entirety of the 10:46:10</p> <p>11 Abstract to yourself and just let me know when 10:46:13</p> <p>12 you're ready. 10:46:15</p> <p>13 A. Okay. 10:46:43</p> <p>14 Q. Does the first sentence of the Abstract of 10:46:44</p> <p>15 the patents-in-suit state that an aqueous liquid 10:46:47</p> <p>16 preparation of the present invention containing 10:46:50</p> <p>17 bromfenac and tyloxapol is stable? 10:46:52</p> <p>18 A. Yes. 10:47:01</p> <p>19 Q. Do you have any basis to disagree with that 10:47:02</p> <p>20 statement? 10:47:05</p> <p>21 A. At the moment with an Abstract there's 10:47:06</p> <p>22 insufficient information to make that, so no. 10:47:10</p>	Page 128	<p>1 Q. Do you have any basis at all to disagree with 10:49:24</p> <p>2 that statement? 10:49:27</p> <p>3 A. I don't think this -- that I have enough 10:49:34</p> <p>4 information here to say one way or another. 10:49:36</p> <p>5 Q. Take a look, if you would, at lines 63 to 64 10:49:39</p> <p>6 in column 2. It starts with a number 3 and it says, 10:49:44</p> <p>7 "The aqueous liquid preparation" -- I apologize. 10:49:52</p> <p>8 A. Yeah. 10:49:52</p> <p>9 Q. So, it's actually 62 to 64. 10:49:56</p> <p>10 A. That's okay. 10:49:58</p> <p>11 Q. And read that to yourself, if you would, and 10:49:59</p> <p>12 let me know when you're ready. 10:50:01</p> <p>13 A. Yes. 10:50:10</p> <p>14 Q. Is tyloxapol an example of an alkyl aryl 10:50:11</p> <p>15 polyether alcohol type polymer? 10:50:16</p> <p>16 A. Yes. That's one way you can call it, one way 10:50:18</p> <p>17 of describing it. 10:50:22</p> <p>18 Q. Is tyloxapol a polyoxyethylene sorbitan 10:50:23</p> <p>19 n-acyl ester? 10:50:30</p> <p>20 A. No. 10:50:30</p> <p>21 Q. Take a look actually, if you would, at 10:50:31</p> <p>22 paragraph 60 of your declaration. It's on page 16. 10:50:34</p>
Page 127	<p>1 Q. Take a look, if you would, at the '290 10:47:13</p> <p>2 patent, column 2, lines 6 through 12. Read that to 10:47:19</p> <p>3 yourself and let me know when you're ready. 10:47:31</p> <p>4 A. Okay. 10:47:49</p> <p>5 Q. Does the specification of the patents-in-suit 10:47:50</p> <p>6 state that the prior art references identified in 10:47:54</p> <p>7 the patents-in-suit provide no disclosure that alkyl 10:47:58</p> <p>8 aryl polyether alcohol type polymers or polyethylene 10:48:02</p> <p>9 glycol fatty acid esters are able to stabilize an 10:48:08</p> <p>10 aqueous liquid preparation of bromfenac and inhibit 10:48:11</p> <p>11 decrease in preservative effect of benzalkonium 10:48:15</p> <p>12 chloride and other quaternary ammonium compounds? 10:48:19</p> <p>13 MR. MARGOLIS: Objection. 10:48:21</p> <p>14 Mischaracterizing the documents. 10:48:23</p> <p>15 THE WITNESS: It does. 10:48:24</p> <p>16 Q. Do you have any basis to disagree with that 10:48:25</p> <p>17 statement? 10:48:28</p> <p>18 A. Let me just have a think. 10:48:29</p> <p>19 So, the question was do I have any -- 10:49:07</p> <p>20 Q. Basis to disagree with that statement? 10:49:09</p> <p>21 A. When you say "basis," based on this 10:49:16</p> <p>22 information here or other information? 10:49:20</p>	Page 129	<p>1 A. Okay. I've got it. 10:50:47</p> <p>2 Q. Okay. And just a minute ago we read the 10:50:48</p> <p>3 Abstract of the '290 patent. 10:50:50</p> <p>4 Do you remember that? 10:50:52</p> <p>5 A. Yes. 10:50:53</p> <p>6 Q. And in paragraph 60 you quote the Abstract in 10:50:53</p> <p>7 your "See e.g." citation and you say, "An aqueous 10:50:58</p> <p>8 liquid preparation of the present invention 10:51:02</p> <p>9 containing 2-amino-3-(4-bromobenzoyl) phenylacetic 10:51:04</p> <p>10 acid or its pharmacologically acceptable salt or a 10:51:09</p> <p>11 hydrate thereof, an alkyl aryl polyether alcohol 10:51:13</p> <p>12 type polymer such as tyloxapol, or a polyethylene 10:51:17</p> <p>13 glycol fatty acid ester such as polyethylene glycol 10:51:21</p> <p>14 monostearate is staple." 10:51:25</p> <p>15 Do you see that? 10:51:26</p> <p>16 A. Yes. 10:51:27</p> <p>17 Q. You provide no basis for disagreement with 10:51:27</p> <p>18 that statement. 10:51:29</p> <p>19 Do you see that? 10:51:30</p> <p>20 MR. MARGOLIS: Objection. Vague. 10:51:37</p> <p>21 THE WITNESS: I provide no basis -- that 10:51:38</p> <p>22 was not the point of that statement. 10:51:40</p>

Page 130	Page 132
1 Q. You provide no basis for disagreement with 10:51:42	1 preparations of the patents-in-suit? 10:55:09
2 that, do you? 10:51:44	2 A. Not specifically, no. 10:55:12
3 A. That's just bizarre because the point of the 10:51:45	3 Q. Could an aqueous liquid preparation of 10:55:17
4 statement was to talk about there's no clarity 10:51:49	4 bromfenac have sufficient preservative efficacy as 10:55:22
5 around the meaning of stability. I wasn't dealing 10:51:52	5 an eye drop without containing benzalkonium 10:55:25
6 with whether or not that statement is correct. I'm 10:51:57	6 chloride? 10:55:31
7 just saying that statement has no definition of 10:52:00	7 MR. MARGOLIS: Objection. Vague. Lack 10:55:31
8 stability. 10:52:04	8 of foundation. 10:55:47
9 Q. Do you provide any basis for disagreement 10:52:04	9 THE WITNESS: I'm sorry. I'm going to 10:55:48
10 with that statement anywhere in your declaration? 10:52:06	10 have to take my time answering this one. 10:55:55
11 A. I would have to have a look. 10:52:11	11 Apologies. Without reference to what is 10:55:58
12 Okay. I was asked to particularly look at 10:53:26	12 written in the patents elsewhere, I would say 10:56:37
13 claim construction. I don't consider that to be 10:53:30	13 that without a preservative in the 10:56:42
14 part of claim construction. It is in my report 10:53:32	14 formulation, it would not be possible to 10:56:46
15 because it's actually demonstrating that it's a 10:53:35	15 produce an eyedrop that's preserved 10:56:50
16 supporting statement that indicates they don't 10:53:38	16 bromfenac. 10:56:55
17 define stability clearly. 10:53:41	17 Q. My question is a little different. Could an 10:56:55
18 Q. You provide no basis for disagreement with 10:53:42	18 aqueous liquid preparation of bromfenac have 10:56:56
19 that statement anywhere in your declaration, 10:53:44	19 sufficient preservative efficacy as an eye drop 10:56:58
20 correct? 10:53:47	20 without containing benzalkonium chloride? 10:57:01
21 A. The statement is only there because it's to 10:53:48	21 MR. MARGOLIS: Objection. Vague. 10:57:05
22 support the discussion about stability. 10:53:51	22 THE WITNESS: The simple answer, which 10:57:07
Page 131	Page 133
1 Q. You provide no basis for disagreement with 10:53:53	1 sounds a bit facetious, is if you had a 10:57:15
2 that statement, correct? 10:53:55	2 different preservative, of course. 10:57:18
3 A. The point of this declaration was to look at 10:54:00	3 Q. How would a person of ordinary skill in the 10:57:20
4 claim construction. 10:54:04	4 art determine whether an aqueous liquid preparation 10:57:22
5 Q. Doctor, I will ask you again. You provide no 10:54:05	5 of bromfenac without benzalkonium chloride have 10:57:25
6 basis for disagreement with that statement, correct? 10:54:07	6 sufficient preservative efficacy as an eye drop? 10:57:29
7 A. I provide no basis for agreement with that 10:54:09	7 MR. MARGOLIS: Objection. Vague. 10:57:32
8 statement either. 10:54:13	8 THE WITNESS: There are several answers 10:57:36
9 Q. Okay. Take a look, if you would, at the -- 10:54:13	9 to that question. The most -- if you were 10:57:54
10 back to the '290 patent, Experimental Example 3. 10:54:17	10 going to optimize your formulation, you would 10:57:58
11 You considered Experimental Example 3 in connection 10:54:30	11 do formulation optimization and test it with 10:58:01
12 with your opinions in this case, correct? 10:54:33	12 preservative -- against appropriate -- 10:58:04
13 A. Yes. 10:54:35	13 sorry -- doing appropriate -- doing 10:58:08
14 Q. Does Experimental Example 3 address 10:54:39	14 appropriate compendial tests to ensure it has 10:58:12
15 preservative efficacy of the aqueous liquid 10:54:41	15 appropriate preservative activity. 10:58:17
16 preparations of the patents-in-suit? 10:54:44	16 Q. Did you have anything else to provide? 10:58:26
17 A. Sorry. This is Experimental Example 3? 10:54:48	17 A. Well, the bottom line is it is vague and 10:58:28
18 Q. Correct. 10:54:51	18 answering, you know, if it's -- perhaps if you took 10:58:35
19 A. You're asking me does it address preservative 10:54:52	19 an example they took the preservative out, 10:58:38
20 efficacy? 10:54:55	20 benzalkonium chloride out, you would have to do 10:58:41
21 Q. Correct. Does Experimental Example 3 10:54:56	21 tests to ensure it had preservative activity. 10:58:44
22 address preservative efficacy of the aqueous liquid 10:54:59	22 Q. Take a look back now at your declaration, if 10:58:47

Page 134	<p>1 you would, on page 5, paragraph 17, please. If you 10:58:50</p> <p>2 would just read that paragraph to yourself. 10:59:04</p> <p>3 Actually, I'm sorry, I think you're on the wrong 10:59:07</p> <p>4 page. 10:59:09</p> <p>5 A. Oh, sorry. 10:59:09</p> <p>6 Q. So, page 5? 10:59:10</p> <p>7 A. Oh, right. Okay. Sorry. What number did 10:59:10</p> <p>8 you say? 10:59:14</p> <p>9 Q. Paragraph 17. It's Section III, Materials 10:59:14</p> <p>10 Reviewed. Just read that to yourself and let me 10:59:17</p> <p>11 know when you're ready. 10:59:20</p> <p>12 A. Ready. 10:59:34</p> <p>13 Q. Okay. Which document or documents do you 10:59:35</p> <p>14 consider most important to your opinions in this 10:59:37</p> <p>15 case? 10:59:40</p> <p>16 MR. MARGOLIS: Objection. Vague. 10:59:42</p> <p>17 Compound. 10:59:44</p> <p>18 Q. You may answer. 10:59:45</p> <p>19 MR. MARGOLIS: And lacks foundation. 10:59:50</p> <p>20 THE WITNESS: In terms of the court, 11:00:01</p> <p>21 it's obviously the intrinsic evidence, which 11:00:03</p> <p>22 would be the claims themselves and patent 11:00:06</p>
Page 135	<p>1 specification and the prosecution history. 11:00:08</p> <p>2 Q. Which document or documents do you consider 11:00:10</p> <p>3 least important to your opinions in this case? 11:00:13</p> <p>4 MR. MARGOLIS: Objection. Vague. 11:00:16</p> <p>5 Compound. Lacks foundation. 11:00:18</p> <p>6 Q. You may answer. 11:00:20</p> <p>7 A. That would be very difficult because that 11:00:21</p> <p>8 would depend what the intrinsic evidence was. 11:00:24</p> <p>9 Q. Which document did you consider first in 11:00:27</p> <p>10 connection with your opinions in this case? 11:00:30</p> <p>11 MR. MARGOLIS: Objection. Vague. 11:00:33</p> <p>12 Compound. 11:00:35</p> <p>13 THE WITNESS: The first documents to do 11:00:40</p> <p>14 with this case that I read were the patents 11:00:43</p> <p>15 themselves, the whole specifications. 11:00:46</p> <p>16 Q. From whom did you obtain the documents that 11:00:48</p> <p>17 you considered in connection with your opinions in 11:00:51</p> <p>18 this case? 11:00:53</p> <p>19 MR. MARGOLIS: Objection. Compound. 11:00:54</p> <p>20 Vague. 11:00:56</p> <p>21 Q. You may answer. 11:00:58</p> <p>22 A. The attorneys. 11:01:02</p>
Page 136	<p>1 Q. And in your previous answer when you said the 11:01:04</p> <p>2 patents themselves with the whole specifications 11:01:09</p> <p>3 were the documents that you considered first in 11:01:13</p> <p>4 connection with your opinions in this case, you are 11:01:15</p> <p>5 referring to the patents-in-suit, correct? 11:01:17</p> <p>6 A. I am. 11:01:19</p> <p>7 MR. HASFORD: It looks like we're about 11:01:22</p> <p>8 ready for another tape change. Is this a 11:01:23</p> <p>9 good time for a break? 11:01:26</p> <p>10 A. This is an excellent time for a break. 11:01:27</p> <p>11 THE VIDEOGRAPHER: The time is 11:01:31</p> <p>12 approximately 11:02 a.m., Friday, September 11:01:36</p> <p>13 4, 2015. This is the end of tape number two 11:01:45</p> <p>14 of the videotaped deposition of Dr. Jayne 11:01:48</p> <p>15 Lawrence. We are off the record. 11:01:51</p> <p>16 (Recess from 11:02 to 11:21.) 11:01:53</p> <p>17 THE VIDEOGRAPHER: The time is 11:19:18</p> <p>18 approximately 11:21 a.m., Friday, September 11:19:58</p> <p>19 4, 2015. This is tape number three of the 11:20:05</p> <p>20 videotaped deposition of Dr. Jayne Lawrence. 11:20:08</p> <p>21 We are back on the record. 11:20:11</p> <p>22 BY MR. HASFORD: 11:20:13</p>
Page 137	<p>1 Q. Turn if you would, Doctor, to page 5 of your 11:20:13</p> <p>2 declaration and look at paragraph 18. It says, "I 11:20:16</p> <p>3 understand that for claim construction purposes, the 11:20:21</p> <p>4 Court will look to the meaning a person having 11:20:23</p> <p>5 ordinary skill in the art at the time of the 11:20:25</p> <p>6 invention would have ascribed to disputed claim 11:20:28</p> <p>7 terms, in view of the specification and prosecution 11:20:31</p> <p>8 history." 11:20:34</p> <p>9 Do you see that? 11:20:34</p> <p>10 A. I do. 11:20:35</p> <p>11 Q. Do you have an understanding of the 11:20:35</p> <p>12 significance of the plain language of the claims for 11:20:37</p> <p>13 claim construction purposes? 11:20:40</p> <p>14 A. I do. 11:20:43</p> <p>15 Q. What is your understanding? 11:20:44</p> <p>16 A. I thought I put it in there. I'm not an 11:20:52</p> <p>17 attorney. So I have an understanding, but I -- I 11:21:14</p> <p>18 thought I had written it down, but I don't have it 11:21:17</p> <p>19 written down. 11:21:21</p> <p>20 Q. What is your general understanding of the 11:21:23</p> <p>21 significance of the plain language of the claims for 11:21:25</p> <p>22 claim construction purposes? 11:21:28</p>

Page 138	Page 140
<p>1 MR. MARGOLIS: Objection. Vague. 11:21:30</p> <p>2 THE WITNESS: Explain -- to me, it means 11:21:39</p> <p>3 the plain and ordinary means what anybody who 11:21:50</p> <p>4 is skilled in the art would understand to be 11:21:54</p> <p>5 correct. Is that okay? 11:21:57</p> <p>6 Q. I'm just asking for your understanding. Take 11:21:59</p> <p>7 a look at paragraph 19, if you would. And the first 11:22:06</p> <p>8 sentence says, "With respect to the level of 11:22:10</p> <p>9 ordinary skill in the art at the relevant times 11:22:12</p> <p>10 applicable to the subject patents, I understand that 11:22:15</p> <p>11 factors such as the education level of those working 11:22:17</p> <p>12 in the field, the sophistication of the technology, 11:22:20</p> <p>13 the types of problems encountered in the art, the 11:22:23</p> <p>14 prior art solutions to those problems, and the speed 11:22:25</p> <p>15 at which innovations are made may help establish the 11:22:28</p> <p>16 level of skill in the art." 11:22:31</p> <p>17 Do you see that? 11:22:33</p> <p>18 A. I do. 11:22:33</p> <p>19 Q. What is your understanding of the 11:22:34</p> <p>20 sophistication of the technology of the 11:22:36</p> <p>21 patents-in-suit? 11:22:38</p> <p>22 A. Can I just check I've got the correct 11:22:49</p>	<p>1 A. Okay. 11:23:53</p> <p>2 Q. So, let me ask the question again just to be 11:23:53</p> <p>3 clear. 11:23:56</p> <p>4 How complex are the types of problems 11:23:56</p> <p>5 encountered in the art of the patents-in-suit? 11:24:00</p> <p>6 MR. MARGOLIS: Objection. Vague. 11:24:04</p> <p>7 THE WITNESS: I could list some examples 11:24:07</p> <p>8 of formulations that are encountered. 11:24:10</p> <p>9 Q. Please do. 11:24:15</p> <p>10 A. If it's a solution formulation, it's 11:24:18</p> <p>11 important that there are no large particulate 11:24:25</p> <p>12 contaminants in the formulation. If it's a 11:24:30</p> <p>13 suspension formulation, it's important that the 11:24:34</p> <p>14 particles or the suspension are small enough and not 11:24:37</p> <p>15 too large. That could be a problem due to poor 11:24:42</p> <p>16 stability of the formulation. So that's an example 11:24:47</p> <p>17 of a type of problem encountered. 11:24:49</p> <p>18 Q. Are there any other examples? 11:24:52</p> <p>19 A. One very practical problem is getting the 11:24:56</p> <p>20 formulation viscous enough to stay in the eye but 11:25:03</p> <p>21 not too viscous to come out of the eye drop bottle, 11:25:08</p> <p>22 for example. 11:25:13</p>
Page 139	Page 141
<p>1 understanding? So, you're asking me what I think of 11:22:52</p> <p>2 the formulations that are contained in the patents 11:22:55</p> <p>3 at the time of the patents? 11:23:00</p> <p>4 Q. I think that is generally correct. I'm just 11:23:01</p> <p>5 looking for your understanding because you used the 11:23:04</p> <p>6 phrase sophistication of technology here. So then 11:23:06</p> <p>7 my question is what is your understanding of the 11:23:09</p> <p>8 sophistication of the technology of the 11:23:12</p> <p>9 patents-in-suit? 11:23:13</p> <p>10 A. They are relatively simple ophthalmic 11:23:15</p> <p>11 preparations, nothing particularly sophisticated 11:23:22</p> <p>12 about the formulation at all. It contains standard 11:23:25</p> <p>13 ingredients. 11:23:31</p> <p>14 Q. How complex are the types of problems 11:23:31</p> <p>15 encountered in the art of the patents-in-suit? 11:23:33</p> <p>16 MR. MARGOLIS: Objection. Vague. 11:23:38</p> <p>17 THE WITNESS: Could you give me some 11:23:40</p> <p>18 examples of the problems? 11:23:41</p> <p>19 Q. Well, I'm trying to get at your statement 11:23:43</p> <p>20 here. In paragraph 19 you say the types of problems 11:23:46</p> <p>21 encountered in the art. 11:23:49</p> <p>22 Do you see that? 11:23:51</p>	<p>1 Q. Are there any other examples? 11:25:13</p> <p>2 A. We spoke about stability in respect to 11:25:16</p> <p>3 particulates, but there might be stability in the 11:25:24</p> <p>4 container that you choose to put the formulation in, 11:25:26</p> <p>5 there might be problems once you -- there's two 11:25:31</p> <p>6 types of stability. There's the shelf-life 11:25:34</p> <p>7 stability, and then there's the stability once the 11:25:39</p> <p>8 formulation is opened, and they may be -- opened and 11:25:41</p> <p>9 in use, and they may be different, and that is 11:25:44</p> <p>10 something else that you need to consider. 11:25:47</p> <p>11 You need to make sure you're not introducing 11:25:50</p> <p>12 anything damaging that's going to irritate into the 11:25:53</p> <p>13 eye. 11:25:56</p> <p>14 Q. Are there any other examples? 11:25:57</p> <p>15 A. I'm sure there are, but they are the ones 11:26:01</p> <p>16 that I can think of at the moment. 11:26:03</p> <p>17 Q. Take a look at the last sentence in the 11:26:05</p> <p>18 paragraph, and it's going to be at the top of page 11:26:09</p> <p>19 6. The last sentence in paragraph 19 of your 11:26:13</p> <p>20 declaration at the top of page 6, it says, "A person 11:26:16</p> <p>21 of ordinary skill in the art is also a person of 11:26:18</p> <p>22 ordinary creativity, not a robot." 11:26:20</p>

Page 142	<p>1 Do you see that? 11:26:23</p> <p>2 A. I do. 11:26:23</p> <p>3 Q. Why is it significant that a person of 11:26:24</p> <p>4 ordinary skill in the art of the patents-in-suit is 11:26:26</p> <p>5 a person of ordinary creativity, not a robot? 11:26:28</p> <p>6 MR. MARGOLIS: Objection. Lack of 11:26:32</p> <p>7 foundation. 11:26:34</p> <p>8 Q. You may answer. 11:26:35</p> <p>9 A. The person who is skilled in the art has to 11:26:37</p> <p>10 have some ability to problem-solve once problems are 11:26:41</p> <p>11 encountered with the formulation. They should also 11:26:47</p> <p>12 be able to take ideas perhaps from one field and 11:26:52</p> <p>13 apply it to another field. 11:26:57</p> <p>14 Q. And when you say problem-solve, are you 11:26:58</p> <p>15 referring to the problems about which you just 11:27:01</p> <p>16 testified? 11:27:04</p> <p>17 A. It could be wider than that, but yes, that is 11:27:05</p> <p>18 included. 11:27:07</p> <p>19 Q. Okay. Take a look at page 6 of your 11:27:08</p> <p>20 declaration, paragraph 20. 11:27:12</p> <p>21 A. Yes. 11:27:14</p> <p>22 Q. Read that to yourself and let me know when 11:27:15</p>	Page 144	<p>1 definitions that any courts have adopted in other 11:28:16</p> <p>2 cases? 11:28:19</p> <p>3 A. I did not. 11:28:21</p> <p>4 Q. In proposing your definition of a person of 11:28:22</p> <p>5 ordinary skill in the art, did you consider the 11:28:24</p> <p>6 education level of the inventors of the 11:28:26</p> <p>7 patents-in-suit? 11:28:28</p> <p>8 A. Not explicitly. 11:28:38</p> <p>9 Q. What art do you consider relevant to the 11:28:41</p> <p>10 patents-in-suit? 11:28:42</p> <p>11 MR. MARGOLIS: Objection. Vague. 11:28:44</p> <p>12 THE WITNESS: So, "what arts" did you 11:29:01</p> <p>13 say? 11:29:03</p> <p>14 Q. Yes. What art do you consider relevant to 11:29:03</p> <p>15 the patents-in-suit? 11:29:06</p> <p>16 MR. MARGOLIS: Objection. Vague. 11:29:08</p> <p>17 THE WITNESS: It's important that the 11:29:10</p> <p>18 person has a high level of understanding of 11:29:13</p> <p>19 pharmaceutical science, has expertise in 11:29:17</p> <p>20 formulating products, pharmaceuticals in 11:29:22</p> <p>21 general, has experience of conducting a 11:29:29</p> <p>22 research, ideally has experience of 11:29:32</p>
Page 143	<p>1 you're ready. 11:27:23</p> <p>2 A. Yes. 11:27:24</p> <p>3 Q. Do you cite anything in support of your 11:27:24</p> <p>4 proposed definition of a person of ordinary skill in 11:27:27</p> <p>5 the art of the patents-in-suit? 11:27:30</p> <p>6 A. No. 11:27:33</p> <p>7 Q. In proposing your definition of a person of 11:27:34</p> <p>8 ordinary skill in the art, did you consider the 11:27:36</p> <p>9 definitions that any other experts have provided in 11:27:38</p> <p>10 other cases? 11:27:41</p> <p>11 A. I thought very long and hard about this 11:27:45</p> <p>12 definition. It comes from having experience of 11:27:50</p> <p>13 something like the pharmaceutical industry at that 11:27:56</p> <p>14 period and the average qualifications of somebody. 11:27:58</p> <p>15 Q. Okay. My question is just a little 11:28:01</p> <p>16 different. In proposing your definition of a person 11:28:03</p> <p>17 of ordinary skill in the art, did you consider the 11:28:05</p> <p>18 definitions that any other experts have provided in 11:28:07</p> <p>19 other cases? 11:28:10</p> <p>20 A. I did not. 11:28:11</p> <p>21 Q. In proposing your definition of a person of 11:28:12</p> <p>22 ordinary skill in the art, did you consider the 11:28:14</p>	Page 145	<p>1 conducting a research program, which is why 11:29:36</p> <p>2 we talk about the ordinary creativity because 11:29:39</p> <p>3 somebody with a Ph.D. is proven to have those 11:29:43</p> <p>4 skills, and somebody who has experience in 11:29:47</p> <p>5 parenteral -- ideally parenteral formulation. 11:29:52</p> <p>6 Q. As of 2003, would a person of ordinary skill 11:29:55</p> <p>7 in the art of the patents-in-suit have been 11:29:59</p> <p>8 generally aware of U.S. Food & Drug Administration 11:30:01</p> <p>9 regulations? 11:30:04</p> <p>10 A. They would. 11:30:05</p> <p>11 Q. In your opinion, would the inventors of the 11:30:06</p> <p>12 patents-in-suit be considered persons of ordinary 11:30:08</p> <p>13 skill in the art? 11:30:11</p> <p>14 MR. MARGOLIS: Objection. Lack of 11:30:12</p> <p>15 foundation. 11:30:14</p> <p>16 THE WITNESS: I can't answer that 11:30:14</p> <p>17 question. 11:30:16</p> <p>18 Q. In your opinion, would the patent examiner 11:30:17</p> <p>19 who allowed the patents-in-suit be considered a 11:30:19</p> <p>20 person of ordinary skill in the art? 11:30:22</p> <p>21 MR. MARGOLIS: Objection. Lacks 11:30:24</p> <p>22 foundation. 11:30:25</p>

Page 146	Page 148
<p>1 THE WITNESS: I have no experience of 11:30:29</p> <p>2 the education level of the person working in 11:30:32</p> <p>3 the patents office, so I can't answer. 11:30:35</p> <p>4 Q. Would a biomedical engineer be a person of 11:30:37</p> <p>5 ordinary skill in the art of the patents-in-suit? 11:30:40</p> <p>6 MR. MARGOLIS: Objection. Vague. Calls 11:30:43</p> <p>7 for speculation. 11:30:45</p> <p>8 THE WITNESS: I would have to look at 11:30:47</p> <p>9 his CV or her CV to be able to answer that 11:30:50</p> <p>10 one. I'm sorry. 11:30:53</p> <p>11 Q. Would a medical doctor be a person of 11:30:54</p> <p>12 ordinary skill in the art of the patents-in-suit? 11:30:55</p> <p>13 MR. MARGOLIS: Objection. Vague. Calls 11:30:58</p> <p>14 for speculation. 11:31:00</p> <p>15 THE WITNESS: I really can't answer that 11:31:01</p> <p>16 one either. I suspect most medics won't be, 11:31:04</p> <p>17 but then some medics could be. So I just 11:31:07</p> <p>18 can't answer. I don't have the information 11:31:10</p> <p>19 in front of me to do that. 11:31:14</p> <p>20 Q. Do you know Dr. Robert O. Williams, III? 11:31:15</p> <p>21 A. No. 11:31:19</p> <p>22 Q. Take a look, if you would, at again page 6 of 11:31:19</p>	<p>1 claims and put them into context of the correct -- 11:32:19</p> <p>2 I'm not going to explain this very well -- in the 11:32:23</p> <p>3 correct science or understanding at that time. 11:32:26</p> <p>4 Q. And what is the correct science or 11:32:33</p> <p>5 understanding as of 2003 in your view with respect 11:32:35</p> <p>6 to the patents-in-suit? 11:32:39</p> <p>7 A. That is a very wide question. It would 11:32:42</p> <p>8 depend, obviously, on the particular aspect of the 11:32:46</p> <p>9 patents you're looking at. 11:32:50</p> <p>10 Q. What aspects could it touch on? 11:32:51</p> <p>11 A. Again, that is very wide. I don't know what 11:33:04</p> <p>12 you mean by what aspects could it touch on? Sorry. 11:33:08</p> <p>13 It's just too vague for me to answer. You need to 11:33:11</p> <p>14 be more specific. 11:33:14</p> <p>15 Q. Well, as of 2003, what is -- let me strike 11:33:14</p> <p>16 that. 11:33:18</p> <p>17 What is your understanding of the state of 11:33:18</p> <p>18 the art as of 2003 with respect to the 11:33:21</p> <p>19 patents-in-suit? 11:33:24</p> <p>20 MR. MARGOLIS: Objection. Vague. 11:33:27</p> <p>21 THE WITNESS: That is really hard to 11:33:34</p> <p>22 answer. I'm not certain what you are asking 11:33:36</p>
Page 147	Page 149
<p>1 your declaration, at now paragraph 23. In paragraph 11:31:25</p> <p>2 23 you state, "I understand that to determine how 11:31:28</p> <p>3 the skilled person would have understood disputed 11:31:30</p> <p>4 claim language, courts first look to the 'intrinsic 11:31:34</p> <p>5 evidence,' the words of the claims themselves, the 11:31:37</p> <p>6 patent specification and the prosecution history. I 11:31:40</p> <p>7 understand that statements in related patent 11:31:44</p> <p>8 applications can also be relevant to claim 11:31:46</p> <p>9 construction." 11:31:48</p> <p>10 Do you see that? 11:31:49</p> <p>11 A. I do. 11:31:49</p> <p>12 Q. Do you have an understanding of the plain and 11:31:50</p> <p>13 ordinary meaning of the claims of the 11:31:53</p> <p>14 patents-in-suit? 11:31:55</p> <p>15 A. I thought you already asked that -- I 11:31:56</p> <p>16 answered that. I believe I do. 11:31:59</p> <p>17 Q. What is your understanding of the plain and 11:32:01</p> <p>18 ordinary mean of the claims of the patents-in-suit? 11:32:04</p> <p>19 MR. MARGOLIS: Objection. Compound. 11:32:07</p> <p>20 Vague. 11:32:09</p> <p>21 Q. You may answer. 11:32:10</p> <p>22 A. My understanding of that is you take the 11:32:14</p>	<p>1 me. What aspect of the patents you are 11:33:40</p> <p>2 asking me about. 11:33:42</p> <p>3 Q. Well, I'm asking you about the patents as a 11:33:43</p> <p>4 whole now. What is your understanding of the state 11:33:46</p> <p>5 of the art as of 2003 with respect to the 11:33:48</p> <p>6 patents-in-suit? 11:33:50</p> <p>7 MR. MARGOLIS: Objection. Vague. 11:33:53</p> <p>8 THE WITNESS: It seems like you're 11:34:00</p> <p>9 asking me about the sophistication and the 11:34:02</p> <p>10 technology. 11:34:04</p> <p>11 Q. Is that your understanding of the state of 11:34:06</p> <p>12 the art? 11:34:08</p> <p>13 A. That is part of the state of the art. It's 11:34:09</p> <p>14 not completely the state of the art. 11:34:16</p> <p>15 Q. So, what is your understanding of the state 11:34:18</p> <p>16 of the art as of 2003 with respect to 11:34:21</p> <p>17 patents-in-suit? 11:34:24</p> <p>18 MR. MARGOLIS: Objection. Vague. 11:34:25</p> <p>19 THE WITNESS: I'm really not too sure to 11:34:54</p> <p>20 what you are trying to get me to answer. I 11:34:58</p> <p>21 can talk about whether the patents were 11:35:01</p> <p>22 particularly ground-breaking or whether they 11:35:03</p>

Page 150	<p>1 were more pedestrian, whether they were 11:35:07</p> <p>2 advancement in the knowledge. I can talk 11:35:10</p> <p>3 about that, but I don't know if that's what 11:35:13</p> <p>4 you mean. 11:35:15</p> <p>5 Q. My question is a little bit more basic. 11:35:15</p> <p>6 Do you have an understanding of the state of 11:35:18</p> <p>7 the art as of 2003 -- 11:35:19</p> <p>8 A. What people were doing formulations with 11:35:21</p> <p>9 ophthalmic, yeah. 11:35:24</p> <p>10 Q. -- with respect to the patents-in-suit? 11:35:24</p> <p>11 A. What people -- I understand what people were 11:35:26</p> <p>12 doing with ophthalmic preparations, yes. 11:35:28</p> <p>13 Q. And what is your understanding? 11:35:30</p> <p>14 MR. MARGOLIS: Objection. Vague. 11:35:32</p> <p>15 THE WITNESS: So, the state of the art 11:35:35</p> <p>16 at the time, people were really starting to 11:35:37</p> <p>17 look at more novel formulations to improve 11:35:40</p> <p>18 delivery to the eye. The formulation we have 11:35:44</p> <p>19 here is not particularly exciting in terms of 11:35:47</p> <p>20 novelty. 11:35:52</p> <p>21 Q. Do you have any reason to dispute that the 11:35:53</p> <p>22 formulations of the patents-in-suit are novel? 11:35:57</p>	Page 152	<p>1 patents-in-suit in light of the prosecution 11:37:30</p> <p>2 histories? 11:37:32</p> <p>3 A. Sorry. You have to ask that question again. 11:37:36</p> <p>4 Q. Okay. Well, actually, let me -- you 11:37:38</p> <p>5 mentioned the prosecution -- 11:37:40</p> <p>6 A. Yes. 11:37:40</p> <p>7 Q. -- history in paragraph 23. Do you see that? 11:37:41</p> <p>8 Is it proper for a person of ordinary skill in the 11:37:43</p> <p>9 art to interpret the claims of the patents-in-suit 11:37:45</p> <p>10 in light of the prosecution histories? 11:37:48</p> <p>11 A. I believe it is, yes. 11:37:50</p> <p>12 Q. And then in the last sentence in that 11:37:52</p> <p>13 paragraph you talk about related patent 11:37:54</p> <p>14 applications. 11:37:58</p> <p>15 Do you see that? 11:37:59</p> <p>16 A. Yes. 11:37:59</p> <p>17 Q. And do you understand that claims in related 11:38:00</p> <p>18 patents can also be relevant to claim construction? 11:38:02</p> <p>19 A. Yes. 11:38:05</p> <p>20 Q. Take a look now at paragraph 24. I want to 11:38:05</p> <p>21 direct your attention to the second sentence in that 11:38:11</p> <p>22 paragraph, which is the first full sentence at the 11:38:13</p>
Page 151	<p>1 MR. MARGOLIS: Objection. Vague. 11:36:01</p> <p>2 THE WITNESS: I don't know how to answer 11:36:15</p> <p>3 that. So the question was specifically do I 11:36:17</p> <p>4 have any reasons to -- at the time of the 11:36:19</p> <p>5 patent, there were a large number of aqueous 11:36:22</p> <p>6 continuous phase formulations that contained 11:36:30</p> <p>7 surfactant, the ingredients of the patent and 11:36:33</p> <p>8 drug. That was not -- that was a fairly 11:36:39</p> <p>9 typical ophthalmic preparation at the time. 11:36:43</p> <p>10 Q. Let me go back, actually, to page 6 of your 11:36:54</p> <p>11 declaration, paragraph 23. You refer to the 11:36:57</p> <p>12 specification in that paragraph. 11:37:02</p> <p>13 Do you see that? 11:37:04</p> <p>14 A. 23 or 22? 11:37:05</p> <p>15 Q. 23. 11:37:07</p> <p>16 A. 23, yes, I do. I do, yes. 11:37:08</p> <p>17 Q. Is it proper for a person of ordinary skill 11:37:10</p> <p>18 in the art to interpret the claims of the 11:37:13</p> <p>19 patents-in-suit in light of the specification? 11:37:15</p> <p>20 A. I think that would be commonly done, yes. 11:37:23</p> <p>21 Q. Is it proper for a person of ordinary skill 11:37:26</p> <p>22 in the art to interpret the claims of the 11:37:28</p>	Page 153	<p>1 top of page 7. It says, "I understand that while 11:38:16</p> <p>2 courts may rely on extrinsic evidence, it is less 11:38:19</p> <p>3 significant than the patent and prosecution history 11:38:23</p> <p>4 in determining the meaning of claim language." 11:38:26</p> <p>5 Why is it your understanding that extrinsic 11:38:31</p> <p>6 evidence is less significant than the patent and 11:38:34</p> <p>7 prosecution history in determining the meaning of 11:38:36</p> <p>8 claim language? 11:38:39</p> <p>9 A. That's what I've been advised by the 11:38:40</p> <p>10 attorneys. 11:38:43</p> <p>11 Q. Take a look now at paragraph 25 on page 7. 11:38:44</p> <p>12 The first sentence says, "I understand that a claim 11:38:50</p> <p>13 term is indefinite, and therefore the claim is 11:38:53</p> <p>14 invalid, when the claim read in light of the 11:38:56</p> <p>15 specification and the prosecution history, fail to 11:38:59</p> <p>16 inform, with a reasonable certainty, those skilled 11:39:01</p> <p>17 in the art about the scope of the claimed 11:39:05</p> <p>18 invention." 11:39:08</p> <p>19 Do you see that? 11:39:08</p> <p>20 A. I do. 11:39:09</p> <p>21 Q. Is the standard for definiteness whether a 11:39:10</p> <p>22 claim makes sense to you or whether a claim informs 11:39:13</p>

Page 154	Page 156
1 with reasonable certainty those skilled in the art 11:39:17	1 Do you see that? 11:41:13
2 about the scope of the claimed invention? 11:39:19	2 A. I do. 11:41:14
3 MR. MARGOLIS: Objection. Vague. Calls 11:39:22	3 Q. What does it mean that bromfenac is a 11:41:14
4 for a legal conclusion. 11:39:25	4 non-steroidal anti-inflammatory drug or NSAID? 11:41:17
5 Q. You may answer. 11:39:28	5 A. That's quite a descriptive name. It is an 11:41:22
6 A. Say it again to make sure I get it correct? 11:39:37	6 anti-inflammatory drug, so it reduces inflammation 11:41:26
7 Q. Well, let me ask it more simply. Is the 11:39:39	7 in the body, so it's very good for things like 11:41:30
8 standard for definiteness whether a claim makes 11:39:41	8 muscle damage, for example. Non-steroidal means it 11:41:35
9 sense to you? 11:39:44	9 is not a steroid. Simple as that. 11:41:39
10 MR. MARGOLIS: Objection. Vague. Calls 11:39:45	10 Q. Do you have an understanding of the physical 11:41:42
11 for a legal conclusion. 11:39:46	11 and chemical properties of bromfenac? 11:41:44
12 THE WITNESS: To me personally? 11:39:48	12 MR. MARGOLIS: Objection. Vague. 11:41:48
13 Q. Correct. 11:39:49	13 THE WITNESS: It is vague. I have some 11:41:50
14 A. If I am somebody that is -- if I know about 11:39:51	14 understanding of the physical properties, 11:41:58
15 the art, it should make sense to me, but it should 11:39:55	15 yes. 11:42:02
16 also make sense to those skilled in the art. 11:39:59	16 Q. With what physical properties of bromfenac 11:42:02
17 Q. Are you a person of ordinary skill in the art 11:40:01	17 are you familiar? 11:42:04
18 or are you a person of something higher than 11:40:03	18 A. I'm familiar with its structure, I'm familiar 11:42:06
19 ordinary skill in the art? 11:40:06	19 with its aqueous solubility are the main two. 11:42:11
20 MR. MARGOLIS: Objection. Vague. 11:40:08	20 Q. What is your understanding of the aqueous 11:42:16
21 THE WITNESS: I consider myself to be an 11:40:10	21 solubility of bromfenac? 11:42:18
22 expert, but I have to understand -- I 11:40:13	22 A. I'm just looking at that definition there, 11:42:20
Page 155	Page 157
1 obviously still have to understand the terms. 11:40:15	1 and bromfenac sodium salt is actually very water 11:42:23
2 Q. Well, let me go back to the original question 11:40:19	2 soluble. The free acid is far less so. In the 11:42:29
3 then. Is the standard for definiteness whether a 11:40:22	3 literature, there's a lot of debate about the 11:42:35
4 claim makes sense to you personally or whether a 11:40:24	4 absolute levels of those solubilities, but certainly 11:42:39
5 claim informs with reasonable certainty those 11:40:26	5 the free acid is very insoluble compared to the 11:42:42
6 skilled in the art about the scope of the claimed 11:40:29	6 salt. 11:42:47
7 invention? 11:40:31	7 Q. How many different NSAIDs are known to exist? 11:42:47
8 A. It has to inform with reasonable certainty to 11:40:32	8 A. Quite a lot. 11:42:52
9 those skilled in the art about the claimed 11:40:35	9 Q. Do you know how many? 11:42:53
10 invention. 11:40:37	10 A. 20, 30, that sort of number. 11:42:55
11 Q. Take a look, if you would, at page 8, 11:40:37	11 Q. What are some of the different physical and 11:42:58
12 paragraph 32. 11:40:40	12 chemical properties that different NSAIDs possess? 11:43:01
13 A. Yes. 11:40:42	13 MR. MARGOLIS: Objection. Vague. Lack 11:43:05
14 Q. The first sentence says, "The patents-in-suit 11:40:43	14 of foundation. 11:43:07
15 are generally directed to anti-inflammatory 11:40:46	15 THE WITNESS: That is really difficult 11:43:08
16 ophthalmic formulations containing (1) 11:40:49	16 to talk about because there are sub-classes 11:43:10
17 2-amino-3-(4-bromobenzoyl) phenylacetic acid (also 11:40:53	17 of NSAIDs anyway, and they have different 11:43:15
18 known as bromfenac), a non-steroidal 11:40:59	18 structures. So it's slightly open-ended. 11:43:21
19 anti-inflammatory drug ('NSAID'), and (2) tyloxapol, 11:40:59	19 You need to be a little bit more specific. 11:43:25
20 a non-ionic surfactant, and methods for treating an 11:41:07	20 Q. Well -- and thank you for pointing out that 11:43:27
21 inflammatory disease by administering such 11:41:10	21 they have different structures. 11:43:30
22 formulations." 11:41:12	22 Can the physical and chemical properties of 11:43:32

Page 158	Page 160
<p>1 an NSAID be predicted from the physical and chemical 11:43:34</p> <p>2 properties of a different NSAID with a different 11:43:38</p> <p>3 chemical structure? 11:43:41</p> <p>4 MR. MARGOLIS: Objection. Vague. Calls 11:43:42</p> <p>5 for speculation. 11:43:43</p> <p>6 THE WITNESS: It is very vague, but 11:43:46</p> <p>7 somebody who is experienced in formulating 11:43:50</p> <p>8 would be able to look at a drug and the first 11:43:53</p> <p>9 approximation be able to expect its 11:44:00</p> <p>10 solubility to be insoluble, soluble, very 11:44:03</p> <p>11 soluble. 11:44:08</p> <p>12 Q. Have you ever accurately predicted the 11:44:08</p> <p>13 physical and chemical properties of an NSAID based 11:44:10</p> <p>14 on the physical and chemical properties of a 11:44:13</p> <p>15 different NSAID with a different chemical structure? 11:44:15</p> <p>16 A. You would not need to do that. 11:44:17</p> <p>17 Q. Why do different NSAIDs have different 11:44:19</p> <p>18 physical and chemical properties? 11:44:23</p> <p>19 MR. MARGOLIS: Objection. Lack of 11:44:25</p> <p>20 foundation. 11:44:27</p> <p>21 THE WITNESS: Because if the drug, if 11:44:32</p> <p>22 the NSAID is going to exert its effect, it's 11:44:41</p>	<p>1 So if it's in water, you may not. 11:45:54</p> <p>2 There are packages for predicting pKa 11:45:56</p> <p>3 and log P, not very reliably, but there are 11:45:59</p> <p>4 packages. Based on that information, coupled 11:46:03</p> <p>5 with what your dose of the drug is intended, 11:46:07</p> <p>6 wanted, desired dose of the drug, plus an 11:46:11</p> <p>7 intended route of administration, you could 11:46:16</p> <p>8 start to select some solvents and look at 11:46:20</p> <p>9 solubility. 11:46:24</p> <p>10 Q. Why would a person of ordinary skill in the 11:46:24</p> <p>11 art want to formulate new aqueous liquid 11:46:26</p> <p>12 preparations of NSAIDs? 11:46:29</p> <p>13 MR. MARGOLIS: Objection. Lack of 11:46:31</p> <p>14 foundation. Calls for speculation. 11:46:33</p> <p>15 THE WITNESS: There may be re-purposing 11:46:37</p> <p>16 of the drug. They might have decided that 11:46:43</p> <p>17 the drug could be used for some other 11:46:45</p> <p>18 purpose, or repositioning. It may be that 11:46:48</p> <p>19 the company wants to extend a product line. 11:46:52</p> <p>20 There's sort of a whole variety of reasons. 11:46:55</p> <p>21 Q. And are all of those part of the innovative 11:46:59</p> <p>22 scientific process of drug companies? 11:47:02</p>
Page 159	Page 161
<p>1 got to work at a particular site in the body, 11:44:44</p> <p>2 and some structural properties of the drug 11:44:48</p> <p>3 may be important for that interaction. The 11:44:53</p> <p>4 rest of the molecule might not be important. 11:44:55</p> <p>5 Q. How would a person of ordinary skill in the 11:44:59</p> <p>6 art go about formulating new aqueous liquid 11:45:01</p> <p>7 preparations of NSAIDs? 11:45:05</p> <p>8 MR. MARGOLIS: Objection. Vague. Calls 11:45:06</p> <p>9 for speculation. 11:45:08</p> <p>10 THE WITNESS: Okay. So the question was 11:45:11</p> <p>11 to look at formulating in water? 11:45:13</p> <p>12 Q. Yes. So, how would a person of ordinary 11:45:17</p> <p>13 skill in the art go about formulating new aqueous 11:45:19</p> <p>14 liquid preparations of NSAIDs? 11:45:23</p> <p>15 MR. MARGOLIS: Objection. Vague. Calls 11:45:26</p> <p>16 for speculation. 11:45:28</p> <p>17 THE WITNESS: Yeah, I can speculate 11:45:29</p> <p>18 vaguely. It's the same as any drug. NSAIDs 11:45:32</p> <p>19 are no different than any other drug molecule 11:45:37</p> <p>20 you would be looking at. You may have some 11:45:40</p> <p>21 physical data such as the measured log P, the 11:45:46</p> <p>22 pKa, its solubility, for instance, in water. 11:45:50</p>	<p>1 A. They would like to think so, yes. 11:47:04</p> <p>2 Q. Is there any limit -- sorry. Let me strike 11:47:08</p> <p>3 that and try again. 11:47:12</p> <p>4 Is there a limit to the number of different 11:47:13</p> <p>5 possible ways to formulate aqueous liquid 11:47:16</p> <p>6 preparations of NSAIDs? 11:47:19</p> <p>7 MR. MARGOLIS: Objection. Vague. 11:47:21</p> <p>8 THE WITNESS: It is vague, but there are 11:47:24</p> <p>9 a large number of ways you can try to 11:47:29</p> <p>10 formulate, some more successful than others. 11:47:32</p> <p>11 It would depend upon the dose and the route 11:47:42</p> <p>12 of administration you needed. 11:47:44</p> <p>13 Q. Would it depend on anything else? 11:47:46</p> <p>14 A. Well, it obviously depends -- well, it 11:47:56</p> <p>15 potentially depends upon whether you wanted a salt 11:47:58</p> <p>16 or a free acid or base, but there are other 11:48:02</p> <p>17 considerations. 11:48:07</p> <p>18 Q. How would a person of ordinary skill in the 11:48:08</p> <p>19 art go about characterizing the physical and 11:48:10</p> <p>20 chemical properties of aqueous liquid preparations 11:48:13</p> <p>21 of NSAIDs? 11:48:16</p> <p>22 MR. MARGOLIS: Objection. Vague. 11:48:19</p>

Page 162		Page 164	
1	Compound.	11:48:22	
2	THE WITNESS: This is -- what you're	11:48:27	
3	asking me to describe effectively is the	11:48:29	
4	pre-formulation process. If you wanted to	11:48:31	
5	formulate your drug in aqueous solution, you	11:48:41	
6	would mix the ingredients that you're	11:48:46	
7	interested in and then assay it in some way	11:48:48	
8	generally as a function of time to see	11:48:54	
9	whether the drug has remained intact, whether	11:49:00	
10	the physical state of the formulation hasn't	11:49:08	
11	changed, et cetera. We've discussed some of	11:49:11	
12	them before, basically. It's no different	11:49:16	
13	than the ones we discussed before.	11:49:17	
14	Q. Any others?	11:49:20	
15	A. I can't remember what I discussed before, to	11:49:21	
16	be honest.	11:49:24	
17	Q. Okay. Why would a person of ordinary skill	11:49:24	
18	in the art want to characterize the physical and	11:49:29	
19	chemical properties of aqueous liquid preparations	11:49:32	
20	of NSAIDs?	11:49:35	
21	MR. MARGOLIS: Objection. Lacks	11:49:36	
22	foundation.	11:49:39	
Page 163		Page 165	
1	THE WITNESS: If you were formulating an	11:49:42	
2	NSAID or other drug with a view to getting a	11:49:47	
3	marketing authorization, you would obviously	11:49:52	
4	have to have done the appropriate studies	11:49:55	
5	beforehand to submit to the regulatory	11:49:58	
6	authorities to get it on the market. So, at	11:50:01	
7	the very least, you have to do it from a	11:50:03	
8	regulatory point of view.	11:50:05	
9	Q. Any other reasons?	11:50:07	
10	A. By understanding stability or lack of and	11:50:10	
11	what type of lack of stability, you might be able to	11:50:15	
12	improve your formulation.	11:50:20	
13	Q. Any other reasons?	11:50:23	
14	A. I think it gives you an understanding and	11:50:31	
15	knowledge of the systems you're looking at, and then	11:50:33	
16	that is building up your database to be able to	11:50:35	
17	better formulate. That's what gives somebody skill	11:50:38	
18	in the art.	11:50:42	
19	Q. Any other reasons?	11:50:43	
20	A. I can't think of any offhand.	11:50:47	
21	Q. Do you have an understanding of the	11:50:49	
22	pharmacokinetic properties of bromfenac?	11:50:51	
1	MR. MARGOLIS: Objection. Vague.	11:50:56	
2	THE WITNESS: That is vague, and it	11:50:57	
3	would depend on the formulation route of	11:50:58	
4	administration anyway, so.	11:51:00	
5	Q. Do you have an understanding of the	11:51:01	
6	pharmacokinetic properties of any aqueous liquid	11:51:03	
7	preparations of bromfenac?	11:51:06	
8	MR. MARGOLIS: Objection. Vague.	11:51:09	
9	THE WITNESS: No.	11:51:10	
10	Q. Do you have an understanding of the	11:51:11	
11	pharmacodynamic properties of any aqueous liquid	11:51:12	
12	preparations of bromfenac?	11:51:15	
13	MR. MARGOLIS: Objection. Vague.	11:51:18	
14	THE WITNESS: No, I don't believe -- no,	11:51:19	
15	I don't believe I do.	11:51:20	
16	Q. Do you have an understanding of the	11:51:21	
17	toxicological properties of bromfenac?	11:51:22	
18	MR. MARGOLIS: Objection. Vague.	11:51:28	
19	THE WITNESS: Again, that really does	11:51:34	
20	depend upon how you're going to formulate it	11:51:36	
21	and route of administration, whether -- about	11:51:39	
22	the toxicology.	11:51:42	
1	Q. Do you have an understanding of the	11:51:43	
2	toxicological properties of any formulation of	11:51:45	
3	bromfenac?	11:51:47	
4	MR. MARGOLIS: Objection. Vague.	11:51:50	
5	THE WITNESS: No. But I have experience	11:51:53	
6	of working off other steroids, and it's not a	11:51:55	
7	particularly unusual steroid. I'm sorry.	11:52:00	
8	NSAID. Sorry. I didn't mean to say steroid,	11:52:03	
9	did I.	11:52:06	
10	Q. Do you have an understanding of the	11:52:06	
11	toxicological properties of any oral formulation of	11:52:08	
12	bromfenac?	11:52:12	
13	A. No.	11:52:13	
14	Q. Do you know the oil and water partition	11:52:14	
15	coefficient of bromfenac?	11:52:19	
16	A. No. I couldn't find it in the search.	11:52:21	
17	Q. Do you have -- I'm sorry. Were you finished	11:52:23	
18	with your answer?	11:52:26	
19	A. No. No. I searched for it and I couldn't	11:52:27	
20	find it.	11:52:28	
21	Q. Okay. Do you have an understanding of the	11:52:28	
22	properties of any oral formulations of bromfenac?	11:52:30	

Page 166	<p>1 MR. MARGOLIS: Objection. Vague. 11:52:35</p> <p>2 THE WITNESS: Such as? 11:52:40</p> <p>3 Q. Any of the properties? 11:52:42</p> <p>4 MR. MARGOLIS: Objection. Vague. 11:52:53</p> <p>5 THE WITNESS: I have some understanding 11:52:54</p> <p>6 of some issues around stability and of the 11:52:55</p> <p>7 solubility as a function of pH, that sort of 11:53:02</p> <p>8 thing. That's fairly obvious. 11:53:05</p> <p>9 Q. Take a look, if you would, in paragraph 32 11:53:07</p> <p>10 again of your declaration, page 8. We've talked a 11:53:14</p> <p>11 lot about non-ionic surfactants today and tyloxapol, 11:53:20</p> <p>12 and you referred to tyloxapol in paragraph 32 as a 11:53:24</p> <p>13 non-ionic surfactant. 11:53:27</p> <p>14 Do you see that? 11:53:29</p> <p>15 A. Yes. 11:53:30</p> <p>16 Q. What does it mean that tyloxapol is a 11:53:30</p> <p>17 non-ionic surfactant? 11:53:34</p> <p>18 A. Surfactants are amphiphilic molecules that 11:53:36</p> <p>19 have a hydrophobic and a hydrophilic head group and 11:53:42</p> <p>20 self-assembling solution. They are classified on 11:53:49</p> <p>21 the basis and natures of the head group. Two main 11:53:54</p> <p>22 classifications are non-ionic and ionic. Ionic can 11:54:00</p>	Page 168	<p>1 not fact, but that's sort of up to say 15, 20 11:55:12</p> <p>2 percent for micelles. 11:55:16</p> <p>3 Q. What is the critical micelle concentration of 11:55:18</p> <p>4 tyloxapol in aqueous liquid preparations? 11:55:20</p> <p>5 A. I can't remember that. I would have to look 11:55:23</p> <p>6 that up. 11:55:25</p> <p>7 Q. Have you ever determined the solubilizing 11:55:25</p> <p>8 capacity of tyloxapol based on the liquid nature of 11:55:28</p> <p>9 the micellar core? 11:55:32</p> <p>10 A. On the liquid nature of the micellar core? 11:55:35</p> <p>11 Okay. I have determined the solubility of drugs in 11:55:38</p> <p>12 tyloxapol micelles. 11:55:44</p> <p>13 Q. What drugs? 11:55:44</p> <p>14 A. Particularly steroids, but a range of drugs, 11:55:46</p> <p>15 phenylbutazone, which is an anti-inflammatory, 11:55:52</p> <p>16 aspirin, a whole variety of drugs. 11:55:55</p> <p>17 Q. Have you ever done that for bromfenac? 11:55:58</p> <p>18 A. No. 11:56:00</p> <p>19 Q. Does tyloxapol form vesicles in aqueous 11:56:01</p> <p>20 liquid preparations? 11:56:06</p> <p>21 MR. MARGOLIS: Objection. Vague. 11:56:07</p> <p>22 THE WITNESS: No, not to my knowledge. 11:56:12</p>
Page 167	<p>1 be positive and negative charged. Non-ionic has no 11:54:08</p> <p>2 charge. Sometimes lipids are included as non-ionic 11:54:12</p> <p>3 surfactants. These are molecules that have -- are 11:54:16</p> <p>4 zwitterionic, they're positive and negative charge 11:54:22</p> <p>5 in close proximity. 11:54:24</p> <p>6 Q. Is tyloxapol a polyethylene oxide surfactant? 11:54:26</p> <p>7 A. Yes, it is. 11:54:31</p> <p>8 Q. Does tyloxapol form micelles in aqueous 11:54:32</p> <p>9 liquid preparations? 11:54:36</p> <p>10 A. Yes. 11:54:36</p> <p>11 MR. MARGOLIS: Objection. Vague. 11:54:37</p> <p>12 Q. Under what circumstances does tyloxapol form 11:54:38</p> <p>13 micelles in aqueous liquid preparations? 11:54:42</p> <p>14 A. At relatively low concentrations it will 11:54:45</p> <p>15 self-assemble into micelles. 11:54:48</p> <p>16 Q. At what concentrations will it do that? 11:54:50</p> <p>17 MR. MARGOLIS: Objection. Vague. 11:54:54</p> <p>18 THE WITNESS: I don't have that, but 11:54:56</p> <p>19 certainly it will be -- I don't have the 11:54:58</p> <p>20 exact figures, but I can certainly make an 11:55:02</p> <p>21 estimate. It will be between point 0, 11:55:04</p> <p>22 perhaps 0 one percent, but I don't -- that's 11:55:09</p>	Page 169	<p>1 Q. Do you have an understanding of the physical 11:56:14</p> <p>2 and chemical properties of tyloxapol? 11:56:15</p> <p>3 A. Yes, I do. 11:56:18</p> <p>4 Q. With what physical and chemical properties of 11:56:19</p> <p>5 tyloxapol are you familiar? 11:56:21</p> <p>6 A. I'm familiar with its -- I don't have the 11:56:25</p> <p>7 figures in front of me, but I'm familiar with 11:56:29</p> <p>8 properties such as its ability to form micelles, the 11:56:31</p> <p>9 size of the micelles, the viscosity, the behavior of 11:56:36</p> <p>10 those micelles, the upper limit before it changes 11:56:40</p> <p>11 phase behavior, its cloud points. 11:56:45</p> <p>12 Q. How do those properties affect aqueous liquid 11:56:53</p> <p>13 preparations of NSAIDs that contain tyloxapol? 11:56:58</p> <p>14 MR. MARGOLIS: Objection. Lack of 11:57:02</p> <p>15 foundation. Vague. 11:57:04</p> <p>16 THE WITNESS: It would be very much 11:57:04</p> <p>17 looking on a case-by-case basis. 11:57:08</p> <p>18 Q. And why would it be very much looking on a 11:57:10</p> <p>19 case-by-case basis? 11:57:13</p> <p>20 A. Because an understanding of interaction 11:57:16</p> <p>21 between surfactants and drugs is quite complex. So 11:57:20</p> <p>22 you could predict possibly this drug's got low 11:57:27</p>

Page 170	Page 172
1 solubility, so it may solubilize or it may coat the 11:57:35	1 A. Yes. 11:59:30
2 drug, but you would have to check to prove it 11:57:38	2 Q. Do you see that? 11:59:31
3 unambiguously. 11:57:41	3 A. Yes. 11:59:31
4 Q. Can the physical and chemical properties of 11:57:43	4 Q. Is EDTA also known as edetic acid or 11:59:32
5 tyloxapol be predicted from the physical and 11:57:45	5 ethylenediaminetetraacetic acid? 11:59:36
6 chemical properties of a different non-ionic 11:57:48	6 A. Yes. 11:59:37
7 surfactant with a different chemical structure? 11:57:51	7 Q. Have you accurately depicted the chemical 11:59:39
8 MR. MARGOLIS: Objection. Vague. 11:57:55	8 structure of EDTA in paragraph 35 of your 11:59:42
9 THE WITNESS: We've already discussed 11:57:57	9 declaration? 11:59:45
10 this. There are certain rules you can use, 11:58:01	10 A. I believe I have, yes. 11:59:46
11 but it would depend upon the structure you're 11:58:06	11 Q. Take a look, if you would, now at page 11 of 11:59:48
12 talking about. In the absence of a 11:58:12	12 your declaration. 11:59:52
13 structure, it's very hard to say. 11:58:14	13 A. Yes. 11:59:52
14 Q. Have you ever accurately predicted the 11:58:16	14 Q. And let's look at paragraph 42. In the first 11:59:53
15 physical and chemical properties of tyloxapol -- 11:58:18	15 two sentences you say, "When present as a salt form, 11:59:56
16 A. Why would? 11:58:18	16 EDTA is generally referred to as an edetate salt. 12:00:00
17 Q. -- based on -- 11:58:20	17 Thus, there are four different edetate salts 12:00:03
18 A. Why would I need to? 11:58:21	18 consisting of EDTA and sodium: A monosodium, 12:00:06
19 Q. Sorry. Let me just. Sorry. Let me ask my 11:58:23	19 disodium, trisodium, and tetrasodium edetate salt." 12:00:10
20 question, just so we -- 11:58:26	20 Are those true statements? 12:00:15
21 A. Sorry. 11:58:26	21 A. Yes. 12:00:23
22 Q. -- have a clear record. No problem. 11:58:27	22 Q. Is EDTA a well-known chelating agent? 12:00:24
Page 171	Page 173
1 Have you ever accurately predicted the 11:58:28	1 A. It is. 12:00:29
2 physical and chemical properties of tyloxapol based 11:58:30	2 Q. What does it mean that EDTA is a chelating 12:00:29
3 on the physical and chemical properties of a 11:58:33	3 agent? 12:00:34
4 different non-ionic surfactant with a different 11:58:35	4 A. It will grab particularly ions and interact 12:00:36
5 chemical structure? 11:58:38	5 with them. So, in theory, it could, in theory, 12:00:42
6 MR. MARGOLIS: Objection. Vague. 11:58:39	6 interact with an ion with four positive charges on 12:00:48
7 THE WITNESS: I have used tyloxapol. I 11:58:42	7 it, but it typically is -- it's very well-known to 12:00:53
8 have measured its size, its behavior. I have 11:58:44	8 interact or chelate or sequester things like calcium 12:00:56
9 never had the need to do as you suggest. 11:58:48	9 with two charges. 12:01:00
10 Q. Have you ever determined the membrane active 11:58:52	10 Q. How does EDTA act as a chelating agent? 12:01:01
11 effects of tyloxapol? 11:58:56	11 A. You've got your ion, you've got the charges, 12:01:08
12 A. Not tyloxapol, no. 11:58:58	12 and the negative head groups interact with the 12:01:10
13 Q. Are you familiar with the various equilibrium 11:59:04	13 calcium. 12:01:14
14 phases of tyloxapol in aqueous liquid preparations? 11:59:07	14 Q. In EDTA sodium salt, is it the edetate or is 12:01:15
15 A. Yes. 11:59:10	15 it the sodium that is responsible for chelation? 12:01:20
16 Q. Take a look, if you would, now back to your 11:59:12	16 A. In the what? In the salt? It's the free 12:01:23
17 declaration, page 9, paragraph 35. 11:59:16	17 acids -- it's the acids, the ionized form. 12:01:27
18 A. Yes. 11:59:19	18 Q. The edetate? 12:01:28
19 Q. And you say, "EDTA, otherwise known as edetic 11:59:19	19 A. The ionized form of the edetate, yes. 12:01:30
20 acid or ethylenediaminetetraacetic acid, has the 11:59:23	20 Q. Do both the disodium and tetrasodium salts of 12:01:33
21 following chemical structure:" And then you provide 11:59:27	21 EDTA function as chelating agents? 12:01:37
22 a chemical structure. 11:59:30	22 A. Yes. 12:01:40

Page 174	Page 176
<p>1 Q. With both the disodium and tetrasodium salts 12:01:41</p> <p>2 of EDTA, does the edetate function as a chelating 12:01:44</p> <p>3 agent by binding and sequestering certain metal ions 12:01:48</p> <p>4 in solution? 12:01:53</p> <p>5 A. That's one way it can act as a chelator. 12:01:55</p> <p>6 Q. What other ways can it act? 12:01:58</p> <p>7 A. I don't know. I'm just trying to think. It 12:01:59</p> <p>8 doesn't have to be in solution, I think. I'm just 12:02:02</p> <p>9 trying to think about that one. That's why I 12:02:06</p> <p>10 qualified that. 12:02:08</p> <p>11 Q. What results from the chelation of metal ions 12:02:09</p> <p>12 by the disodium and tetrasodium salts of EDTA? 12:02:12</p> <p>13 MR. MARGOLIS: Objection. Vague. 12:02:17</p> <p>14 THE WITNESS: Sorry? 12:02:18</p> <p>15 Q. What results from the chelation of metal ions 12:02:19</p> <p>16 by the disodium and tetrasodium salts of EDTA? 12:02:21</p> <p>17 A. That's really vague. 12:02:21</p> <p>18 MR. MARGOLIS: Objection. Vague. 12:02:25</p> <p>19 Compound. 12:02:26</p> <p>20 THE WITNESS: That's really vague. I 12:02:26</p> <p>21 don't know how to -- what results? 12:02:27</p> <p>22 Q. Okay. I'm sorry. 12:02:30</p>	<p>1 to the meaning to the term besides the words 12:04:05</p> <p>2 themselves." 12:04:07</p> <p>3 Do you see that? 12:04:08</p> <p>4 A. I do. 12:04:08</p> <p>5 Q. Is it fair to say that the plain language of 12:04:09</p> <p>6 the claims of the patents-in-suit does not limit the 12:04:12</p> <p>7 phrases sodium edetate or EDTA sodium salt to edetic 12:04:15</p> <p>8 acid, tetrasodium salt or tetrasodium edetate? 12:04:20</p> <p>9 MR. MARGOLIS: Objection. Vague. 12:04:24</p> <p>10 THE WITNESS: I believe it does because 12:04:26</p> <p>11 the plain and ordinary language is sodium 12:04:29</p> <p>12 edetate is a particular form of EDTA. It's a 12:04:34</p> <p>13 particular salt of EDTA. 12:04:36</p> <p>14 Q. Do the terms or the -- let me strike that and 12:04:38</p> <p>15 try again. 12:04:40</p> <p>16 Do the phrases edetic acid, tetrasodium salt 12:04:41</p> <p>17 or tetrasodium edetate appear anywhere in the claims 12:04:44</p> <p>18 of the patents-in-suit? 12:04:47</p> <p>19 A. Do the words -- 12:04:49</p> <p>20 Q. Do the phrases edetic acid, tetrasodium salt 12:04:52</p> <p>21 or tetrasodium edetate appear anywhere in the claims 12:04:56</p> <p>22 of the patents-in-suit? 12:04:59</p>
Page 175	Page 177
<p>1 A. Sorry. 12:02:31</p> <p>2 Q. Yeah. Yeah. I apologize. I'm -- so, let me 12:02:32</p> <p>3 try to rephrase it for you. 12:02:36</p> <p>4 What is the result of the chelation process 12:02:37</p> <p>5 by the disodium and tetrasodium salts of EDTA? 12:02:41</p> <p>6 MR. MARGOLIS: Objection. Vague. 12:02:45</p> <p>7 Compound. 12:02:46</p> <p>8 THE WITNESS: In what circumstances? 12:02:47</p> <p>9 Q. In an aqueous liquid preparation. 12:02:49</p> <p>10 MR. MARGOLIS: Same objections. 12:02:52</p> <p>11 THE WITNESS: Yeah. If there are -- if 12:02:53</p> <p>12 there's calcium there, it may bind the 12:03:02</p> <p>13 calcium. 12:03:04</p> <p>14 Q. Okay. I apologize, Doctor. Take a look, if 12:03:15</p> <p>15 you would, at page 11, paragraph 43 of your 12:03:44</p> <p>16 declaration. 12:03:47</p> <p>17 A. Okay. 12:03:48</p> <p>18 Q. And you say, "I have reviewed the 12:03:50</p> <p>19 patents-in-suit, including the specification and the 12:03:54</p> <p>20 claims, and have found the terms 'sodium edetate' 12:03:56</p> <p>21 and 'EDTA sodium salt' used, but there is no 12:03:59</p> <p>22 explanation or definition or any other indication as 12:04:02</p>	<p>1 A. I would have to re-read them again. 12:05:03</p> <p>2 Q. Take as much time as you need. 12:05:06</p> <p>3 A. I'm just -- let me get this right. I'm very 12:05:11</p> <p>4 sorry to ask you yet again. Apologies. 12:05:14</p> <p>5 Q. That's okay. 12:05:17</p> <p>6 A. You're asking do the words sodium -- 12:05:17</p> <p>7 Q. Do the phrases edetic acid, tetrasodium salt 12:05:21</p> <p>8 or tetrasodium edetate appear anywhere in the claims 12:05:26</p> <p>9 of the patents-in-suit? 12:05:29</p> <p>10 A. I already looked at the first two patents, 12:07:01</p> <p>11 and I don't believe they do, but I don't see why 12:07:04</p> <p>12 they would appear because you don't give the full 12:07:06</p> <p>13 names of other chemicals in there either. 12:07:09</p> <p>14 Q. Is it fair to say that the specification of 12:07:12</p> <p>15 the patents-in-suit does not limit the phrases 12:07:14</p> <p>16 sodium edetate or EDTA sodium salt to edetic acid, 12:07:17</p> <p>17 tetrasodium salt or tetrasodium edetate? 12:07:23</p> <p>18 MR. MARGOLIS: Objection. Vague. 12:07:26</p> <p>19 THE WITNESS: I believe it does because 12:07:27</p> <p>20 it is -- sodium edetate and edetate sodium 12:07:30</p> <p>21 salt means something specific. 12:07:35</p> <p>22 Q. Do the patents say that? 12:07:37</p>

Page 178	Page 180
<p>1 MR. MARGOLIS: Objection. Vague. 12:07:42</p> <p>2 THE WITNESS: But they don't give the 12:07:45</p> <p>3 full names of any material. 12:07:48</p> <p>4 Q. The patents-in-suit nowhere use the term 12:07:49</p> <p>5 tetrasodium, do they? 12:07:52</p> <p>6 A. Well, there's no need to use the term 12:07:53</p> <p>7 tetrasodium because I think it's very -- it's 12:07:56</p> <p>8 explicit what they are. 12:07:58</p> <p>9 Q. Is it a fact that the patents-in-suit do not 12:07:59</p> <p>10 use the term tetrasodium? 12:08:02</p> <p>11 A. But they use the term sodium edetate and EDTA 12:08:07</p> <p>12 sodium salt, which is exactly the same material. 12:08:12</p> <p>13 Q. The patents-in-suit don't use the term 12:08:14</p> <p>14 tetrasodium, do they, Doctor? 12:08:17</p> <p>15 A. There's no need to use the term, though. 12:08:19</p> <p>16 Q. Take a look, if you would, at page 11, 12:08:23</p> <p>17 paragraph 44 of your declaration. 12:08:27</p> <p>18 A. Yes. 12:08:29</p> <p>19 Q. The first two sentences say, "I have reviewed 12:08:29</p> <p>20 the prosecution histories of the patents-in-suit and 12:08:33</p> <p>21 note that during prosecution of U.S. Patent No. 12:08:36</p> <p>22 8,129,431, the Applicants stated, '[n]ote that 12:08:39</p>	<p>1 Merck Index in connection with your opinions in this 12:09:48</p> <p>2 case? 12:09:49</p> <p>3 A. Yes. 12:09:49</p> <p>4 Q. And I believe it's Exhibit 2 to your 12:09:50</p> <p>5 declaration. If you could turn there? If I refer 12:09:54</p> <p>6 to Exhibit 2 to your declaration as excerpts from 12:10:00</p> <p>7 the 2001 Merck Index, will you understand what I 12:10:03</p> <p>8 mean? 12:10:06</p> <p>9 A. Yes. 12:10:06</p> <p>10 Q. Okay. Please turn to page 620 of the 2001 12:10:07</p> <p>11 Merck Index which bears Bates number LUPIN018905. 12:10:11</p> <p>12 Do you see entry number 3544 for edetate 12:10:17</p> <p>13 sodium in the 2001 Merck Index? 12:10:24</p> <p>14 A. Yes. 12:10:27</p> <p>15 Q. Do you see the Use designation toward the 12:10:27</p> <p>16 bottom of the entry 3544 for edetate sodium in the 12:10:40</p> <p>17 2001 Merck Index? 12:10:44</p> <p>18 Do you see that? 12:10:51</p> <p>19 A. I do. 12:10:52</p> <p>20 Q. It says, "Use: Sequestering agent: One gram 12:10:53</p> <p>21 complexes 215 milligrams calcium carbonate. Usually 12:11:02</p> <p>22 added to pharmaceuticals in the form of the calcium 12:11:06</p>
Page 179	Page 181
<p>1 sodium tetraborate is also known as borax, and EDTA 12:08:44</p> <p>2 sodium salt is also known as sodium edetate.' This 12:08:47</p> <p>3 statement suggests that 'EDTA sodium salt' is 12:08:51</p> <p>4 synonymous with 'sodium edetate,' but provides no 12:08:54</p> <p>5 further clarification of the meaning of these 12:08:56</p> <p>6 terms." 12:08:59</p> <p>7 A. Um-mm. 12:08:59</p> <p>8 Q. Does the prosecution history of the '431 12:09:00</p> <p>9 patent make clear that EDTA sodium salt is 12:09:02</p> <p>10 synonymous with sodium edetate? 12:09:05</p> <p>11 A. That's what I take the meaning of that 12:09:11</p> <p>12 sentence to be. 12:09:14</p> <p>13 Q. Did you see anywhere in the prosecution 12:09:15</p> <p>14 histories of the patents-in-suit where the phrases 12:09:18</p> <p>15 sodium edetate or EDTA sodium salt were limited to 12:09:21</p> <p>16 the tetrasodium forms? 12:09:25</p> <p>17 MR. MARGOLIS: Objection. Vague. 12:09:28</p> <p>18 THE WITNESS: There was no need to 12:09:32</p> <p>19 because it was very clear what they meant. 12:09:34</p> <p>20 Q. Take a look, if you would, at page 12 of your 12:09:36</p> <p>21 declaration, paragraph 45. 12:09:40</p> <p>22 Are you relying on the 2001 Edition of the 12:09:44</p>	<p>1 disodium salt to prevent calcium-depleting action in 12:11:09</p> <p>2 the body." 12:11:13</p> <p>3 Do you see that? 12:11:14</p> <p>4 A. I do. 12:11:14</p> <p>5 Q. The edetate sodium entry in the 2001 Merck 12:11:15</p> <p>6 Index states that it is usually added to 12:11:20</p> <p>7 pharmaceuticals in the form of a calcium disodium 12:11:21</p> <p>8 salt, correct? 12:11:24</p> <p>9 MR. MARGOLIS: Objection. 12:11:25</p> <p>10 Mischaracterizes the document. 12:11:26</p> <p>11 THE WITNESS: It's talking about a 12:11:27</p> <p>12 different form. It doesn't mean it's a 12:11:29</p> <p>13 sodium edetate. It's not the same thing. 12:11:32</p> <p>14 It's talking about a different material 12:11:34</p> <p>15 altogether. 12:11:36</p> <p>16 Q. But does it say that it's talking about a 12:11:36</p> <p>17 different material? 12:11:38</p> <p>18 A. Well, I think it's quite clear that it's 12:11:38</p> <p>19 talking about different materials because of the -- 12:11:40</p> <p>20 they've got different cast numbers. They've all got 12:11:43</p> <p>21 distinctly different cast numbers. 12:11:50</p> <p>22 Q. The statement about usually added to 12:11:52</p>

Page 182	Page 184
1 pharmaceuticals in the form of a calcium disodium 12:11:53	1 Edetate Calcium Disodium." 12:13:33
2 salt is specific to entry 3544 for sodium edetate, 12:11:57	2 Do you see that? 12:13:35
3 correct? 12:12:00	3 A. Oh, the bottom left thing, yeah. 12:13:39
4 MR. MARGOLIS: Objection. Vague. 12:12:01	4 Q. Do both the edetate sodium and the edetate 12:13:41
5 THE WITNESS: But it doesn't say -- it 12:12:03	5 disodium entries in the 2001 Merck Index refer to 12:13:44
6 doesn't say that they are synonymous. 12:12:05	6 the calcium disodium salt? 12:13:48
7 Q. But it doesn't say that they are not 12:12:08	7 A. I think you're confusing what I think is 12:13:51
8 synonymous, does it? 12:12:09	8 actually quite clear. Instead of actually 12:13:57
9 A. Well, anybody looking at this would know that 12:12:11	9 reproducing similar structures, somebody who had 12:14:00
10 it was this particular compound that they were 12:12:13	10 some basic knowledge in the area would know the 12:14:03
11 talking about rather than that compound. I'm sorry. 12:12:15	11 difference, the subtle differences between the 12:14:07
12 I'm pointing to that they would know that they were 12:12:17	12 various salt forms. 12:14:10
13 talking about the edetate calcium disodium entry 12:12:20	13 Q. My question is a little simpler than that. 12:14:11
14 3542 rather than 3544, which is the edetate sodium. 12:12:24	14 Do both the edetate sodium and the edetate disodium 12:14:14
15 Q. Let me ask it this way. Is the calcium 12:12:29	15 entries in the 2001 Merck Index refer to the calcium 12:14:17
16 disodium salt of EDTA different from the tetrasodium 12:12:32	16 disodium salt? 12:14:21
17 salt of EDTA? 12:12:36	17 MR. MARGOLIS: Objection. Vague. 12:14:23
18 A. It's the dicalcium salt -- or the calcium 12:12:38	18 THE WITNESS: That's putting words into 12:14:24
19 salt. 12:12:42	19 my mouth because lots of these things are 12:14:26
20 Q. Is the calcium disodium salt of EDTA 12:12:42	20 cross-referenced to each other. It doesn't 12:14:32
21 different from the tetrasodium salt of EDTA? 12:12:45	21 mean they're the same material. That's often 12:14:34
22 A. Yes. They're distinct different chemicals. 12:12:48	22 the case. 12:14:36
Page 183	Page 185
1 Q. Let me direct your attention to the edetate 12:12:50	1 Q. Well, I'm not trying to put words in your 12:14:37
2 disodium entry in the 2001 Merck Index which spans 12:12:53	2 mouth, Doctor. I'm just asking what the reference 12:14:39
3 the bottom of the left-hand column and the top of 12:12:57	3 teaches. 12:14:41
4 the right-hand column on page 620. It's entry 12:13:00	4 Do both the edetate sodium and edetate 12:14:41
5 number 3543. 12:13:04	5 disodium entries in the 2001 Merck Index refer to 12:14:45
6 Do you see that? 12:13:05	6 the calcium disodium salt? 12:14:48
7 A. Yes. 12:13:06	7 A. I don't think that's a teaching. 12:14:49
8 Q. Let me direct your attention to the last 12:13:07	8 Q. What do you think it is? 12:14:51
9 sentence of the paragraph spanning those two 12:13:09	9 A. I think it's just saving space that they've 12:14:52
10 columns. It says, "For structure, see Edetate 12:13:12	10 got -- why repeat -- reproduce four very similar 12:14:56
11 Calcium Disodium." 12:13:16	11 structures? 12:15:00
12 Do you see that? 12:13:17	12 Q. Take a look back to entry number 3544 for 12:15:00
13 A. Yes. Sorry. This is spanning the two 12:13:19	13 edetate sodium. And I want you to look about 12:15:04
14 columns? 12:13:24	14 halfway down through that entry, the line that 12:15:07
15 Q. Okay. Well, so, entry 3543 spans the two 12:13:24	15 begins with "Versene." 12:15:07
16 columns. It starts at the bottom of the left-hand 12:13:28	16 Do you see that? 12:15:11
17 column --	17 A. Um-mm. 12:15:12
18 A. That's right. Yeah.	18 Q. The second entry says, "Sequestrene." 12:15:12
19 Q. -- and goes to the top of the right-hand	19 Do you see that? 12:15:15
20 column.	20 A. Yes. 12:15:15
21 A. Yeah.	21 Q. Does the 2001 Merck Index identify 12:15:15
22 Q. And then it says, "For structure: See 12:13:31	22 Sequestrene as a synonym for edetate sodium? 12:15:20

Page 186	<p>1 A. Yep. 12:15:27</p> <p>2 Q. Does the 2001 Merck Index limit Sequestrene 12:15:27</p> <p>3 to the tetrasodium salt? 12:15:32</p> <p>4 A. I believe it does. 12:15:36</p> <p>5 Q. Do the claims of the patents -- let me strike 12:15:39</p> <p>6 that and try again. 12:15:42</p> <p>7 Do the claims of the patents-in-suit refer to 12:15:42</p> <p>8 the Merck Index? 12:15:46</p> <p>9 A. No. 12:15:47</p> <p>10 Q. Does the specification of the patents-in-suit 12:15:47</p> <p>11 refer to the Merck Index? 12:15:50</p> <p>12 A. No. This is extrinsic evidence. 12:15:52</p> <p>13 Q. Do the prosecution histories of the 12:15:55</p> <p>14 patents-in-suit refer to the Merck Index? 12:15:56</p> <p>15 A. No. 12:15:59</p> <p>16 Q. Take a look back at your declaration now, and 12:16:00</p> <p>17 let me direct your attention to page 12 and 12:16:03</p> <p>18 paragraph 47. 12:16:09</p> <p>19 Are you relying on the 2000 Edition of The 12:16:20</p> <p>20 Handbook of Pharmaceutical Excipients in connection 12:16:23</p> <p>21 with your opinions in this case? 12:16:26</p> <p>22 A. I am. 12:16:27</p>	Page 188	<p>1 Edition of The Handbook of Pharmaceutical 12:17:37</p> <p>2 Excipients? 12:17:39</p> <p>3 A. I think so. I think that was one of the ones 12:17:40</p> <p>4 that I did. And it's a joint American, British 12:17:43</p> <p>5 publication between the American Hospital 12:17:48</p> <p>6 Association -- or the American Association of 12:17:52</p> <p>7 Pharmaceutical Industries and the Royal 12:17:55</p> <p>8 Pharmaceutical Society. 12:17:57</p> <p>9 Q. In 2003, would a person of ordinary skill in 12:17:59</p> <p>10 the art have looked to The Handbook of 12:18:02</p> <p>11 Pharmaceutical Excipients -- 12:18:04</p> <p>12 A. Yes. 12:18:04</p> <p>13 Q. -- when formulating an aqueous liquid 12:18:05</p> <p>14 preparation? 12:18:07</p> <p>15 A. Definitely. 12:18:07</p> <p>16 Q. In 2003, would a person of ordinary skill in 12:18:08</p> <p>17 the art have considered The Handbook of 12:18:18</p> <p>18 Pharmaceutical Excipients an important reference for 12:18:21</p> <p>19 formulating an aqueous liquid preparation? 12:18:23</p> <p>20 MR. MARGOLIS: Objection. Vague. 12:18:27</p> <p>21 THE WITNESS: I think most formulators 12:18:29</p> <p>22 would have had a copy on their desk, a 12:18:31</p>
Page 187	<p>1 Q. And in the first sentence you say, "Another 12:16:27</p> <p>2 reference commonly used by a person of skill in the 12:16:29</p> <p>3 art to identify excipients in pharmaceutical 12:16:32</p> <p>4 formulations was The Handbook of Pharmaceutical 12:16:35</p> <p>5 Excipients ('Kibbe') by Arthur H. Kibbe, Ph.D. 12:16:38</p> <p>6 ('Kibbe')." 12:16:41</p> <p>7 Do you see that? 12:16:42</p> <p>8 A. I do. 12:16:43</p> <p>9 Q. Why is it your opinion that the 2000 Edition 12:16:43</p> <p>10 of The Handbook of Pharmaceutical Excipients was a 12:16:47</p> <p>11 reference commonly used by a person of ordinary 12:16:50</p> <p>12 skill in the art to identify excipients in 12:16:52</p> <p>13 pharmaceutical formulations? 12:16:54</p> <p>14 A. It's a book that is -- this is the third -- I 12:16:58</p> <p>15 think it's the third edition that we're talking 12:17:03</p> <p>16 about -- and that when you're looking at formulation 12:17:06</p> <p>17 and you want to formulate, there's a few places that 12:17:09</p> <p>18 you will go to to ensure that those excipients are 12:17:12</p> <p>19 suitable for pharmaceutical formulation, and the two 12:17:16</p> <p>20 most common places somebody would go to would be the 12:17:20</p> <p>21 SGA GRAS List and the handbook, this book. 12:17:31</p> <p>22 Q. Have you authored any monographs in the 2000 12:17:32</p>	Page 189	<p>1 standard reference copy. 12:18:35</p> <p>2 Q. In 2003, would a person of ordinary skill in 12:18:37</p> <p>3 the art have considered The Handbook of 12:18:39</p> <p>4 Pharmaceutical Excipients an important reference for 12:18:42</p> <p>5 formulating an aqueous liquid preparation? 12:18:43</p> <p>6 A. Yes, it would. 12:18:45</p> <p>7 MR. MARGOLIS: Objection. Vague. 12:18:47</p> <p>8 Q. Take a look, if you would, now at Exhibit 3 12:18:48</p> <p>9 to your declaration. And if I refer to Exhibit 3 to 12:18:51</p> <p>10 your declaration as excerpts from the 2000 Edition 12:18:56</p> <p>11 of The Handbook of Pharmaceutical Excipients, will 12:18:59</p> <p>12 you understand what I mean? 12:19:02</p> <p>13 A. Yes. 12:19:03</p> <p>14 Q. Take a look at page 191. It bears Bates 12:19:05</p> <p>15 number LUPIN010505. And let me direct your 12:19:09</p> <p>16 attention to part 7. 12:19:15</p> <p>17 A. Yes. 12:19:19</p> <p>18 Q. In that first paragraph the first sentence 12:19:21</p> <p>19 says, "Edetic acid and edetate salts are used in 12:19:25</p> <p>20 pharmaceutical formulations, cosmetics, and foods as 12:19:29</p> <p>21 chelating agents; that is, they form stable 12:19:33</p> <p>22 water-soluble complexes (chelates) with alkaline 12:19:36</p>

Page 190	<p>1 earth and heavy metal ions." 12:19:41</p> <p>2 Does this statement apply to both the 12:19:44</p> <p>3 disodium salt of EDTA and the tetrasodium salt of 12:19:46</p> <p>4 EDTA? 12:19:51</p> <p>5 A. Yes. 12:19:52</p> <p>6 Q. The second sentence reads, "The chelated form 12:19:53</p> <p>7 has few of the properties of the free ion, and for 12:19:56</p> <p>8 this reason chelating agents are often described as 12:20:00</p> <p>9 'removing' ions from solution; this process is also 12:20:04</p> <p>10 called sequestering." 12:20:08</p> <p>11 Does this statement apply to both the 12:20:10</p> <p>12 disodium salt of EDTA and the tetrasodium salt of 12:20:12</p> <p>13 EDTA? 12:20:17</p> <p>14 A. Yes. 12:20:23</p> <p>15 Q. And then the next sentence says, "The 12:20:24</p> <p>16 stability of the metal-edetate complex depends on 12:20:26</p> <p>17 the metal ion involved and also on the pH." 12:20:29</p> <p>18 Does this statement apply to both disodium 12:20:33</p> <p>19 edetate and tetrasodium edetate? 12:20:36</p> <p>20 A. It applies to all the edetate salts, yes. 12:20:39</p> <p>21 Q. Take a look, if you would, at page 192. It 12:20:42</p> <p>22 bears Bates number LUPIN010506. And take a look at 12:20:47</p>	Page 192	<p>1 would. Let me direct your attention to page 14, 12:22:03</p> <p>2 paragraph 50. 12:22:08</p> <p>3 Are you relying on the Burdock reference in 12:22:14</p> <p>4 connection with your opinions in this case? 12:22:16</p> <p>5 A. I am. 12:22:18</p> <p>6 Q. I believe it's Exhibit 7 in your tabs. If I 12:22:19</p> <p>7 refer to Exhibit 7 -- 12:22:29</p> <p>8 A. Yes. 12:22:30</p> <p>9 Q. -- to your declaration as the Burdock 12:22:31</p> <p>10 reference, will you understand what I mean? 12:22:33</p> <p>11 A. I will. 12:22:35</p> <p>12 Q. Take a look, if you would, at page 916 of the 12:22:36</p> <p>13 Burdock reference. It bears Bates number 12:22:40</p> <p>14 PROLENSA00006182. 12:22:44</p> <p>15 A. Yes. 12:22:48</p> <p>16 Q. Are you relying on the EDTA disodium entry in 12:22:49</p> <p>17 the Burdock reference in connection with your 12:22:55</p> <p>18 opinions in this case? 12:22:57</p> <p>19 A. I am. 12:22:58</p> <p>20 Q. The EDTA disodium entry in the Burdock 12:22:59</p> <p>21 reference lists a number of synonyms for EDTA 12:23:03</p> <p>22 disodium. 12:23:06</p>
Page 191	<p>1 number 18, Related Substances. 12:20:55</p> <p>2 A. Um-mm. 12:20:57</p> <p>3 Q. Does the 2000 Edition of The Handbook of 12:20:59</p> <p>4 Pharmaceutical Excipients identify the disodium salt 12:21:03</p> <p>5 of EDTA and the tetrasodium salt of EDTA as related 12:21:05</p> <p>6 substances to edetic acid and edetate salts? 12:21:11</p> <p>7 A. Yes. 12:21:16</p> <p>8 Q. Does the 2000 Edition of The Handbook of 12:21:17</p> <p>9 Pharmaceutical Excipients state that the phrases 12:21:21</p> <p>10 sodium edetate or EDTA sodium salt are defined to 12:21:22</p> <p>11 exclude the disodium salt of EDTA? 12:21:27</p> <p>12 MR. MARGOLIS: Objection. Vague. 12:21:31</p> <p>13 THE WITNESS: I'm really very sorry 12:21:33</p> <p>14 here. It is very clearly sodium edetate with 12:21:35</p> <p>15 a particular formula of a particular cast 12:21:39</p> <p>16 number that's different than another -- than 12:21:41</p> <p>17 this disodium edetate. They are clearly 12:21:44</p> <p>18 different compounds. If they were the same 12:21:47</p> <p>19 material or the same name, they would 12:21:54</p> <p>20 actually make that explicit in here so there 12:21:56</p> <p>21 would be no confusion. 12:22:00</p> <p>22 Q. Take a look back at your declaration, if you 12:22:00</p>	Page 193	<p>1 Do you -- 12:23:06</p> <p>2 A. Yes. 12:23:06</p> <p>3 Q. -- see that? Is that a "yes"? 12:23:07</p> <p>4 A. Yes. Sorry. 12:23:10</p> <p>5 Q. Back to paragraph 50 now of your 12:23:11</p> <p>6 declaration -- you might want to put a finger or a 12:23:16</p> <p>7 tab or something in there. So, paragraph 50 of your 12:23:18</p> <p>8 declaration, third sentence, it says, "The synonyms 12:23:28</p> <p>9 for 'EDTA, disodium' includes edetate disodium." 12:23:34</p> <p>10 In your opinion, does the Burdock reference 12:23:37</p> <p>11 state that the synonyms for EDTA disodium include 12:23:39</p> <p>12 edetate disodium? 12:23:43</p> <p>13 A. Ask the question again? I'm sorry. I lost 12:23:56</p> <p>14 you. 12:23:58</p> <p>15 Q. Sure. Okay. In your opinion, does the 12:23:58</p> <p>16 Burdock reference state that the synonyms for EDTA 12:23:59</p> <p>17 disodium include edetate disodium? 12:24:03</p> <p>18 A. Yes. 12:24:23</p> <p>19 Q. And so if you go back to the EDTA disodium 12:24:24</p> <p>20 entry in the Burdock reference -- 12:24:28</p> <p>21 A. Yes. 12:24:30</p> <p>22 Q. -- turn now to the next page, page 917, which 12:24:30</p>

Page 194	Page 196
1 bears Bates number PROLENSA00006183. 12:24:33	1 collectively as Edetates)." 12:26:27
2 A. Yes. 12:24:39	2 Are the salts of EDTA, including the disodium 12:26:29
3 Q. And let me direction your attention to the 12:24:40	3 salt of EDTA and the tetrasodium salt of EDTA 12:26:32
4 fifth line from the top. 12:24:43	4 collectively known as edetates? 12:26:36
5 A. Yes. 12:24:44	5 A. Yes. That's been stated earlier. 12:26:39
6 Q. Do you see that? 12:24:45	6 Q. And now take a look, if you would, at page 12:26:41
7 A. Yes. 12:24:47	7 96. It bears Bates number LUPIN018914. 12:26:44
8 Q. It says "EDTA sodium"? 12:24:47	8 A. Yes. 12:26:50
9 A. Yes. 12:24:49	9 Q. And toward the bottom it says, "Tetrasodium 12:26:51
10 Q. The Burdock reference states that EDTA sodium 12:24:49	10 EDTA." 12:26:57
11 is a synonym for EDTA disodium. 12:24:52	11 Do you see that? 12:26:58
12 A. Yes. 12:24:52	12 A. I do. 12:26:59
13 Q. Do you see that? 12:24:55	13 Q. In connection with your opinions in this 12:27:01
14 A. I'm aware of that. 12:24:56	14 case, are you relying on the entry entitled 12:27:03
15 Q. And then down to the fourth line from the 12:24:57	15 "Tetrasodium EDTA" that spans pages 95 -- sorry -- 12:27:06
16 bottom of the top section of page 917, the line that 12:24:58	16 96 to 97 of the Lanigan reference? 12:27:10
17 begins with "Sequestrene sodium." 12:25:02	17 A. I am. 12:27:13
18 Do you see that? 12:25:05	18 Q. At page 96, the bottom paragraph says, 12:27:14
19 A. Yes. 12:25:05	19 "Tetrasodium EDTA is also known as Edetate Sodium." 12:27:19
20 Q. And the next entry, the Burdock reference 12:25:06	20 And then page 97, the second line says, "EDTA 12:27:25
21 states that sodium ethylenediaminetetraacetate is a 12:25:08	21 Disodium." 12:27:32
22 synonym for EDTA disodium. 12:25:13	22 Do you see that? 12:27:32
Page 195	Page 197
1 Do you see that? 12:25:15	1 A. Yes. 12:27:33
2 A. Yes. 12:25:16	2 Q. In the entry entitled "Tetrasodium EDTA" on 12:27:33
3 Q. Okay. Take a look now back at -- on your 12:25:16	3 pages 96 to 97 of the Lanigan reference, does the 12:27:37
4 declaration, page 13, paragraph 48. 12:25:19	4 Lanigan reference treat edetate sodium and EDTA 12:27:42
5 Are you relying on the Lanigan reference -- 12:25:31	5 disodium as one and the same? 12:27:46
6 A. I am. 12:25:34	6 MR. MARGOLIS: Objection. Vague. 12:27:49
7 Q. -- in connection with your opinions in this 12:25:34	7 THE WITNESS: Under the -- under the 12:27:51
8 case? 12:25:36	8 heading Trisodium EDTA, you're directing me 12:27:58
9 And I apologize, Doctor, just for the court 12:25:36	9 to look at what? 12:28:06
10 reporter, if we could wait until I am finished 12:25:38	10 Q. No. No. I'm directing you to look at the 12:28:07
11 asking the question. So, I'll try it again. 12:25:42	11 second line at the top of page 97. 12:28:09
12 Are you relying on the Lanigan reference in 12:25:43	12 Do you see that it says, "EDTA Disodium"? 12:28:13
13 connection with your opinions in this case? 12:25:45	13 A. I do. 12:28:16
14 A. I am. 12:25:47	14 Q. And that's within the entry for Tetrasodium 12:28:16
15 Q. Okay. Thank you. If I refer to Exhibit 4 to 12:25:47	15 EDTA? 12:28:21
16 your declaration as the Lanigan reference, will you 12:25:52	16 A. Yes. 12:28:21
17 understand what I mean? 12:25:53	17 Q. Do you see that? 12:28:22
18 A. Yes. Yes. Sorry. 12:25:55	18 A. I do. 12:28:22
19 Q. Take a look at page 95 of the Lanigan 12:26:03	19 Q. Okay. In the entry entitled Tetrasodium EDTA 12:28:22
20 reference. It bears Bates number LUPIN018913. And 12:26:14	20 on pages 96 to 97 -- 12:28:40
21 at the top of the right-hand column, the first full 12:26:20	21 A. Yes. 12:28:42
22 sentence starts, "EDTA and its salts (known 12:26:23	22 Q. -- of the Lanigan reference, does the Lanigan 12:28:42

Page 198	Page 200
<p>1 reference treat edetate sodium and EDTA disodium as 12:28:45</p> <p>2 one and the same? 12:28:50</p> <p>3 MR. MARGOLIS: Objection. Vague. 12:28:52</p> <p>4 THE WITNESS: I agree with you that it's 12:28:53</p> <p>5 in there. But, quite clearly, it's a 12:28:56</p> <p>6 typographical as it is in the other 12:28:58</p> <p>7 reference, because if it wasn't a 12:29:01</p> <p>8 typographical mistake, it would be really 12:29:03</p> <p>9 explicit and it wouldn't just be one out of a 12:29:06</p> <p>10 list, in some cases of 30, it would be -- 12:29:10</p> <p>11 there wouldn't be two separate entries. So, 12:29:13</p> <p>12 I believe that is clearly a typographical 12:29:15</p> <p>13 error. 12:29:18</p> <p>14 Q. Do you typically rely on documents that have 12:29:18</p> <p>15 typographic errors? 12:29:20</p> <p>16 A. No. It's very unfortunate, and I must 12:29:22</p> <p>17 apologize. My two primary references were obviously 12:29:29</p> <p>18 the Merck, which is an encyclopedia, and the 12:29:35</p> <p>19 Pharmaceutical Handbook. I could have chosen from a 12:29:39</p> <p>20 whole list of references, and I, unfortunately, 12:29:43</p> <p>21 didn't spot these at the time. 12:29:46</p> <p>22 Q. Take a look, if you would, at the Disodium 12:29:48</p>	<p>1 A. Just let me -- I will have to read that. 12:31:09</p> <p>2 Sorry. 12:31:13</p> <p>3 It's really small writing. I didn't realize 12:31:34</p> <p>4 my eyes were this bad. The edetate sodium has 12:31:37</p> <p>5 Sequestrene NA2 after it. 12:31:41</p> <p>6 Q. In Lanigan? 12:31:46</p> <p>7 A. No. In the Merck Index. 12:31:48</p> <p>8 Q. In the Merck Index the edetate sodium entry 12:31:51</p> <p>9 has Sequestrene without a number, correct? 12:31:55</p> <p>10 A. In the Merck Index the sodium edetate has 12:31:57</p> <p>11 Sequestrene without a number, but EDTA sodium has 12:32:00</p> <p>12 Sequestrene NA2, which is reproduced for -- in The 12:32:06</p> <p>13 Pharmaceutical Handbook under disodium edetate. 12:32:13</p> <p>14 It's really confusing. 12:32:18</p> <p>15 Q. Well, let's take another look. 12:32:24</p> <p>16 Is it fair to say that this really isn't as 12:32:29</p> <p>17 clear as you made out in your earlier testimony? 12:32:31</p> <p>18 A. No. I think there are -- 12:32:33</p> <p>19 MR. MARGOLIS: Objection. 12:32:33</p> <p>20 Mischaracterizing testimony. 12:32:35</p> <p>21 THE WITNESS: -- are typographical 12:32:35</p> <p>22 errors, unfortunately. 12:32:37</p>
Page 199	Page 201
<p>1 EDTA entry. 12:29:50</p> <p>2 A. For Lannigan or for -- 12:29:53</p> <p>3 Q. From Lannigan. Um-mm. I believe it is on 12:29:54</p> <p>4 page 96. 12:30:05</p> <p>5 A. Yes. Um. Yes. 12:30:13</p> <p>6 Q. And do you see the bottom paragraph of that 12:30:13</p> <p>7 entry says, "Synonyms for Disodium EDTA include"? 12:30:15</p> <p>8 A. Yes. 12:30:21</p> <p>9 Q. And then toward the bottom of that it 12:30:22</p> <p>10 identifies Sequestrene? 12:30:25</p> <p>11 A. Yes. 12:30:28</p> <p>12 Q. Does the Lanigan reference identify 12:30:28</p> <p>13 Sequestrene as a synonym for disodium EDTA? 12:30:30</p> <p>14 A. I am going to say that I haven't followed 12:30:35</p> <p>15 this one through, but it's been very clear when you 12:30:38</p> <p>16 are talking to me in certain cases some references 12:30:41</p> <p>17 have Sequestrene and a number afterwards, so it's 12:30:44</p> <p>18 not straightforward and I wouldn't like to comment. 12:30:47</p> <p>19 I'm sorry. 12:30:51</p> <p>20 Q. The Lanigan reference uses the term 12:31:00</p> <p>21 Sequestrene in the same way that the Merck Index 12:31:02</p> <p>22 uses Sequestrene without a number, correct? 12:31:06</p>	<p>1 I think it is clear. And the reason I'm 12:32:37</p> <p>2 going to say -- the reason I believe it is 12:32:41</p> <p>3 very clear is because if they were synonyms 12:32:42</p> <p>4 for each other, you would not be having 12:32:46</p> <p>5 separate cast numbers, you would not be 12:32:48</p> <p>6 having separate identifications. 12:32:50</p> <p>7 Q. Take a look -- 12:32:52</p> <p>8 A. And you can buy separate -- and when you buy 12:32:53</p> <p>9 the material, you buy them as separate materials as 12:32:55</p> <p>10 well. 12:32:58</p> <p>11 Q. You've got the documents side-by-side here, 12:32:58</p> <p>12 correct? 12:33:00</p> <p>13 A. Well, yes. 12:33:02</p> <p>14 Q. And you see on page 3541 of the Merck Index 12:33:03</p> <p>15 that entry number 3544 for edetate sodium uses the 12:33:11</p> <p>16 term Sequestrene with no number, correct? 12:33:16</p> <p>17 A. Correct. 12:33:18</p> <p>18 Q. And on page 96 of the Lanigan reference, the 12:33:19</p> <p>19 disodium EDTA entry also uses Sequestrene in the 12:33:24</p> <p>20 same way without a number, correct? 12:33:28</p> <p>21 A. Correct. But then if we look at both the 12:33:32</p> <p>22 Merck and the Pharmaceutical Excipients Handbook, 12:33:35</p>

Page 202		Page 204	
1	they both have Sequestrene NA2 after -- have NA2	12:33:39	1 A. No. 12:35:46
2	after the Sequestrene.	12:33:46	2 Q. Does the specification of the patents-in-suit
3	Q. On page 96 of the Lanigan reference, disodium	12:33:48	3 refer to the Lewis reference? 12:35:49
4	EDTA -- let me strike that and try again.	12:33:52	4 A. No. 12:35:51
5	On page 96 of the Lanigan reference, the	12:33:55	5 Q. Do the prosecution histories of the
6	entry for disodium EDTA identifies as a synonym	12:33:57	6 patents-in-suit refer to the Lewis reference? 12:35:53
7	Sequestrene with no number, correct?	12:34:02	7 A. No. 12:35:55
8	A. That is correct.	12:34:04	8 MR. HASFORD: Actually, I'm going to go
9	Q. Let's take a look back at --	12:34:07	9 to a new exhibit, but I don't know what time
10	A. But that is obviously a typographical error	12:34:10	10 it is. Is this a good time for a lunch break
11	in the basis of both the Merck and the Excipient	12:34:13	11 or are we still -- do we still have a ways to
12	Handbook.	12:34:17	12 go? 12:36:11
13	Q. There's a lot of typographical errors in the	12:34:17	13 MR. MARGOLIS: Well, it's probably about
14	documents on which you're relying, aren't there,	12:34:20	14 time for a break. I guess we can go off the
15	Doctor?	12:34:22	15 record. 12:36:13
16	A. Unfortunately, in the secondary exhibits,	12:34:22	16 MR. HASFORD: Yeah. Why don't we go off
17	yes. In the two main exhibits, no.	12:34:25	17 the record and discuss for just a second
18	Q. Take a look, if you would, at page 13,	12:34:27	18 because I'm going to start into another line
19	paragraph 49 of your declaration.	12:34:32	19 here. 12:36:21
20	Are you relying on the Lewis reference in	12:34:44	20 THE VIDEOGRAPHER: The time is
21	connection with your opinions in this case?	12:34:47	21 approximately 12:37 p.m., Friday, September
22	A. Yes.	12:34:48	22 4th, 2015. This is the end of tape number
Page 203		Page 205	
1	Q. If I refer to Exhibit 6 to your declaration	12:34:49	1 three of the videotaped deposition of Dr.
2	as the Lewis reference, will you understand what I	12:34:52	2 Jayne Lawrence. We are off the record.
3	mean?	12:34:55	3 (Lunch recess from 12:37 to 1:27.)
4	A. Yes.	12:34:55	4 THE VIDEOGRAPHER: Good afternoon. The
5	Q. Turn there, please, and let me direct your	12:34:56	5 time is approximately 1:27 p.m., Friday,
6	attention to page 438. It bears Bates number	12:35:02	6 September 4, 2015. This is tape number four
7	PROLENSA00006191. And at the bottom of the	12:35:06	7 of the videotaped deposition of Dr. Jayne
8	left-hand column, there's an edetate entry.	12:35:14	8 Lawrence. We are back on the record.
9	Do you see that?	12:35:18	9 BY MR. HASFORD: 13:26:12
10	A. Yes.	12:35:19	10 Q. Good afternoon, Doctor. 13:26:12
11	Q. Does the Lewis reference state that edetate	12:35:20	11 A. Good afternoon. 13:26:13
12	refers to "any salt or ester of edetic acid"?	12:35:22	12 Q. Would you please turn to page 20 of your CV
13	A. Yes.	12:35:27	13 for me? Let me direct your attention to item 5
14	Q. Does this statement apply to both the	12:35:28	14 under Articles in Academic Journals. 13:26:22
15	disodium salt of EDTA and the tetrasodium salt of	12:35:32	15 MS. HASFORD: I'm handing the court
16	EDTA?	12:35:33	16 reporter what I would ask to be marked as
17	A. Yes. And I believe that's in my -- that	12:35:34	17 Lawrence Exhibit 2. 13:26:31
18	that's in my report under point 42.	12:35:36	18 For the record, Lawrence Exhibit 2
19	Q. Do the patents -- let me strike that and try	12:35:39	19 corresponds to item number 5 under Articles
20	again.	12:35:42	20 in Academic Journals on Dr. Lawrence's
21	Do the claims of the patents-in-suit refer to	12:35:42	21 curriculum vitae. 13:26:41
22	the Lewis reference?	12:35:45	22 (Whereupon, Plaintiff's Deposition 13:26:41

Page 206			Page 208		
1	Exhibit No. Lawrence 2 was marked for	13:27:04	1	diclofenac sodium and disodium	13:29:27
2	Identification.)	13:27:05	2	ethylenediaminetetraacetate on electrical	13:29:30
3	Q. Is Lawrence Exhibit 2 publication number 5 on	13:27:05	3	parameters of the mucosal membrane and their	13:29:34
4	your curriculum vitae?	13:27:09	4	relation to the permeability enhancing	13:29:37
5	A. Yes.	13:27:12	5	effects in the rat jejunum" by Yamashita,	13:29:40
6	Q. Are you the M.J. Lawrence who co-authored	13:27:12	6	et al, in the J. Pharm. Pharmacol. 1987,	13:29:45
7	Lawrence Exhibit 2?	13:27:16	7	volume 39, pages 621 to 626.	13:29:48
8	A. Yes.	13:27:17	8	(Whereupon, Plaintiff's Deposition	13:30:13
9	Q. Please turn to page 154 of Lawrence Exhibit	13:27:17	9	Exhibit No. Lawrence 3 was marked for	13:30:13
10	2. Let me direct your attention to the first	13:27:26	10	Identification.)	13:30:14
11	sentence of the second paragraph. Would you read	13:27:30	11	Q. Is Lawrence Exhibit 3 the 1987 Yamashita	13:30:14
12	that to yourself, please, and then let me know when	13:27:36	12	article that you cite in reference 47 of Lawrence	13:30:18
13	you're ready.	13:27:37	13	Exhibit 2?	13:30:21
14	A. Okay.	13:27:51	14	A. It looks like it, yes.	13:30:22
15	Q. In Lawrence Exhibit 2 you use the term EDTA	13:27:52	15	Q. Take a look at the first sentence of the	13:30:23
16	and you cite to footnote 47.	13:27:57	16	second paragraph of the body. It starts, "In an	13:30:30
17	Do you see that?	13:27:59	17	earlier report"?	13:30:34
18	A. Yes. To reference 47, yes.	13:28:00	18	A. Yes.	13:30:41
19	Q. Turn, then, to page 167 of Lawrence Exhibit 2	13:28:03	19	Q. Does Lawrence Exhibit 3 use the broad term	13:30:42
20	and take a look at reference 47. Read that to	13:28:08	20	EDTA interchangeably with disodium	13:30:47
21	yourself, if you would, and let me know when you're	13:28:14	21	ethylenediaminetetraacetate which is the disodium	13:30:50
22	ready.	13:28:17	22	salt of EDTA?	13:30:54
Page 207			Page 209		
1	A. Yes, I'm ready.	13:28:17	1	MR. MARGOLIS: Objection. Vague.	13:30:56
2	Q. Reference 47 in Lawrence Exhibit 2 is a 1987	13:28:19	2	THE WITNESS: It's defining -- it's	13:31:03
3	journal article by Yamashita, et al, entitled	13:28:26	3	saying it's going to define disodium -- you	13:31:05
4	"Effects of diclofenac sodium and disodium	13:28:31	4	can say it better than me --	13:31:08
5	ethylenediaminetetraacetate on electrical parameters	13:28:34	5	ethylenediaminetetraacetate as EDTA.	13:31:12
6	of the mucosal membrane and their relation to the	13:28:39	6	Q. You may put this document aside.	13:31:12
7	permeability enhancing effects in the rat jejunum."	13:28:43	7	A. Okay.	13:31:15
8	Do you see that?	13:28:49	8	Q. Take a look now, if you would, back at your	13:31:15
9	A. I do.	13:28:49	9	declaration, and let me direct your attention to	13:31:18
10	Q. Is disodium ethylenediaminetetraacetate the	13:28:49	10	page 15.	13:31:23
11	disodium salt of EDTA?	13:28:54	11	A. Yes.	13:31:25
12	A. Yes.	13:28:57	12	Q. And, in particular, paragraph 58. Are you	13:31:26
13	Q. In Lawrence Exhibit 2 do you use the term	13:28:58	13	relying on the 2000 Edition of Remington's The	13:31:33
14	EDTA broadly to refer to the disodium salt of EDTA?	13:29:01	14	Science and Practice of Pharmacy in connection with	13:31:38
15	A. I think I used it incorrectly.	13:29:05	15	your opinions in this case?	13:31:40
16	Q. Okay. Take a look now -- actually, let me	13:29:07	16	A. Yes.	13:31:42
17	mark a new document.	13:29:09	17	Q. And in the second sentence in paragraph 58 of	13:31:43
18	MR. HASFORD: I'm handing the court	13:29:19	18	your declaration it starts, "For example, the 2000	13:31:47
19	reporter what I ask to be marked as Lawrence	13:29:20	19	edition of Remington's, a reference that would have	13:31:50
20	Exhibit 3.	13:29:22	20	been well-known to the person of ordinary skill in	13:31:53
21	For the record, Lawrence Exhibit 3 is a	13:29:22	21	the art, provides the following definition of	13:31:56
22	copy of the article entitled, "Effects of	13:29:24	22	stability."	13:31:59

Page 210		Page 212		
1	Does the 2000 edition of Remington's provide	13:32:00	1 administration"?	13:34:21
2	a definition of stability of a pharmaceutical	13:32:03	2 A. That's administration into the body by any	13:34:22
3	product?	13:32:06	3 other route than enteral. So it includes	13:34:25
4	A. Yes.	13:32:09	4 ophthalmic, intravenous, intramuscular, et cetera.	13:34:30
5	Q. Does the 2000 edition of Remington's provide	13:32:09	5 Q. Turn, if you would, to Exhibit 8 to your	13:34:34
6	understanding to a person of ordinary skill in the	13:32:13	6 claim construction declaration. If I refer to	13:34:39
7	art of the meaning of stability of a pharmaceutical	13:32:15	7 Exhibit 8 to your declaration as the Vadas	13:34:50
8	product?	13:32:18	8 reference, will you understand what I mean?	13:34:53
9	A. Let me just read the -- can you ask me the	13:32:18	9 A. Yes.	13:34:55
10	question again, please?	13:32:44	10 Q. Now, go back, if you would, to your	13:34:56
11	Q. Certainly.	13:32:44	11 declaration. Please look at paragraphs 53 through	13:35:00
12	A. Yes.	13:32:44	12 72 of your declaration. They span pages 14 through	13:35:04
13	Q. Does the 2000 edition of Remington's provide	13:32:44	13 21. Let me know when you're ready.	13:35:18
14	understanding to a person of ordinary skill in the	13:32:47	14 A. Okay.	13:38:42
15	art of the meaning of stability of a pharmaceutical	13:32:50	15 Q. Do paragraphs 53 through 72 of your	13:38:43
16	product?	13:32:53	16 declaration set forth your opinions in this case on	13:38:47
17	MR. MARGOLIS: Objection. Vague.	13:32:55	17 the claim term "stable" and the phrase "in an amount	13:38:50
18	THE WITNESS: It defines -- it gives a	13:32:59	18 sufficient to stabilize said first component"?	13:38:54
19	good practical definition of stability with	13:33:04	19 A. Yes.	13:38:58
20	somebody skilled in the art in my opinion.	13:33:08	20 Q. In connection with your opinions in this case	13:38:59
21	Q. Okay. And now read the rest of the sentence	13:33:10	21 on the claim term "stable" and the phrase "in an	13:39:01
22	to yourself, that sentence in paragraph 58 of your	13:33:12	22 amount sufficient to stabilize said first	13:39:04
Page 211		Page 213		
1	declaration that spans pages 15 and 16, and let me	13:33:16	1 component," do you cite any item of extrinsic	13:39:07
2	know when you're ready.	13:33:21	2 evidence other than the Vadas reference?	13:39:11
3	A. I'm ready.	13:33:31	3 A. No, I don't.	13:39:21
4	Q. You mention microbiological specifications.	13:33:32	4 Q. Take a look, if you would, back at the Vadas	13:39:25
5	Do you see that?	13:33:35	5 reference, and let me direct your attention to page	13:39:29
6	A. Yes.	13:33:35	6 987. That bears Bates number LUPIN018965. I know	13:39:32
7	Q. Do microbiological specifications deal with	13:33:36	7 the type is kind of small.	13:39:43
8	bacterial and fungal counts?	13:33:41	8 Let me direct your attention to the	13:39:51
9	A. Amongst other things, yes.	13:33:44	9 right-hand column.	13:39:53
10	Q. Does the concept of stability of an aqueous	13:33:45	10 A. Okay.	13:39:54
11	liquid preparation encompass microbiological	13:33:48	11 Q. Does the Vadas reference discuss	13:39:55
12	stability?	13:33:51	12 pharmaceutical product stability?	13:40:00
13	MR. MARGOLIS: Objection. Vague.	13:33:52	13 A. Yes.	13:40:05
14	THE WITNESS: It depends what type of	13:33:54	14 Q. Under that subheading or that title Product	13:40:05
15	liquid formulation.	13:33:56	15 Stability, could you read that first paragraph	13:40:09
16	Q. Under what circumstances does the concept of	13:33:58	16 beginning "Many factors," and let me know when	13:40:11
17	stability of an aqueous liquid preparation encompass	13:34:00	17 you're ready.	13:40:13
18	microbiological stability?	13:34:05	18 A. Okay.	13:40:27
19	A. It would be of particular importance if the	13:34:10	19 Q. Does the Vadas reference state that, "Many	13:40:28
20	formulation was intended for parenteral	13:34:14	20 factors affect the stability of a pharmaceutical	13:40:31
21	administration.	13:34:18	21 product, including the stability of the active	13:40:34
22	Q. What do you mean by "parenteral	13:34:19	22 ingredient or ingredients; the potential interaction	13:40:36

Page 214		Page 216		
1	between active and inactive ingredients; the	13:40:40	1 THE WITNESS: In theory, a researcher	13:42:40
2	manufacturing process; the dosage form; the	13:40:44	2 could decide any conditions, but to do that	13:42:45
3	container-liner-closure system; and the	13:40:48	3 they must be certain that the degradation	13:42:49
4	environmental conditions encountered during	13:40:51	4 instabilities are the same at the	13:42:54
5	shipment, storage, and handling; and length of time	13:40:54	5 temperatures they're measuring it at as the	13:42:56
6	between manufacturing and usage"?	13:40:57	6 one they predict it to be -- as the ones at	13:43:00
7	A. It does.	13:41:00	7 use -- of use.	13:43:04
8	Q. Do you agree with that?	13:41:01	8 Q. Take a look, if you would, at page 990 of the	13:43:05
9	A. They are potential factors affecting	13:41:04	9 Vadas reference, and look at the second full	13:43:10
10	stability, yes.	13:41:08	10 paragraph. The first two sentences read, "Oxidation	13:43:22
11	Q. Take a look now at the bottom of the	13:41:09	11 may be inhibited by the use of antioxidants called	13:43:25
12	right-hand column on page 987 of the Vadas	13:41:11	12 negative catalysts. They are very effective in	13:43:28
13	reference, and let me direct your attention to Table	13:41:16	13 stabilizing pharmaceutical products undergoing a	13:43:32
14	52-1 entitled Stability Protocols.	13:41:19	14 free-radical-mediated chain reaction."	13:43:35
15	A. Yes.	13:41:22	15 Do you see that?	13:43:38
16	Q. Do you see that?	13:41:22	16 A. It -- sorry. I do.	13:43:39
17	A. I do.	13:41:23	17 Q. Does the term stabilizing in this context	13:43:41
18	Q. Does the Vadas reference provide various	13:41:24	18 refer to chemical stability?	13:43:44
19	stability protocols for testing the chemical	13:41:27	19 A. It could be physical as well.	13:43:51
20	stability of a pharmaceutical product?	13:41:29	20 Q. Does the term stabilizing in that context	13:43:53
21	A. It does.	13:41:32	21 encompass chemical stability?	13:43:56
22	Q. Are the stability protocols disclosed in the	13:41:33	22 A. It does.	13:43:58
Page 215		Page 217		
1	Vadas reference the only stability protocols that	13:41:37	1 Q. Are antioxidants added to pharmaceutical	13:44:00
2	can be used for testing the chemical stability of	13:41:39	2 products to prevent chemical degradation?	13:44:03
3	the pharmaceutical product?	13:41:39	3 MR. MARGOLIS: Objection. Vague.	13:44:08
4	A. The chemical?	13:41:39	4 THE WITNESS: To some products they may	13:44:10
5	Q. I'll repeat it. Are the stability protocols	13:41:50	5 be, yes.	13:44:12
6	disclosed in the Vadas reference the only stability	13:41:50	6 Q. Take a look, if you would, at the fourth full	13:44:12
7	protocols that can be used for testing the chemical	13:41:51	7 paragraph.	13:44:17
8	stability of a pharmaceutical product?	13:41:54	8 A. Yes.	13:44:17
9	MR. MARGOLIS: Objection. Vague.	13:41:57	9 Q. And the first sentence says, "The commonly	13:44:18
10	THE WITNESS: There are standardized	13:42:00	10 used antioxidants for aqueous systems include sodium	13:44:21
11	International -- ICH -- International	13:42:07	11 sulfite, sodium metabisulfite, sodium bisulfite,	13:44:25
12	Conference and Harmonization guidelines,	13:42:09	12 sodium thiosulfate, and ascorbic acid."	13:44:30
13	which tend to be used by most -- a lot of	13:42:12	13 Do you see that?	13:44:36
14	regulators and a lot of researchers.	13:42:15	14 A. I do.	13:44:36
15	So, you are correct that there were the	13:42:18	15 Q. Do you agree with the Vadas reference that	13:44:37
16	conditions, but normally people would use the	13:42:21	16 sodium sulfite is a commonly used antioxidant for	13:44:39
17	standardized conditions.	13:42:24	17 aqueous systems?	13:44:43
18	Q. What other conditions besides those disclosed	13:42:26	18 A. That's not actually what the reference is	13:44:48
19	in Table 52-1 of the Vadas reference can be used for	13:42:30	19 saying. It's saying what the most frequent used	13:44:51
20	testing the chemical stability of a pharmaceutical	13:42:35	20 antioxidants are. It's not saying antioxidants are	13:44:53
21	product?	13:42:38	21 commonly used, in my opinion.	13:44:58
22	MR. MARGOLIS: Objection. Vague.	13:42:38	22 Q. Well, it says, "The commonly used	13:44:59

Page 218	Page 220
1 antioxidants for aqueous systems include sodium 13:45:01	1 THE WITNESS: It explains that you can 13:47:24
2 sulfite." 13:45:01	2 misinterpret your data by using the wrong 13:47:29
3 Do you see that? 13:45:05	3 analysis. That's what it's telling you. 13:47:32
4 A. That it is one of the more frequently used. 13:45:05	4 Q. Based on the teachings of the Vadas 13:47:35
5 What I'm saying is it doesn't tell you that lots of 13:45:08	5 reference, would a person of ordinary skill in the 13:47:37
6 formulations have antioxidants in it. That's 13:45:11	6 art understand that chemical stability testing 13:47:39
7 different. 13:45:14	7 results are more reliable at higher temperatures or 13:47:42
8 Q. When, if at all, would a person of ordinary 13:45:15	8 lower temperatures? 13:47:45
9 skill in the art be motivated to use an antioxidant 13:45:18	9 MR. MARGOLIS: Objection. Lack of 13:47:48
10 in an aqueous liquid preparation? 13:45:23	10 foundation. 13:47:49
11 MR. MARGOLIS: Objection. Vague. 13:45:27	11 THE WITNESS: That's not possible to 13:47:50
12 THE WITNESS: If they suspected their 13:45:31	12 answer because you're basing that on clearly 13:47:54
13 formulation was going to be unstable in its 13:45:34	13 incorrect or deficient analysis of the 13:48:00
14 absence. 13:45:39	14 Arrhenius equation. 13:48:04
15 Q. Take a look, if you would, at page 992 of the 13:45:40	15 It goes on to say that it's better to 13:48:07
16 Vadas reference. And let me direct your attention 13:45:46	16 have a weighted least-squares analysis so you 13:48:10
17 to the right-hand column and, in particular, the 13:45:50	17 avoid this effect. 13:48:13
18 last full paragraph and the first three sentences. 13:45:53	18 Q. I'm just asking in general. Based on the 13:48:15
19 It states, "According to the Arrhenius relationship, 13:45:58	19 teachings of the Vadas reference, would a person of 13:48:17
20 faster degradation occurs at the higher 13:46:01	20 ordinary skill in the art understand that chemical 13:48:20
21 temperatures; hence, assays for the high-temperature 13:46:04	21 stability testing results are more reliable at 13:48:22
22 data usually are run more often but for a shorter 13:46:08	22 higher temperatures or lower temperatures? 13:48:25
Page 219	Page 221
1 period of time. The effect of simple least-squares 13:46:11	1 A. I don't believe it teaches that. I'm sorry. 13:48:27
2 analysis of this type of data is to force the 13:46:17	2 Q. Okay. Does the Vadas reference state that 13:48:29
3 Arrhenius equation through the low temperature data 13:46:20	3 the term stable is an indefinite term? 13:48:32
4 and essentially ignore the high temperature 13:46:24	4 MR. MARGOLIS: Objection. Vague. 13:48:36
5 information. Thus, much more credence is placed in 13:46:27	5 THE WITNESS: It doesn't use legal 13:48:40
6 the point estimates of the low temperature than is 13:46:30	6 language to define stability, no. 13:48:41
7 warranted." 13:46:34	7 Q. Does the Vadas reference state that a 13:48:43
8 Do you see that? 13:46:34	8 particular threshold under -- let me strike that and 13:48:45
9 A. Just let me re-read this. Sorry. 13:46:38	9 try again. 13:48:49
10 Q. Take as much time as you need to read it to 13:46:41	10 Does the Vadas reference state that a 13:48:50
11 yourself and tell me when you're ready. 13:46:44	11 particular threshold under particular measurement 13:48:51
12 A. Okay. 13:46:57	12 conditions must be specified to permit distinction 13:48:54
13 Q. Does the Vadas reference state that in 13:46:58	13 between formulations that are stable and those that 13:48:58
14 chemical stability testing much more credence is 13:47:01	14 are not? 13:49:00
15 placed in the point estimates of the low temperature 13:47:04	15 MR. MARGOLIS: Objection. Vague. 13:49:02
16 than is warranted? 13:47:06	16 THE WITNESS: Ask the question again? 13:49:22
17 A. No, it doesn't. 13:47:08	17 Q. Sure. Actually, before I ask that question, 13:49:23
18 Q. Does the Vadas reference teach that chemical 13:47:12	18 let me go back to one of your previous answers 13:49:25
19 stability testing results are more reliable at high 13:47:14	19 because you mentioned legal language. 13:49:30
20 temperatures or low temperatures? 13:47:18	20 Do you remember that? 13:49:33
21 MR. MARGOLIS: Objection. Lack of 13:47:22	21 A. Yes. 13:49:33
22 foundation. 13:47:23	22 Q. Does the Vadas reference state that the term 13:49:34

Page 222	Page 224
1 stable is a scientifically indefinite term? 13:49:38	1 that a particular threshold under particular 13:52:12
2 MR. MARGOLIS: Objection. Vague. 13:49:45	2 measurement conditions must be specified to permit 13:52:15
3 THE WITNESS: I don't understand what -- 13:49:45	3 distinction between formulations that are stable and 13:52:17
4 scientifically indefinite term is not a 13:49:48	4 those that are not? 13:52:20
5 phrase I'm familiar with. 13:49:50	5 A. To remain within its physical, chemical, 13:52:20
6 Q. Could there be a circumstance under which a 13:49:53	6 microbiologic, therapeutic and toxicological 13:52:23
7 term has no scientifically definite meaning? 13:49:57	7 specifications, I believe does answer that -- does 13:52:26
8 A. There are cases where the science perhaps is 13:50:22	8 address it. 13:52:28
9 in a debate and people might argue about the 13:50:25	9 Q. The Vadas reference doesn't state that 13:52:29
10 definition, yes. 13:50:28	10 though, does it? 13:52:31
11 Q. Does the Vadas reference state that the term 13:50:29	11 MR. MARGOLIS: Objection. Vague. 13:52:33
12 stable is an unclear or incomprehensible term? 13:50:33	12 THE WITNESS: I'm confused now by your 13:54:00
13 A. No. It does clearly state, however, that you 13:50:38	13 question because the comments I have in -- in 13:54:04
14 have to define what you mean by stability in the 13:50:41	14 quotation marks here, which I just quoted to 13:54:10
15 pharmaceutical context. 13:50:44	15 you from about remaining within physical, 13:54:14
16 Q. And in your previous answer you talked about 13:50:47	16 chemical, microbiologic, therapeutic and 13:54:18
17 circumstances under which a term might have no 13:50:50	17 toxicological specifications is a direct 13:54:21
18 scientifically definite meaning. 13:50:53	18 quote from Vadas. 13:54:25
19 Does the Vadas reference state that the term 13:50:55	19 Q. Does that quote in the Vadas reference state 13:54:29
20 stable has no scientifically definite meaning? 13:50:57	20 that a particular threshold under particular 13:54:32
21 MR. MARGOLIS: Objection. Asked and 13:51:02	21 measurement conditions must be specified to permit 13:54:34
22 answered. 13:51:04	22 distinction between formulations that are stable and 13:54:37
Page 223	Page 225
1 THE WITNESS: In as far as it tells you 13:51:05	1 those that are not? 13:54:40
2 that you have to define it yourself, your 13:51:07	2 A. Why would you have -- otherwise, why would 13:54:43
3 particular conditions required. So that 13:51:13	3 you have specifications? You're defining your 13:54:46
4 means that stability will have a potentially 13:51:15	4 stability and specifying it. And it goes on to give 13:54:52
5 different meaning for a different 13:51:20	5 other examples of this. 13:54:57
6 pharmaceutical context. 13:51:23	6 Q. Take a look back at your declaration, if you 13:55:01
7 Q. Take a look, if you would, at -- oh, sorry. 13:51:25	7 would, page 16, paragraph 59. And let me direct 13:55:04
8 Let me go back to another question that I asked you. 13:51:30	8 your attention to the second sentence. Read that to 13:55:10
9 You asked me to reask it. 13:51:33	9 yourself, if you would, and let me know when you're 13:55:15
10 Does the Vadas reference state that a 13:51:35	10 ready. 13:55:18
11 particular threshold under particular measurement 13:51:38	11 A. Okay. 13:55:30
12 conditions must be specified to permit distinction 13:51:41	12 Q. Are chemical stability and physical stability 13:55:30
13 between formulations that are stable and those that 13:51:46	13 the same or different types of stability? 13:55:33
14 are not? 13:51:48	14 A. They're generally considered as different 13:55:40
15 MR. MARGOLIS: Objection. Vague. 13:51:50	15 types of stability. 13:55:44
16 THE WITNESS: I believe that's what that 13:51:53	16 Q. Does the concept of chemical stability deal 13:55:44
17 first definition is telling you, that you 13:51:55	17 with the propensity toward chemical degradation? 13:55:46
18 have to have a capability of a particular 13:51:58	18 A. Yes, but it may influence the physical 13:55:55
19 formulation and you define its 13:52:02	19 stability as a result. I was going to give the 13:56:00
20 stability and -- and I think that answers the 13:52:05	20 example of liposomes when they're oxidized they may 13:56:03
21 question. 13:52:09	21 become unstable. So, it's very hard to totally or 13:56:07
22 Q. Does the Vadas reference explicitly state 13:52:09	22 to totally divorce them. 13:56:12

Page 226		Page 228	
1	Q. Generally, does the concept of chemical stability deal with the propensity toward degradation?	13:56:12	13:56:15
2			
3	A. It does.	13:56:17	13:56:18
4			
5	Q. Generally, does the concept of physical stability deal with the propensity toward changes in appearance or other physical properties?	13:56:19	13:56:21
6			
7	A. It does.	13:56:25	13:56:27
8			
9	Q. Take a look, if you would, at page 17 of your declaration, paragraph 61.	13:56:28	13:56:32
10			
11	A. Yes.	13:56:36	13:56:37
12			
13	Q. The first sentence states, "The specification does state that an object of the invention is to provide a formulation that is 'stable within a pH range giving no irritation to the eyes' and that the preservative effect 'does not substantially deteriorate.'"	13:56:40	13:56:45
14			
15	You're referring to the specification of the patents-in-suit, correct?	13:56:49	13:56:52
16			
17	A. Yes.	13:56:54	13:56:57
18			
19	Q. Is that a true statement?	13:56:58	13:57:00
20			
21	A. From -- from the patents? Yes.	13:57:03	13:57:03
22			
Page 227		Page 229	
1	Q. Okay. Take a look now at paragraph 62 in your declaration. And the first sentence states, "Experimental Examples 1 and 2, entitled 'Stability Test of Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate,' disclose specific conditions under which stability may be measured."	13:57:06	13:57:12
2			
3	Is that a true statement?	13:57:15	13:57:19
4			
5	A. Yes.	13:57:26	13:57:28
6			
7	Q. Take a look now at paragraph 63 of your declaration on page 18. You state, "Experimental Example 1 tested four formulations with identical compositions except for variations in the type and amount of surfactant. Comparison Example 1 used 0.15 grams of polysorbate 80, sample A-02 used 0.15 grams of polyoxyl 40 stearate, sample A-02 used 0.15 grams of tyloxapol, and sample A-03 used 0.02 grams of tyloxapol."	13:57:30	13:57:34
8			
9	Is that a true statement?	13:57:38	13:57:47
10			
11	A. Yes.	13:57:49	13:57:53
12			
13	Q. Does Experimental Example 1 test against the closest prior art for comparison purposes?	13:57:58	13:58:03
14			
15	MR. MARGOLIS: Objection. Vague. Calls	13:58:03	13:58:10
16			
17			
18			
19			
20			
21			
22			
1	for a legal conclusion.	13:58:29	13:58:33
2			
3	THE WITNESS: What do you consider the closest prior art?	13:58:35	13:58:37
4			
5	Q. What do you consider the closest prior art?	13:58:37	13:58:40
6			
7	MR. MARGOLIS: Objection. Vague.	13:58:40	13:58:44
8			
9	THE WITNESS: I don't have all that information to hand, so I cannot answer.	13:58:44	13:58:46
10			
11	Q. Do you know whether Experimental Example 1 tests against the closest prior art for comparison purposes?	13:58:48	13:58:51
12			
13	MR. MARGOLIS: Objection. Vague. Calls	13:58:54	13:58:55
14			
15	for a legal conclusion. Asked and answered.	13:58:56	13:59:00
16			
17	THE WITNESS: I don't have that information to hand to make that comparison.	13:59:00	13:59:01
18			
19	Q. Take a look, if you would, at page 18 of your declaration, paragraph 64. And the first sentence says that, "The discussion after Experimental Example 1 states that the bromfenac 'in each eye drop was stable in the order of tyloxapol-containing preparation greater than polyoxyl 40 stearate-containing preparation greater than polysorbate 80-containing preparation.'"	13:59:04	13:59:09
20			
21			
22			
1	Is that a true statement?	13:59:13	13:59:17
2			
3	A. It is.	13:59:17	13:59:24
4			
5	Q. And then in the next sentence you say, "Experimental Example 1 also states that the composition containing 0.02 percent weight per volume tyloxapol is 'more stable' than a composition containing 0.15 percent weight per volume tyloxapol."	13:59:24	13:59:27
6			
7	Is that a true statement?	13:59:27	13:59:29
8			
9	A. It is.	13:59:29	13:59:32
10			
11	Q. Take a look now at page 19 of your declaration, paragraph 65. You state, "Experimental Example 2 has a similar design where the formulation remains constant except for the surfactant: Sample A-04 used 0.02 grams of tyloxapol, sample A-05" -- in paragraph 65 of your declaration you state, "Experimental Example 2 has a similar design where the formulation remains constant except for the surfactant: Sample A-04 used 0.02 grams of tyloxapol, sample A-05 used 0.05 grams of tyloxapol, sample A-06 used 0.03 grams of tyloxapol, sample A-07 used 0.02 grams of polyoxyl 40 stearate, and	13:59:34	13:59:35
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			

Page 230			Page 232		
1	sample A-08 used 0.05 grams of polyoxyl 40	14:00:59	1	Q. Correct.	14:05:05
2	stearate."	14:01:05	2	A. No.	14:05:07
3	Is that a true statement?	14:01:05	3	Q. Did you ever ask anyone whether Lupin has any	14:05:08
4	A. Yes.	14:01:07	4	patents using the claim term stable like the	14:05:12
5	Q. Take a look now at paragraph 19 -- I'm	14:01:08	5	patents-in-suit?	14:05:14
6	sorry -- page 19, paragraph 66. The first sentence	14:01:12	6	A. No. Because, I didn't feel it was relevant	14:05:18
7	states, "Experimental Example 2 states that, with	14:01:16	7	because I was considering only these patents.	14:05:21
8	certain formulations, the amount of bromfenac in the	14:01:20	8	MR. HASFORD: I'm handing the court	14:05:24
9	formulation is not less than 90 percent after	14:01:24	9	reporter what I would ask to be marked as	14:05:26
10	storage at 60 degrees Celsius for four weeks, which	14:01:28	10	Lawrence Exhibit 4.	14:05:29
11	'indicates that [the tested] compositions have	14:01:33	11	For the record, Lawrence Exhibit 4 is a	14:05:31
12	sufficient stability for eye drops."	14:01:35	12	copy of United States Patent No. 8,192,755.	14:05:33
13	Is that a true statement?	14:01:38	13	(Whereupon, Plaintiff's Deposition	14:05:59
14	A. It's a reproduction from the -- yes.	14:01:42	14	Exhibit No. Lawrence 4 was marked for	14:05:59
15	Q. Take a look, if you would, at page 20 of your	14:01:46	15	Identification.)	14:06:01
16	declaration, paragraph 67. In the first sentence	14:01:50	16	Q. If I refer to U.S. Patent No. 8,192,755 as	14:06:01
17	you write, "That preparations having a less than 90	14:01:54	17	the '755 patent, will you understand what I mean?	14:06:08
18	percent remaining rate may also qualify as 'stable'	14:01:57	18	A. Yes.	14:06:11
19	is confirmed by the results of Experimental Example	14:02:01	19	Q. On the front page of the '755 patent do you	14:06:12
20	1, discussed above."	14:02:04	20	see that the '755 patent is assigned to Lupin	14:06:15
21	Is that a true statement?	14:02:06	21	Limited?	14:06:19
22	A. That's the implications of what's said, yes.	14:02:12	22	A. Yes.	14:06:20
Page 231			Page 233		
1	Q. In the next sentence you say, "All of the	14:02:14	1	Q. Are you providing opinions in this case on	14:06:20
2	results of Experimental Example 1 were less than 90	14:02:17	2	behalf of Lupin Limited?	14:06:23
3	percent, and the applicants pointed to this example	14:02:20	3	A. I am.	14:06:24
4	to support their claims to 'stable' preparations	14:02:23	4	Q. Turn to column 21 of Lupin's '755 patent.	14:06:25
5	during prosecution."	14:02:26	5	Let me direct your attention to claim 16. Claim 16	14:06:31
6	Is that a true statement?	14:02:27	6	reads, "A stable improved pharmaceutical composition	14:06:39
7	A. Yes.	14:02:29	7	for controlled release of Beta-lactam antibiotic or	14:06:42
8	Q. Now, look at paragraph 69 on page 20. And I	14:02:30	8	its pharmaceutically acceptable salts, the	14:06:47
9	want you to read to yourself paragraphs 69, 70 and	14:02:36	9	composition comprising a hydrophilic matrix and an	14:06:51
10	71 spanning over to page 21.	14:02:41	10	adjuvant, the adjuvant comprising probenecid,	14:06:56
11	A. Okay.	14:02:44	11	wherein the hydrophilic matrix and the adjuvant are	14:07:02
12	Q. Let me know when you're ready.	14:02:45	12	compressed together into a tablet dosage form or	14:07:07
13	A. Okay.	14:04:33	13	compressed separately into tablets and packed in a	14:07:10
14	Q. In paragraph 69 through 71 of your	14:04:34	14	way to be administered simultaneously."	14:07:15
15	declaration, do you set forth and respond to	14:04:38	15	Do you see that?	14:07:17
16	plaintiffs' proposed constructions of the term	14:04:41	16	A. I do.	14:07:18
17	"stable" and the phrase "in an amount sufficient to	14:04:45	17	Q. Claim 16 of Lupin's '755 patent is directed	14:07:18
18	stabilize said first component"?	14:04:48	18	to a stable improved pharmaceutical composition.	14:07:22
19	A. I do.	14:04:51	19	Do you see that?	14:07:25
20	Q. In paragraph 69 through 71 of your	14:04:51	20	A. Claim 16, you said? Yes.	14:07:26
21	declaration, do you cite any document?	14:04:54	21	Q. Correct.	14:07:29
22	A. If I cite a document to support my claim?	14:04:58	22	A. Yes.	14:07:30

Page 234		Page 236			
1	Q. Does Lupin's use of the term stable in claim	14:07:30	1	information in there.	14:15:53
2	16 of the '755 patent make that claim invalid for	14:07:33	2	Q. Take a look again at claim 16. Does Lupin's	14:15:54
3	indefiniteness?	14:07:37	3	'755 patent provide a definition of stable as that	14:15:59
4	MR. MARGOLIS: Objection. Lack of	14:07:38	4	claim term is used in claim 16?	14:16:03
5	foundation. Calls for a legal conclusion.	14:07:40	5	MR. MARGOLIS: Objection. Lack of	14:16:07
6	THE WITNESS: Unless I read the whole	14:07:42	6	foundation. Asked and answered.	14:16:08
7	patent and all the claims, I really can't	14:07:44	7	THE WITNESS: Could you repeat the	14:16:11
8	comment on just one claim taken from the	14:07:47	8	question, please?	14:16:13
9	patent. Obviously, that would have to be	14:07:52	9	Q. Sure. Does Lupin's '755 patent provide a	14:16:14
10	examined, but I can't comment definitively	14:07:55	10	definition of the term stable as that term is used	14:16:18
11	one way or another because I have not seen it	14:07:57	11	in claim 16?	14:16:21
12	before.	14:08:00	12	MR. MARGOLIS: Objection. Asked and	14:16:23
13	Q. Well, take as much time as you need to read	14:08:00	13	answered. Calls for a legal conclusion.	14:16:24
14	it.	14:08:02	14	THE WITNESS: I think to make any more	14:16:50
15	A. Okay. Okay.	14:08:03	15	conclusions, I would need to take some legal	14:16:53
16	Q. Does Lupin's use of the term stable in claim	14:13:48	16	advice as to what takes precedence over what.	14:17:00
17	16 of the '755 patent make that claim invalid for	14:13:53	17	So, I don't feel qualified at the present	14:17:03
18	indefiniteness?	14:13:58	18	time having read this so quickly to make a	14:17:06
19	MR. MARGOLIS: Objection. Lack of	14:13:59	19	definitive comment.	14:17:09
20	foundation. Calls for a legal conclusion.	14:14:01	20	Q. And I'm not asking you for a legal	14:17:11
21	Q. You may answer.	14:14:05	21	conclusion.	14:17:13
22	A. Well, I've got a couple of general comments	14:14:08	22	A. No. No.	14:17:13
Page 235		Page 237			
1	from my quick reading of the patent. It normally	14:14:13	1	Q. I'm just asking whether Lupin's '755 patent	14:17:14
2	takes me a lot longer to read the patents.	14:14:18	2	provides a definition of the term stable as that	14:17:18
3	First of all, I don't believe it's a main	14:14:21	3	term is used in claim 16?	14:17:20
4	claim, is it? The main claim of the patent. But	14:14:27	4	MR. MARGOLIS: Objection. Vague. Asked	14:17:23
5	they do specifically define ICH storage conditions.	14:14:31	5	and answered.	14:17:30
6	They do compare before and after.	14:14:39	6	THE WITNESS: I believe there is some an	14:17:31
7	So, while I agree it's not a perfect patent,	14:14:42	7	attempt at a definition.	14:17:35
8	it does have a lot more information than the ones	14:14:46	8	Q. You can put that document aside.	14:17:37
9	we're considering today.	14:14:51	9	A. Okay.	14:17:39
10	Q. Did you see any definition of stable in the	14:14:53	10	Q. Did you ever ask anyone whether Innopharma	14:17:40
11	patent?	14:14:56	11	has any patents or patent applications using the	14:17:43
12	MR. MARGOLIS: Objection. Vague.	14:14:57	12	claim term stabilize of the patents-in-suit?	14:17:46
13	THE WITNESS: "The pharmaceutical	14:15:08	13	A. I did not.	14:17:49
14	composition of claim 1, further comprising a	14:15:12	14	MR. HASFORD: I'm handing the court	14:18:04
15	matrix stabilizing agent; wherein the	14:15:15	15	reporter what I ask to be marked as Lawrence	14:18:05
16	in vitro dissolution characteristics of the	14:15:19	16	Exhibit 5.	14:18:07
17	composition are essentially maintained upon	14:15:29	17	For the record, Lawrence Exhibit 5 is a	14:18:08
18	storage for one month under accelerated	14:15:34	18	copy of U.S. Patent Application Publication	14:18:10
19	stability conditions of 40 degrees and 75	14:15:38	19	No. 2013/0210878.	14:18:14
20	percent relative humidity."	14:15:43	20	(Whereupon, Plaintiff's Deposition	14:18:45
21	I agree it's not the most obvious	14:15:46	21	Exhibit No. Lawrence 5 was marked for	14:18:46
22	definition of stability, but there is some	14:15:51	22	Identification.)	14:18:47

Page 238		Page 240		
1	Q. If I refer to U.S. Patent Application	14:18:47	1 reporter what I would ask to be marked as	14:21:52
2	Publication No. 2013/0210878 as the '878	14:18:52	2 Lawrence Exhibit 6.	14:21:55
3	application, will you understand what I mean?	14:19:00	3 For the record, Lawrence Exhibit 6	14:21:56
4	A. I will.	14:19:02	4 corresponds to item number 6 in the Book	14:21:57
5	Q. On the front page of the '878 application, do	14:19:03	5 Chapters identified in Dr. Lawrence's	14:22:01
6	you see that it is assigned to Innopharma, Inc.?	14:19:07	6 curriculum vitae.	14:22:03
7	A. I do.	14:19:10	7 (Whereupon, Plaintiff's Deposition	14:22:16
8	Q. Are you providing opinions in this case on	14:19:10	8 Exhibit No. Lawrence 6 was marked for	14:22:17
9	behalf of Innopharma?	14:19:13	9 Identification.)	14:22:44
10	A. I am.	14:19:14	10 Q. Does Lawrence Exhibit 6 correspond to item	14:22:44
11	Q. Turn to page 6, claim 10. Read that to	14:19:16	11 number 6 in the Chapters in Books listed on page 19	14:22:47
12	yourself and let me know when you're ready.	14:19:32	12 of your curriculum vitae?	14:22:52
13	A. Claim 6?	14:19:51	13 A. It does.	14:22:54
14	Q. Claim 10.	14:19:51	14 Q. Take a look at page 74 of Lawrence Exhibit 6.	14:22:55
15	A. Page 6. Sorry. Okay.	14:19:53	15 Read that page and let me know when you're ready.	14:23:16
16	Q. Claim 10 of Innopharma's '878 application	14:20:21	16 A. Yes.	14:24:15
17	states that, "The precipitating amount of chloride	14:20:26	17 Q. Let me direct your attention to the first	14:24:16
18	is effective to stabilize Bendamustine in the	14:20:29	18 sentence under Table 3.	14:24:19
19	mixture."	14:20:32	19 A. Yep.	14:24:20
20	Do you see that?	14:20:33	20 Q. You write, "The vesicles have been shown to	14:24:21
21	A. I do.	14:20:34	21 be very stable with respect to time over periods of	14:24:25
22	Q. Does Innopharma's use of the term stabilize	14:20:34	22 several months (Table 3)."	14:24:29
Page 239		Page 241		
1	in claim 10 of the '878 application make that claim	14:20:38	1 Do you see that?	14:24:31
2	invalid for indefiniteness?	14:20:41	2 A. I do.	14:24:32
3	MR. MARGOLIS: Objection. Lack of	14:20:44	3 Q. And then the title of Table 3 is "Stability	14:24:32
4	foundation. Calls for a legal conclusion.	14:20:45	4 of vesicle preparations with respect to size."	14:24:37
5	THE WITNESS: I don't even know what the	14:20:48	5 Do you see that?	14:24:40
6	formulation is. I don't really, if I'm	14:20:50	6 A. I do.	14:24:41
7	honest, even understand that claim.	14:20:54	7 Q. In Lawrence Exhibit 6, do you define a	14:24:41
8	Q. You can put that document aside.	14:20:55	8 particular numerical value at which the vesicles are	14:24:45
9	A. Good.	14:20:57	9 no longer stable?	14:24:49
10	Q. Did you ever tell Lupin's or Innopharma's	14:21:02	10 A. No. This is interesting because the	14:24:51
11	counsel in this case that you have used the term	14:21:05	11 technique it's measured -- this is a paper that is	14:24:54
12	stable in your peer-reviewed publications?	14:21:08	12 actually -- I'll start again. Sorry.	14:24:58
13	MR. MARGOLIS: Hold on one second. I	14:21:12	13 These sizes are determined using PCS, but I	14:25:14
14	just want to caution the witness not to	14:21:14	14 don't know whether I can find that -- people who use	14:25:20
15	reveal communications between yourself	14:21:16	15 PCS would know automatically what this meant, but I	14:25:24
16	and counsel --	14:21:18	16 can't see any methodology. I'm assuming you do know	14:25:30
17	MR. HASFORD: I'm just asking for yes or	14:21:18	17 that these are not peer-reviewed book chapters.	14:25:39
18	no.	14:21:20	18 That's why they are not rated as well in the -- as	14:25:43
19	MR. MARGOLIS: Okay. Just take it	14:21:20	19 a --	14:25:48
20	carefully. You can answer it yes or no.	14:21:21	20 Q. You authored Lawrence Exhibit 6, correct?	14:25:48
21	THE WITNESS: I believe I have.	14:21:26	21 A. I did.	14:25:54
22	MR. HASFORD: I'm handing the court	14:21:49	22 Q. You can put it aside now.	14:25:55

Page 242			Page 244		
1	Let me go to page 22 of your declaration.	14:25:57	1	Q. Do claims 26 through 30 of the '290 patent	14:28:50
2	A. Yes.	14:26:01	2	refer to the preservative efficacy standard of EP	14:28:53
3	Q. And paragraph 74, it says, "The phrase	14:26:01	3	criteria B of the European Pharmacopeia?	14:28:57
4	'satisfied the preservative efficacy standard...'	14:26:10	4	A. They do.	14:29:01
5	appears in claims 25 to 29 of the '131 patent.	14:26:13	5	Q. Why do you believe that claims 29 through 36	14:29:01
6	Claim 25 is copied below." And then you copy claim	14:26:17	6	of the '290 patent refer to the preservative	14:29:05
7	25.	14:26:21	7	efficacy standard of EP criteria B of the European	14:29:08
8	Do you see that?	14:26:22	8	Pharmacopeia?	14:29:12
9	A. I do.	14:26:23	9	MR. MARGOLIS: Objection. Vague. Calls	14:29:14
10	Q. And then in the first sentence of paragraph	14:26:24	10	for speculation.	14:29:16
11	75 you write, "While the claim states that the	14:26:27	11	Q. You may answer.	14:29:17
12	preparation must satisfy the U.S. Pharmacopeia	14:26:29	12	A. Because I checked them.	14:29:22
13	standards ('USP') 'as follows,' the standards that	14:26:33	13	Q. How did you check them?	14:29:29
14	follow actually appear to reflect the European	14:26:36	14	A. By going and getting the Pharmacopeia	14:29:31
15	Pharmacopeia ('EP') criteria-B standards."	14:26:39	15	standards.	14:29:34
16	Do you see that?	14:26:43	16	Q. Does the plain language of claims 26 through	14:29:35
17	A. I do.	14:26:44	17	30 of the '290 patent refer to the preservative	14:29:39
18	Q. Earlier today you talked about typographical	14:26:45	18	efficacy standard of EP criteria B of the European	14:29:42
19	errors.	14:26:47	19	Pharmacopeia?	14:29:48
20	Do you remember that?	14:26:48	20	A. Could you repeat the question, please?	14:29:51
21	A. I did.	14:26:49	21	Q. Sure. Does the plain language of claims 26	14:29:52
22	Q. And you relied on certain documents that had	14:26:49	22	through 30 of the '290 patent refer to the	14:29:57
Page 243			Page 245		
1	typographical errors in them.	14:26:52	1	preservative efficacy standard of EP criteria B of	14:30:00
2	Do you remember that?	14:26:54	2	the European Pharmacopeia?	14:30:04
3	A. I did.	14:26:55	3	A. In terms of what it says, yes.	14:30:08
4	Q. Would this suggest to a person of ordinary	14:26:55	4	Q. Is the language of claims 26 through 30 of	14:30:11
5	skill in the art that the words U.S. Pharmacopeia in	14:26:58	5	the '290 patent that refers to the preservative	14:30:14
6	claims 25 to 29 of the '131 patent are typographical	14:27:01	6	efficacy standard of EP criteria B of the European	14:30:18
7	errors that should read EP criteria B of the	14:27:05	7	Pharmacopeia consistent with the specification of	14:30:22
8	European Pharmacopeia?	14:27:10	8	the '290 patent?	14:30:24
9	MR. MARGOLIS: Objection. Vague.	14:27:13	9	MR. MARGOLIS: Objection. Vague.	14:30:27
10	THE WITNESS: One moment. It was made	14:27:22	10	THE WITNESS: I'm very sorry. I'm not	14:30:30
11	six consecutive times, though.	14:28:03	11	too certain what you're asking me.	14:30:37
12	Q. You relied on multiple typographic errors in	14:28:05	12	Q. Take a look at Experimental Example 3. You	14:30:39
13	documents that you reviewed today.	14:28:09	13	reviewed Experimental Example 3 in connection with	14:30:43
14	Do you remember that?	14:28:11	14	your opinions in this case, correct?	14:30:46
15	A. A slight difference. It wasn't a consistent	14:28:11	15	A. Yes.	14:30:48
16	error. They were spasmodic.	14:28:14	16	Q. Take a look at it and tell me when you're	14:30:49
17	Q. Let's go to the '290 patent, shall we? It's	14:28:17	17	ready.	14:30:53
18	going to be Exhibit 13, I believe, to your	14:28:21	18	A. I'm ready.	14:30:56
19	declaration. You reviewed claims 26 through 30 of	14:28:24	19	Q. Is the language of claims 26 through 30 of	14:30:57
20	the '290 patent in connection with your opinions in	14:28:38	20	the '290 patent that refers to the preservative	14:31:01
21	this case, correct?	14:28:41	21	efficacy standard of EP criteria B of the European	14:31:03
22	A. Yes.	14:28:49	22	Pharmacopeia consistent with the specification of	14:31:08

Page 246	Page 248
<p>1 the '290 patent? 14:31:11</p> <p>2 MR. MARGOLIS: Objection. Vague. 14:31:13</p> <p>3 THE WITNESS: Why did you ask me to read 14:31:27</p> <p>4 Example 3? I'm sorry. I'm confused. 14:31:31</p> <p>5 MR. MARGOLIS: I think she's looking at 14:31:39</p> <p>6 Example 3 instead of Experimental Example 3. 14:31:41</p> <p>7 Q. You need to look at Experimental Example 3 14:31:44</p> <p>8 which spans column 8 through 10. 14:31:47</p> <p>9 A. Sorry. 14:31:50</p> <p>10 Q. No problem. 14:31:51</p> <p>11 A. Now ask the question? 14:31:51</p> <p>12 Q. Certainly. Certainly. Is the language of 14:31:53</p> <p>13 claims 26 through 30 of the '290 patent that refers 14:31:56</p> <p>14 to the preservative efficacy standard of EP criteria 14:32:00</p> <p>15 B of the European Pharmacopeia consistent with the 14:32:04</p> <p>16 specification of the '290 patent? 14:32:08</p> <p>17 MR. MARGOLIS: Objection. Vague. 14:32:11</p> <p>18 Q. You may answer. 14:32:13</p> <p>19 A. Yes. 14:32:17</p> <p>20 Q. Does the specification of the '290 patent 14:32:18</p> <p>21 inform a person of ordinary skill in the art that 14:32:20</p> <p>22 claims 26 through 30 of the '290 patent that refer 14:32:24</p>	<p>1 Q. Well, my question is a little different. 14:33:39</p> <p>2 Would a person of ordinary skill in the art consider 14:33:41</p> <p>3 the specification of the patents-in-suit when 14:33:43</p> <p>4 interpreting the claims? 14:33:46</p> <p>5 A. They would consult, did you say? 14:33:56</p> <p>6 Q. Consider. 14:33:59</p> <p>7 A. I guess so, yes. Yeah. 14:34:08</p> <p>8 Q. When you reached your conclusion that the 14:34:10</p> <p>9 preservative efficacy claims of the '131 patent were 14:34:12</p> <p>10 indefinite, you did not indicate that you had looked 14:34:16</p> <p>11 at the specification, correct? 14:34:19</p> <p>12 MR. MARGOLIS: Objection. 14:34:20</p> <p>13 Mischaracterizes her declaration. 14:34:21</p> <p>14 THE WITNESS: The specification would 14:34:29</p> <p>15 not have made it any clearer. 14:34:34</p> <p>16 Q. So, when you reached your conclusion that the 14:34:39</p> <p>17 preservative efficacy claims of the '131 patent were 14:34:41</p> <p>18 indefinite, you did not look at the specification, 14:34:45</p> <p>19 correct? 14:34:48</p> <p>20 MR. MARGOLIS: Objection. 14:34:48</p> <p>21 Mischaracterizes her testimony. 14:34:49</p> <p>22 THE WITNESS: I didn't say that, no. 14:34:53</p>
Page 247	Page 249
<p>1 to the preservative efficacy -- sorry. Let me 14:32:28</p> <p>2 strike that and try again. 14:32:32</p> <p>3 Does the specification of the '290 patent 14:32:32</p> <p>4 inform a person of ordinary skill in the art that 14:32:37</p> <p>5 claims 26 through 30 of the '290 patent refer to the 14:32:41</p> <p>6 preservative efficacy standard of EP criteria B of 14:32:44</p> <p>7 the European Pharmacopeia? 14:32:49</p> <p>8 MR. MARGOLIS: Objection. Vague. 14:32:54</p> <p>9 THE WITNESS: Yes. On the condition 14:32:57</p> <p>10 that they got it correct in the 14:32:59</p> <p>11 specifications, obviously. 14:33:03</p> <p>12 Q. And earlier today you confirmed that the 14:33:04</p> <p>13 specification of the '290 patent is essentially the 14:33:07</p> <p>14 same as that of the other patents-in-suit, including 14:33:10</p> <p>15 that of the '131 patent, correct? 14:33:13</p> <p>16 A. It is essentially the same, yes. 14:33:16</p> <p>17 Q. Would a person of ordinary skill in the art 14:33:18</p> <p>18 consider the specification of the patents-in-suit 14:33:20</p> <p>19 with interpreting the claims? 14:33:23</p> <p>20 A. Yes, but the confusion would mean that I have 14:33:27</p> <p>21 to search the primary sources to try and understand 14:33:33</p> <p>22 definitively what's the situation. 14:33:37</p>	<p>1 Q. Your conclusions regarding the preservative 14:34:56</p> <p>2 efficacy claims of the '131 patent are based on less 14:34:59</p> <p>3 than all of the intrinsic evidence, correct? 14:35:03</p> <p>4 MR. MARGOLIS: Objection. 14:35:06</p> <p>5 Mischaracterizes the document. 14:35:07</p> <p>6 THE WITNESS: No, not correct. 14:35:08</p> <p>7 Q. You just testified that the specification of 14:35:09</p> <p>8 this patent informs a skilled artisan that the 14:35:14</p> <p>9 claims refer to the preservative efficacy standard 14:35:18</p> <p>10 of EP criteria B of the European Pharmacopeia. 14:35:21</p> <p>11 Do you remember that? 14:35:24</p> <p>12 MR. MARGOLIS: Objection. 14:35:25</p> <p>13 Mischaracterizes the testimony. 14:35:26</p> <p>14 THE WITNESS: Anybody who is skilled in 14:35:28</p> <p>15 the art would be irresponsible not to go and 14:35:29</p> <p>16 check out with the Pharmacopeia which ones 14:35:35</p> <p>17 were correct. I wouldn't rely on the -- just 14:35:39</p> <p>18 on the patent. 14:35:53</p> <p>19 Q. Take a look again at claims -- at the claims 14:35:56</p> <p>20 of the '131 patent, claims 25 through 29. The test 14:35:59</p> <p>21 conditions set forth in claims 29 through 29 -- let 14:36:24</p> <p>22 me try again. 14:36:24</p>

Page 250		Page 252			
1	The test conditions set forth in claims 25	14:36:31	1	MR. MARGOLIS: Objection. Vague.	14:38:40
2	through 29 of the '131 patent correspond to the	14:36:35	2	THE WITNESS: I read the prosecution	14:38:49
3	preservative efficacy standard of EP criteria B of	14:36:42	3	histories, but I didn't discuss that	14:38:52
4	the European Pharmacopeia, correct?	14:36:46	4	obviously in my report.	14:38:56
5	MR. MARGOLIS: Objection. Vague.	14:36:49	5	Q. Take a look, if you would, at Exhibit 5 to	14:38:57
6	THE WITNESS: Well, I checked them out.	14:36:53	6	your declaration. If I refer to Exhibit 5 to your	14:39:06
7	Yes, that was correct.	14:36:55	7	declaration as the Moser reference, will you	14:39:39
8	Q. Take a look now, if you would, at page 23 of	14:36:56	8	understand what I mean?	14:39:42
9	your declaration, paragraph 76. In the first	14:37:01	9	A. Yes.	14:39:43
10	sentence you write, "While similar, the USP	14:37:16	10	Q. Are you relying on the Moser reference in	14:39:43
11	standards differ in some respects from the EP	14:37:19	11	connection with your opinions in this case?	14:39:46
12	standards."	14:37:21	12	A. I am.	14:39:47
13	Is that a true statement?	14:37:21	13	Q. Does the Moser reference prior art to the	14:39:48
14	A. Yes.	14:37:22	14	patents-in-suit?	14:39:50
15	Q. In the second sentence you write, "The USP	14:37:23	15	MR. MARGOLIS: Objection. Calls for a	14:39:54
16	standards likewise differ from the standards recited	14:37:25	16	legal conclusion.	14:39:56
17	in these claims in several ways, including the	14:37:28	17	THE WITNESS: No, it's not.	14:39:58
18	organisms tested, the times at which data are	14:37:32	18	Q. Take a look at page 226 of the Moser	14:39:59
19	collected, and the permissible limits."	14:37:35	19	reference. It bears Bates number LUPIN018800.	14:40:05
20	Is that a true statement?	14:37:37	20	A. Yes.	14:40:11
21	A. It is.	14:37:38	21	Q. And take a look at the Conclusion and read	14:40:13
22	Q. In the next sentence you write, "For example,	14:37:38	22	the first sentence of the Conclusion to yourself and	14:40:17
Page 251		Page 253			
1	the claim-recited standards require that the	14:37:40	1	let me know when you're ready.	14:40:20
2	bacteria count decrease to 1/1000 at day 7, while	14:37:43	2	A. Yes.	14:40:55
3	the USP standard requires only a 1/10 reduction by	14:37:48	3	Q. Does the Moser reference teach that	14:40:56
4	day 7."	14:37:52	4	preservative efficacy testing for pharmaceutical	14:40:59
5	Is that a true statement?	14:37:53	5	products measures antimicrobial effectiveness?	14:41:02
6	A. It is.	14:37:54	6	A. Well, preservative effectiveness, yes.	14:41:07
7	Q. In the next sentence you write, "As another	14:37:55	7	Q. Does the Moser reference state that the	14:41:10
8	example, the USP requires that E. coli be among the	14:37:57	8	antimicrobial effectiveness or preservative efficacy	14:41:12
9	bacteria tested, while the claim-recited standards	14:38:01	9	test is described in the U.S. Pharmacopeia, the	14:41:16
10	do not."	14:38:04	10	European Pharmacopeia, and the Japanese	14:41:20
11	Is that a true statement?	14:38:05	11	Pharmacopeia?	14:41:23
12	A. It is.	14:38:06	12	A. It does.	14:41:24
13	Q. In the next sentence you write, "Yet	14:38:07	13	Q. Are the U.S. Pharmacopeia, the European	14:41:24
14	another -- the USP requires no increase in fungi	14:38:09	14	Pharmacopeia, and the Japanese Pharmacopeia the	14:41:27
15	counts at days 7, 14 and 28, while the	14:38:13	15	three compendia identified in the Moser reference?	14:41:31
16	claims-recited standards require a 1/10 reduction in	14:38:18	16	A. They are.	14:41:36
17	fungi counts at day 14, but do not require any	14:38:21	17	Q. Take a look at the last sentence of the	14:41:36
18	earlier testing."	14:38:25	18	Conclusion and let me know when you're ready.	14:41:39
19	Is that a true statement?	14:38:26	19	A. Yes.	14:41:44
20	A. It is.	14:38:27	20	Q. In the last sentence of the Conclusion, the	14:41:45
21	Q. Did you consider how claims 25 through 29 of	14:38:30	21	Moser reference states that one preservative	14:41:47
22	the '131 patent were added during prosecution?	14:38:34	22	efficacy test can be performed that satisfies all of	14:41:50

Page 254	<p>1 the compendia and their acceptance criteria. 14:41:54</p> <p>2 Do you see that? 14:41:57</p> <p>3 A. I do. 14:41:57</p> <p>4 Q. Take a look now, if you would, at the '131 14:41:58</p> <p>5 patent -- actually, I apologize. Take a look, if 14:42:03</p> <p>6 you would, at page 24 of your declaration, paragraph 14:42:12</p> <p>7 78. 14:42:24</p> <p>8 In paragraph 78 of your declaration, do you 14:42:30</p> <p>9 set forth and respond to plaintiffs' position 14:42:33</p> <p>10 regarding claims 25 through 29 of the '131 patent? 14:42:36</p> <p>11 A. I do. 14:42:40</p> <p>12 Q. In paragraph 78 of your declaration do you 14:42:41</p> <p>13 cite any document? 14:42:43</p> <p>14 A. No. 14:42:52</p> <p>15 MS. HASFORD: Let's go off the record. 14:42:53</p> <p>16 We need to do a tape change. And I think 14:42:54</p> <p>17 we're fairly close to being wrapped up. 14:42:57</p> <p>18 THE VIDEOGRAPHER: The time is 14:43:00</p> <p>19 approximately 2:44 p.m., Friday, September 4, 14:43:02</p> <p>20 2015. This is the end of tape number four of 14:43:11</p> <p>21 the videotaped deposition of Dr. Jayne 14:43:15</p> <p>22 Lawrence. We are off the record. 14:43:18</p>	Page 256	<p>1 enhancement, sometimes by up to tenfold, over that 15:00:37</p> <p>2 achieved using the more conventional polyethylene 15:00:42</p> <p>3 oxide surfactants." 15:00:45</p> <p>4 Does the art teach that amine-N-oxide 15:00:49</p> <p>5 surfactants are preferable to polyethylene oxide 15:00:52</p> <p>6 surfactants for drug solubilization? 15:00:55</p> <p>7 MR. MARGOLIS: Objection. Vague. 15:00:59</p> <p>8 THE WITNESS: On the basis of that 15:01:03</p> <p>9 statement, it's not possible to say. You 15:01:06</p> <p>10 would want more information. I would like to 15:01:09</p> <p>11 explain why. 15:01:12</p> <p>12 Q. What more information would you want? 15:01:12</p> <p>13 A. For example, are they sensitive to 15:01:15</p> <p>14 electrolytes? What is their CMC? So, there is 15:01:19</p> <p>15 other extraneous information there -- there's other 15:01:24</p> <p>16 extraneous information required to make that 15:01:28</p> <p>17 judgment. 15:01:31</p> <p>18 Q. Is there any other information you would 15:01:32</p> <p>19 want? 15:01:35</p> <p>20 A. Effect of temperature on these systems. 15:01:38</p> <p>21 Q. How about pH? 15:01:42</p> <p>22 A. Yes, pH as well. 15:01:45</p>
Page 255	<p>1 (Recess from 2:44 to 3:00.) 14:43:20</p> <p>2 THE VIDEOGRAPHER: The time is 14:58:44</p> <p>3 approximately 3:00 p.m., Friday, September 4, 14:59:22</p> <p>4 2015. This is tape number five of the 14:59:28</p> <p>5 videotaped deposition of Dr. Jayne Lawrence. 14:59:32</p> <p>6 We are back on the record. 14:59:35</p> <p>7 BY MR. HASFORD: 14:59:36</p> <p>8 Q. I want to direct your attention back to 14:59:36</p> <p>9 Lawrence Exhibit 6, which was item number 6 in the 14:59:39</p> <p>10 Book Chapters on your CV. Turn, if you would, to 14:59:43</p> <p>11 page 66 and let me direct your attention to the 14:59:47</p> <p>12 second paragraph under heading 2.1 Previous Work. 14:59:50</p> <p>13 A. Yes. 14:59:58</p> <p>14 Q. Okay. It says, "At about the same time as 14:59:59</p> <p>15 the studies performed by Elworthy and co-workers, 15:00:02</p> <p>16 other researchers were investigating an alternative 15:00:06</p> <p>17 approach to increasing micellar solubilization, 15:00:09</p> <p>18 which involved replacement of the usual 15:00:13</p> <p>19 polyoxyethylene hydrophile present in most non-ionic 15:00:16</p> <p>20 surfactants with a heterocyclic amine-N-oxide group. 15:00:22</p> <p>21 Drug solubilization in the micelles produced by 15:00:28</p> <p>22 these amine-N-oxide surfactants showed a significant 15:00:32</p>	Page 257	<p>1 Q. Anything else? 15:01:48</p> <p>2 A. pH, temperature, dilutability would be 15:01:50</p> <p>3 related to the CMC, electrolyte -- have I said that, 15:01:57</p> <p>4 the presence of electrolyte? That may affect -- 15:02:04</p> <p>5 they would be the main information. 15:02:07</p> <p>6 Q. You can put that document aside. 15:02:10</p> <p>7 MR. HASFORD: I'm handing the court 15:02:21</p> <p>8 reporter what I would ask to be marked as 15:02:23</p> <p>9 Lawrence Exhibit 7. 15:02:24</p> <p>10 For the record, Lawrence Exhibit 7 15:02:26</p> <p>11 corresponds to item number 7 in Chapters in 15:02:28</p> <p>12 Books on Dr. Lawrence's CV. 15:02:31</p> <p>13 (Whereupon, Plaintiff's Deposition 15:02:51</p> <p>14 Exhibit No. Lawrence 7 was marked for 15:02:52</p> <p>15 Identification.) 15:02:53</p> <p>16 Q. Are you the M.J. Lawrence who co-authored 15:02:53</p> <p>17 Lawrence Exhibit 7? 15:03:00</p> <p>18 A. I am. 15:03:01</p> <p>19 Q. Does Lawrence Exhibit 7 correspond to item 15:03:02</p> <p>20 number 7 in the Chapters in Books on your curriculum 15:03:04</p> <p>21 vitae? 15:03:09</p> <p>22 A. It does. 15:03:09</p>

Page 258	Page 260
<p>1 Q. Turn, if you would, to page 325 in Lawrence 15:03:10</p> <p>2 Exhibit 7. Let me direct your attention to Section 15:03:13</p> <p>3 11.1. And in the second paragraph it begins, 15:03:18</p> <p>4 "Pharmaceutics is an extremely broadly based 15:03:26</p> <p>5 discipline which takes input from areas as diverse 15:03:30</p> <p>6 as molecular biology, thermodynamics, and materials 15:03:34</p> <p>7 engineering, in order to convert pharmacologically 15:03:39</p> <p>8 active chemicals to medicines. Increasingly, these 15:03:43</p> <p>9 medicines are not simple tablets or syrups, but 15:03:46</p> <p>10 consist of highly sophisticated systems designed to 15:03:49</p> <p>11 deliver drugs to specific sites and to regulate the 15:03:53</p> <p>12 dose of drug to the patient." 15:03:57</p> <p>13 Are ophthalmic formulations highly 15:04:00</p> <p>14 sophisticated systems designed to deliver drugs to 15:04:03</p> <p>15 specific sites and to regulate the dose of drug to 15:04:07</p> <p>16 the patient? 15:04:10</p> <p>17 MR. MARGOLIS: Objection. Vague. 15:04:11</p> <p>18 THE WITNESS: If we're talking about the 15:04:13</p> <p>19 ophthalmic preparations we're discussing 15:04:15</p> <p>20 today, they're not highly sophisticated. 15:04:19</p> <p>21 Q. And I'm asking you generally, are ophthalmic 15:04:22</p> <p>22 formulations highly sophisticated systems designed 15:04:26</p>	<p>1 curriculum vitae? 15:05:42</p> <p>2 A. It does. 15:05:43</p> <p>3 Q. Did Lawrence Exhibit 8 publish in 2000? 15:05:44</p> <p>4 A. Yes. 15:05:48</p> <p>5 Q. Take a look, if you would, at page 10 of 15:05:49</p> <p>6 Lawrence Exhibit 8. Let me direct your attention to 15:05:53</p> <p>7 the first full paragraph. And the first sentence 15:05:58</p> <p>8 says, "Sadly, our understanding is not yet 15:06:01</p> <p>9 sufficiently advanced that we are able simply to 15:06:04</p> <p>10 take the covalent structure of a surfactant and from 15:06:07</p> <p>11 this then to predict the 3D structure and properties 15:06:11</p> <p>12 of the vesicles it will form." 15:06:15</p> <p>13 In 2000, was the state of the art not 15:06:17</p> <p>14 sufficiently advanced to simply take the chemical 15:06:19</p> <p>15 structure of a surfactant and from this then predict 15:06:22</p> <p>16 the three-dimensional structure and properties of a 15:06:26</p> <p>17 surfactant? 15:06:28</p> <p>18 MR. MARGOLIS: Objection. 15:06:29</p> <p>19 Mischaracterizes the document. 15:06:30</p> <p>20 THE WITNESS: I think it was trivial at 15:06:32</p> <p>21 that time to predict it would form vesicles. 15:06:35</p> <p>22 That was fairly routine. What this is 15:06:40</p>
Page 259	Page 261
<p>1 to deliver drugs to specific sites and to regulate 15:04:29</p> <p>2 the dose of drug to the patient? 15:04:32</p> <p>3 MR. MARGOLIS: Objection. Vague. 15:04:34</p> <p>4 THE WITNESS: It's really not possible 15:04:36</p> <p>5 to answer that. There are some sophisticated 15:04:38</p> <p>6 formulations. There are some very pedestrian 15:04:42</p> <p>7 type formulations. 15:04:46</p> <p>8 Q. You can put that document aside. 15:04:48</p> <p>9 MR. HASFORD: I'm handing the court 15:05:01</p> <p>10 reporter what I would ask to be marked as 15:05:02</p> <p>11 Lawrence 8. 15:05:03</p> <p>12 For the record, Lawrence Exhibit 8 15:05:04</p> <p>13 corresponds to item number 8 in Chapters in 15:05:06</p> <p>14 Books on Dr. Lawrence's curriculum vitae. 15:05:09</p> <p>15 (Whereupon, Plaintiff's Deposition 15:05:31</p> <p>16 Exhibit No. Lawrence 8 was marked for 15:05:32</p> <p>17 Identification.) 15:05:32</p> <p>18 Q. Are you the M.J. Lawrence who co-authored 15:05:32</p> <p>19 Lawrence Exhibit 8? 15:05:35</p> <p>20 A. I am. 15:05:36</p> <p>21 Q. Does Lawrence Exhibit 8 correspond to item 15:05:36</p> <p>22 number 8 in the Chapters in Books section of your 15:05:39</p>	<p>1 specifically talking about is the 3-D 15:06:44</p> <p>2 structure and resulting properties. That was 15:06:47</p> <p>3 harder. And it's particularly dealing with a 15:06:49</p> <p>4 particular system that demonstrated some 15:06:53</p> <p>5 quite unusual properties. 15:06:57</p> <p>6 Q. When, if ever, did the state of the art 15:06:58</p> <p>7 become sufficiently advanced to simply take the 15:07:01</p> <p>8 chemical structure of a surfactant and from this 15:07:04</p> <p>9 then predict the three-dimensional structure of the 15:07:07</p> <p>10 properties of the surfactant? 15:07:11</p> <p>11 MR. MARGOLIS: Objection. Vague. And 15:07:13</p> <p>12 mischaracterizes her testimony. 15:07:25</p> <p>13 Q. You may answer. 15:07:27</p> <p>14 A. I think great leaps forward have been made 15:07:30</p> <p>15 with the combination of experimental work coupled 15:07:35</p> <p>16 with molecular dynamic simulations, which have 15:07:40</p> <p>17 probably been increasingly available from I guess 15:07:45</p> <p>18 around the time of this abstract -- this report. 15:07:53</p> <p>19 Q. When did the great leaps forward take place? 15:07:58</p> <p>20 A. When computing power got sufficiently 15:08:04</p> <p>21 advanced to be able to perform the difficult 15:08:08</p> <p>22 calculations that are required, difficult and 15:08:10</p>

Page 262	<p>1 time-consuming calculations required to do the 3-D 15:08:15</p> <p>2 modeling. 15:08:19</p> <p>3 Q. Do you remember what year that was? 15:08:19</p> <p>4 A. No. And to be honest with you, it probably 15:08:23</p> <p>5 varied depending whether somebody had access to a 15:08:28</p> <p>6 Super Computer and was doing the calculations on 15:08:31</p> <p>7 that or doing them on a little lap-based computer. 15:08:33</p> <p>8 Q. You can put that aside. 15:08:36</p> <p>9 MR. HASFORD: I'm handing the court 15:09:00</p> <p>10 reporter what I would ask to be marked as 15:09:01</p> <p>11 Lawrence Exhibit 9. 15:09:02</p> <p>12 For the record, Lawrence Exhibit 9 15:09:03</p> <p>13 corresponds to item number 14 in Chapters in 15:09:05</p> <p>14 Books on Dr. Lawrence's curriculum vitae. 15:09:09</p> <p>15 15:09:32</p> <p>16 (Whereupon, Plaintiff's Deposition 15:09:32</p> <p>17 Exhibit No. Lawrence 9 was marked for 15:09:33</p> <p>18 Identification.) 15:09:34</p> <p>19 Q. Are you the M. Jayne Lawrence who co-authored 15:09:34</p> <p>20 Lawrence Exhibit 9? 15:09:37</p> <p>21 A. I am. 15:09:38</p> <p>22 Q. Does Lawrence Exhibit 9 correspond to item 15:09:39</p>	Page 264	<p>1 foundation. 15:10:52</p> <p>2 THE WITNESS: Yeah, taking all 15:10:53</p> <p>3 formulations, including intravenous 15:10:55</p> <p>4 formulations for which these surfactants are 15:10:59</p> <p>5 particularly suitable, I believe that to be 15:11:02</p> <p>6 true. 15:11:05</p> <p>7 Q. You can put that document aside. 15:11:05</p> <p>8 MR. HASFORD: I'm handing the court 15:11:31</p> <p>9 reporter what I would ask to be marked as 15:11:33</p> <p>10 Lawrence Exhibit 10. 15:11:34</p> <p>11 THE WITNESS: I'm impressed you got 15:11:36</p> <p>12 that. 15:11:39</p> <p>13 Q. I'm glad you are. 15:11:39</p> <p>14 MR. HASFORD: For the record, Lawrence 15:11:40</p> <p>15 Exhibit 10 corresponds to item number 15 in 15:11:42</p> <p>16 Chapters in Books on Dr. Lawrence's CV. 15:11:48</p> <p>17 A. No, it doesn't. 15:11:51</p> <p>18 Q. Oh, sorry. Did I get that wrong? 15:11:52</p> <p>19 A. Yes, you did. It's not 15 at all. 15:11:54</p> <p>20 Q. Oops. Which one is it? Well, let me -- let 15:11:57</p> <p>21 me mark it and then -- 15:12:00</p> <p>22 A. Okay. 15:12:02</p>
Page 263	<p>1 number 14 in the Chapters in Books section of your 15:09:41</p> <p>2 curriculum vitae? 15:09:45</p> <p>3 A. It does. 15:09:46</p> <p>4 Q. Did Lawrence Exhibit 9 publish in 2006? 15:09:47</p> <p>5 A. It did. 15:09:50</p> <p>6 Q. Take a look, if you would, at page 137. Let 15:09:52</p> <p>7 me direct your attention to the third full 15:09:59</p> <p>8 paragraph. It states, "Perhaps the most widely used 15:10:05</p> <p>9 non-ionic surfactants in pharmaceutical formulations 15:10:08</p> <p>10 are the polyoxyethylene sorbitan n-acyl esters, 15:10:12</p> <p>11 i.e., the Tweens and in particular, Tween 20 and 15:10:18</p> <p>12 Tween 80, both of which are used parenterally and 15:10:23</p> <p>13 orally." 15:10:28</p> <p>14 Was that a true statement as of 2006? 15:10:29</p> <p>15 A. I believe so, yes. 15:10:34</p> <p>16 Q. As of 2003, was it also true that the most 15:10:35</p> <p>17 widely used non-ionic surfactants in pharmaceutical 15:10:38</p> <p>18 formulations were the polyoxyethylene sorbitan 15:10:43</p> <p>19 n-acyl esters, i.e., the Tweens, and in particular 15:10:47</p> <p>20 Tween 20 and Tween 80? 15:10:50</p> <p>21 A. Taking -- 15:10:51</p> <p>22 MR. MARGOLIS: Objection. Lack of 15:10:51</p>	Page 265	<p>1 Q. Oh, I apologize. So, we're on -- we're on 15:12:02</p> <p>2 item -- we're on Lawrence 10. Okay. I know what I 15:12:12</p> <p>3 did. I skipped one. I pulled the wrong thing out 15:12:17</p> <p>4 of my folder. 15:12:27</p> <p>5 MR. MARGOLIS: It happens. 15:12:28</p> <p>6 MR. HASFORD: I'm handing the court 15:12:30</p> <p>7 reporter what I'd ask to be marked as 15:12:31</p> <p>8 Lawrence Exhibit 10. 15:12:33</p> <p>9 (Whereupon, Plaintiff's Deposition 15:12:33</p> <p>10 Exhibit No. Lawrence 10 was marked for 15:12:42</p> <p>11 Identification.) 15:12:42</p> <p>12 Q. Does Lawrence Exhibit 10 correspond to item 15:12:42</p> <p>13 number 15 in Chapters in Books on your curriculum 15:12:45</p> <p>14 vitae? 15:12:49</p> <p>15 A. It does. 15:12:49</p> <p>16 Q. And you are -- you are the M. Jayne Lawrence 15:12:50</p> <p>17 who co-authored Lawrence Exhibit 10, correct? 15:13:00</p> <p>18 A. I am. 15:13:02</p> <p>19 Q. Turn, if you would, to page 1054, and look, 15:13:05</p> <p>20 if you would, at the section entitled 15:13:18</p> <p>21 Surfactant/Water Mixtures. 15:13:23</p> <p>22 In the first sentence you write, "Surfactants 15:13:28</p>

Page 266	<p>1 are amphiphilic molecules which, when dispersed in a 15:13:30</p> <p>2 solvent, spontaneously self-assemble to form a wide 15:13:34</p> <p>3 variety of structures, including spherical and 15:13:38</p> <p>4 asymmetric micelles, hexagonal, lamellar, and a 15:13:41</p> <p>5 plethora of cubic phases." 15:13:46</p> <p>6 Is that a true statement? 15:13:48</p> <p>7 A. Yes, in the absence of additives. As I 15:13:51</p> <p>8 demonstrate, that will change things. 15:13:54</p> <p>9 Q. In the next sentence you write, "With the 15:13:56</p> <p>10 exception of the lamellar phase, each of these phase 15:13:58</p> <p>11 structures can exist in both normal and reverse 15:14:02</p> <p>12 orientations with the hydrophobic chains on the 15:14:05</p> <p>13 exterior of the aggregate, in contact with solvent 15:14:08</p> <p>14 or vice versa orientation." 15:14:13</p> <p>15 Is that a true statement? 15:14:15</p> <p>16 A. Yes. 15:14:16</p> <p>17 Q. In the next sentence you write, "The range of 15:14:17</p> <p>18 structures a particular surfactant forms and the 15:14:19</p> <p>19 concentration range over which they form, depends 15:14:21</p> <p>20 upon the molecular architecture of the surfactant, 15:14:25</p> <p>21 its concentration, and the solvent in which it is 15:14:28</p> <p>22 dispersed." 15:14:31</p>	Page 268	<p>1 paragraph you write, "Taking a drug molecule from 15:15:38</p> <p>2 concept through formulation, clinical trials, 15:15:43</p> <p>3 manufacture and the strict regulatory process to its 15:15:47</p> <p>4 ultimate use as a medicine by the patient is an 15:15:50</p> <p>5 expensive, complex and lengthy process with a great 15:15:54</p> <p>6 many hurdles at which a potential drug may fall." 15:15:58</p> <p>7 Is that a true statement? 15:16:01</p> <p>8 MR. MARGOLIS: Objection. Vague. 15:16:03</p> <p>9 Q. You may answer. 15:16:04</p> <p>10 A. I believe so. 15:16:05</p> <p>11 Q. Turn, please, to page 14, and let me direct 15:16:06</p> <p>12 your attention to Selection of Drug Molecules. In 15:16:12</p> <p>13 the first sentence you state, "The range of 15:16:15</p> <p>14 potential drug molecules is enormous." 15:16:18</p> <p>15 Is that a true statement? 15:16:20</p> <p>16 A. Yes. 15:16:22</p> <p>17 Q. And then let me direct your attention to the 15:16:23</p> <p>18 section entitled Medicines Development and 15:16:26</p> <p>19 Preclinical Testing. You state, "Once a lead 15:16:28</p> <p>20 compound has been identified, a decision has to be 15:16:33</p> <p>21 made as to whether it is possible to develop the 15:16:36</p> <p>22 molecule into a safe, effective medicine." 15:16:38</p>
Page 267	<p>1 Is that a true statement? 15:14:32</p> <p>2 A. Yes. 15:14:32</p> <p>3 Q. You may put this document aside. 15:14:33</p> <p>4 MR. HASFORD: Now, I'm handing the court 15:14:41</p> <p>5 reporter what I ask to be marked as Lawrence 15:14:43</p> <p>6 Exhibit 11. 15:14:45</p> <p>7 For the record, Lawrence Exhibit 11 15:14:46</p> <p>8 corresponds to item number 12 in Other 15:14:48</p> <p>9 Outputs on Dr. Lawrence's CV. 15:14:51</p> <p>10 (Whereupon, Plaintiff's Deposition 15:15:08</p> <p>11 Exhibit No. Lawrence 11 was marked for 15:15:09</p> <p>12 Identification.) 15:15:10</p> <p>13 Q. Did I get it right this time, Doctor? 15:15:10</p> <p>14 A. That's correct. 15:15:10</p> <p>15 Q. Does this correspond to item number 12 in 15:15:12</p> <p>16 your Outputs? 15:15:13</p> <p>17 A. Yes, it does. 15:15:14</p> <p>18 Q. Very good. Thank you. And you are the Jayne 15:15:15</p> <p>19 Lawrence who authored Lawrence Exhibit 11, correct? 15:15:17</p> <p>20 A. Well, I was one of the team. 15:15:20</p> <p>21 Q. Okay. Let me direct your attention to page 15:15:23</p> <p>22 13, and in particular section 1.2. In the second 15:15:28</p>	Page 269	<p>1 Is that a true statement? 15:16:41</p> <p>2 MR. MARGOLIS: Objection. Vague. 15:16:44</p> <p>3 Q. You may answer. 15:16:45</p> <p>4 A. I believe so. 15:16:47</p> <p>5 Q. In the next sentence you state, "To do this 15:16:48</p> <p>6 the compounds physiochemical properties as well as 15:16:50</p> <p>7 its fate and behaviour in the body all have to be 15:16:55</p> <p>8 assessed." 15:16:58</p> <p>9 Is that a true statement? 15:16:58</p> <p>10 A. Yes. 15:16:59</p> <p>11 Q. In the next sentence you state, "Particular 15:17:00</p> <p>12 attention is given to the efficacy and toxicity of 15:17:02</p> <p>13 the lead compound as these are the main reasons for 15:17:05</p> <p>14 failure of a compound to progress beyond this 15:17:09</p> <p>15 stage." 15:17:12</p> <p>16 Is that a true statement? 15:17:12</p> <p>17 A. Yes. 15:17:14</p> <p>18 MR. MARGOLIS: Objection. Vague. 15:17:14</p> <p>19 Q. If a compound were demonstrated to have liver 15:17:15</p> <p>20 toxicity, would that compound be an attractive 15:17:18</p> <p>21 candidate for use in a new ophthalmic formulation or 15:17:21</p> <p>22 would it be better to select a different compound? 15:17:24</p>

Page 270	<p>1 MR. MARGOLIS: Objection. Vague. Calls 15:17:27 2 for speculation. 15:17:28 3 Q. You may answer. 15:17:30 4 A. You'd need a lot more information to decide 15:17:32 5 than just that statement. 15:17:36 6 Q. What more information would you need? 15:17:37 7 A. A variety of information. For example, it 15:17:39 8 might be a particularly nasty eye condition that 15:17:45 9 there are no drugs for, and it might be worth the 15:17:49 10 risk of some liver toxicity if you were going to 15:17:54 11 perhaps save somebody's sight or something. So it 15:17:58 12 really isn't a comment I can answer. 15:18:01 13 Q. What other information would you need? 15:18:03 14 A. The frequency of use, the dose of use, how 15:18:07 15 much is going to be absorbed into the body, how long 15:18:14 16 it's going to be used, if I have not said that, if 15:18:21 17 there are any other ways in negating the toxicity. 15:18:26 18 Q. Are there any other -- 15:18:31 19 A. Probably, but -- 15:18:33 20 Q. -- items of information you would need? 15:18:33 21 A. Probably, but -- 15:18:35 22 Q. Sitting here today -- 15:18:38</p>	Page 272	<p>1 are affected by the likely excipients that 15:19:44 2 you're going to add to the formulation, the 15:19:48 3 effect of temperature on that formulation. I 15:19:50 4 think pH is obviously included in there as 15:19:53 5 well because that may be -- may affect the 15:19:58 6 stability of the drug, how it's likely to be 15:20:02 7 degraded, what's the best formulation, what's 15:20:04 8 the best solvent you're going to add. 15:20:07 9 Q. Anything else? 15:20:10 10 A. I think I've given a reasonable start. 15:20:12 11 Q. Take a look, if you would, at page 31 of 15:20:15 12 Lawrence Exhibit 11. And let me direct your 15:20:18 13 attention to the section entitled Physicochemical 15:20:27 14 Properties and their Influence on Formulation. 15:20:30 15 In the first sentence you write, "In order to 15:20:34 16 determine whether it is possible to successfully 15:20:36 17 formulate a drug as a medicine, it is essential to 15:20:38 18 determine the drug's basic physicochemical 15:20:41 19 properties, including its water solubility, its 15:20:46 20 partitioning between oil and water and its behaviour 15:20:48 21 in different pH environments." 15:20:51 22 Is this a true statement? 15:20:53</p>
Page 271	<p>1 A. I summarized a reasonable amount. 15:18:38 2 Q. Take a look at the section on page 14 15:18:41 3 entitled Formulation Challenges. In the first 15:18:44 4 sentence you state, "There can be considerable 15:18:48 5 challenges encountered in the preparation of an 15:18:49 6 appropriate formulation or delivery form of a drug, 15:18:52 7 with the formulation being used for pre-clinical 15:18:55 8 studies unlikely to be the formulation used in man." 15:18:58 9 What are some of the considerable challenges 15:19:02 10 encountered in the preparation of an appropriate 15:19:05 11 ophthalmic formulation? 15:19:08 12 MR. MARGOLIS: Objection. Vague. Lack 15:19:10 13 of foundation. 15:19:12 14 Q. You may answer. 15:19:14 15 A. I believe I've already answered this question 15:19:15 16 earlier. 15:19:17 17 Q. Could you summarize them, please? 15:19:18 18 MR. MARGOLIS: Same objections. 15:19:22 19 THE WITNESS: There would be -- what you 15:19:27 20 would need to understand what the dose was, 15:19:31 21 the dosing frequency, physicochemical 15:19:32 22 properties of the drug, how those properties 15:19:41</p>	Page 273	<p>1 MR. MARGOLIS: Objection. Vague. 15:20:55 2 Mischaracterizes the document. 15:20:57 3 Q. You may answer. 15:20:59 4 A. I believe I've told you this information is 15:21:02 5 important in formulating a drug. 15:21:09 6 Q. Take a look, if you would, at page 32, and 15:21:15 7 let me direct your attention to the third sentence. 15:21:22 8 It starts, "A successful drug." 15:21:24 9 Do you see that? 15:21:26 10 A. Yes. 15:21:30 11 Q. It says, "A successful drug requires a 15:21:31 12 balance to be struck between potency/selectivity and 15:21:33 13 its pharmacokinetic properties." 15:21:37 14 Is that a true statement? 15:21:40 15 A. It is. 15:21:41 16 Q. Take a look now at the fifth sentence. It 15:21:42 17 says, "To achieve successful delivery and therefore 15:21:45 18 optimal exposure of the drug to the body, however, 15:21:49 19 requires an appropriate balance of oil and water 15:21:52 20 solubility." 15:21:55 21 Is that a true statement? 15:21:56 22 MR. MARGOLIS: Objection. Vague. 15:21:58</p>

Page 274			Page 276		
1	THE WITNESS: That is taken out of	15:22:00	1	solubility and therefore permeability of the	15:23:52
2	context. It needs to be read with the	15:22:03	2	drug across the membrane, and unless it's	15:23:55
3	previous sentence.	15:22:04	3	being -- that's been the case for a while and	15:23:59
4	Q. Is it a true statement?	15:22:05	4	will continue to be the case.	15:24:02
5	MR. MARGOLIS: Objection. Vague.	15:22:07	5	Q. Was that true as of 2003?	15:24:03
6	THE WITNESS: In the context of the	15:22:08	6	MR. MARGOLIS: Objection. Vague.	15:24:07
7	previous statement, yes.	15:22:10	7	THE WITNESS: My focus of research since	15:24:09
8	Q. And the previous statement says, "In	15:22:15	8	I started as an academic was looking at ways	15:24:13
9	particular, there is often a lack of appreciation	15:22:20	9	of increasing the solubility of poorly	15:24:16
10	that a molecule will not become a successful	15:22:22	10	water-soluble drugs to improve their	15:24:29
11	medicine if it is not adequately distributed within	15:22:25	11	delivery. So, this is something that's been	15:24:32
12	the body."	15:22:28	12	a problem for a long time.	15:24:40
13	Is that a true statement?	15:22:29	13	Q. In your opinion as of 2003 --	15:24:41
14	A. I'm confused. You asked me, "To achieve	15:22:30	14	A. Yes.	15:24:44
15	successful delivery and therefore optimal exposure	15:22:33	15	Q. -- was the --	15:24:44
16	of the drug to the body." The previous statement	15:22:37	16	A. Sorry.	15:24:44
17	is --	15:22:39	17	Q. -- search still ongoing?	15:24:45
18	Q. I apologize. Go ahead. You can read it.	15:22:39	18	MR. MARGOLIS: Objection.	15:24:47
19	A. Okay. "The focus of the hit-to-lead	15:22:41	19	THE WITNESS: The search was in	15:24:47
20	optimization programmes is to drive for potency at	15:22:44	20	progress, yes.	15:24:48
21	the in vitro level, which often translates to	15:22:48	21	Q. Okay. Take a look, if you would, at the top	15:24:49
22	increased lipophilicity."	15:22:52	22	of the right-hand column on page 32. And I direct	15:24:53
Page 275			Page 277		
1	So, this is all talking about a story. I	15:22:54	1	your attention to the last sentence in the first	15:25:00
2	don't think it can be taken -- some statements are	15:22:57	2	paragraph. It says, "For example, if a drug is	15:25:04
3	obviously independently correct, but other	15:23:00	3	intended for the treatment of a simple headache,	15:25:09
4	statements relate to the previous sentence, so you	15:23:04	4	then the expense associated with the preparation of	15:25:11
5	have to be very careful how you read it.	15:23:06	5	an injection would not be justified." I apologize.	15:25:14
6	Q. Certainly. Let me direct your attention to	15:23:08	6	That was the second to last sentence.	15:25:17
7	the very bottom sentence of the left-hand column.	15:23:11	7	The last sentence is, "In order to formulate	15:25:18
8	It says, "The search therefore goes on for	15:23:14	8	a drug for delivery, other than by the oral route,	15:25:20
9	technologies to overcome the solubility/permeability	15:23:17	9	significant advantage needs to be demonstrated over	15:25:24
10	problems encountered with the formulation of drugs	15:23:21	10	the oral route of administration or else the drug	15:25:26
11	as medicines."	15:23:23	11	needs to be the first in its class."	15:25:29
12	Is that a true statement?	15:23:24	12	Is that a true statement?	15:25:32
13	A. Yes.	15:23:25	13	A. I believe it to be, yes.	15:25:35
14	Q. Was it true as of 2003 that the search was	15:23:25	14	Q. Take a look, if you would, at page 35. The	15:25:36
15	still ongoing for technologies to overcome the	15:23:29	15	first statement says, "The pharmaceutical scientist	15:25:51
16	solubility and permeability problems encountered	15:23:32	16	is always searching for new and safe materials that	15:25:53
17	with the formulation of drugs as medicines?	15:23:36	17	can be used to improve the formulation of a	15:25:56
18	MR. MARGOLIS: Objection. Vague.	15:23:39	18	medicine. These are known as excipients."	15:25:59
19	Q. You may answer.	15:23:40	19	Are those true statements?	15:26:02
20	MR. MARGOLIS: Lack of foundation.	15:23:41	20	A. Yes.	15:26:04
21	THE WITNESS: One of the limitations of	15:23:44	21	Q. Take a look, if you would, at page 39. I	15:26:04
22	drug delivery is getting the optimal	15:23:47	22	direct your attention to Section 2.4	15:26:10

Page 278	Page 280
<p>1 Pharmacokinetics and Pharmacodynamics. It says, 15:26:13</p> <p>2 "Once a potential drug candidate has been 15:26:17</p> <p>3 identified, its fate and behaviour in the body have 15:26:19</p> <p>4 to be assessed before a decision can be made whether 15:26:22</p> <p>5 it is possible to develop the molecule into a safe, 15:26:25</p> <p>6 effective medicine." 15:26:28</p> <p>7 Is that a true statement? 15:26:30</p> <p>8 MR. MARGOLIS: Objection. Vague. 15:26:31</p> <p>9 THE WITNESS: I believe it is. 15:26:35</p> <p>10 Q. In the next sentence you write, "In 15:26:36</p> <p>11 particular, the drug's physicochemical, 15:26:38</p> <p>12 pharmacokinetic, pharmacodynamic and toxicological 15:26:41</p> <p>13 properties all have to be established." 15:26:46</p> <p>14 Is that a true statement? 15:26:47</p> <p>15 MR. MARGOLIS: Objection. 15:26:49</p> <p>16 THE WITNESS: Can I just -- sorry. 15:26:49</p> <p>17 Sorry. Can I just clarify? This document 15:26:52</p> <p>18 was written as a team, and the various 15:26:54</p> <p>19 sections of these documents were written by 15:26:58</p> <p>20 experts in their particular fields. Just to 15:27:01</p> <p>21 clarify. 15:27:04</p> <p>22 Q. And this document went out under your name, 15:27:05</p>	<p>1 A. I am. 15:28:20</p> <p>2 Q. Does Lawrence Exhibit 12 correspond to item 15:28:20</p> <p>3 number 1 in Articles in Academic Journals on your 15:28:22</p> <p>4 curriculum vitae? 15:28:26</p> <p>5 A. It does. 15:28:27</p> <p>6 Q. Take a look at page 1903. The first sentence 15:28:28</p> <p>7 of the body of the document states, "Previous 15:28:32</p> <p>8 studies of the effects of structural variation of 15:28:35</p> <p>9 non-ionic surfactants on micellar properties and 15:28:38</p> <p>10 solubilization have emphasized the importance of the 15:28:42</p> <p>11 liquid nature of the micellar core in determining 15:28:46</p> <p>12 solubilizing capacity." 15:28:49</p> <p>13 Is that a true statement 15:28:51</p> <p>14 A. I believe it is. 15:28:52</p> <p>15 Q. You can put that document aside. 15:28:53</p> <p>16 MR. HASFORD: I'm handing the court 15:29:05</p> <p>17 reporter what I would ask to be marked as 15:29:07</p> <p>18 Lawrence Exhibit 13. 15:29:09</p> <p>19 For the record, Lawrence Exhibit 13 15:29:09</p> <p>20 corresponds to item number 2 in Articles in 15:29:11</p> <p>21 Academic Journals on Dr. Lawrence's 15:29:14</p> <p>22 curriculum vitae. 15:29:16</p>
Page 279	Page 281
<p>1 correct? 15:27:08</p> <p>2 A. No. It went out under the name of the 15:27:08</p> <p>3 pharmaceutical sciences advisory panel, of which I 15:27:14</p> <p>4 was part of the team. 15:27:16</p> <p>5 Q. You're identified as a co-author on this 15:27:17</p> <p>6 document, correct? 15:27:19</p> <p>7 A. I am, yes. 15:27:19</p> <p>8 Q. You can put this document aside. 15:27:20</p> <p>9 MR. HASFORD: I'm handing the court 15:27:46</p> <p>10 reporter what I would ask to be marked as 15:27:47</p> <p>11 Lawrence Exhibit 12. 15:27:49</p> <p>12 For the record, Lawrence Exhibit 12 15:27:51</p> <p>13 corresponds to item number 1 in Articles in 15:27:55</p> <p>14 Academic Journals on Dr. Lawrence's 15:27:59</p> <p>15 curriculum vitae. 15:28:01</p> <p>16 15:28:14</p> <p>17 (Whereupon, Plaintiff's Deposition 15:28:14</p> <p>18 Exhibit No. Lawrence 12 was marked for 15:28:15</p> <p>19 Identification.) 15:28:15</p> <p>20 BY MR. HASFORD: 15:28:16</p> <p>21 Q. Are you the M. Jayne Lawrence who co-authored 15:28:16</p> <p>22 Lawrence Exhibit 12? 15:28:19</p>	<p>1 (Whereupon, Plaintiff's Deposition 15:29:35</p> <p>2 Exhibit No. Lawrence 13 was marked for 15:29:35</p> <p>3 Identification.) 15:29:36</p> <p>4 Q. Are you the M.J. Lawrence who co-authored 15:29:36</p> <p>5 Lawrence Exhibit 13? 15:29:39</p> <p>6 A. I am. 15:29:40</p> <p>7 Q. Does Lawrence Exhibit 13 correspond to item 15:29:40</p> <p>8 number 2 in Articles in Academic Journals on your 15:29:42</p> <p>9 curriculum vitae? 15:29:46</p> <p>10 A. It does. 15:29:47</p> <p>11 Q. Take a look at the first page and the first 15:29:48</p> <p>12 sentence. It says, "Previous studies" -- and then 15:29:51</p> <p>13 there's a citation -- "have reported that the 15:29:53</p> <p>14 lengthening" -- I apologize -- "that lengthening the 15:29:59</p> <p>15 alkyl chain of a series of n-alkylpolyoxyethylene 15:30:00</p> <p>16 glycol mono ether surfactants [general formula 15:30:06</p> <p>17 CmE1-25m] above m equals 16, although causing an 15:30:13</p> <p>18 increase in micellar size did not result in the 15:30:17</p> <p>19 enhanced solubilization of a range of drugs." 15:30:20</p> <p>20 Do you see that? 15:30:23</p> <p>21 A. I do. 15:30:24</p> <p>22 Q. Is it fair to say that different non-ionic 15:30:24</p>

Page 282		Page 284			
1	surfactants having different chemical structures	15:30:27	1	Is it fair to say that cyclodextrins	15:32:44
2	exhibit different solubilizing abilities?	15:30:31	2	materially impact the solubility of drug molecules	15:32:47
3	MR. MARGOLIS: Objection. Vague.	15:30:34	3	in aqueous liquid preparations?	15:32:49
4	THE WITNESS: Not from that statement	15:30:36	4	MR. MARGOLIS: Objection. Vague.	15:32:53
5	it's not, no.	15:30:37	5	THE WITNESS: It so much depends upon	15:32:55
6	Q. Is it fair to say that in general?	15:30:39	6	the drug and which cyclodextrin you're	15:32:58
7	MR. MARGOLIS: Objection. Vague.	15:30:41	7	looking at. They're not necessarily very	15:33:02
8	THE WITNESS: No. I think you're taking	15:30:45	8	efficient for formulation or used as	15:33:06
9	that statement out of context.	15:30:48	9	formulation excipients.	15:33:11
10	Q. Well, then pretend I didn't show you that	15:30:50	10	Q. Is it fair to say that cyclodextrins can	15:33:13
11	statement. Is it fair to say that different	15:30:53	11	materially impact the solubility of drug molecules	15:33:16
12	non-ionic surfactants having different chemical	15:30:57	12	in aqueous liquid preparations?	15:33:20
13	structures exhibit different solubilizing abilities?	15:30:58	13	MR. MARGOLIS: Objection. Vague. Calls	15:33:22
14	MR. MARGOLIS: Objection. Vague.	15:31:02	14	for a legal conclusion.	15:33:23
15	THE WITNESS: It is vague. And I will	15:31:03	15	THE WITNESS: For a limited number of	15:33:26
16	reiterate what I believe I said earlier in	15:31:06	16	drugs that may be the case, yes.	15:33:29
17	the proceedings, that would depend very much	15:31:08	17	Q. You can put that document aside.	15:33:32
18	on the similarity or the difference in	15:31:13	18	MR. HASFORD: I'm handing the court	15:33:42
19	structure.	15:31:15	19	reporter what I would ask to be marked as	15:33:43
20	Q. Okay. You can put this document aside.	15:31:16	20	Lawrence Exhibit 15.	15:33:45
21	MR. HASFORD: I'm handing the court	15:31:32	21	For the record, Lawrence Exhibit 15	15:33:46
22	reporter what I would ask to be marked as	15:31:33	22	corresponds to item number 9 in Articles in	15:33:48
Page 283		Page 285			
1	Lawrence Exhibit 14.	15:31:34	1	Academic Journals on Dr. Lawrence's	15:33:53
2	For the record, Lawrence Exhibit 14	15:31:35	2	curriculum vitae.	15:33:54
3	corresponds to item number 8 in Articles in	15:31:37	3	(Whereupon, Plaintiff's Deposition	15:34:31
4	Academic Journals on Dr. Lawrence's	15:31:41	4	Exhibit No. Lawrence 15 was marked for	15:34:31
5	curriculum vitae.	15:31:44	5	Identification.)	15:34:31
6	(Whereupon, Plaintiff's Deposition	15:32:09	6	THE WITNESS: I can't believe that	15:34:31
7	Exhibit No. Lawrence 14 was marked for	15:32:09	7	picture.	15:34:31
8	Identification.)	15:32:10	8	(Discussion off the record.)	15:34:32
9	Q. Are you the M. Jayne Lawrence who co-authored	15:32:10	9	Q. Are you the M. Jayne Lawrence who authored	15:34:32
10	Lawrence Exhibit 14?	15:32:13	10	Lawrence Exhibit 15?	15:34:40
11	A. I am.	15:32:15	11	A. I am.	15:34:41
12	Q. Does Lawrence Exhibit 14 correspond to item	15:32:15	12	Q. Does Lawrence Exhibit 15 correspond to item	15:34:41
13	number 8 in Articles in Academic Journals on your	15:32:18	13	number 9 in Articles in Academic Journals on your	15:34:44
14	curriculum vitae?	15:32:22	14	curriculum vitae?	15:34:47
15	A. It does.	15:32:23	15	A. It does.	15:34:48
16	Q. Take a look at first page, page 27.	15:32:24	16	Q. Turn, if you would, to page 423, and let me	15:34:49
17	A. Yes.	15:32:26	17	direct your attention to the conclusion. About	15:34:52
18	Q. The bottom of the left-hand column, second to	15:32:27	18	halfway through the first paragraph of the	15:34:58
19	last sentence reads, "For example, cyclodextrin	15:32:29	19	conclusion you write, "Before attempting to	15:35:00
20	complexes have been used for increasing the apparent	15:32:33	20	formulate a drug the limitations of each type of	15:35:03
21	aqueous solubility of drug molecules and also for	15:32:37	21	system need to be thoroughly understood."	15:35:07
22	reducing their surface activity."	15:32:40	22	Is that a true statement?	15:35:09

Page 286	<p>1 MR. MARGOLIS: Objection. Vague. 15:35:10</p> <p>2 THE WITNESS: In the context of using 15:35:13</p> <p>3 surfactant systems to solubilize drugs, yes. 15:35:15</p> <p>4 Q. In the next sentence you write, "For example, 15:35:19</p> <p>5 it is no use trying to increase the aqueous 15:35:21</p> <p>6 solubility of a water-soluble hydrophilic drug in an 15:35:24</p> <p>7 aqueous-based surfactant system." 15:35:29</p> <p>8 Is that a true statement? 15:35:31</p> <p>9 MR. MARGOLIS: Objection. Vague. 15:35:33</p> <p>10 THE WITNESS: Yeah, it's vague. It 15:35:34</p> <p>11 isn't the best written. There are some drugs 15:35:37</p> <p>12 that are quite water soluble and will 15:35:39</p> <p>13 actually form mixed aggregates with 15:35:40</p> <p>14 surfactants, which I didn't know about at the 15:35:43</p> <p>15 time. 15:35:45</p> <p>16 Q. Did you qualify your statement in any way in 15:35:45</p> <p>17 Lawrence Exhibit 15? 15:35:48</p> <p>18 A. In Lawrence Exhibit 15? 15:35:50</p> <p>19 Q. The document we're looking at. 15:35:53</p> <p>20 A. Oh. No. No. No. This is the document -- 15:35:55</p> <p>21 when I wrote this, I believed that to be true. I've 15:35:57</p> <p>22 subsequently realized that's not true because 15:36:01</p>	Page 288	<p>1 For the record, Lawrence Exhibit 16 15:37:33</p> <p>2 corresponds to item number 12 in Articles in 15:37:36</p> <p>3 Academic Journals on Dr. Lawrence's 15:37:41</p> <p>4 curriculum vitae. 15:37:42</p> <p>5 (Whereupon, Plaintiff's Deposition 15:38:14</p> <p>6 Exhibit No. Lawrence 16 was marked for 15:38:14</p> <p>7 Identification.) 15:38:15</p> <p>8 Q. Are you the M. Jayne Lawrence who authored 15:38:15</p> <p>9 Lawrence 16? 15:38:31</p> <p>10 A. I am. 15:38:31</p> <p>11 Q. Does that correspond to item number 12 in 15:38:32</p> <p>12 Articles in Academic Journals on your curriculum 15:38:35</p> <p>13 vitae? 15:38:37</p> <p>14 A. It does. 15:38:38</p> <p>15 Q. Take a look at page 258, please, and let me 15:38:38</p> <p>16 direct your attention to the Introduction, the last 15:38:43</p> <p>17 full sentence in the left-hand column. It says, 15:38:46</p> <p>18 "When dispersed in water surfactant molecules 15:38:49</p> <p>19 self-associate to form a wide variety of equilibrium 15:38:52</p> <p>20 phase structures in which the hydrophobic chains are 15:38:57</p> <p>21 removed from contact with water." 15:39:00</p> <p>22 Is that a true statement? 15:39:02</p>
Page 287	<p>1 certain drugs can be quite soluble, but have some 15:36:04</p> <p>2 amphiphilic nature. 15:36:09</p> <p>3 Q. When did you realize that? 15:36:10</p> <p>4 A. Probably -- just let me -- I have to look at 15:36:12</p> <p>5 that. When were the Olympic Games in Barcelona? 15:36:19</p> <p>6 Q. You're asking the wrong guy. 15:36:38</p> <p>7 A. I remember I had a student who was Spanish 15:36:41</p> <p>8 and brought me back a mug and she was doing the work 15:36:45</p> <p>9 on it at the time. So I realized probably just 15:36:48</p> <p>10 after I'd written this review when I realized that 15:36:51</p> <p>11 you could form with some quite hydrophilic 15:36:55</p> <p>12 compounds, and sodium diclofenac is one of them, you 15:36:59</p> <p>13 can form mix with micelles, and I didn't know at the 15:37:02</p> <p>14 time. 15:37:05</p> <p>15 Q. Do you remember about what time that was when 15:37:06</p> <p>16 you came to that realization? 15:37:07</p> <p>17 A. It would have been not much difference from 15:37:09</p> <p>18 this. I can't remember the exact time, though. 15:37:11</p> <p>19 Q. You can put Exhibit 15 aside. 15:37:13</p> <p>20 MR. HASFORD: I'm handing the court 15:37:29</p> <p>21 reporter what I would ask to be marked as 15:37:30</p> <p>22 Lawrence Exhibit 16. 15:37:32</p>	Page 289	<p>1 A. Yes. 15:39:03</p> <p>2 Q. Is it fair to say that the aggregate that 15:39:04</p> <p>3 would be formed by tyloxapol in an aqueous liquid 15:39:06</p> <p>4 preparation is different from the aggregate that 15:39:10</p> <p>5 would be formed in the same aqueous liquid 15:39:12</p> <p>6 preparation by a different non-ionic surfactant with 15:39:15</p> <p>7 a different chemical structure? 15:39:18</p> <p>8 MR. MARGOLIS: Objection. Vague. 15:39:21</p> <p>9 THE WITNESS: Yes, I don't understand 15:39:22</p> <p>10 how you mean is different. 15:39:23</p> <p>11 Q. Would there be any difference? 15:39:24</p> <p>12 MR. MARGOLIS: Objection. Vague. 15:39:28</p> <p>13 THE WITNESS: Polymeric surfactants 15:39:31</p> <p>14 self-assemble into micelles. That's very 15:39:33</p> <p>15 well-established with surfactants such as 15:39:37</p> <p>16 Pluronic. They, as far as I know, form into 15:39:39</p> <p>17 traditional micelles with the hydrophobic 15:39:47</p> <p>18 core and with the polyoxyl chains on the 15:39:51</p> <p>19 outside. There'd be no thermodynamic reason 15:39:54</p> <p>20 for them not to. 15:39:56</p> <p>21 Q. Would the aggregate that would be formed by 15:39:57</p> <p>22 tyloxapol in an aqueous liquid preparation be any 15:39:59</p>

Page 290	Page 292
<p>1 different in any way from the aggregate that would 15:40:03</p> <p>2 be formed in the same aqueous liquid preparation by 15:40:06</p> <p>3 a different non-ionic surfactant with a different 15:40:10</p> <p>4 chemical structure? 15:40:13</p> <p>5 MR. MARGOLIS: Objection. Vague. 15:40:14</p> <p>6 THE WITNESS: Potentially. Potentially 15:40:16</p> <p>7 not. It depends how different the structures 15:40:18</p> <p>8 are. 15:40:21</p> <p>9 Q. Why does it depend on how different the 15:40:22</p> <p>10 structures are? 15:40:24</p> <p>11 A. A number of parameters affect the 15:40:25</p> <p>12 self-assembly of the micelles. The hydrophobic 15:40:31</p> <p>13 chain, the ratio, the balance of the hydrophobic 15:40:39</p> <p>14 chain in the head group, and concentration they're 15:40:44</p> <p>15 at, salt concentration, pH, all of those will 15:40:50</p> <p>16 affect -- I don't think I'm answering the question. 15:40:53</p> <p>17 What was your question again? I think I've got off 15:40:54</p> <p>18 the point. I'm sorry. 15:40:57</p> <p>19 Q. Well, I might need the court reporter to read 15:40:58</p> <p>20 it back because now I can't see it on the screen. 15:41:00</p> <p>21 A. Sorry. 15:41:00</p> <p>22 (Question read back as follows:) 15:41:00</p>	<p>1 Q. Take a look, if you would, at Table 3. Is it 15:42:27</p> <p>2 fair to say that there are a wide variety of 15:42:31</p> <p>3 non-equilibrium surfactant systems that can be used 15:42:34</p> <p>4 in aqueous drug formulations? 15:42:37</p> <p>5 MR. MARGOLIS: Objection. Vague. 15:42:41</p> <p>6 THE WITNESS: There are, yes. 15:42:43</p> <p>7 Q. You can put this document aside. 15:42:44</p> <p>8 MR. HASFORD: I'm handing the court 15:42:57</p> <p>9 reporter what I would ask to be marked as 15:42:58</p> <p>10 Lawrence Exhibit 17. 15:43:00</p> <p>11 For the record, Lawrence Exhibit 17 15:43:01</p> <p>12 corresponds to item number 16 in Articles in 15:43:04</p> <p>13 Academic Journals on Dr. Lawrence's 15:43:08</p> <p>14 curriculum vitae. 15:43:10</p> <p>15 (Whereupon, Plaintiff's Deposition 15:43:35</p> <p>16 Exhibit No. Lawrence 17 was marked for 15:43:36</p> <p>17 Identification.) 15:43:37</p> <p>18 Q. Are you the M. Jayne Lawrence who co-authored 15:43:37</p> <p>19 Lawrence Exhibit 17? 15:43:41</p> <p>20 A. I am. 15:43:43</p> <p>21 Q. Does Lawrence Exhibit 17 correspond to item 15:43:44</p> <p>22 number 16 in Articles in Academic Journals on your 15:43:47</p>
Page 291	Page 293
<p>1 "QUESTION: Why does it depend on how 15:40:22</p> <p>2 different the structures are?" 15:40:24</p> <p>3 MR. HASFORD: The previous question. 15:40:24</p> <p>4 A. It predominantly depends on the ratio between 15:41:16</p> <p>5 the hydrophobic chain and the hydrophobic head 15:41:19</p> <p>6 group. The relative driving force is -- the driving 15:41:24</p> <p>7 force for aggregation from the hydrophobic chain and 15:41:28</p> <p>8 the head groups providing the repulsive force to 15:41:31</p> <p>9 stop the aggregation. 15:41:40</p> <p>10 Q. Would the resulting solutions need to be 15:41:43</p> <p>11 tested to determine the differences between them? 15:41:46</p> <p>12 A. They would. 15:41:49</p> <p>13 Q. Take a look, if you would -- actually, take a 15:41:50</p> <p>14 look, if you would, at Table 2 on page 258 of 15:41:55</p> <p>15 Lawrence Exhibit 16. Tell me when you're ready. 15:42:01</p> <p>16 A. Yes. 15:42:10</p> <p>17 Q. Is it fair to say that there are a wide 15:42:11</p> <p>18 variety of equilibrium surfactant systems that can 15:42:14</p> <p>19 be used in aqueous drug formulations? 15:42:18</p> <p>20 MR. MARGOLIS: Objection. Vague. 15:42:22</p> <p>21 THE WITNESS: Potentially there are, 15:42:26</p> <p>22 yes. 15:42:27</p>	<p>1 curriculum vitae? 15:43:51</p> <p>2 A. It does. 15:43:52</p> <p>3 Q. Take a look, if you would, at page 58, and in 15:43:53</p> <p>4 the section entitled Discussion, the first full -- 15:44:02</p> <p>5 the first sentence, rather, states, "The non-ionic 15:44:06</p> <p>6 surfactants used in the present study have 15:44:17</p> <p>7 structural features in common with 15:44:20</p> <p>8 phosphatidylcholines, but the vesicles they form 15:44:22</p> <p>9 have physicochemical properties that differ 15:44:26</p> <p>10 significantly from those of the phospholipid 15:44:30</p> <p>11 liposomes." 15:44:34</p> <p>12 Is that a true statement? 15:44:34</p> <p>13 A. Yes. 15:44:36</p> <p>14 Q. Is it also fair to say that different 15:44:40</p> <p>15 non-ionic surfactants may have structural 15:44:43</p> <p>16 similarities, yet have physicochemical properties 15:44:46</p> <p>17 that differ significantly? 15:44:49</p> <p>18 MR. MARGOLIS: Objection. Vague. 15:44:51</p> <p>19 THE WITNESS: It's -- this is part -- I 15:44:54</p> <p>20 think there's a -- to understand that 15:45:14</p> <p>21 statement you need to appreciate the 15:45:18</p> <p>22 difference between having a zwitterionic 15:45:19</p>

Page 294	<p>1 phospholipid head group and the polymeric 15:45:24</p> <p>2 non-ionic head group. And I think I've 15:45:27</p> <p>3 stated earlier that very different structures 15:45:30</p> <p>4 would have very different effects. So, the 15:45:35</p> <p>5 similarity in this case is its two 15:45:38</p> <p>6 hydrophobic chains and what we call a 15:45:42</p> <p>7 backbone, a semi-polar backbone. The head 15:45:45</p> <p>8 groups are very different. So, those are 15:45:51</p> <p>9 some structural similarities. There's also 15:45:55</p> <p>10 some quite big differences. 15:45:57</p> <p>11 Q. In general, is it also fair to say that 15:45:59</p> <p>12 different non-ionic surfactants may have structural 15:46:03</p> <p>13 similarities, yet have physicochemical properties 15:46:07</p> <p>14 that differ significantly? 15:46:10</p> <p>15 MR. MARGOLIS: Objection. Vague. 15:46:12</p> <p>16 THE WITNESS: You would really have to 15:46:14</p> <p>17 look at that on a case-by-case basis. 15:46:18</p> <p>18 Q. Would you have to test the different 15:46:20</p> <p>19 surfactants to determine that? 15:46:22</p> <p>20 MR. MARGOLIS: Objection. Vague. Calls 15:46:24</p> <p>21 for speculation. 15:46:25</p> <p>22 THE WITNESS: No, not necessarily. 15:46:27</p>	Page 296	<p>1 the hydrophilic nature of the surfactant and, as a 15:48:08</p> <p>2 consequence, it is made harder to achieve the 15:48:12</p> <p>3 correct balance of the hydrophobic and hydrophilic 15:48:15</p> <p>4 portions of the surfactant required for production 15:48:20</p> <p>5 of a microemulsion; instead this balance has to be 15:48:22</p> <p>6 achieved by the use of a cosurfactant." 15:48:26</p> <p>7 Is it fair to say that small structural 15:48:30</p> <p>8 differences in non-ionic surfactants can cause 15:48:33</p> <p>9 considerable changes in their physical and chemical 15:48:37</p> <p>10 properties? 15:48:40</p> <p>11 MR. MARGOLIS: Objection. Vague. Calls 15:48:41</p> <p>12 for speculation. 15:48:42</p> <p>13 Q. You may answer. 15:48:44</p> <p>14 A. You need to read the previous statement which 15:48:44</p> <p>15 is talking specifically about sucrose esters and 15:48:47</p> <p>16 polyglycerol fatty acid esters. They are very 15:48:58</p> <p>17 different molecules than the non-surfactants we're 15:49:04</p> <p>18 talking about here. A sugar has a much more -- one 15:49:09</p> <p>19 sugar is much more hydrophilic than several 15:49:14</p> <p>20 polyoxyethylene chains. So, in this case, it makes 15:49:18</p> <p>21 a huge difference in the properties. 15:49:20</p> <p>22 Q. In general, is it fair to say that small 15:49:23</p>
Page 295	<p>1 Q. You can put this document aside. 15:46:28</p> <p>2 MR. HASFORD: I'm handing the court 15:46:44</p> <p>3 reporter what I would ask to be marked as 15:46:46</p> <p>4 Lawrence Exhibit 18. 15:46:47</p> <p>5 For the record, Lawrence Exhibit 18 15:46:48</p> <p>6 corresponds to item number 18 in Articles in 15:46:50</p> <p>7 Academic Journals on Dr. Lawrence's 15:46:54</p> <p>8 curriculum vitae. 15:46:55</p> <p>9 (Whereupon, Plaintiff's Deposition 15:47:18</p> <p>10 Exhibit No. Lawrence 18 was marked for 15:47:19</p> <p>11 Identification.) 15:47:20</p> <p>12 Q. Are you the M. Jayne Lawrence who authored 15:47:20</p> <p>13 Lawrence Exhibit 18? 15:47:42</p> <p>14 A. I am. 15:47:43</p> <p>15 Q. Does Lawrence Exhibit 18 correspond to item 15:47:44</p> <p>16 number 18 in Articles in Academic Journals on your 15:47:47</p> <p>17 curriculum vitae? 15:47:50</p> <p>18 A. It does. 15:47:51</p> <p>19 Q. Take a look, if you would, at page 827. Let 15:47:52</p> <p>20 me direct your attention to the right-hand column. 15:47:58</p> <p>21 About halfway down it says, "Therefore, the addition 15:48:02</p> <p>22 of one extra unit causes a considerable increase in 15:48:04</p>	Page 297	<p>1 structural differences in non-ionic surfactants can 15:49:27</p> <p>2 cause considerable changes in their physical and 15:49:30</p> <p>3 chemical properties? 15:49:33</p> <p>4 MR. MARGOLIS: Objection. Vague. 15:49:34</p> <p>5 THE WITNESS: For normal common 15:49:35</p> <p>6 polyoxyethylene ester surfactants and 15:49:37</p> <p>7 unrelated molecules, no, it doesn't make a 15:49:42</p> <p>8 huge difference. There's a very gradual 15:49:45</p> <p>9 difference, and I state that in a number of 15:49:48</p> <p>10 papers. 15:49:50</p> <p>11 Q. You may put Exhibit 18 aside. 15:49:52</p> <p>12 MR. HASFORD: I'm handing the court 15:50:16</p> <p>13 reporter what I'd ask to be marked as 15:50:18</p> <p>14 Lawrence Exhibit 19. 15:50:20</p> <p>15 For the record, Lawrence Exhibit 19 15:50:21</p> <p>16 corresponds to item number 20 in Articles in 15:50:23</p> <p>17 Academic Journals on Dr. Lawrence's 15:50:27</p> <p>18 curriculum vitae. 15:50:28</p> <p>19 (Whereupon, Plaintiff's Deposition 15:50:53</p> <p>20 Exhibit No. Lawrence 19 was marked for 15:50:53</p> <p>21 Identification.) 15:50:54</p> <p>22 Q. Are you the M. Jayne Lawrence who co-authored 15:50:54</p>

Page 298		Page 300			
1	Lawrence Exhibit 19?	15:50:57	1	the drug-solubilizing capacity of most of the	15:52:56
2	A. I am.	15:50:59	2	commonly used surfactants is too low to be of	15:52:59
3	Q. Does Lawrence Exhibit 19 correspond to item	15:50:59	3	widespread practical use?	15:53:02
4	number 20 in the Articles in Academic Journals on	15:51:02	4	MR. MARGOLIS: Objection. Vague.	15:53:05
5	your curriculum vitae?	15:51:06	5	THE WITNESS: I believe so, yes.	15:53:10
6	A. It does.	15:51:07	6	Q. Take a look, if you would, at the next page.	15:53:13
7	Q. Take a look at the first sentence in the body	15:51:08	7	It's going to be page 799. In the first full	15:53:18
8	of the document. You state, "It is well-established	15:51:11	8	paragraph it says, "The physicochemical	15:53:27
9	that the molecular geometry of a surfactant	15:51:14	9	characterization and solubilization behavior of	15:53:30
10	influences the nature of the aggregate it forms when	15:51:17	10	DDCPNO are reported here. The properties of this	15:53:34
11	dispersed in aqueous solution at low	15:51:20	11	surfactant are compared with those of a	15:53:38
12	concentrations."	15:51:24	12	nonbiodegradable N-oxide derivative of comparable	15:53:43
13	Is that a true statement?	15:51:25	13	hydrophobic chain length (namely, N,	15:53:47
14	A. Yes.	15:51:26	14	N-dimethyldodecylamine-N-oxide (DDNO) to investigate	15:53:51
15	Q. You can put this document aside.	15:51:26	15	the consequences of inserting a propoxy linker	15:53:58
16	MR. HASFORD: I'm handing the court	15:51:33	16	moiety between the hydrophobe and head group."	15:54:02
17	reporter what I would ask to be marked	15:51:34	17	Do you see that?	15:54:05
18	Lawrence Exhibit 20.	15:51:37	18	A. Yes.	15:54:07
19	For the record, Lawrence Exhibit 20	15:51:38	19	Q. In Lawrence Exhibit 20, did you report the	15:54:07
20	corresponds to item 33 in Articles in	15:51:39	20	results of adding a propoxy linker to a non-ionic	15:54:10
21	Academic Journals on Dr. Lawrence's CV.	15:51:42	21	surfactant?	15:54:14
22	(Whereupon, Plaintiff's Deposition	15:52:08	22	A. Yes, I did.	15:54:16
Page 299		Page 301			
1	Exhibit No. Lawrence 20 was marked for	15:52:08	1	Q. Does a propoxy linker have three carbon atoms	15:54:18
2	Identification.)	15:52:09	2	and an oxygen atom?	15:54:21
3	Q. Are you the M. Jayne Lawrence who co-authored	15:52:09	3	A. Yes.	15:54:27
4	Lawrence Exhibit 20?	15:52:13	4	Q. Would you characterize adding a propoxy	15:54:27
5	A. I am.	15:52:14	5	linker to a non-ionic surfactant as a major chemical	15:54:30
6	Q. Does Lawrence Exhibit 20 correspond to item	15:52:14	6	change or a minor chemical change?	15:54:34
7	number 33 in Articles in Academic Journals on your	15:52:17	7	MR. MARGOLIS: Objection. Vague. Lack	15:54:37
8	curriculum vitae?	15:52:20	8	of foundation.	15:54:42
9	A. It does.	15:52:21	9	THE WITNESS: I think you should look at	15:54:42
10	Q. Was Lawrence Exhibit 20 published in 2000?	15:52:22	10	the results here because it's actually very	15:54:44
11	A. It was.	15:52:26	11	interesting. You highlighted before in one	15:54:46
12	Q. Take a look, if you would, at the	15:52:27	12	of my papers about adding a unit making a big	15:54:52
13	Introduction?	15:52:30	13	change, and I stated that's because it was a	15:54:56
14	A. Yes.	15:52:30	14	sugar moiety. You have to remember with	15:55:00
15	Q. And the first two sentences read,	15:52:31	15	non-ionic -- non -- N-oxide surfactants, that	15:55:03
16	"Surfactants have been investigated as agents to	15:52:35	16	is an all-or-nothing change. You have a head	15:55:11
17	solubilize poorly water soluble drugs in	15:52:37	17	group, an oxide head group, or you don't have	15:55:13
18	pharmaceutical formulations for many years.	15:52:40	18	an oxide head group. So you find any changes	15:55:15
19	Unfortunately, however, the drug-solubilizing	15:52:43	19	making with this type of non-ionic surfactant	15:55:18
20	capacity of most of the commonly used surfactants is	15:52:46	20	greater than the polyoxyethylene surfactant,	15:55:21
21	too low to be of widespread practical use."	15:52:50	21	and I've stated that in a number of my	15:55:26
22	As of 2000, was it understood in the art that	15:52:53	22	papers.	15:55:27

Page 302	Page 304
<p>1 So, there are changes, but actually 15:55:27</p> <p>2 they're not as much as you might expect. 15:55:29</p> <p>3 There were less than I expected. In some 15:55:33</p> <p>4 cases it behaved very similarly, but it was 15:55:35</p> <p>5 what we expected. 15:55:39</p> <p>6 Q. And would you characterize adding a propoxy 15:55:40</p> <p>7 linker to a non-ionic surfactant as a minor chemical 15:55:43</p> <p>8 change? 15:55:47</p> <p>9 MR. MARGOLIS: Objection. Asked and 15:55:47</p> <p>10 answered. Vague. 15:55:49</p> <p>11 THE WITNESS: It would depend on what 15:55:49</p> <p>12 type of non-ionic surfactant. 15:55:51</p> <p>13 Q. Take a look at the Conclusion of your paper. 15:55:53</p> <p>14 In the first sentence you state, "The introduction 15:55:58</p> <p>15 of a linker moiety into a surfactant containing a 15:56:01</p> <p>16 small head group has been shown to greatly alter the 15:56:04</p> <p>17 physicochemical and solubilization behavior of a low 15:56:07</p> <p>18 molecular weight surfactant." 15:56:10</p> <p>19 Is it fair to say that a structural change in 15:56:13</p> <p>20 a non-ionic surfactant can greatly alter the 15:56:16</p> <p>21 physicochemical and solubilization behavior of the 15:56:19</p> <p>22 surfactant? 15:56:22</p>	<p>1 MR. HASFORD: I'm handing the court 15:57:33</p> <p>2 reporter what I would ask to be marked as 15:57:34</p> <p>3 Lawrence Exhibit 21. 15:57:36</p> <p>4 For the record, Lawrence Exhibit 21 15:57:37</p> <p>5 corresponds to item number 47 in Articles in 15:57:40</p> <p>6 Academic Journals on Dr. Lawrence's 15:57:43</p> <p>7 curriculum vitae. 15:57:45</p> <p>8 (Whereupon, Plaintiff's Deposition 15:58:09</p> <p>9 Exhibit No. Lawrence 21 was marked for 15:58:10</p> <p>10 Identification.) 15:58:11</p> <p>11 Q. You are the M. Jayne Lawrence who co-authored 15:58:11</p> <p>12 Exhibit 21? 15:58:14</p> <p>13 A. I am. 15:58:15</p> <p>14 Q. Does Lawrence Exhibit 21 correspond to item 15:58:15</p> <p>15 number 47 in Articles in Academic Journals on your 15:58:18</p> <p>16 curriculum vitae? 15:58:21</p> <p>17 A. It does. 15:58:22</p> <p>18 Q. Turn, if you would, to page 866, and look at 15:58:23</p> <p>19 the first full paragraph. The first sentence reads, 15:58:30</p> <p>20 "From the discussion just presented, it is clear 15:58:35</p> <p>21 that the membrane-active effects of a surfactant are 15:58:38</p> <p>22 a complex interplay of several competing effects." 15:58:41</p>
Page 303	Page 305
<p>1 MR. MARGOLIS: Objection. Vague. 15:56:23</p> <p>2 THE WITNESS: I've said all the way 15:56:25</p> <p>3 through this by looking at the structure and 15:56:27</p> <p>4 understanding the behavior it's possible to 15:56:31</p> <p>5 predict these changes. With this type of 15:56:33</p> <p>6 moiety, sorry, this type of head group, it's 15:56:37</p> <p>7 a very small head group, I would expect the 15:56:42</p> <p>8 linker to have a big change. If I then 15:56:44</p> <p>9 transferred that to a polyoxyethylene 15:56:47</p> <p>10 surfactant or some other polymer head group, 15:56:49</p> <p>11 I would expect the change to be minimal. 15:56:51</p> <p>12 Q. In general, is it fair to say that a 15:56:53</p> <p>13 structural change in a non-ionic surfactant can 15:56:55</p> <p>14 greatly alter the physicochemical and solubilization 15:56:58</p> <p>15 behavior of the surfactant? 15:57:02</p> <p>16 A. It would depend on -- 15:57:03</p> <p>17 MR. MARGOLIS: Objection. Asked and 15:57:03</p> <p>18 answered. 15:57:04</p> <p>19 Q. You may answer. 15:57:04</p> <p>20 A. It depends on the surfactant you're looking 15:57:05</p> <p>21 at. 15:57:08</p> <p>22 Q. You can put this document aside. 15:57:08</p>	<p>1 Is that a true statement? 15:58:44</p> <p>2 MR. MARGOLIS: Objection. Vague. Calls 15:58:46</p> <p>3 for speculation. 15:58:47</p> <p>4 THE WITNESS: I haven't read this paper 15:58:50</p> <p>5 for a long time, so I hope it's correct. But 15:58:52</p> <p>6 without re-reading it -- 15:58:57</p> <p>7 Q. Do you have any reason to believe that it's 15:58:58</p> <p>8 not a true statement? / 15:59:01</p> <p>9 A. I would hope it would be correct. 15:59:02</p> <p>10 Q. You can put that document aside. 15:59:03</p> <p>11 MR. HASFORD: I'm handing the court 15:59:15</p> <p>12 reporter what I would ask to be marked as 15:59:17</p> <p>13 Lawrence Exhibit 22. 15:59:19</p> <p>14 For the record, Lawrence Exhibit 22 15:59:20</p> <p>15 corresponds to item number 49 in Articles in 15:59:22</p> <p>16 Academic Journals on Dr. Lawrence's 15:59:27</p> <p>17 curriculum vitae. 15:59:28</p> <p>18 (Whereupon, Plaintiff's Deposition 15:59:52</p> <p>19 Exhibit No. Lawrence 22 was marked for 15:59:53</p> <p>20 Identification.) 15:59:54</p> <p>21 Q. Are you the M. Jayne Lawrence who co-authored 15:59:54</p> <p>22 Lawrence Exhibit 22? 15:59:57</p>

Page 306	Page 308
1 A. I am. 15:59:58	1 surfactants predictable or unpredictable? 16:02:06
2 Q. And does Lawrence Exhibit 22 correspond to 15:59:59	2 MR. MARGOLIS: Objection. Vague. Calls 16:02:09
3 item number 49 in Articles in Academic Journals on 16:00:04	3 for speculation. 16:02:10
4 your curriculum vitae? 16:00:08	4 THE WITNESS: It is vague because the 16:02:11
5 A. It does. 16:00:10	5 solubility properties of some drugs will 16:02:14
6 Q. Turn to page 82, please, in Conclusions, and 16:00:10	6 increase and decrease, some will become polar 16:02:15
7 look at the right-hand column. About halfway down 16:00:19	7 and non-polar as a function of temperature. 16:02:18
8 it says, "The differences arise because the 16:00:23	8 Q. Take a look -- I'm sorry. Let me mark a new 16:02:21
9 solubility of ionic surfactants increases as a 16:00:25	9 document. 16:02:36
10 function of temperature, whereas the solubility of 16:00:30	10 MR. HASFORD: I'm handing the court 16:02:41
11 non-ionic surfactants decreases." 16:00:32	11 reporter what I would ask to be marked as 16:02:43
12 Is this a true statement? 16:00:35	12 Lawrence Exhibit 23. 16:02:45
13 MR. MARGOLIS: Objection. Vague. 16:00:37	13 For the record, Lawrence Exhibit 23 16:02:46
14 THE WITNESS: I can't even see it. 16:00:39	14 corresponds to item number 87 in Articles in 16:02:50
15 Sorry. 16:00:41	15 Academic Journals on Dr. Lawrence's CV. 16:02:55
16 Q. It's about halfway down, right below the 16:00:41	16 (Whereupon, Plaintiff's Deposition 16:03:22
17 acronym LTPB. 16:00:45	17 Exhibit No. Lawrence 23 was marked for 16:03:22
18 A. Okay. 16:00:47	18 Identification.) 16:03:23
19 Q. Let me know if you need me to read it again. 16:00:48	19 Q. Are you the M. Jayne Lawrence who co-authored 16:03:23
20 A. If I'm honest, I'm not too sure about the 16:01:02	20 Lawrence Exhibit 23? 16:03:30
21 first part, but certainly the second part is right. 16:01:04	21 A. I am. 16:03:32
22 Q. Which part is the second part that you're 16:01:07	22 Q. Does Lawrence Exhibit 23 correspond to item 16:03:33
Page 307	Page 309
1 referring to? 16:01:09	1 number 87 in Articles in Academic Journals on your 16:03:37
2 A. The solubility of non-ionic surfactants 16:01:09	2 curriculum vitae? 16:03:40
3 decreases, correct. 16:01:12	3 A. It does. 16:03:42
4 Q. Would you expect non-ionic surfactants to 16:01:14	4 Q. Take a look, if you would, at the second 16:03:42
5 have greater solubilizing capabilities at higher or 16:01:17	5 sentence. It says, "This wide usage is due to the 16:03:45
6 lower temperatures? 16:01:20	6 fact that surfactants display diverse structures in 16:03:49
7 A. Higher. 16:01:21	7 aqueous environments depending on their 16:03:53
8 Q. You may put this document aside. 16:01:23	8 concentration, the temperature, pH, and the presence 16:03:56
9 A. That would be -- you have to be very careful 16:01:26	9 of other species in the system (i.e., ions and 16:03:58
10 which non-ionic surfactants because some non-ionic 16:01:30	10 oils)." 16:04:02
11 surfactants don't exhibit that behavior in their 16:01:35	11 Is it true that surfactants display diverse 16:04:02
12 pharmaceutically accessible temperature regime. 16:01:36	12 structures in aqueous environments depending on 16:04:06
13 Q. Is the temperature dependency of the 16:01:46	13 their concentration, the temperature, pH, and the 16:04:09
14 solubilizing effect of non-ionic surfactants 16:01:50	14 presence of other species in the system? 16:04:11
15 predictable or unpredictable? 16:01:54	15 MR. MARGOLIS: Objection. Vague. 16:04:14
16 MR. MARGOLIS: Objection. Vague. Calls 16:01:57	16 THE WITNESS: Can you repeat that 16:04:16
17 for speculation. 16:01:58	17 question? 16:04:18
18 THE WITNESS: What was the question? Is 16:02:00	18 Q. Certainly. Is it true that surfactants 16:04:18
19 the solubility -- 16:02:01	19 display diverse structures in aqueous environments 16:04:21
20 Q. Is the temperature dependency -- 16:02:02	20 depending on their concentration, the temperature, 16:04:24
21 A. Ah. Yeah. 16:02:02	21 pH, and the presence of other species in the system? 16:04:27
22 Q. -- of the solubilizing effects of non-ionic 16:02:04	22 MR. MARGOLIS: Objection. Vague. 16:04:31

Page 310	Page 312
<p>1 THE WITNESS: It is vague. You have to 16:04:33</p> <p>2 remember the number of surfactant structures 16:04:37</p> <p>3 possible is absolutely huge. So, if you take 16:04:41</p> <p>4 surfactants as a whole, ionic, cationic, 16:04:46</p> <p>5 anionic, zwitterionic, non-ionic, that 16:04:54</p> <p>6 statement will be true. 16:05:12</p> <p>7 Q. Is it true that surfactants display diverse 16:05:14</p> <p>8 properties in aqueous environments depending on 16:05:19</p> <p>9 their concentration, the temperature, the pH, and 16:05:22</p> <p>10 the presence of other species in the system? 16:05:25</p> <p>11 A. How are you defining -- 16:05:27</p> <p>12 MR. MARGOLIS: Objection. Vague. 16:05:27</p> <p>13 THE WITNESS: Yeah. How are you 16:05:29</p> <p>14 defining properties? 16:05:30</p> <p>15 Q. Well, let me say it this way. Is it true 16:05:31</p> <p>16 that surfactants display diverse physical and 16:05:33</p> <p>17 chemical properties in aqueous environments 16:05:36</p> <p>18 depending on their concentration, the temperature, 16:05:39</p> <p>19 the pH, and the presence of other species in the 16:05:42</p> <p>20 system? 16:05:46</p> <p>21 MR. MARGOLIS: Objection. Vague. Calls 16:05:47</p> <p>22 for speculation. 16:05:48</p>	<p>1 journal. So, it's actually dating from 2000 and -- 16:06:55</p> <p>2 from 2000. 16:06:55</p> <p>3 Q. Okay. Thank you for that clarification. 16:07:33</p> <p>4 (Whereupon, Plaintiff's Deposition 16:07:33</p> <p>5 Exhibit No. Lawrence 24 was marked for 16:07:34</p> <p>6 Identification.) 16:07:34</p> <p>7 Q. Are you the M. Jayne Lawrence who co-authored 16:07:34</p> <p>8 Lawrence Exhibit 24? 16:07:37</p> <p>9 A. I am. 16:07:38</p> <p>10 Q. Does Lawrence Exhibit 24 correspond to item 16:07:38</p> <p>11 number 102 in Articles in Academic Journals on your 16:07:41</p> <p>12 curriculum vitae? 16:07:45</p> <p>13 A. Yes, but I do want to stress that this is a 16:07:46</p> <p>14 re-publication, an exact copy of the paper that is 16:07:49</p> <p>15 39 on this reference, and I think should be viewed 16:07:54</p> <p>16 in that context. This is a special issue of the 16:07:59</p> <p>17 journal, which is why it's a supplement just for a 16:08:03</p> <p>18 few papers that were very highly cited. 16:08:06</p> <p>19 Q. Is there anything else you would like to 16:08:11</p> <p>20 explain about that paper? 16:08:13</p> <p>21 A. No. That's fine. 16:08:14</p> <p>22 Q. Please, if you would like to. 16:08:15</p>
Page 311	Page 313
<p>1 THE WITNESS: Yes. Remember, we're 16:05:49</p> <p>2 talking here in this context from anything 16:05:51</p> <p>3 from naught to a hundred percent of 16:05:55</p> <p>4 surfactants. So, we're not talking about 16:05:58</p> <p>5 concentrations of surfactants that will be 16:06:00</p> <p>6 routinely used in pharmaceutical 16:06:03</p> <p>7 formulations. So, I think that's slightly 16:06:06</p> <p>8 out of context. 16:06:07</p> <p>9 Q. You can put this document aside. 16:06:09</p> <p>10 MR. HASFORD: I'm handing the court 16:06:18</p> <p>11 reporter what I would ask to be marked as 16:06:20</p> <p>12 Lawrence Exhibit 24. 16:06:22</p> <p>13 For the record, Lawrence Exhibit 24 16:06:23</p> <p>14 corresponds to item number 102 in Articles in 16:06:25</p> <p>15 Academic Journals on Dr. Lawrence's 16:06:31</p> <p>16 curriculum vitae. 16:06:32</p> <p>17 A. Can I just point something out about that 16:06:33</p> <p>18 reference? 16:06:37</p> <p>19 Q. Oh, you certainly may. Of course. 16:06:38</p> <p>20 A. That reference was first published in 2002 16:06:39</p> <p>21 and is reference 39 on my list. It was re-published 16:06:45</p> <p>22 because it was a very highly cited paper by the 16:06:50</p>	<p>1 Take a look, if you would, on page 176, and 16:08:17</p> <p>2 let me direct your attention to the left-hand 16:08:20</p> <p>3 column. The last full sentence says, "On dispersal 16:08:22</p> <p>4 in water, surfactants self-associate into a variety 16:08:27</p> <p>5 of equilibrium phases, the nature of which stems 16:08:31</p> <p>6 directly from the interplay of the various inter and 16:08:34</p> <p>7 intermolecular forces as well as entropy 16:08:38</p> <p>8 considerations." 16:08:42</p> <p>9 Is that a true statement? 16:08:43</p> <p>10 MR. MARGOLIS: Objection. Vague. 16:08:45</p> <p>11 THE WITNESS: In the context of that 16:08:52</p> <p>12 paragraph, yes. 16:08:53</p> <p>13 Q. You can put that document aside. 16:08:54</p> <p>14 What did you do to prepare for your 16:08:59</p> <p>15 deposition today? 16:09:00</p> <p>16 MR. MARGOLIS: I just ask you not to 16:09:05</p> <p>17 reveal the communications between yourself 16:09:07</p> <p>18 and the attorneys, but you can otherwise 16:09:09</p> <p>19 answer his question generally. 16:09:11</p> <p>20 THE WITNESS: I did re-reading of the 16:09:13</p> <p>21 relevant material that I used to prepare the 16:09:17</p> <p>22 declaration in the first place. 16:09:22</p>

Page 314	Page 316
<p>1 Q. Which material was that? 16:09:24</p> <p>2 A. Well, it was obviously the patents, the 16:09:26</p> <p>3 patent histories, I looked at the references that I 16:09:30</p> <p>4 had cited and tried to, you know, basically remember 16:09:33</p> <p>5 what I had written and why I'd written it. 16:09:41</p> <p>6 Q. Did you review any documents other than those 16:09:43</p> <p>7 that you cite in your declaration in preparation for 16:09:45</p> <p>8 today's deposition? 16:09:49</p> <p>9 A. I did read some related information that I 16:09:51</p> <p>10 thought might be useful. For example, I remember I 16:09:57</p> <p>11 refreshed my memory of the last patent case I did 16:10:02</p> <p>12 and information like that. 16:10:07</p> <p>13 Q. What other materials did you review? 16:10:08</p> <p>14 A. Other patents that I'd read at the same time 16:10:11</p> <p>15 that aren't in here for various reasons, papers that 16:10:24</p> <p>16 I'd read that supported the work. I just did quite 16:10:29</p> <p>17 a bit of reading, general reading around looking 16:10:33</p> <p>18 back to what I was reading at the time that I made 16:10:35</p> <p>19 the statements. 16:10:38</p> <p>20 Q. When you reviewed the opinions you provided 16:10:39</p> <p>21 in those other cases, did it refresh your 16:10:41</p> <p>22 recollection as to what those opinions were? 16:10:43</p>	<p>1 A. Just the day. 16:11:36</p> <p>2 Q. Do you remember how many hours it was? 16:11:37</p> <p>3 A. I didn't count. 16:11:39</p> <p>4 MR. HASFORD: We have nothing further at 16:11:46</p> <p>5 this point. 16:11:47</p> <p>6 MR. MARGOLIS: If we could just go off 16:11:50</p> <p>7 the record for a couple of minutes and we 16:11:52</p> <p>8 could talk. 16:11:53</p> <p>9 THE VIDEOGRAPHER: We only have about 16:11:53</p> <p>10 five minutes left on the tape. 16:11:53</p> <p>11 MR. MARGOLIS: That should probably be 16:11:53</p> <p>12 fine. You know what, let's just go off the 16:11:53</p> <p>13 record. 16:11:55</p> <p>14 THE VIDEOGRAPHER: The time is 16:11:55</p> <p>15 approximately 4:13 p.m. We are off the 16:12:03</p> <p>16 record. 16:12:09</p> <p>17 (Recess from 4:13 to 4:18.) 16:16:59</p> <p>18 THE VIDEOGRAPHER: The time is 16:16:59</p> <p>19 approximately 4:18 p.m. We are back on the 16:17:37</p> <p>20 record. 16:17:41</p> <p>21 MR. MARGOLIS: Lupin doesn't have any 16:17:42</p> <p>22 questions. I'm just going to designate the 16:17:45</p>
Page 315	Page 317
<p>1 A. Oh, no, I didn't read all the opinions. I 16:10:45</p> <p>2 just read some of the information around it. 16:10:48</p> <p>3 Q. Did any of that -- 16:10:50</p> <p>4 A. -- so. Sorry. 16:10:51</p> <p>5 Q. Go ahead. Did any of that refresh your 16:10:52</p> <p>6 recollection as to the opinions you provided in 16:10:55</p> <p>7 those other cases? 16:10:57</p> <p>8 A. No. I didn't go that far into it. 16:10:59</p> <p>9 Q. Okay. Did you review any documents that 16:11:02</p> <p>10 contradicted any of your opinions set forth in your 16:11:05</p> <p>11 declaration? 16:11:08</p> <p>12 A. To be honest, no. 16:11:14</p> <p>13 Q. With whom did you meet in preparation for 16:11:16</p> <p>14 your deposition today? 16:11:18</p> <p>15 A. I met with the attorneys yesterday. 16:11:20</p> <p>16 Q. Which attorneys? 16:11:22</p> <p>17 A. The two people sitting here. 16:11:25</p> <p>18 Q. These two gentlemen? 16:11:27</p> <p>19 A. Yes. 16:11:29</p> <p>20 Q. Okay. How long did you meet with Lupin's and 16:11:29</p> <p>21 Innopharma's counsel in preparation for your 16:11:34</p> <p>22 deposition today? 16:11:36</p>	<p>1 transcript confidential. 16:17:48</p> <p>2 MR. HASFORD: On what basis? Because we 16:17:50</p> <p>3 didn't go into any confidential information, 16:17:51</p> <p>4 I don't think. 16:17:53</p> <p>5 MR. MARGOLIS: Yeah, I'm sorry. I 16:17:54</p> <p>6 haven't had a chance to look back to make 16:17:55</p> <p>7 sure that there wasn't. I don't recall 16:17:57</p> <p>8 anything specifically right now. 16:18:00</p> <p>9 MR. HASFORD: Okay. Well, why don't 16:18:02</p> <p>10 you -- why don't you look at it after we're 16:18:02</p> <p>11 off the record and e-mail it because I'd 16:18:04</p> <p>12 prefer that we don't designate it 16:18:07</p> <p>13 confidential ab initio. Look back at it once 16:18:10</p> <p>14 it comes out. If you see anything in there, 16:18:13</p> <p>15 give me a call or shoot me an e-mail and we 16:18:14</p> <p>16 can talk about it or we can do portions. I 16:18:16</p> <p>17 just don't want us to blanket designate the 16:18:18</p> <p>18 whole thing -- 16:18:20</p> <p>19 MR. MARGOLIS: Okay. 16:18:20</p> <p>20 MR. HASFORD: -- because that's kind of 16:18:21</p> <p>21 contrary to the protective order, you know. 16:18:21</p> <p>22 MR. MARGOLIS: That's fair. As long as 16:18:23</p>

<p style="text-align: right;">Page 318</p> <p>1 the -- 16:18:23</p> <p>2 MR. HASFORD: I won't argue that you 16:18:25</p> <p>3 waived anything. 16:18:27</p> <p>4 MR. MARGOLIS: Okay. As long as that's 16:18:27</p> <p>5 fine. I can't recall right now. 16:18:30</p> <p>6 MR. HASFORD: I won't argue that you 16:18:31</p> <p>7 waived anything. 16:18:33</p> <p>8 MR. MARGOLIS: Okay. 16:18:34</p> <p>9 MR. HASFORD: Innopharma, you got 16:18:34</p> <p>10 anything? 16:18:36</p> <p>11 MR. ABE: I have nothing further. 16:18:36</p> <p>12 MR. HASFORD: Okay. All right. 16:18:39</p> <p>13 Q. Well, thank you, Doctor. 16:18:39</p> <p>14 A. Thank you. Some of those papers I've not 16:18:40</p> <p>15 seen for years. 16:18:45</p> <p>16 THE VIDEOGRAPHER: The time is 16:18:47</p> <p>17 approximately 4:19 p.m., Friday, September 4, 16:18:52</p> <p>18 2015. This is the end of tape number five 16:19:00</p> <p>19 and completes the videotaped deposition of 16:19:03</p> <p>20 Dr. Jayne Lawrence. We are off the record. 16:19:06</p> <p>21 (Whereupon, the deposition was</p> <p>22 concluded at 4:19 p.m.)</p>	
<p style="text-align: right;">Page 319</p> <p>1 I HEREBY CERTIFY that I have read this transcript of</p> <p>2 my deposition and that this transcript accurately</p> <p>3 states the testimony given by me, with the changes</p> <p>4 of corrections, if an, as noted.</p> <p>5</p> <p>6</p> <p>7 X _____</p> <p>8</p> <p>9 Subscribed and sworn to be before this day of</p> <p>10 2014</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>	

<p>A</p> <p>ab 317:13</p> <p>Abe 4:7 16:17,17 19:16 19:21 318:11</p> <p>abilities 282:2,13</p> <p>ability 142:10 169:8</p> <p>able 73:8 79:21 88:7 101:3,19 127:9 142:12 146:9 158:8,9 163:11,16 260:9 261:21</p> <p>absence 170:12 218:14 266:7</p> <p>absolute 114:6 157:4</p> <p>absolutely 310:3</p> <p>absorbed 270:15</p> <p>Absorption 5:15</p> <p>abstract 109:15 126:9 126:11,14,21 129:3,6 261:18</p> <p>academia 55:6,10</p> <p>academic 9:9,20 10:8 10:15 11:10,17 12:8 12:14 13:11,18 14:8 14:16,22 21:20 32:7,9 32:16,19 63:8,10,19 63:20 65:21 66:4 205:14,20 276:8 279:14 280:3,21 281:8 283:4,13 285:1 285:13 288:3,12 292:13,22 295:7,16 297:17 298:4,21 299:7 304:6,15 305:16 306:3 308:15 309:1 311:15 312:11</p> <p>accelerated 235:18</p> <p>accept 46:14</p> <p>acceptable 124:16 129:10 233:8</p> <p>acceptance 254:1</p> <p>accepted 31:10 56:11</p> <p>access 262:5</p> <p>accessible 307:12</p> <p>accuracy 78:3,4,15</p> <p>accurately 17:17 18:5 77:17 78:2 158:12 170:14 171:1 172:7 319:2</p> <p>Ace-Federal 16:2,5</p> <p>achieve 273:17 274:14 296:2</p> <p>achieved 256:2 296:6</p> <p>acid 29:16 33:5 105:15 105:21 119:9 124:8 127:9 129:10,13</p>	<p>155:17 157:2,5 161:16 171:20,20 172:4,5 176:8,16,20 177:7,16 189:19 191:6 203:12 217:12 296:16</p> <p>acids 173:17,17</p> <p>acknowledged 62:15</p> <p>acronym 29:15 306:17</p> <p>ACS 14:14</p> <p>act 173:10 174:5,6</p> <p>Acta 10:7</p> <p>acted 53:6</p> <p>action 1:5,11 15:14 181:1</p> <p>active 49:6,11 50:19 51:1 72:13 171:10 213:21 214:1 258:8</p> <p>activities 20:6,7 21:15 21:18,19 22:12</p> <p>activity 25:1 133:15,21 283:22</p> <p>acts 31:21</p> <p>add 35:20 272:2,8</p> <p>added 180:22 181:6,22 217:1 251:22</p> <p>adding 102:12 300:20 301:4,12 302:6</p> <p>addition 49:11 295:21</p> <p>additives 266:7</p> <p>address 17:7 131:14,19 131:22 224:8</p> <p>adequately 274:11</p> <p>adjusted 125:11</p> <p>adjuvant 233:10,10,11</p> <p>administer 122:21</p> <p>administered 27:21 29:18 233:14</p> <p>administering 155:21</p> <p>administration 59:4,9 108:1 145:8 160:7 161:12 164:4,21 211:21 212:1,2 277:10</p> <p>adopted 144:1</p> <p>advanced 14:20 260:9 260:14 261:7,21</p> <p>advancement 150:2</p> <p>Advances 8:4</p> <p>advantage 277:9</p> <p>advice 236:16</p> <p>advise 53:20</p> <p>advised 153:9</p> <p>advisory 279:3</p> <p>affect 49:12 169:12 213:20 257:4 272:5 290:11,16</p>	<p>affirm 16:20</p> <p>afternoon 205:4,10,11</p> <p>agent 172:22 173:3,10 174:3 180:20 235:15</p> <p>agents 173:21 189:21 190:8 299:16</p> <p>aggregate 266:13 289:2 289:4,21 290:1 298:10</p> <p>aggregates 286:13</p> <p>aggregation 12:9 82:14 86:7 291:7,9</p> <p>ago 25:19 32:11,17 38:14 56:6 129:2</p> <p>agree 15:10 19:16,19 198:4 214:8 217:15 235:7,21</p> <p>agreement 131:7</p> <p>Ah 307:21</p> <p>ahead 96:16 274:18 315:5</p> <p>al 6:12 15:13,14 207:3 208:6</p> <p>alcohol 127:8 128:15 129:11</p> <p>alkaline 189:22</p> <p>alkyl 127:7 128:14 129:11 281:15</p> <p>allowed 145:19</p> <p>all-or-nothing 301:16</p> <p>Alston 4:3 16:17</p> <p>alter 302:16,20 303:14</p> <p>alternative 81:19 255:16</p> <p>altogether 181:15</p> <p>American 45:6 188:4,5 188:6</p> <p>amineoxide 13:7</p> <p>amine-N-oxide 255:20 255:22 256:4</p> <p>ammonium 127:12</p> <p>amount 35:19,19,21,21 44:7 49:21 80:1 88:17 114:14 212:17 212:22 227:13 230:8 231:17 238:17 271:1</p> <p>amounts 50:1 88:6 101:20</p> <p>amphiphilic 67:8 166:18 266:1 287:2</p> <p>analogous 66:20</p> <p>analysis 10:4 219:2 220:3,13,16</p> <p>analytically 82:10</p> <p>analyzed 37:2</p> <p>Angeles 4:6</p> <p>anion 29:19 32:2 48:1</p>	<p>48:13 53:15 54:2</p> <p>anionic 310:5</p> <p>answer 17:16,20 18:1 19:15 20:13,20 21:9 22:1,2,9 25:7 26:2,11 26:15 30:7 31:8 34:1 34:21 35:7,9,13,14 40:1 41:11 42:3 43:7 44:15 52:21 58:19 77:3,13 80:8 84:16 85:7 93:5 96:3 104:5 106:5 110:19 123:8 132:22 134:18 135:6 135:21 136:1 142:8 145:16 146:3,9,15,18 147:21 148:13,22 149:20 151:2 154:5 165:18 220:12 222:16 224:7 228:7 234:21 239:20 244:11 246:18 259:5 261:13 268:9 269:3 270:3,12 271:14 273:3 275:19 296:13 303:19 313:19</p> <p>answered 35:2 40:17 93:4 104:4 112:13 121:7 147:16 222:22 228:12 236:6,13 237:5 271:15 302:10 303:18</p> <p>answering 132:10 133:18 290:16</p> <p>answers 32:12 133:8 221:18 223:20</p> <p>antibiotic 233:7</p> <p>antimicrobial 37:19 38:2,10,17 253:5,8</p> <p>antioxidant 217:16 218:9</p> <p>antioxidants 216:11 217:1,10,20,20 218:1 218:6</p> <p>anti-inflammatory 80:5 155:15,19 156:4 156:6 168:15</p> <p>anybody 54:13 73:13 85:15 99:2,18 109:22 138:3 182:9 249:14</p> <p>anyway 118:10 157:17 164:4</p> <p>Apologies 132:11 177:4</p> <p>apologize 107:20 128:7 175:2,14 195:9 198:17 254:5 265:1 274:18 277:5 281:14</p> <p>apparent 113:11 283:20</p>	<p>appear 18:20 176:17 176:21 177:8,12 242:14</p> <p>appearance 226:7</p> <p>appears 242:5</p> <p>appendices 5:12 18:12 18:17</p> <p>Appendix 19:4,5</p> <p>APPERANCES 4:1</p> <p>applicable 103:18 138:10</p> <p>applicants 178:22 231:3</p> <p>application 6:17 69:2,5 69:9,13 237:18 238:1 238:3,5,16 239:1</p> <p>applications 7:14 45:16 68:13,15,20 147:8 152:14 237:11</p> <p>applies 190:20</p> <p>apply 19:17 142:13 190:2,11,18 203:14</p> <p>Appointments 54:21 55:18</p> <p>appreciate 293:21</p> <p>appreciation 274:9</p> <p>approach 255:17</p> <p>appropriate 39:16 42:13 43:1,4,18 59:18 85:19 133:12,13,14 133:15 163:4 271:6 271:10 273:19</p> <p>appropriately 108:5</p> <p>approximately 15:21 80:17 81:1 136:12,18 204:21 205:5 254:19 255:3 316:15,19 318:17</p> <p>approximation 158:9</p> <p>aqueous 9:6 12:11 23:15 34:17 35:10 36:8,15 39:11,19 40:6 40:14,22 41:3,9,18 44:1 50:18,22 62:3,7 62:14,16 65:3,9,18 67:22 69:10 75:19 80:4 86:2,17,22 87:12 87:20 88:16 98:17 99:6,10,15 100:8,11 100:20 101:11,16 102:2,9 107:8,16,22 108:15 109:18 110:16 111:12,21 112:10 114:12 116:9 118:4 124:15 125:10,17 126:3,15 127:10 128:7 129:7 131:15</p>
---	---	---	--	---

<p>131:22 132:3,18 133:4 151:5 156:19 156:20 159:6,13 160:11 161:5,20 162:5,19 164:6,11 167:8,13 168:4,19 169:12 171:14 175:9 188:13,19 189:5 211:10,17 217:10,17 218:1,10 283:21 284:3,12 286:5 289:3 289:5,22 290:2 291:19 292:4 298:11 309:7,12,19 310:8,17 aqueous-based 65:8 286:7 Archaeology 25:5 architecture 266:20 area 21:4 27:3 39:4 41:12 73:7 184:10 areas 19:11 20:2,9,14 20:16 21:7,11,12,13 21:21 22:4,6,14 23:19 23:20 24:1,9,11,13,17 25:3,4 258:5 argue 222:9 318:2,6 Arrhenius 218:19 219:3 220:14 art 36:19 79:22 83:1 84:11,19 85:1,10 86:21 87:10,19 88:5 88:14 97:22 98:17 99:3,5,14 100:11,20 101:6,10,15 102:1,9 106:14 107:7,15,22 108:15 109:10,17 110:16 111:12,20 112:3,10 120:8 121:2 121:17 122:8,14 123:14 125:17 126:3 127:6 133:4 137:5 138:4,9,13,14,16 139:15,21 140:5 141:21 142:4,9 143:5 143:8,17,22 144:5,9 144:14 145:7,13,20 146:5,12 148:18 149:5,12,13,14,16 150:7,15 151:18,22 152:9 153:17 154:1 154:15,16,17,19 155:6,9 159:6,13 160:11 161:19 162:18 163:18 187:3,12 188:10,17 189:3 209:21 210:7,15,20 218:9 220:6,20</p>	<p>227:21 228:3,4,9 243:5 246:21 247:4 247:17 248:2 249:15 252:13 256:4 260:13 261:6 299:22 Arthur 187:5 article 66:7 67:9,14,21 207:3,22 208:12 articles 9:9,19 10:8,14 11:10,17 12:7,14 13:10,17 14:8,16,21 65:20 66:3 205:14,19 279:13 280:3,20 281:8 283:3,13 284:22 285:13 288:2 288:12 292:12,22 295:6,16 297:16 298:4,20 299:7 304:5 304:15 305:15 306:3 308:14 309:1 311:14 312:11 artisan 249:8 arts 144:12 aryl 127:8 128:14 129:11 ascorbic 217:12 ascribed 137:6 Ashford 17:10 aside 52:2,17 53:1,13 53:22 55:9 117:21 209:6 237:8 239:8 241:22 257:6 259:8 262:8 264:7 267:3 279:8 280:15 282:20 284:17 287:19 292:7 295:1 297:11 298:15 303:22 305:10 307:8 311:9 313:13 asked 17:19 18:8 25:7 35:5,6 40:16 54:13 90:5 92:7 93:3,7 104:3 130:12 147:15 222:21 223:8,9 228:12 236:6,12 237:4 274:14 302:9 303:17 asking 21:5 22:5 24:6,7 34:8 48:10,17 96:4 102:21 103:20 131:19 138:6 139:1 148:22 149:2,3,9 162:3 177:6 185:2 195:11 220:18 236:20 237:1 239:17 245:11 258:21 287:6 aspect 148:8 149:1 aspects 7:8 148:10,12 aspirin 168:16</p>	<p>assay 162:7 assayed 42:12 assays 218:21 assessed 269:8 278:4 assessing 44:7 assessment 88:8 assigned 232:20 238:6 associated 277:4 Association 9:4 188:6,6 assume 18:1 35:19 102:11 119:21 assuming 35:17 93:22 112:17 241:16 assumptions 35:15 asymmetric 266:4 atom 301:2 atoms 301:1 attempt 237:7 attempting 285:19 attention 54:20 58:6 62:21 69:16 96:17 98:8 106:8 107:1 108:8 110:13 113:3 114:9 152:21 183:1,8 186:17 189:16 192:1 194:3 203:6 205:13 206:10 209:9 213:5,8 214:13 218:16 225:8 233:5 240:17 255:8 255:11 258:2 260:6 263:7 267:21 268:12 268:17 269:12 272:13 273:7 275:6 277:1,22 285:17 288:16 295:20 313:2 attorney 137:17 attorneys 3:4,15 4:4 135:22 153:10 313:18 315:15,16 attractive 269:20 audio 15:8 authored 50:17,21 51:3 187:22 241:20 267:19 285:9 288:8 295:12 authorities 163:6 authorization 163:3 automatically 241:15 available 79:12 83:12 85:8 121:14 261:17 Avenue 2:3 3:5,17 15:20 average 143:14 avoid 220:17 awards 24:22 89:4 aware 29:15 37:21 39:2 51:11 145:8 194:14 A-O3 115:19</p>	<p>A-02 227:14,15 A-03 113:22 114:21 115:9,16 227:16 A-04 116:2,4 229:15,19 A-05 229:15,20 A-06 229:21 A-07 229:22 A-08 230:1 a.m 2:5 15:22 80:17 81:1 136:12,18 A1 6:18 B B 5:6 6:1 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 38:21 39:6 108:22 243:7 244:3,7 244:18 245:1,6,21 246:15 247:6 249:10 250:3 back 47:1 69:15 71:19 81:4 90:4 106:7 112:22 131:10 133:22 136:21 151:10 155:2 171:16 185:12 186:16 191:22 193:5,19 195:3 202:9 205:8 209:8 212:10 213:4 221:18 223:8 225:6 255:6,8 287:8 290:20 290:22 314:18 316:19 317:6,13 backbone 294:7,7 bacteria 105:11 251:2 251:9 bacterial 211:8 bad 200:4 balance 77:5 273:12,19 290:13 296:3,5 Barcelona 287:5 base 161:16 based 21:5 35:3,20 36:7 48:10 77:19 78:6 96:4 99:3,21 101:9,14 101:18,18,22 102:7 102:21 106:13 107:6 107:14,20 108:13 109:8,16 111:19 112:8 125:15 126:1 127:21 158:13 160:4 168:8 170:17 171:2 220:4,18 249:2 258:4 basic 85:18 150:5 184:10 272:18 basically 162:12 314:4 basing 220:12 basis 126:19 127:16,20</p>	<p>127:21 128:1 129:17 129:21 130:1,9,18 131:1,6,7 166:21 169:17,19 202:11 256:8 294:17 317:2 Bates 180:11 189:14 190:22 192:13 194:1 195:20 196:7 203:6 213:6 252:19 battery 82:13 Bausch 1:3,4 16:10,13 BBA 10:6 bears 180:11 189:14 190:22 192:13 194:1 195:20 196:7 203:6 213:6 252:19 beginning 213:16 begins 185:15 194:17 258:3 behalf 16:10,13 233:2 238:9 behave 42:22 43:3 66:19 behaved 302:4 behavior 74:15 169:9 169:11 171:8 300:9 302:17,21 303:4,15 307:11 behaviour 269:7 272:20 278:3 believe 23:4 39:12,14 40:2 56:16 65:7,12,14 66:5,16,17 94:20 97:10 99:18 103:4 104:13,20 106:21 108:18 109:22 116:6 147:16 152:11 164:14 164:15 172:10 176:10 177:11,19 180:4 186:4 192:6 198:12 199:3 201:2 203:17 221:1 223:16 224:7 235:3 237:6 239:21 243:18 244:5 263:15 264:5 268:10 269:4 271:15 273:4 277:13 278:9 280:14 282:16 285:6 300:5 305:7 believed 286:21 Bendamustine 238:18 benzalkonium 124:19 127:11 132:5,20 133:5,20 best 77:13 272:7,8 286:11 Beta-Cyclodextrin 10:5</p>
--	---	--	--	--

<p>Beta-lactam 233:7 better 8:15,16 163:17 209:4 220:15 269:22 beyond 269:14 big 294:10 301:12 303:8 biggest 35:18 Bilayers 7:6 bind 175:12 binder 106:21 110:12 binding 174:3 bioavailability 73:19 Biochimica 10:6 Biodegradable 13:7 biology 258:6 biomedical 146:4 Biopharmaceutical 5:16 Biophysica 10:7 biostatistics 37:11,16 Bird 4:3 16:17 bisulfite 217:11 bit 20:7 96:16 110:6 116:17 124:12 133:1 150:5 157:19 314:17 bizarre 130:3 blanket 317:17 body 156:7 159:1 181:2 208:16 212:2 269:7 270:15 273:18 274:12 274:16 278:3 280:7 298:7 book 7:10,17,22 8:9,14 50:21 51:2,3,4 63:4,7 63:16 64:2,7,10,17 65:2,11 187:14,21 240:4 241:17 255:10 Books 62:22 240:11 257:12,20 259:14,22 262:14 263:1 264:16 265:13 borax 179:1 bottle 121:9,13 123:10 123:19 140:21 bottom 55:1 133:17 180:16 183:3,16 184:3 194:16 196:9 196:18 199:6,9 203:7 214:11 275:7 283:18 brain 75:3 break 17:18,20 80:14 136:9,10 204:10,14 brief 83:8 British 63:8,18 95:19 188:4 broad 208:19 broadly 97:8 207:14</p>	<p>258:4 bromfenac 27:21 28:6 30:5,8 33:1,8 47:13 52:4,10,13,15,18 124:9,11,16 126:17 127:10 132:4,16,18 133:5 155:18 156:3 156:11,16,21 157:1 163:22 164:7,12,17 165:3,12,15,22 168:17 228:18 230:8 bromobenzoyl 119:4 brought 287:8 Bryan 3:8 16:12 bryan.diner@finneg... 3:12 building 3:16 15:20 163:16 Burdock 192:3,9,13,17 192:20 193:10,16,20 194:10,20 buy 201:8,8,9 B2 6:16</p> <hr/> <p style="text-align: center;">C</p> <hr/> <p>C 3:1,8 15:1 74:13 calcium 103:18 173:8 173:13 175:12,13 180:21,22 181:7 182:1,13,15,18,20 183:11 184:1,6,15 185:6 calcium-depleting 181:1 calculations 261:22 262:1,6 California 4:6 call 128:16 294:6 317:15 called 53:20 190:10 216:11 Calls 84:13 87:5 98:19 126:6 146:6,13 154:3 154:10 158:4 159:8 159:15 160:14 227:22 228:11 234:5,20 236:13 239:4 244:9 252:15 270:1 284:13 294:20 296:11 305:2 307:16 308:2 310:21 candidate 269:21 278:2 capabilities 307:5 capability 223:18 capacity 53:10 82:16 83:13 168:8 280:12 299:20 300:1 carbon 301:1</p>	<p>carbonate 180:21 careful 275:5 307:9 carefully 92:17,18 239:20 carried 113:12 119:17 Carriers 8:8 carry 97:22 106:15 120:10 121:4,20 122:9 123:5 carrying 122:15 123:15 case 17:14 18:17,21 19:2 20:22 24:3,5,8 42:9 45:18 46:3,9,13 46:16 47:1,2,8,11 52:2,17 53:1,11,13,22 69:18,21 70:2,7,14 71:3,7,11,17,18 72:5 72:22 73:10 90:13,19 91:3,9,16 92:4 97:17 98:11 105:1 107:4 108:11 113:6 131:12 134:15 135:3,10,14 135:18 136:4 180:2 184:22 186:21 192:4 192:18 195:8,13 196:14 202:21 209:15 212:16,20 233:1 238:8 239:11 243:21 245:14 252:11 276:3 276:4 284:16 294:5 296:20 314:11 cases 45:10 70:17,18,21 143:10,19 144:2 198:10 199:16 222:8 302:4 314:21 315:7 case-by-case 169:17,19 294:17 cast 181:20,21 191:15 201:5 catalysts 216:12 categorically 106:6 cationic 66:18 310:4 cause 296:8 297:2 causes 295:22 causing 281:17 caution 239:14 Celsius 113:13 114:16 119:1,7 230:10 certain 92:12 93:1,10 93:20 94:9 121:15 148:22 170:10 174:3 199:16 216:3 230:8 242:22 245:11 287:1 certainly 20:2 33:15 63:11 87:18 93:8 108:12 115:8 157:4 167:19,20 210:11</p>	<p>246:12,12 275:6 306:21 309:18 311:19 certainty 153:16 154:1 155:5,8 Certified 2:6 CERTIFY 319:1 cetera 75:15 162:11 212:4 chain 79:14,16,16 83:13 216:14 281:15 290:13,14 291:5,7 300:13 chains 81:20 266:12 288:20 289:18 294:6 296:20 chair 21:15 challenges 271:3,5,9 chance 317:6 change 80:15 136:8 254:16 266:8 301:6,6 301:13,16 302:8,19 303:8,11,13 changed 43:12 162:11 changes 169:10 226:6 296:9 297:2 301:18 302:1 303:5 319:3 chapter 51:3,4 63:16 64:2,7,10,17 65:2,18 chapters 7:10,17,22 8:9 8:14 50:21 62:22 63:4,7 65:7,11 240:5 240:11 241:17 255:10 257:11,20 259:13,22 262:13 263:1 264:16 265:13 characteristics 9:4 235:16 characterization 11:13 74:4,8,12,16 75:7 85:18,20 86:2 300:9 characterize 82:6,10 85:10 87:2 162:18 301:4 302:6 characterized 81:13,22 86:15 114:12 characterizing 161:19 charge 167:2,4 charged 167:1 charges 173:6,9,11 check 64:9,15 66:16 106:1 108:21 109:12 138:22 170:2 244:13 249:16 checked 244:12 250:6 checking 82:11 chelate 173:8 chelated 190:6</p>	<p>chelates 189:22 chelating 172:22 173:2 173:10,21 174:2 189:21 190:8 chelation 173:15 174:11,15 175:4 chelator 174:5 chemical 7:8 10:13 45:6 49:13 75:10,17 76:22 77:7,9,10,18,19 77:21 78:5,7,8,12 79:2,3,5 80:2 82:1,19 82:21 85:10 87:2 95:12,16,22 96:7 116:9 117:4,5,12,16 118:2 124:7,9,12 156:11 157:12,22 158:1,3,13,14,15,18 161:20 162:19 169:2 169:4 170:4,6,7,15 171:2,3,5,21,22 172:7 214:19 215:2,4,7,20 216:18,21 217:2 219:14,18 220:6,20 224:5,16 225:12,16 225:17 226:1,2 260:14 261:8 282:1 282:12 289:7 290:4 296:9 297:3 301:5,6 302:7 310:17 chemicals 177:13 182:22 258:8 chemistry 9:7 44:13,17 44:18,19,20,22 45:3,4 45:9 54:9,14 chief 21:16,18 56:17 chloride 124:20 127:12 132:6,20 133:5,20 238:17 choose 141:4 chosen 198:19 circumstance 222:6 circumstances 38:8 61:10 80:10 84:22 100:15 167:12 175:8 211:16 222:17 citation 66:14 129:7 281:13 cite 143:3 206:16 208:12 213:1 231:21 231:22 254:13 314:7 cited 311:22 312:18 314:4 Civil 1:5,11 15:14 claim 18:16,20 19:1,5 27:14 45:21 46:6,19 90:6 92:8 97:15,16,22</p>
---	--	---	--	---

<p>98:9,9,17 99:6,16 100:11,20 101:5,11 101:16 102:2,9,14,22 103:1,6,9,21,22 104:14,17 106:9,15 107:2,2,8,16,22 108:9 108:10,15,20 109:18 110:13,16 111:12,21 112:10,14 114:9,10 114:22 115:10,17 116:5 130:13,14 131:4 137:3,6,13,22 147:4,8 152:18 153:4 153:8,12,13,14,22,22 154:8 155:4,5 212:6 212:17,21 231:22 232:4 233:5,5,17,20 234:1,2,8,16,17 235:4 235:4,14 236:2,4,4,11 237:3,12 238:11,13 238:14,16 239:1,1,7 242:6,6,11 claimed 116:9 118:5 125:17 126:3 153:17 154:2 155:6,9 claims 92:11,22 93:2,9 93:10,14,15,19,20 94:8,10 97:1,4 104:12 107:5 114:1,2 134:22 137:12,21 147:5,13 147:18 148:1 151:18 151:22 152:9,17 175:20 176:6,17,21 177:8 186:5,7 203:21 231:4 234:7 242:5 243:6,19 244:1,5,16 244:21 245:4,19 246:13,22 247:5,19 248:4,9,17 249:2,9,19 249:19,20,21 250:1 250:17 251:21 254:10 claims-recited 251:16 claim-recited 251:1,9 clarification 20:15 34:4 34:8 179:5 312:3 clarified 35:8 clarify 20:7 33:4 35:4 278:17,21 clarifying 32:14 clarity 130:4 class 7:6 277:11 classes 89:8 classic 66:15 classifications 166:22 classified 166:20 clause 114:11 clear 88:12 96:6 100:18</p>	<p>104:8 105:12 140:3 170:22 179:9,19 181:18 184:8 199:15 200:17 201:1,3 304:20 clearer 248:15 clearly 130:17 191:14 191:17 198:5,12 220:12 222:13 clinical 36:17,20 37:1,2 37:3,4,7 268:2 close 167:5 254:17 closely 47:15 77:14 closest 227:21 228:3,4 228:9 cloud 169:11 CMC 256:14 257:3 CmE1-25m 281:17 coat 170:1 coefficient 165:15 coli 105:10 251:8 colleagues 55:20 collected 250:19 collectively 91:22 196:1 196:4 College 21:20 57:3 89:9 Colloid 12:6 colloidal 60:10 Colloids 14:15 column 97:14 98:8 107:1 108:7 110:13 113:3 117:14 123:21 125:2,3 127:2 128:6 183:3,4,17,20 195:21 203:8 213:9 214:12 218:17 233:4 246:8 275:7 276:22 283:18 288:17 295:20 306:7 313:3 columns 117:15 183:10 183:14,16 combination 13:15 49:9 261:15 come 140:21 comes 143:12 317:14 comment 61:20 199:18 234:8,10 236:19 270:12 comments 224:13 234:22 commercially 83:11 common 54:4 187:20 293:7 297:5 commonly 151:20 187:2,11 217:9,16,21 217:22 299:20 300:2 communications</p>	<p>239:15 313:17 companies 54:6 160:22 company 15:13 53:7,8 55:11 56:4,6,8,13,22 57:7,10,16 58:3 67:13 68:18 160:19 comparable 300:12 compare 235:6 compared 157:5 300:11 comparing 87:11,19 88:15 comparison 227:13,21 228:9,14 compendia 253:15 254:1 compendial 133:14 competing 304:22 complement 110:9 completely 121:15 149:14 completes 318:19 complex 83:19 84:1 139:14 140:4 169:21 190:16 268:5 304:22 complexes 10:6 180:21 189:22 283:20 complicated 50:5 83:4 84:7 component 54:7 114:14 117:18 212:18 213:1 231:18 components 118:20 119:5 composition 229:5,6 233:6,9,18 235:14,17 compositions 87:13,21 88:17 227:12 230:11 compound 31:7 32:6 77:2 78:10 79:7 105:9 126:7 134:17 135:5,12,19 147:19 162:1 174:19 175:7 182:10,11 268:20 269:13,14,19,20,22 compounds 127:12 191:18 269:6 287:12 compressed 233:12,13 comprising 118:19 119:4 124:15 233:9 233:10 235:14 computer 262:6,7 computing 261:20 concentration 36:1 76:8,19 168:3 266:19 266:21 290:14,15 309:8,13,20 310:9,18</p>	<p>concentrations 167:14 167:16 298:12 311:5 concept 43:22 44:1 116:7 211:10,16 225:16 226:1,5 268:2 concern 121:10 concerned 71:3 73:6 84:4 112:4 concerning 46:5 52:3 concluded 318:22 conclusion 154:4,11 228:1,12 234:5,20 236:13,21 239:4 248:8,16 252:16,21 252:22 253:18,20 284:14 285:17,19 302:13 conclusions 236:15 249:1 306:6 Condensed 7:15 9:8 condition 43:16 247:9 270:8 conditions 88:3 113:13 117:6 214:4 215:16 215:17,18 216:2 221:12 223:3,12 224:2,21 227:5 235:5 235:19 249:21 250:1 conduct 36:22 38:13,16 41:2,8,17 42:1,7,16 87:11,19 88:15 conducted 30:4,9 32:1 36:20 38:9 40:21 41:19,21 42:4,6 conducting 14:5 144:21 145:1 Conference 215:12 confidential 53:9 58:15 62:13 67:12 317:1,3 317:13 confirmed 230:19 247:12 confused 224:12 246:4 274:14 confusing 184:7 200:14 confusion 191:21 247:20 connection 90:12,19 91:3,9,15 92:4 97:17 98:10 104:22 107:3 108:11 113:5 131:11 135:10,17 136:4 180:1 186:20 192:4 192:17 195:7,13 196:13 202:21 209:14 212:20 243:20 245:13 252:11</p>	<p>connections 56:2 consecutive 243:11 consequence 296:2 consequences 300:15 consider 19:11 20:2,16 21:7 24:10,21 25:2 36:18 50:12 92:11,22 93:8,18 95:1 97:16,20 98:9,14 104:9 107:2 108:10 130:13 134:14 135:2,9 141:10 143:8 143:17,22 144:5,9,14 154:21 228:2,4 247:18 248:2,6 251:21 considerable 271:4,9 295:22 296:9 297:2 considerations 50:12 161:17 313:8 considered 33:11,17 34:17 36:3,8 40:10 94:6,18 131:11 135:17 136:3 145:12 145:19 188:17 189:3 225:14 considering 232:7 235:9 consist 258:10 consistent 243:15 245:7 245:22 246:15 consisting 49:9 172:18 constant 229:14,18 construction 18:16,20 19:1,5 130:13,14 131:4 137:3,13,22 147:9 152:18 212:6 constructions 231:16 consult 54:13 72:18,21 248:5 consultant 56:5 consulted 51:15 52:3 52:18 53:2,14 54:1,5 54:9,16,19 70:4 73:3 consulting 55:19 contact 266:13 288:21 contain 29:4 30:1 65:7 169:13 contained 139:2 151:6 container 43:17 113:11 117:20,22 118:21 119:6,20 120:3,10 121:4,20 122:9,13 123:5,11,13 141:4 containers 119:17,19 container-liner-closu... 214:3 containing 28:10 29:1</p>
--	--	---	---	---

<p>29:7,12,19 30:10,20 32:2 33:10,16 34:16 47:17,20 48:1,5,13 49:6 50:19 51:1 53:3 53:15 72:9,11 73:12 126:16 129:9 132:5 132:20 155:16 229:5 229:7 302:15 contains 139:12 contaminants 140:12 contaminated 43:20 contamination 43:20 content 51:5,8,18,21 119:8 contents 64:22 context 20:21 21:18 53:5 89:16,22 94:1 95:22 107:19 148:1 216:17,20 222:15 223:6 274:2,6 282:9 286:2 311:2,8 312:16 313:11 continue 15:9 276:4 CONTINUED 4:1 continuous 65:9,18 86:14 151:6 contracts 57:5 58:15 60:13 contradicted 315:10 contrary 317:21 contributed 51:5,8,18 51:21 controlled 233:7 controlling 120:18 conventional 256:2 conversations 15:5 convert 258:7 copied 242:6 copy 19:6 188:22 189:1 207:22 232:12 237:18 242:6 312:14 core 168:9,10 280:11 289:18 CORP 1:4 correct 23:21 51:3 57:3 58:22 60:7 63:14 75:7 117:15 124:9,10 130:6,20 131:2,6,12 131:18,21 136:5 138:5,22 139:4 148:1 148:3,4 154:6,13 181:8 182:3 199:22 200:9 201:12,16,17 201:20,21 202:7,8 215:15 226:19 232:1 233:21 241:20 243:21 245:14 247:10,15</p>	<p>248:11,19 249:3,6,17 250:4,7 265:17 267:14,19 275:3 279:1,6 296:3 305:5,9 307:3 correcting 113:10 117:19 correction 117:21 corrections 319:4 correspond 240:10 250:2 257:19 259:21 262:22 265:12 267:15 280:2 281:7 283:12 285:12 288:11 292:21 295:15 298:3 299:6 304:14 306:2 308:22 312:10 corresponds 205:19 240:4 257:11 259:13 262:13 264:15 267:8 279:13 280:20 283:3 284:22 288:2 292:12 295:6 297:16 298:20 304:5 305:15 308:14 311:14 cosmetics 189:20 cosurfactant 296:6 counsel 16:7 19:16,17 239:11,16 315:21 count 251:2 316:3 country 96:1 counts 211:8 251:15,17 couple 234:22 316:7 coupled 160:4 261:15 course 88:13 98:15 122:11 133:2 311:19 court 1:1 15:16 16:1,20 18:7 45:8,10 46:14 47:5,6 53:10 70:1,5,6 70:12,14,17,18,21 71:11 84:15 134:20 137:4 195:9 205:15 207:18 232:8 237:14 239:22 257:7 259:9 262:9 264:8 265:6 267:4 279:9 280:16 282:21 284:18 287:20 290:19 292:8 295:2 297:12 298:16 304:1 305:11 308:10 311:10 courts 144:1 147:4 153:2 covalent 260:10 covering 27:4,4 co-author 279:5 co-authored 206:6 257:16 259:18 262:19</p>	<p>265:17 279:21 281:4 283:9 292:18 297:22 299:3 304:11 305:21 308:19 312:7 co-founded 57:6 co-workers 255:15 creativity 141:22 142:5 145:2 credence 219:5,14 credit 63:19,20 credited 60:12 criteria 37:19,22 38:2 38:11,18,21 39:6 42:11 108:22 109:12 243:7 244:3,7,18 245:1,6,21 246:14 247:6 249:10 250:3 254:1 criteria-B 242:15 critical 168:3 cross-referenced 184:20 cubic 266:5 current 12:5 60:15 currently 55:22 57:2 89:8 curriculum 19:6,8 23:5 54:18 58:8 63:3 65:20 66:2,22 68:10 68:12 89:3 205:21 206:4 240:6,12 257:20 259:14 260:1 262:14 263:2 265:13 279:15 280:4,22 281:9 283:5,14 285:2 285:14 288:4,12 292:14 293:1 295:8 295:17 297:18 298:5 299:8 304:7,16 305:17 306:4 309:2 311:16 312:12 CV 5:18 7:10,17,22 8:9 8:14,18 9:10,20 10:9 10:15 11:11,18 12:8 12:15 13:11,18 14:9 14:17,22 24:19 58:6 62:10,11,19 146:9,9 205:12 255:10 257:12 264:16 267:9 298:21 308:15 cyclodextrin 283:19 284:6 cyclodextrins 284:1,10 Cyclosporin 72:15</p>	<p>damage 156:8 damaging 141:12 Dan 16:15 DANIEL 3:19 data 159:21 218:22 219:2,3 220:2 250:18 database 163:16 dating 312:1 day 122:22 251:2,4,17 316:1 319:9 days 251:15 DDCPNO 300:10 DDNO 300:14 deal 67:7,8 68:21 117:11 118:2 211:7 225:16 226:2,6 dealing 46:18 50:17,22 64:3,8,11,18 65:3 66:8 67:1,10,15,22 69:2,6,10 73:11 130:5 261:3 deals 67:5 117:16 dealt 71:20 debate 157:3 222:9 decide 216:2 270:4 decided 160:16 decision 268:20 278:4 declaration 5:10 18:11 18:17,21 19:2,5 22:17 22:19 23:2,5 69:16 74:1 80:12 81:7 88:22 90:4,12,19 91:3 91:9,15 96:16 97:11 106:4 128:22 130:10 130:19 131:3 133:22 137:2 141:20 142:20 147:1 151:11 166:10 171:17 172:9,12 175:16 178:17 179:21 180:5,6 186:16 189:9 189:10 191:22 192:9 193:6,8 195:4,16 202:19 203:1 209:9 209:18 211:1 212:6,7 212:11,12,16 225:6 226:10 227:2,10 228:16 229:12,16 230:16 231:15,21 242:1 243:19 248:13 250:9 252:6,7 254:6,8 254:12 313:22 314:7 315:11 decrease 127:11 251:2 308:6 decreases 306:11 307:3 defend 71:17 Defendant 3:15 4:4</p>	<p>defendants 1:10,14 15:14 16:16,18 defendees 71:18 deficient 220:13 define 57:13 89:20 117:6 130:17 209:3 221:6 222:14 223:2 223:19 235:5 241:7 defined 44:9 94:20 191:10 defines 210:18 defining 209:2 225:3 310:11,14 definite 222:7,18,20 definitely 46:2,22 67:20 188:15 definiteness 153:21 154:8 155:3 definition 36:7 95:16 95:18,19 130:7 143:4 143:7,12,16,21 144:4 156:22 175:22 209:21 210:2,19 222:10 223:17 235:10,22 236:3,10 237:2,7 definitions 143:9,18 144:1 definitive 236:19 definitively 234:10 247:22 degradation 216:3 217:2 218:20 225:17 226:3 degraded 43:9 272:7 degrees 113:13 114:15 118:22 119:7 230:10 235:19 Del 4:15 16:3 deliver 73:14 258:11,14 259:1 delivery 7:9 8:6,10 10:12 11:6 12:4 14:19,20 23:11 40:11 40:20 42:17,18,20 58:21 95:6,11 150:18 271:6 273:17 274:15 275:22 276:11 277:8 demonstrate 266:8 demonstrated 261:4 269:19 277:9 demonstrating 130:15 depend 36:1,11 41:5,6 41:14 49:20,21,22 50:8 75:12,21 76:2,4 76:5 79:10,20 86:7,9 86:12 87:6 135:8 148:8 161:11,13</p>
---	---	---	---	--

D

D 5:1 15:1

<p>164:3,20 170:11 282:17 290:9 291:1 302:11 303:16 dependency 307:13,20 dependent 82:7 85:21 depending 35:22 36:12 50:14 82:16 262:5 309:7,12,20 310:8,18 depends 20:12 31:20 36:6 49:18 79:8 83:22 84:1 161:14,15 190:16 211:14 266:19 284:5 290:7 291:4 303:20 depicted 172:7 deponent 15:11 deposed 17:11 deposition 1:15 2:1 15:8,18 17:13 18:13 47:10,12 80:19 81:3 136:14,20 205:1,7,22 208:8 232:13 237:20 240:7 254:21 255:5 257:13 259:15 262:16 265:9 267:10 279:17 281:1 283:6 285:3 288:5 292:15 295:9 297:19 298:22 304:8 305:18 308:16 312:4 313:15 314:8 315:14 315:22 318:19,21 319:2 derivative 300:12 describe 58:9 81:15 162:3 described 58:11 190:8 253:9 describing 128:17 DESCRIPTION 5:8 6:3 7:3 8:3 9:3 10:3 11:3 12:3 13:3 14:3 descriptive 156:5 design 83:17 84:5,8,9 229:13,17 designate 316:22 317:12,17 designation 180:15 designed 37:2,7 74:22 83:16 258:10,14,22 designing 50:13 84:20 desired 160:6 desk 188:22 destroys 83:13 detailed 109:14 111:7,8 112:19 deteriorate 124:22 226:17</p>	<p>determine 24:7 87:8 133:4 147:2 272:16 272:18 291:11 294:19 determined 168:7,11 171:10 241:13 determining 153:4,7 280:11 develop 268:21 278:5 Development 268:18 Dexel 46:10 70:19 dicalcium 182:18 diclofenac 6:5 207:4 208:1 287:12 differ 43:22 82:21 250:11,16 293:9,17 294:14 difference 184:11 243:15 282:18 287:17 289:11 293:22 296:21 297:8,9 differences 97:12 184:11 291:11 294:10 296:8 297:1 306:8 different 35:5 44:10 75:1,9,10,17,18 76:21 76:22 77:9,10,20,21 78:7,8,11 79:4,5,9,10 80:1,2,3 81:17 83:14 87:12,20 88:6,9,16 92:21 95:16 97:3 119:21 132:17 133:2 141:9 143:16 157:7 157:11,12,17,21 158:2,2,15,15,17,17 159:19 161:4 162:12 170:6,7 171:4,4 172:17 181:12,14,17 181:19,20,21 182:16 182:21,22 191:16,18 218:7 223:5,5 225:13 225:14 248:1 269:22 272:21 281:22 282:1 282:2,11,12,13 289:4 289:6,7,10 290:1,3,3 290:7,9 291:2 293:14 294:3,4,8,12,18 296:17 differently 79:20 difficult 20:13 33:22 39:22 114:3 135:7 157:15 261:21,22 dilutability 257:2 Dimethyldodecylami... 14:13 Diner 3:8 16:12,12 direct 54:20 58:6 62:21 69:16 96:16 98:8</p>	<p>106:8 107:1 108:8 110:13 113:3 114:9 152:21 183:1,8 186:17 189:15 192:1 203:5 205:13 206:10 209:9 213:5,8 214:13 218:16 224:17 225:7 233:5 240:17 255:8 255:11 258:2 260:6 263:7 267:21 268:11 268:17 272:12 273:7 275:6 276:22 277:22 285:17 288:16 295:20 313:2 directed 116:8 155:15 233:17 directing 197:8,10 direction 194:3 directly 313:6 disagree 126:19 127:16 127:20 128:1 disagreement 129:17 130:1,9,18 131:1,6 discipline 258:5 disciplines 22:11 disclose 227:5 disclosed 118:5 214:22 215:6,18 disclosure 117:2 124:1 127:7 discrepancy 111:10 discuss 114:6 204:17 213:11 252:3 discussed 106:17 108:21 110:6 162:11 162:13,15 170:9 230:20 discusses 114:5 discussing 258:19 discussion 121:10 130:22 228:17 285:8 293:4 304:20 disease 27:18 49:3 155:21 disodium 6:6 172:19 173:20 174:1,12,16 175:5 181:1,7 182:1 182:13,16,20 183:2 183:11 184:1,5,6,14 184:16 185:5,6 190:3 190:12,18 191:4,11 191:17 192:16,20,22 193:9,9,11,12,17,17 193:19 194:11,22 196:2,21 197:5,12 198:1,22 199:7,13 200:13 201:19 202:3</p>	<p>202:6 203:15 207:4 207:10,11,14 208:1 208:20,21 209:3 dispense 25:17,19 dispensed 28:6,9,21,22 29:5,8,13 dispersal 76:9 313:3 dispersed 44:8 266:1 266:22 288:18 298:11 display 309:6,11,19 310:7,16 dispute 150:21 disputed 137:6 147:3 dissolution 235:16 distinct 73:15,17 182:22 distinction 221:12 223:12 224:3,22 distinctly 181:21 distress 28:17 distributed 274:11 District 1:1,1 15:16,16 diverse 258:5 309:6,11 309:19 310:7,16 divorce 225:22 dmargolis@goodwin... 3:22 doctor 21:2 81:6 131:5 137:1 146:11 175:14 178:14 185:2 195:9 202:15 205:10 267:13 318:13 document 92:16 134:13 135:2,9 181:10 207:17 209:6 231:21 231:22 237:8 239:8 249:5 254:13 257:6 259:8 260:19 264:7 267:3 273:2 278:17 278:22 279:6,8 280:7 280:15 282:20 284:17 286:19,20 292:7 295:1 298:8,15 303:22 305:10 307:8 308:9 311:9 313:13 documents 127:14 134:13 135:2,13,16 136:3 198:14 201:11 202:14 242:22 243:13 278:19 314:6 315:9 doing 78:21 84:20 110:2 120:17 133:13 133:13 150:8,12 262:6,7 287:8 dominates 79:19 dosage 214:2 233:12 dose 73:18 87:7 118:6</p>	<p>118:13 160:5,6 161:11 258:12,15 259:2 270:14 271:20 dosing 271:21 Double-Chain 12:10 doubt 62:15 Dr 15:11 17:5,9 80:19 81:3 136:14,20 146:20 205:1,7,20 240:5 254:21 255:5 257:12 259:14 262:14 264:16 267:9 279:14 280:21 283:4 285:1 288:3 292:13 295:7 297:17 298:21 304:6 305:16 308:15 311:15 318:20 drive 274:20 driving 291:6,6 drop 113:15 119:9 120:4 122:18,19 123:19 132:5,19 133:6 140:21 228:19 dropper 123:10 drops 30:1,2 118:18 119:3 120:2,4 122:21 230:12 drug 5:14 7:8 8:5,7,10 10:12 11:6,7 12:4 14:19,20 23:11 33:2,8 40:11,19 42:10,17,20 43:9 48:22 58:21 73:14 76:16,19 80:5 81:21 83:7,14 87:7,7 118:6 145:8 151:8 155:19 156:4,6 158:8 158:21 159:2,18,19 160:5,6,16,17,22 162:5,9 163:2 170:2 255:21 256:6 258:12 258:15 259:2 268:1,6 268:12,14 271:6,22 272:6,17 273:5,8,11 273:18 274:16 275:22 276:2 277:2,8,10 278:2 283:21 284:2,6 284:11 285:20 286:6 291:19 292:4 drugs 31:14 49:18,22 50:1,2 59:3,9,19 168:11,13,14,16 169:21 258:11,14 259:1 270:9 275:10 275:17 276:10 281:19 284:16 286:3,11 287:1 299:17 308:5 drug's 169:22 272:18</p>
--	--	---	---	--

<p>278:11 drug-solubilizing 299:19 300:1 due 140:15 309:5 duly 17:1 DUNNER 3:3 dynamic 261:16 Dynamics 14:10 D.C 3:6 16:6</p> <hr/> <p style="text-align: center;">E</p> <p>E 3:1,1 5:1,6 6:1 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 15:1,1 105:10 251:8 earlier 196:5 200:17 208:17 242:18 247:12 251:18 271:16 282:16 294:3 earth 190:1 ease 73:19 easily 99:19 edetate 45:20 89:12 102:19 103:5,10,14 104:1,7,18 105:4,13 105:16,22 172:16,17 172:19 173:14,18,19 174:2 175:20 176:7,8 176:12,17,21 177:8 177:16,17,20,20 178:11 179:2,4,10,15 180:12,16 181:5,13 182:2,13,14 183:1,10 184:1,4,4,14,14 185:4 185:4,13,22 189:19 190:19,19,20 191:6 191:10,14,17 193:9 193:12,17 196:19 197:4 198:1 200:4,8 200:10,13 201:15 203:8,11 edetates 196:1,4 edetic 105:15,21 171:19 172:4 176:7 176:16,20 177:7,16 189:19 191:6 203:12 edited 50:21 51:2 edition 51:6,9,19,22 179:22 186:19 187:9 187:15 188:1 189:10 191:3,8 209:13,19 210:1,5,13 EDTA 29:15,19,19 32:2,3,9,15 45:20 48:1,1,3,5,13,13,20 53:15,15,17 54:1,2,4 54:7,10,14 61:19,22</p>	<p>64:18 67:15,19 69:6 89:12,13 102:15 103:2 105:5 171:19 172:4,8,16,18,22 173:2,10,14,21 174:2 174:12,16 175:5,21 176:7,12,13 177:16 178:11 179:1,3,9,15 182:16,17,20,21 190:3,4,12,13 191:5,5 191:10,11 192:16,20 192:21 193:9,11,16 193:19 194:8,10,11 194:22 195:22 196:2 196:3,3,10,15,19,20 197:2,4,8,12,15,19 198:1 199:1,7,13 200:11 201:19 202:4 202:6 203:15,16 206:15 207:11,14,14 208:20,22 209:5 education 138:11 144:6 146:2 effect 6:5 9:12 79:18 80:3 117:3 124:21 127:11 158:22 219:1 220:17 226:16 256:20 272:3 307:14 effective 72:8 216:12 238:18 268:22 278:6 effectively 119:20 162:3 effectiveness 37:19 38:3,10,17 253:5,6,8 effects 6:11 80:4 171:11 207:4,7,22 208:5 280:8 294:4 304:21,22 307:22 efficacy 46:18 131:15 131:20,22 132:4,19 133:6 242:4 244:2,7 244:18 245:1,6,21 246:14 247:1,6 248:9 248:17 249:2,9 250:3 253:4,8,22 269:12 efficient 284:8 Eighth 2:3 3:17 15:20 either 66:18 68:15,20 131:8 146:16 177:13 electrical 6:8 207:5 208:2 Electrically 14:4 electrolyte 257:3,4 electrolytes 76:19 256:14 Elworthy 255:15 EMA 54:19</p>	<p>emphasized 280:10 encompass 211:11,17 216:21 encountered 138:13 139:15,21 140:5,8,17 142:11 214:4 271:5 271:10 275:10,16 encyclopedia 8:12 198:18 engineer 146:4 engineering 95:13,16 95:21 96:1,8 258:7 enhanced 281:19 enhancement 256:1 enhancing 6:11 207:7 208:4 enormous 268:14 ensure 43:9,12,15,17 43:18,19,20 44:11 50:4 111:17 112:6 116:22 133:14,21 187:18 entails 40:12 enteral 212:3 entirety 92:11,22 93:8 93:14,18,22 94:14 126:10 entitled 58:7 62:22 65:20 196:14 197:2 197:19 207:3,22 214:14 227:3 265:20 268:18 271:3 272:13 293:4 entries 184:5,15 185:5 198:11 entropy 313:7 entry 55:1 180:12,16 181:5 182:2,13 183:2 183:4,15 185:12,14 185:18 192:16,20 193:20 194:20 196:14 197:2,14,19 199:1,7 200:8 201:15,19 202:6 203:8 environmental 214:4 environments 272:21 309:7,12,19 310:8,17 EP 108:22 242:15 243:7 244:2,7,18 245:1,6,21 246:14 247:6 249:10 250:3 250:11 equals 281:17 equation 219:3 220:14 equilibrium 171:13 288:19 291:18 313:5 error 198:13 202:10</p>	<p>243:16 errors 198:15 200:22 202:13 242:19 243:1 243:7,12 especially 125:12,18 126:4 ESQ 3:7,8,19 4:7 essential 272:17 essentially 96:21 97:6 219:4 235:17 247:13 247:16 establish 138:15 established 278:13 ester 128:19 129:13 203:12 297:6 esters 127:9 263:10,19 296:15,16 estimate 77:16 167:21 estimates 219:6,15 et 6:12 10:7 15:13,14 75:15 162:11 207:3 208:6 212:4 ether 281:16 ethylenediaminetetr... 6:7 194:21 207:5,10 208:2,21 209:5 ethylenediaminetetr... 29:16 171:20 172:5 European 11:7 38:20 39:6 51:6 109:1,11 111:6 242:14 243:8 244:3,7,18 245:2,6,21 246:15 247:7 249:10 250:4 253:10,13 Evaluation 13:13 evidence 134:21 135:8 147:5 153:2,6 186:12 213:2 249:3 exact 167:20 287:18 312:14 exactly 178:12 EXAMINATION 5:2 17:3 examined 234:10 examiner 145:18 example 24:4,11 30:13 31:9 43:8 62:8 76:6 78:13 79:12 86:16 102:11,13 106:18 108:3 113:4,5,21 114:20 115:8,15,20 116:2,3 117:10,11 118:1,1 128:14 131:10,11,14,17,21 133:19 140:16,22 156:8 209:18 225:20 227:11,13,20 228:8</p>	<p>228:18 229:4,13,17 230:7,19 231:2,3 245:12,13 246:4,6,6,7 250:22 251:8 256:13 270:7 277:2 283:19 286:4 314:10 examples 83:17 110:21 117:8 119:16 120:10 121:4,20 122:10,15 123:3,5,15 139:18 140:7,18 141:1,14 225:5 227:3 excellent 136:10 exception 266:10 excerpts 180:6 189:10 exciptien 52:15 54:4 85:16 202:11 exciptiens 29:10 50:3 52:8,13,14 53:18 72:16 76:11,12,18 86:11 186:20 187:3,5 187:10,12,18 188:2 188:11,18 189:4,11 191:4,9 201:22 272:1 277:18 284:9 excliting 150:19 exclude 191:11 excuse 48:21 exert 158:22 exhibit 5:10,14 6:5,16 6:17 7:4,12,18 8:4,10 8:15 9:4,12 10:4,11 11:4,13 12:4,9 13:4 13:13 14:4,10,18 18:9 18:10,14,16 97:10 106:21 110:12 180:4 180:6 189:8,9 192:6,7 195:15 203:1 204:9 205:17,18 206:1,3,7,9 206:15,19 207:2,13 207:20,21 208:9,11 208:13,19 212:5,7 232:10,11,14 237:16 237:17,21 240:2,3,8 240:10,14 241:7,20 243:18 252:5,6 255:9 257:9,10,14,17,19 258:2 259:12,16,19 259:21 260:3,6 262:11,12,17,20,22 263:4 264:10,15 265:8,10,12,17 267:6 267:7,11,19 272:12 279:11,12,18,22 280:2,18,19 281:2,5,7 282:2,13 283:1,2,7,10 283:12 284:20,21</p>
---	---	--	---	--

<p>285:4,10,12 286:17 286:18 287:19,22 288:1,6 291:15 292:10,11,16,19,21 295:4,5,10,13,15 297:11,14,15,20 298:1,3,18,19 299:1,4 299:6,10 300:19 304:3,4,9,12,14 305:13,14,19,22 306:2 307:11 308:12 308:13,17,20,22 311:12,13 312:5,8,10 exhibits 5:12 18:12,17 202:16,17 exist 75:2 157:7 266:11 existing 73:15 Exosurf 28:13,16 30:13 expect 80:1 123:12 125:17 126:3 158:9 302:2 303:7,11 307:4 expected 302:3,5 expense 277:4 expensive 268:5 experience 19:9 40:3 94:17 121:18 143:12 144:21,22 145:4 146:1 165:5 experienced 158:7 experiment 87:11,19 88:15 experimental 113:4,4 113:21 114:20 115:8 115:15 116:2,3 117:8 117:10,10,13,22 118:1 119:16 120:10 121:4,20 122:10,15 123:3,15 131:10,11 131:14,17,21 227:3 227:10,20 228:8,17 229:4,12,17 230:7,19 231:2 245:12,13 246:6,7 261:15 expert 19:12 20:3,10,14 20:17,21 21:1,3,7,21 22:7 23:10,19 24:4,9 24:12,15,21 25:2,3,8 25:11,20,22 26:6,9,13 26:16,20 27:1,7 36:17 37:10,16,18 38:1,6,8 38:20 39:4,6,10,19 40:6,11,14 44:13,22 45:9,11 53:6 62:15 70:2,4,7,11,14,16,22 71:2,13,16,20 73:4,7 94:18 95:1 154:22 expertise 21:12,14,17</p>	<p>21:19 22:3,10,11,15 24:10 26:3 40:2,3,19 45:2 144:19 experts 143:9,18 278:20 explain 48:6 57:1 89:19 93:13 99:8 138:2 148:2 256:11 312:20 explained 63:17 78:12 explains 220:1 explanation 175:22 explicit 116:21 178:8 191:20 198:9 explicitly 144:8 223:22 exposure 273:18 274:15 extend 160:19 extensively 61:17 exterior 266:13 external 120:18 extra 295:22 extraneous 256:15,16 extremely 258:4 extrinsic 153:2,5 186:12 213:1 eye 27:19 30:1,2 49:3 113:15 118:18 119:3 119:9 120:2,4 122:18 122:19,22 123:19 132:5,19 133:6 140:20,21 141:13 150:18 228:18 230:12 270:8 eyedrop 132:15 eyes 124:18 200:4 226:15 e-mail 317:11,15 E-X-O-S-U-R-F 28:15 e.g 129:7</p> <p style="text-align: center;">F</p> <p>facetious 133:1 fact 168:1 178:9 309:6 factors 138:11 213:16 213:20 214:9 fail 153:15 failure 269:14 fair 50:5 66:21 79:1 83:19 176:5 177:14 200:16 281:22 282:6 282:11 284:1,10 289:2 291:17 292:2 293:14 294:11 296:7 296:22 302:19 303:12 317:22 fairly 109:2,4,7 151:8 166:8 254:17 260:22</p>	<p>fall 268:6 falls 40:2 112:15 familiar 156:17,18,18 169:5,6,7 171:13 222:5 far 97:19 98:13 100:7 102:4 117:17 157:2 223:1 289:16 315:8 FARABOW 3:2 faster 218:20 fate 269:7 278:3 fatty 127:9 129:13 296:16 Fax 3:10,21 4:9 FDA 54:16 features 293:7 feel 232:6 236:17 felt 108:3 field 23:10 25:11 27:1,7 41:4 44:22 70:21 83:20 94:18 95:2 138:12 142:12,13 fields 278:20 fifth 194:4 273:16 figures 167:20 169:7 filed 69:1,5,9 filled 118:21 119:5 find 20:12 22:2 60:15 116:12,17 121:18 165:16,20 241:14 301:18 findings 78:18 fine 312:21 316:12 318:5 finger 193:6 finished 165:17 195:10 Finnegan 3:2 16:9,12 firm 16:2 first 17:1,12,19 68:17 71:17 73:13 82:5,6 89:2 114:14 118:15 126:14 135:9,13 136:3 138:7 147:4 152:22 153:12 155:14 158:8 172:14 177:10 178:19 187:1 189:18 189:18 195:21 206:10 208:15 212:18,22 213:15 216:10 217:9 218:18 223:17 226:12 227:2 228:16 230:6 230:16 231:18 235:3 240:17 242:10 250:9 252:22 260:7,7 265:22 268:13 271:3 272:15 277:1,11,15 280:6 281:11,11</p>	<p>283:16 285:18 293:4 293:5 298:7 299:15 300:7 302:14 304:19 304:19 306:21 311:20 313:22 five 23:7 32:17 119:3 255:4 316:10 318:18 fixed 57:4 Floor 2:4 4:5 focus 58:17,20 59:1,13 92:12 93:1,9,19 94:9 97:3 274:19 276:7 focused 59:2,7 95:21 focuses 94:12 folder 265:4 follow 109:13 114:3 242:14 followed 199:14 following 171:21 209:21 follows 17:2 242:13 290:22 Food 145:8 foods 189:20 footnote 96:17 206:16 force 219:2 291:6,7,8 forces 313:7 form 88:7 102:16 103:3 103:11 104:2,19 105:5 167:8,12 168:19 169:8 172:15 173:17,19 176:12 180:22 181:7,12 182:1 189:21 190:6 214:2 233:12 260:12 260:21 266:2,19 271:6 286:13 287:11 287:13 288:19 289:16 293:8 Formation 11:13 formed 7:6 289:3,5,21 290:2 forms 179:16 184:12 266:18 298:10 formula 99:21 191:15 281:16 Formulary 51:13,16 formulate 31:21 48:6,9 86:22 101:4 160:11 161:5,10 162:5 163:17 164:20 187:17 272:17 277:7 285:20 formulated 47:13,15 47:16,18,22 48:4,12 48:22 49:2,5 50:1 57:9,22 formulating 57:15 59:3</p>	<p>59:8 62:3,7,13 65:3,8 67:22 68:4 69:10 144:20 158:7 159:6 159:11,13 163:1 188:13,19 189:5 273:5 formulation 14:4 23:11 23:12 30:19 31:20 40:4 41:6,14 42:18,19 42:22 43:3,12,15,18 44:12 46:13 48:8,18 49:9,12,14,19 50:18 50:22 54:15 59:22 60:5,6 61:5,13,19 62:16 64:12,19 65:17 67:11,16 68:8 69:3,7 71:5,14,15,16 72:8,9 72:11,14,17,20 73:6 73:11,14,16 76:16 85:16 86:8,15,17 87:3 87:8 88:6 95:9 96:13 98:22,22 99:9 100:8 109:19 110:1 111:13 112:4 113:22 114:21 115:9,16 116:2,4 118:12,13 122:18,20 132:14 133:10,11 139:12 140:10,12,13 140:16,20 141:4,8 142:11 145:5 150:18 162:10 163:12 164:3 165:2,11 187:16,19 211:15,20 218:13 223:19 226:14 229:13 229:18 230:9 239:6 268:2 269:21 271:3,6 271:7,8,11 272:2,3,7 272:14 275:10,17 277:17 284:8,9 formulations 26:16,17 30:15,17 31:2,3,4,17 31:19 42:10,11 48:2 48:19 53:19 54:5,6 59:1 60:8,10 61:2 62:9 89:16 90:1 108:4 110:22 111:3 112:15,17 121:11 139:2 140:8 150:8,17 150:22 151:6 155:16 155:22 165:22 187:4 187:13 189:20 218:6 221:13 223:13 224:3 224:22 227:11 230:8 258:13,22 259:6,7 263:9,18 264:3,4 291:19 292:4 299:18 311:7</p>
--	--	---	---	---

<p>formulator 49:1 formulators 188:21 forth 212:16 231:15 249:21 250:1 254:9 315:10 forward 261:14,19 found 117:2 175:20 foundation 43:6 49:16 77:2 82:4 83:3 85:5 85:14 87:5 109:21 122:1 123:17 132:8 134:19 135:5 142:7 145:15,22 157:14 158:20 160:14 162:22 169:15 219:22 220:10 234:5,20 236:6 239:4 264:1 271:13 275:20 301:8 founded 57:6 four 60:21 69:18 113:14 114:16 118:18 119:7 172:17 173:6 185:10 205:6 227:11 230:10 254:20 fourth 194:15 217:6 free 33:5 157:2,5 161:16 173:16 190:7 free-radical-mediated 216:14 frequency 270:14 271:21 frequent 217:19 frequently 32:6,7 34:10 34:11 218:4 Friday 2:5 15:22 80:17 81:1 136:12,18 204:21 205:5 254:19 255:3 318:17 front 146:19 169:7 232:19 238:5 fulfills 108:22 full 63:20 111:7 112:5 152:22 177:12 178:3 195:21 216:9 217:6 218:18 260:7 263:7 288:17 293:4 300:7 304:19 313:3 full-time 56:21 57:1,2 function 162:8 166:7 173:21 174:2 306:10 308:7 funded 56:1 68:18 fungal 211:8 fungi 251:14,17 further 82:16 179:5 235:14 316:4 318:11</p>	<p style="text-align: center;">G</p> <p>G 15:1 Games 287:5 GARRETT 3:2 gene 40:11 42:17 58:21 95:5,8,11 96:12 general 102:7 137:20 144:21 220:18 234:22 281:16 282:6 294:11 296:22 303:12 314:17 generally 48:17 71:6 139:4 145:8 155:15 162:8 172:16 225:14 226:1,5 258:21 313:19 gentlemen 315:18 geometry 298:9 getting 24:2 140:19 163:2 244:14 275:22 give 22:3 33:20 77:13 83:16 99:2 101:3 139:17 177:12 178:2 225:4,19 317:15 given 24:22 269:12 272:10 319:3 gives 163:14,17 210:18 giving 124:18 226:15 glad 264:13 Glaxo 55:7 glycol 127:9 129:13,13 281:16 go 15:10 43:21 56:1 59:19 60:14 64:14 83:16 90:10 109:11 110:20 111:5 112:14 151:10 155:2 159:6 159:13 161:19 187:18 187:20 193:19 204:8 204:12,14,16 212:10 221:18 223:8 242:1 243:17 249:15 254:15 274:18 315:5,8 316:6 316:12 317:3 goal 68:4 116:22 GODWIN 3:14 goes 124:2 183:19 220:15 225:4 275:8 going 15:3 21:10 22:9 22:19 42:22 44:16 82:8,17,17 97:10 125:4 132:9 133:10 141:12,18 148:2 158:22 164:20 199:14 201:2 204:8,18 209:3 218:13 225:19 243:18 244:14 270:10,15,16</p>	<p>272:2,8 300:7 316:22 good 15:2 17:5,6 26:3 37:13 39:15 45:3 63:9,21 77:16 80:14 83:9 136:9 156:7 204:10 205:4,10,11 210:19 239:9 267:18 Goodwin 2:3 15:19 16:15 Gosh 56:14 grab 173:4 gradual 297:8 gram 105:11 180:20 grams 227:14,15,16,16 229:15,19,20,21,22 230:1 grant 59:21 60:2 61:3 61:11,14,15,18 62:2,6 grants 58:7,9 60:22 61:8,21 62:12 GRAS 187:21 great 261:14,19 268:5 greater 36:14 113:16 113:18 114:13 228:20 228:21 301:20 307:5 greatly 302:16,20 303:14 ground-breaking 149:22 group 32:11 55:7 76:6 78:14 79:17,18,19 83:9 166:19,21 255:20 290:14 291:6 294:1,2 300:16 301:17,17,18 302:16 303:6,7,10 groups 81:17,18 173:12 291:8 294:8 GSK 57:19 60:12 guess 108:2 118:3 204:14 248:7 261:17 guidance 101:7 guidelines 215:12 guy 287:6</p> <p style="text-align: center;">H</p> <p>H 4:7 5:6 6:1 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 187:5 halfway 185:14 285:18 295:21 306:7,16 hand 228:7,14 handbook 52:8,10,12 52:14 186:20 187:4 187:10,21 188:1,10 188:17 189:3,11 191:3,8 198:19</p>	<p>200:13 201:22 202:12 handing 18:7 205:15 207:18 232:8 237:14 239:22 257:7 259:9 262:9 264:8 265:6 267:4 279:9 280:16 282:21 284:18 287:20 292:8 295:2 297:12 298:16 304:1 305:11 308:10 311:10 handling 214:5 hand-in-hand 59:19 happens 265:5 happy 116:13 hard 22:2 25:7 143:11 148:21 170:13 225:21 harder 261:3 296:2 Harmonization 215:12 Hasford 3:7 5:4 16:9,9 17:4 18:7 19:14,19 80:13 81:5 136:7,22 204:8,16 205:9,15 207:18 232:8 237:14 239:17,22 254:15 255:7 257:7 259:9 262:9 264:8,14 265:6 267:4 279:9,20 280:16 282:21 284:18 287:20 291:3 292:8 295:2 297:12 298:16 304:1 305:11 308:10 311:10 316:4 317:2,9 317:20 318:2,6,9,12 head 76:5 78:14 79:18 79:19 81:17,18 83:9 166:19,21 173:12 290:14 291:5,8 294:1 294:2,7 300:16 301:16,17,18 302:16 303:6,7,10 headache 277:3 headed 22:18 heading 197:8 255:12 heat 120:19 heavy 190:1 held 2:2 26:5,8,19 27:6 39:5,18 44:21 help 138:15 HENDERSON 3:2 heterocyclic 255:20 hexagonal 266:4 high 47:6 144:18 219:4 219:19 higher 154:18 218:20 220:7,22 307:5,7 highlighted 25:3 301:11</p>	<p>highly 54:7 63:7 258:10 258:13,20,22 311:22 312:18 high-temperature 218:21 hired 56:7,10 histories 152:2,10 178:20 179:14 186:13 204:5 252:3 314:3 history 135:1 137:8 147:6 152:7 153:3,7 153:15 179:8 hit-to-lead 274:19 Hobby 25:5 hold 20:9 22:6 23:18 37:15 38:1 239:13 HOLDINGS 1:4 honest 63:7 162:16 239:7 262:4 306:20 315:12 hope 4:5 305:5,9 Hospital 188:5 hours 316:2 huge 27:3 44:19 49:21 83:10 296:21 297:8 310:3 humidity 120:18 235:20 hundred 121:14 122:17 123:1,4 311:3 hurdles 268:6 hydrate 124:17 129:11 hydrocarbon 83:13 hydrophilic 255:19 hydrophilic 33:1,8 77:6 166:19 233:9,11 286:6 287:11 296:1,3 296:19 hydrophobe 300:16 Hydrophobes 9:17 hydrophobic 76:4 77:5 79:14,17 166:19 266:12 288:20 289:17 290:12,13 291:5,5,7 294:6 296:3 300:13 hydroxide 103:16,17 103:18 hypothetical 88:13 Hypothetically 88:20</p> <p style="text-align: center;">I</p> <p>ICH 120:15 215:11 235:5 ideally 100:5 144:22 145:5 ideas 142:12 identical 87:12,21</p>
---	--	--	---	--

<p>88:16 227:11 Identification 18:15 206:2 208:10 232:15 237:22 240:9 257:15 259:17 262:18 265:11 267:12 279:19 281:3 283:8 285:5 288:7 292:17 295:11 297:21 299:2 304:10 305:20 308:18 312:6 identifications 201:6 identified 127:6 240:5 253:15 268:20 278:3 279:5 identifies 199:10 202:6 identify 16:7 185:21 187:3,12 191:4 199:12 ignore 219:4 III 134:9 146:20 impact 284:2,11 implications 230:22 importance 211:19 280:10 important 43:2 134:14 135:3 140:11,13 144:17 159:3,4 188:18 189:4 273:5 impossible 42:2 86:19 impressed 264:11 improve 83:7 150:17 163:12 276:10 277:17 improved 84:6 233:6 233:18 improvements 73:15 73:17 impurities 43:10 inactive 214:1 include 65:12 103:17 111:4 112:20 193:11 193:17 199:7 217:10 218:1 included 142:18 167:2 272:4 includes 25:3 64:6 100:7 193:9 212:3 including 23:13,15 175:19 196:2 213:21 247:14 250:17 264:3 266:3 272:19 incomplete 111:9 incomprehensible 222:12 incorporated 1:4 124:20 incorrect 220:13 incorrectly 207:15</p>	<p>increase 251:14 281:18 286:5 295:22 308:6 increased 274:22 increases 306:9 increasing 255:17 276:9 283:20 increasingly 258:8 261:17 incredibly 24:2 indefinite 89:17 90:1,2 153:13 221:3 222:1,4 248:10,18 indefiniteness 234:3,18 239:2 independently 275:3 Index 51:22 180:1,7,11 180:13,17 181:6 183:2 184:5,15 185:5 185:21 186:2,8,11,14 199:21 200:7,8,10 201:14 indicate 117:17 248:10 indicates 113:10 130:16 230:11 indication 101:19 117:5 175:22 industrial 55:19 95:22 96:2 Industries 188:7 industry 55:19 56:1,2 143:13 infants 28:18 inflammation 156:6 inflammatory 27:18 49:3 155:21 influence 225:18 272:14 influences 298:10 inform 153:16 155:8 246:21 247:4 information 33:20 67:13 79:18 99:22 100:1,9 101:3 119:22 121:19 126:22 127:22 127:22 128:4 146:18 160:4 219:5 228:7,14 235:8 236:1 256:10 256:12,15,16,18 257:5 270:4,6,7,13,20 273:4 314:9,12 315:2 317:3 informs 153:22 155:5 249:8 infringement 70:7 71:18 ingredient 49:12 53:21 72:13 213:22</p>	<p>ingredients 49:6 50:19 51:1 99:1 100:4 102:12 139:13 151:7 162:6 213:22 214:1 Inhalation 55:6 inhibit 127:10 inhibited 216:11 initial 112:18 121:10 initio 317:13 inject 86:17 injection 277:5 Innopharma 1:11,11 1:12,12 4:4 16:18 19:18 237:10 238:6,9 318:9 Innopharma's 238:16 238:22 239:10 315:21 innovations 138:15 innovative 160:21 input 258:5 inserting 300:15 insoluble 157:5 158:10 instabilities 216:4 instance 159:22 instructions 102:5 insufficient 126:22 intact 162:9 integral 40:12,19 53:18 intended 41:7,15 58:22 117:1 160:5,7 211:20 277:3 inter 313:6 interact 173:4,6,8,12 interaction 159:3 169:20 213:22 interchangeably 208:20 interest 44:8 108:3 interested 50:9,14 112:16 162:7 interesting 241:10 301:11 Interestingly 69:12 Interface 12:6 Interfacial 14:11 interfere 15:7 intermolecular 313:7 International 14:6 215:11,11 interplay 304:22 313:6 interpret 151:18,22 152:9 interpretation 45:19 46:4,17 interpreting 101:5 247:19 248:4 Intestinal 5:14</p>	<p>intramuscular 23:14 212:4 intravenous 23:13 212:4 264:3 intrinsic 134:21 135:8 147:4 249:3 introducing 141:11 introduction 288:16 299:13 302:14 invalid 153:14 234:2,17 239:2 invalidate 71:19 invalidated 72:2,3,5 invention 124:1,14 125:11 126:16 129:8 137:6 153:18 154:2 155:7,10 226:13 inventor 45:13,15 inventors 144:6 145:11 investigate 300:14 investigated 299:16 investigating 255:16 Investigations 7:4 involved 190:17 255:18 ion 173:6,11 190:7,17 ionic 166:22,22 306:9 310:4 ionized 173:17,19 ions 173:4 174:3,11,15 190:1,9 309:9 irrelevant 24:5 irresponsible 249:15 irritate 141:12 irritation 124:18 226:15 isolation 110:1 issue 68:16 73:1 312:16 issues 166:6 item 63:13,22 66:6 205:13,19 213:1 240:4,10 255:9 257:11,19 259:13,21 262:13,22 264:15 265:2,12 267:8,15 279:13 280:2,20 281:7 283:3,12 284:22 285:12 288:2 288:11 292:12,21 295:6,15 297:16 298:3,20 299:6 304:5 304:14 305:15 306:3 308:14,22 311:14 312:10 items 270:20 Ivax 46:10 70:20 i.e 23:13 263:11,19 309:9</p>	<p style="text-align: center;">J</p> <p>J 3:7 6:13 208:6 James 4:7 16:17 james.abe@alston.co... 4:10 Japanese 51:19 253:10 253:14 Jayne 1:16 2:1 5:3,10 15:11 16:22 17:9 18:11 80:19 81:3 136:14,20 205:2,7 254:21 255:5 262:19 265:16 267:18 279:21 283:9 285:9 288:8 292:18 295:12 297:22 299:3 304:11 305:21 308:19 312:7 318:20 Jeannette 2:6 16:1 jejunum 6:12 207:7 208:5 Jersey 1:1 15:17 job 56:18 jobs 56:9 joint 55:20 188:4 journal 5:16 9:17 11:7 12:12 13:8,16 14:7,15 45:6 66:7 67:9,14,21 207:3 312:1,17 journals 9:9,20 10:8,15 11:10,17 12:8,14 13:11,18 14:9,17,22 63:10 65:21 66:4 205:14,20 279:14 280:3,21 281:8 283:4 283:13 285:1,13 288:3,12 292:13,22 295:7,16 297:17 298:4,21 299:7 304:6 304:15 305:16 306:3 308:15 309:1 311:15 312:11 judgment 73:8 256:17 justified 277:5 Justin 3:7 16:9 justin.hasford@finn... 3:11</p> <p style="text-align: center;">K</p> <p>kept 63:21 117:1,2 Kibbe 187:5,5,6 kind 213:7 317:20 King's 21:20 57:3 89:9 know 17:18,22 24:7 32:12 34:8,14 40:10 59:18 68:19 70:10 78:19,20 80:13 96:18</p>
--	---	--	--	--

<p>100:3 103:15 105:10 106:2,3 108:17 109:4 118:4 120:5,6 121:18 122:5 124:5 125:6 126:11 127:3 128:12 133:18 134:11 142:22 146:20 148:11 150:3 151:2 154:14 157:9 165:14 174:7,21 182:9,12 184:10 204:9 206:12,21 211:2 212:13 213:6 213:16 225:9 228:8 231:12 238:12 239:5 240:15 241:14,15,16 253:1,18 265:2 286:14 287:13 289:16 306:19 314:4 316:12 317:21 knowing 25:8 knowledge 21:3 50:16 150:2 163:15 168:22 184:10 known 35:21 45:2 75:2 105:9 155:18 157:7 171:19 172:4 179:1,2 195:22 196:4,19 277:18</p> <hr/> <p style="text-align: center;">L</p> <p>laboratory 30:16,18,20 31:5 38:15 41:19 42:12 47:18 48:2,19 55:21,22 78:21 lack 77:2 83:2 85:4,13 121:22 132:7 142:6 145:14 157:13 158:19 160:13 163:10,11 169:14 219:21 220:9 234:4,19 236:5 239:3 263:22 271:12 274:9 275:20 301:7 lacks 43:5 49:15 82:3 87:4 109:20 123:16 134:19 135:5 145:21 162:21 lamellar 266:4,10 landscape 50:11 Langmuir 14:14 language 102:14,21 103:1,9,20,22 104:11 104:14,17 137:12,21 147:4 153:4,8 176:5 176:11 221:6,19 244:16,21 245:4,19 246:12 Lanigan 195:5,12,16</p>	<p>195:19 196:16 197:3 197:4,22,22 199:12 199:20 200:6 201:18 202:3,5 Lannigan 199:2,3 lap-based 262:7 large 39:15 41:4,12 53:19 62:12 83:10 140:11,15 151:5 161:9 larger 83:8 largest 35:19 law 2:2 45:11 Lawrence 1:16 2:1 5:3 5:7,11,15 6:2 7:2 8:2 9:2 10:2 11:2 12:2 13:2 14:2 15:11 16:22 17:5,9 18:9,10 18:11,14,16 80:20 81:3 136:15,20 205:2 205:8,17,18 206:1,3,6 206:7,9,15,19 207:2 207:13,19,21 208:9 208:11,12,19 232:10 232:11,14 237:15,17 237:21 240:2,3,8,10 240:14 241:7,20 254:22 255:5,9 257:9 257:10,14,16,17,19 258:1 259:11,12,16 259:18,19,21 260:3,6 262:11,12,17,19,20 262:22 263:4 264:10 264:14 265:2,8,10,12 265:16,17 267:5,7,11 267:19,19 272:12 279:11,12,18,21,22 280:2,18,19 281:2,4,5 281:7 283:1,2,7,9,10 283:12 284:20,21 285:4,9,10,12 286:17 286:18 287:22 288:1 288:6,8,9 291:15 292:10,11,16,18,19 292:21 295:4,5,10,12 295:13,15 297:14,15 297:20,22 298:1,3,18 298:19 299:1,3,4,6,10 300:19 304:3,4,9,11 304:14 305:13,14,19 305:21,22 306:2 308:12,13,17,19,20 308:22 311:12,13 312:5,7,8,10 318:20 Lawrence's 205:20 240:5 257:12 259:14 262:14 264:16 267:9</p>	<p>279:14 280:21 283:4 285:1 288:3 292:13 295:7 297:17 298:21 304:6 305:16 308:15 311:15 lead 49:1 268:19 269:13 leaps 261:14,19 learnings 95:10 least-squares 219:1 220:16 leave 55:2,5,10 lecture 89:18 led 37:1,4 left 184:3 316:10 left-hand 183:3,16 203:8 275:7 283:18 288:17 313:2 legal 16:4 94:1,3 154:4 154:11 221:5,19 228:1,12 234:5,20 236:13,15,20 239:4 252:16 284:14 length 214:5 300:13 lengthening 281:14,14 lengthy 268:5 let's 116:1 172:14 200:15 202:9 243:17 254:15 316:12 level 26:3 78:3,4 138:8 138:11,16 144:6,18 146:2 274:21 levels 157:4 Lewis 202:20 203:2,11 203:22 204:3,6 LICENSING 1:11,11 light 43:21 74:14 82:14 151:19 152:1,10 153:14 likewise 250:16 limit 105:4 115:21 161:2,4 169:10 176:6 177:15 186:2 limitations 275:21 285:20 limited 89:13 179:15 232:21 233:2 284:15 limits 250:19 line 123:21 124:2,2 133:17 160:19 185:14 194:4,15,16 196:20 197:11 204:18 lines 125:3 127:2 128:5 linker 300:15,20 301:1 301:5 302:7,15 303:8 lipid 66:19 lipids 66:18 67:7 167:2</p>	<p>lipophilicity 274:22 liposomes 225:20 293:11 liquid 23:15 39:11,19 40:6,14,22 41:3,9,18 44:2 50:18,22 62:3,7 65:3 67:22 69:10 75:19 80:4 86:2,22 87:12,20 88:16 98:17 99:6,10,15,19,20 100:11,20 101:11,16 102:2,9 107:8,16,22 108:15 109:18 110:16 111:12,21 112:10 114:12 116:10 118:4 124:15 125:10,17 126:3,15 127:10 128:7 129:8 131:15 131:22 132:3,18 133:4 159:6,14 160:11 161:5,20 162:19 164:6,11 167:9,13 168:4,8,10 168:20 169:12 171:14 175:9 188:13,19 189:5 211:11,15,17 218:10 280:11 284:3 284:12 289:3,5,22 290:2 list 19:8 29:10 63:4 66:3 68:12 90:7 99:1 99:3 140:7 187:21 198:10,20 311:21 listed 58:13,14 76:15 76:18 89:2 102:13 240:11 lists 192:21 literature 79:13 157:3 little 110:6 120:21 132:17 143:15 150:5 157:19 184:13 248:1 262:7 liver 269:19 270:10 LLC 1:11,12 LLP 2:3 3:3,14 4:3 log 159:21 160:3 Lomb 1:3,4 16:11,14 London 21:20 long 38:14 42:3 143:11 270:15 276:12 305:5 315:20 317:22 318:4 longer 235:2 241:9 look 19:4 22:16 24:19 54:18 56:15 58:5 60:21 62:18 63:13,22 64:21 65:19 66:6 67:18 68:9 69:15</p>	<p>73:22 78:20 80:11 81:7 88:21 90:3 96:15 97:14 101:6 103:6 106:4,20 108:7 110:11 116:1 118:15 123:20 125:2 126:9 127:1 128:5,21 130:11,12 131:3,9 133:22 137:2,4 138:7 141:17 142:19 146:8 146:22 147:4 150:17 152:20 153:11 155:11 158:8 159:11 160:8 166:9 168:5 171:16 172:11,14 175:14 178:16 179:20 185:12 185:13 186:16 189:8 189:14 190:21,22 191:22 192:12 195:3 195:19 196:6 197:9 197:10 198:22 200:15 201:7,21 202:9,18 206:20 207:16 208:15 209:8 212:11 213:4 214:11 216:8,9 217:6 218:15 223:7 225:6 226:9 227:1,9 228:15 229:11 230:5,15 231:8 236:2 240:14 245:12,16 246:7 248:18 249:19 250:8 252:5,18,21 253:17 254:4,5 260:5 263:6 265:19 271:2 272:11 273:6,16 276:21 277:14,21 280:6 281:11 283:16 287:4 288:15 291:13,14 292:1 293:3 294:17 295:19 298:7 299:12 300:6 301:9 302:13 304:18 306:7 308:8 309:4 313:1 317:6,10 317:13 looked 57:19 111:1 112:17 177:10 188:10 248:10 314:3 looking 31:20 41:15 42:9 59:17 61:8 62:13 66:13 68:3 75:13,13,22 82:13 116:18 117:7 139:5 148:9 156:22 159:20 163:15 169:17,18 182:9 187:16 246:5 276:8 284:7 286:19 303:3,20 314:17</p>
--	--	---	--	---

<p>looks 136:7 208:14 Los 4:6 lost 193:13 lot 54:6 56:2 66:20 79:12,17 88:2 157:3,8 166:11 202:13 215:13 215:14 235:2,8 270:4 lots 20:14 54:5 56:9 184:19 218:5 low 86:18 167:14 169:22 219:3,6,15,20 298:11 299:21 300:2 302:17 lower 115:21 220:8,22 307:6 LTPB 306:17 lunch 204:10 205:3 Lupin 1:8,8 3:15 15:14 16:16 19:17 232:3,20 233:2 316:21 Lupin's 233:4,17 234:1 234:16 236:2,9 237:1 239:10 315:20 LUPIN010505 189:15 LUPIN010506 190:22 LUPIN018800 252:19 LUPIN018905 180:11 LUPIN018913 195:20 LUPIN018914 196:7 LUPIN018965 213:6</p> <hr/> <p style="text-align: center;">M</p> <p>m 1:16 2:1 5:3,10 16:22 262:19 265:16 279:21 281:17 283:9 285:9 288:8 292:18 295:12 297:22 299:3 304:11 305:21 308:19 312:7 main 22:14,14 70:16 71:2,13 76:20 156:19 166:21 202:17 235:3 235:4 257:5 269:13 maintained 235:17 major 301:5 majority 66:17 making 83:10 301:12 301:19 man 271:8 managed 84:9 manufacture 268:3 manufacturers 122:12 manufacturing 214:2,6 Margaret 17:9 Margolis 3:19 16:15,15 19:13 20:4,11,19 21:8 21:22 22:8 26:1,10,14 26:21 27:2,8 30:6</p>	<p>31:6 33:3,12,18 34:18 35:12 36:5,10 37:12 37:20 38:4,22 39:9,13 39:21 40:16 41:10 43:5 44:3,14 45:1,22 46:8,20 49:15 50:7 52:5,20 53:16 54:3,11 57:11,17 58:18 59:5 59:10 61:6 62:4 64:4 64:13,20 65:5 67:3,17 68:2 71:1,8,12 72:6 73:2 75:20 77:1,11,22 78:9 79:6 80:6 82:3 83:2,21 84:3,13 85:4 85:13 86:4 87:4,15 88:1,19 92:14 93:3,12 93:21 94:11 95:3,14 96:10 97:18 98:2,12 98:19 99:17 100:13 100:22 102:17 103:12 104:3 105:6 106:16 107:10,18 109:3,20 110:18 111:14 112:1 112:12 115:1,12,18 118:8 120:12 121:6 121:22 123:6,16 125:20 126:6 127:13 129:20 132:7,21 133:7 134:16,19 135:4,11,19 138:1 139:16 140:6 142:6 144:11,16 145:14,21 146:6,13 147:19 148:20 149:7,18 150:14 151:1 154:3 154:10,20 156:12 157:13 158:4,19 159:8,15 160:13 161:7,22 162:21 164:1,8,13,18 165:4 166:1,4 167:11,17 168:21 169:14 170:8 171:6 174:13,18 175:6,10 176:9 177:18 178:1 179:17 181:9 182:4 184:17 188:20 189:7 191:12 197:6 198:3 200:19 204:13 209:1 210:17 211:13 215:9,22 217:3 218:11 219:21 220:9 221:4,15 222:2 222:21 223:15 224:11 227:22 228:5,11 234:4,19 235:12 236:5,12 237:4 239:3 239:13,19 243:9</p>	<p>244:9 245:9 246:2,5 246:17 247:8 248:12 248:20 249:4,12 250:5 252:1,15 256:7 258:17 259:3 260:18 261:11 263:22 265:5 268:8 269:2,18 270:1 271:12,18 273:1,22 274:5 275:18,20 276:6,18 278:8,15 282:3,7,14 284:4,13 286:1,9 289:8,12 290:5 291:20 292:5 293:18 294:15,20 296:11 297:4 300:4 301:7 302:9 303:1,17 305:2 306:13 307:16 308:2 309:15,22 310:12,21 313:10,16 316:6,11,21 317:5,19 317:22 318:4,8 mark 207:17 264:21 308:8 marked 18:8,14 205:16 206:1 207:19 208:9 232:9,14 237:15,21 240:1,8 257:8,14 259:10,16 262:10,17 264:9 265:7,10 267:5 267:11 279:10,18 280:17 281:2 282:22 283:7 284:19 285:4 287:21 288:6 292:9 292:16 295:3,10 297:13,20 298:17 299:1 304:2,9 305:12 305:19 308:11,17 311:11 312:5 market 48:16,21 49:4 163:6 marketed 48:22 57:22 marketing 163:3 marks 224:14 material 44:8 101:20 178:3,12 181:14,17 184:21 191:19 201:9 313:21 314:1 materially 284:2,11 materials 100:4,6 134:9 181:19 201:9 258:6 277:16 314:13 matrix 233:9,11 235:15 matter 7:16 15:12 34:22 McCormick 2:6 16:2 mean 20:21 31:18 33:5 33:6 34:6 36:22</p>	<p>40:10 44:16 48:6,14 48:16 71:9 74:11 78:2 84:1 90:16,22 91:6,12,19 92:1 93:14 97:20 98:14 122:5 123:9 147:18 148:12 150:4 156:3 165:8 166:16 173:2 180:8 181:12 184:21 189:12 192:10 195:17 203:3 211:22 212:8 222:14 232:17 238:3 247:20 252:8 289:10 meaning 90:6 92:7 94:3 102:19 103:14 114:1 114:22 115:10,17 116:5 130:5 137:4 147:13 153:4,7 176:1 179:5,11 210:7,15 222:7,18,20 223:5 meaningless 62:1 means 138:2,3 156:8 177:21 223:4 meant 75:4 179:19 241:15 measured 119:10 159:21 171:8 227:6 241:11 measurement 221:11 223:11 224:2,21 measures 253:5 measuring 38:9,16 216:5 Media 14:18 medic 27:12 medical 146:11 medication 25:17,19 27:15 medicine 27:1,3,5,7,14 268:4,22 272:17 274:11 277:18 278:6 medicines 8:15,16,17 258:8,9 268:18 275:11,17 medics 146:16,17 meet 315:13,20 membrane 6:9 171:10 207:6 208:3 276:2 membrane-active 304:21 memory 314:11 mention 64:22 120:17 211:4 mentioned 47:1 48:21 61:1 64:16 152:5 221:19 Merck 51:22 180:1,7</p>	<p>180:11,13,17 181:5 183:2 184:5,15 185:5 185:21 186:2,8,11,14 198:18 199:21 200:7 200:8,10 201:14,22 202:11 met 315:15 metabisulfite 217:11 Metabolism 11:8 metal 174:3,11,15 190:1,17 metal-edetate 190:16 method 97:22 98:4 106:15 methodology 241:16 methods 111:7,8 155:20 micellar 9:14 168:9,10 255:17 280:9,11 281:18 micelle 42:10 83:14 168:3 micelles 14:14 81:21 83:8,10 167:8,13,15 168:2,12 169:8,9,10 255:21 266:4 287:13 289:14,17 290:12 Micelle-forming 82:9 microbial 43:20 microbiological 224:6,16 microbiological 211:4 211:7,11,18 microemulsion 49:10 60:8 62:8 71:4 72:11 73:6,14 296:5 microemulsions 8:5 11:5 12:4 65:13 73:4 Microemulsion-Based 14:5,18 microphones 15:4,7 Middlesex 17:10 mil 122:17 123:1 milligrams 180:21 milliliter 123:4 minimal 303:11 minor 301:6 302:7 minute 129:2 minutes 316:7,10 mischaracterizes 123:7 181:10 248:13,21 249:5,13 260:19 261:12 273:2 Mischaracterizing 127:14 200:20 misinterpret 220:2 missing 63:6 mistake 198:8</p>
---	--	--	--	--

<p>mix 162:6 287:13 mixed 286:13 mixes 83:12 mixing 100:6 mixture 238:19 Mixtures 13:14 265:21 modeling 262:2 Modelling 7:18 10:4 Models 5:14 moiety 76:5 300:16 301:14 302:15 303:6 moisture 113:10 117:19,21 molecular 7:18 14:10 258:6 261:16 266:20 298:9 302:18 molecularly 44:8 molecule 159:4,19 268:1,22 274:10 278:5 molecules 47:15 66:19 67:8 77:15 166:18 167:3 266:1 268:12 268:14 283:21 284:2 284:11 288:18 296:17 297:7 moment 78:22 126:21 141:16 243:10 money 60:11,12 mono 281:16 monographs 52:7,9,12 187:22 Monolayers 7:5 monosodium 172:18 monostearate 129:14 month 235:18 months 55:2,5,9,16 240:22 morning 15:2 17:5,6 Moser 252:7,10,13,18 253:3,7,15,21 motivated 218:9 mouth 184:19 185:2 mouthful 124:12 mucosal 6:9 207:6 208:3 mug 287:8 multiple 49:6 50:19 51:1 243:12 muscle 156:8 MYLAN 1:12,13 M.J 206:6 257:16 259:18 281:4</p> <hr/> <p style="text-align: center;">N</p> <hr/> <p>N 3:1 5:1 15:1 300:13 name 16:3 17:7 29:11</p>	<p>124:7,9,12 156:5 191:19 278:22 279:2 named 45:13,15 names 177:13 178:3 Nanoparticulates 8:7 nasal 23:14 nasty 270:8 National 51:12,15 nature 168:8,10 280:11 287:2 296:1 298:10 313:5 natures 166:21 naught 311:3 NA2 200:5,12 202:1,1 necessarily 84:19 126:8 284:7 294:22 necessary 110:7 121:19 need 17:18 34:19 38:6 38:7 40:8 50:12,13 68:8 80:15 89:20 99:22 100:2,3 112:6 119:22 122:22 141:10 141:11 148:13 157:19 158:16 170:18 171:9 177:2 178:6,15 179:18 219:10 234:13 236:15 246:7 254:16 270:4,6,13,20 271:20 285:21 290:19 291:10 293:21 296:14 306:19 needed 101:20 110:10 161:12 needs 274:2 277:9,11 negating 270:17 negative 105:11 167:1 167:4 173:12 216:12 neutron 7:12,14 8:11 24:4,12,14 42:15 63:11 82:15 never 56:11 171:9 new 1:1,18,18 2:4,4 3:5 3:16,18,18 8:15 15:16 15:19,20,20 82:1,20 84:11,20 85:1,11 159:6,13 160:11 204:9 207:17 269:21 277:16 308:8 non 301:15 nonbiodegradable 300:12 Nonionic 7:7 13:8,14 nonsteroidal 80:5 non-equilibrium 292:3 non-ionic 9:5,13 11:14 12:10 31:12 59:21 60:4 61:8,9 64:3,6,8 66:8,20 67:1,5 68:21</p>	<p>71:4 72:9,12,19 73:12 74:8,17,21 75:1,10,18 76:21 77:8,9,18,20 78:6,7 79:2,4,15 80:1 81:10,12 82:1,20,22 83:9 84:11 85:1,11 86:11 155:20 166:11 166:13,17,22 167:1,2 170:6 171:4 255:19 263:9,17 280:9 281:22 282:12 289:6 290:3 293:5,15 294:2 294:12 296:8 297:1 300:20 301:5,15,19 302:7,12,20 303:13 306:11 307:2,4,10,10 307:14,22 310:5 non-oral 23:13 non-polar 308:7 non-steroidal 155:18 156:4,8 non-surfactants 296:17 normal 29:9 120:2 123:19 266:11 297:5 normally 67:12 120:3 123:12 215:16 235:1 Northwest 16:6 Nos 1:5,11 Notary 2:7 note 15:3 178:21 noted 319:4 notes 72:18,21 Notice 2:2 Novartis 46:10,10 47:1 47:4 70:19,19 novel 7:6 14:19 60:8,10 61:1 62:8 71:3 72:7 74:8,17,21 81:9,12 85:15 86:11 150:17 150:22 novelty 150:20 NSAID 155:19 156:4 158:1,2,13,15,22 163:2 165:8 NSAIDs 157:7,12,17 158:17 159:7,14,18 160:12 161:6,21 162:20 169:13 number 5:8 6:3 7:3 8:3 9:3 10:3 11:3 12:3 13:3 14:3 15:15 22:10 24:10 39:15 43:8 53:19 62:12 63:22 66:6,21 80:18 81:2 128:6 134:7 136:13,19 151:5 157:10 161:4,9</p>	<p>180:11,12 183:5 185:12 189:15 190:22 191:1,16 192:13,21 194:1 195:20 196:7 199:17,22 200:9,11 201:15,16,20 202:7 203:6 204:22 205:6 205:19 206:3 213:6 240:4,11 252:19 254:20 255:4,9 257:11,20 259:13,22 262:13 263:1 264:15 265:13 267:8,15 279:13 280:3,20 281:8 283:3,13 284:15,22 285:13 288:2,11 290:11 292:12,22 295:6,16 297:9,16 298:4 299:7 301:21 304:5,15 305:15 306:3 308:14 309:1 310:2 311:14 312:11 318:18 numbers 181:20,21 201:5 numerical 241:8 numerous 89:4 NW 3:5 N,N-Dimethyl-N 13:5 n-acyl 128:19 263:10 263:19 n-alkylpolyoxyethyle... 281:15 N-dimethyldodecyla... 300:14 N-oxide 300:12 301:15 njote 178:22</p> <hr/> <p style="text-align: center;">O</p> <hr/> <p>O 15:1 74:13 146:20 object 124:14 226:13 objection 19:13 20:4,11 20:19 21:8,22 22:8 26:1,10,14,21 27:2,8 30:6 31:6 33:3,12,18 34:18 35:12 36:5,10 37:12,20 38:4,22 39:9 39:13,21 40:16 41:10 43:5 44:3,14 45:1,22 46:8,20 49:15 50:7 52:5,20 53:16 54:3,11 57:11,17 58:18 59:5 59:10 61:6 62:4 64:4 64:13,20 65:5 67:3,17 68:2 71:1,8,12 72:6 73:2 75:20 77:1,11,22 78:9 79:6 80:6 82:3</p>	<p>83:2,21 84:3,13 85:4 85:13 86:4 87:4,15 88:1,19 92:14 93:3,12 93:21 94:11 95:3,14 96:10,10 97:18 98:2 98:12,19 99:17 100:13,22 102:17 103:12 104:3 105:6 106:16 107:10,18 109:3,20 110:18 111:14 112:1,12 115:1,12,18 118:8 120:12 121:6,22 123:6,16 125:20 126:6 127:13 129:20 132:7,21 133:7 134:16 135:4,11,19 138:1 139:16 140:6 142:6 144:11,16 145:14,21 146:6,13 147:19 148:20 149:7 149:18 150:14 151:1 154:3,10,20 156:12 157:13 158:4,19 159:8,15 160:13 161:7,22 162:21 164:1,8,13,18 165:4 166:1,4 167:11,17 168:21 169:14 170:8 171:6 174:13,18 175:6 176:9 177:18 178:1 179:17 181:9 182:4 184:17 188:20 189:7 191:12 197:6 198:3 200:19 209:1 210:17 211:13 215:9 215:22 217:3 218:11 219:21 220:9 221:4 221:15 222:2,21 223:15 224:11 227:22 228:5,11 234:4,19 235:12 236:5,12 237:4 239:3 243:9 244:9 245:9 246:2,17 247:8 248:12,20 249:4,12 250:5 252:1 252:15 256:7 258:17 259:3 260:18 261:11 263:22 268:8 269:2 269:18 270:1 271:12 273:1,22 274:5 275:18 276:6,18 278:8,15 282:3,7,14 284:4,13 286:1,9 289:8,12 290:5 291:20 292:5 293:18 294:15,20 296:11</p>
---	--	---	--	--

<p>297:4 300:4 301:7 302:9 303:1,17 305:2 306:13 307:16 308:2 309:15,22 310:12,21 313:10 objections 175:10 271:18 objects 19:17 obtain 122:9 135:16 obtained 113:10 obvious 166:8 235:21 obviously 21:19 39:1 59:18 97:12 109:11 109:12 120:1 123:1 134:21 148:8 155:1 161:14 163:3 198:17 202:10 234:9 247:11 252:4 272:4 275:3 314:2 occurs 218:20 offered 56:9,12,18 offhand 163:20 office 15:19 146:3 offices 2:3 oh 24:20 80:13 81:11 134:5,7 184:3 223:7 264:18 265:1 286:20 311:19 315:1 oil 13:15 75:14 165:14 272:20 273:19 oils 309:10 okay 18:2 20:18 21:5 23:9 35:10 42:8 48:10,14 56:14 57:4 58:11 60:3,8,18 62:8 69:1 70:18 74:7 90:11 92:21 93:11,18 94:9 95:20 96:19 103:8 108:13 110:14 114:17 115:4,13,21 117:16 122:13 124:6 124:11 126:13 127:4 128:10 129:1,2 130:12 131:9 134:7 134:13 138:5 140:1 142:19 143:15 152:4 159:10 162:17 165:21 168:11 174:22 175:14 175:17 177:5 180:10 183:15 193:15 195:3 195:15 197:19 206:14 207:16 209:7 210:21 212:14 213:10,18 219:12 221:2 225:11 227:1 231:11,13 234:15,15 237:9 238:15 239:19 255:14</p>	<p>264:22 265:2 267:21 274:19 276:21 282:20 306:18 312:3 315:9 315:20 317:9,19 318:4,8,12 Olympic 287:5 once 108:18 141:5,7 142:10 268:19 278:2 317:13 ones 58:11 63:6 66:18 76:14,20 141:15 162:13 188:3 216:6 235:8 249:16 ongoing 275:15 276:17 Oops 264:20 opened 141:8,8 open-ended 157:18 ophthalmic 23:14 26:17 28:19,20,21,22 29:5,7,12 57:9,15,20 58:1 87:1 100:16,17 100:21 108:1 109:19 110:4 111:13,18 112:7 139:10 150:9 150:12 151:9 155:16 212:4 258:13,19,21 269:21 271:11 ophthalmology 26:13 26:17,20 opinion 12:5 45:19 46:4,11,14,17 47:3 72:4,22 73:10 90:5 92:7 94:16 145:11,18 187:9 193:10,15 210:20 217:21 276:13 opinions 71:6,9,10,21 72:1 92:4 97:17 98:11 104:22 107:3 108:11 113:5 131:12 134:14 135:3,10,17 136:4 180:1 186:21 192:4,18 195:7,13 196:13 202:21 209:15 212:16,20 233:1 238:8 243:20 245:14 252:11 314:20,22 315:1,6,10 opposed 97:4 optimal 273:18 274:15 275:22 optimization 133:11 274:20 optimize 133:10 oral 23:12 165:11,22 277:8,10 orally 263:13 order 79:21 100:6</p>	<p>102:12 113:16 114:5 228:19 258:7 272:15 277:7 317:21 ordinary 36:19 79:22 84:10,18,22 85:9 86:21 87:10,18 88:5 88:14 94:21 97:21 98:16 99:5,14 100:10 100:19 101:6,10,15 102:1,8 106:14 107:7 107:15,21 108:14 109:10,17 110:15 111:11,20 112:3,9 120:8 121:2,17 122:8 122:14 123:14 125:16 126:2 133:3 137:5 138:3,9 141:21,22 142:4,5 143:4,8,17,22 144:5 145:2,6,12,20 146:5,12 147:13,18 151:17,21 152:8 154:17,19 159:5,12 160:10 161:18 162:17 176:11 187:11 188:9 188:16 189:2 209:20 210:6,14 218:8 220:5 220:20 243:4 246:21 247:4,17 248:2 organic 45:4 organisms 250:18 Organogels 14:6 orientation 266:14 orientations 266:12 original 114:14 155:2 Outputs 8:18 267:9,16 outside 289:19 overcome 83:15 275:9 275:15 Oxidation 216:10 oxide 81:18 167:6 256:3,5 301:17,18 oxidized 225:20 oxygen 301:2</p> <hr/> <p style="text-align: center;">P</p> <p>P 3:1,1,19 15:1 159:21 160:3 package 54:15 packages 160:2,4 packed 233:13 page 5:2,8 6:3 7:3 8:3 9:3 10:3 11:3 12:3 13:3 14:3 18:19,20 22:17,19,22 23:5,7,8 23:9 54:20 60:16,17 62:10,11 63:13 68:9 68:12 69:16 80:11</p>	<p>81:6 88:21 90:4 96:15 117:14 128:22 134:1,4,6 137:1 141:18,20 142:19 146:22 151:10 153:1 153:11 155:11 166:10 171:17 172:11 175:15 178:16 179:20 180:10 183:4 186:17 189:14 190:21 192:1,12 193:22,22 194:16 195:4,19 196:6,18,20 197:11 199:4 201:14 201:18 202:3,5,18 203:6 205:12 206:9 206:19 209:10 213:5 214:12 216:8 218:15 225:7 226:9 227:10 228:15 229:11 230:6 230:15 231:8,10 232:19 238:5,11,15 240:11,14,15 242:1 250:8 252:18 254:6 255:11 258:1 260:5 263:6 265:19 267:21 268:11 271:2 272:11 273:6 276:22 277:14 277:21 280:6 281:11 283:16,16 285:16 288:15 291:14 293:3 295:19 300:6,7 304:18 306:6 313:1 pages 6:14 58:5,8 62:18 63:3 65:19 66:2 196:15 197:3,20 208:7 211:1 212:12 panel 279:3 paper 241:11 302:13 305:4 311:22 312:14 312:20 papers 50:17 63:20 67:6,20 297:10 301:12,22 312:18 314:15 318:14 paragraph 22:16,21 23:3,8 69:17 73:22 81:7 88:22 90:4 92:6 113:8 123:22 124:1 128:22 129:6 134:1,2 134:9 137:2 138:7 139:20 141:18,19 142:20 147:1,1 151:11,12 152:7,13 152:20,22 153:11 155:12 166:9,12 171:17 172:8,14 175:15 178:17 179:21</p>	<p>183:9 186:18 189:18 192:2 193:5,7 195:4 196:18 199:6 202:19 206:11 208:16 209:12 209:17 210:22 213:15 216:10 217:7 218:18 225:7 226:10 227:1,9 228:16 229:12,16 230:5,6,16 231:8,14 231:20 242:3,10 250:9 254:6,8,12 255:12 258:3 260:7 263:8 268:1 277:2 285:18 300:8 304:19 313:12 paragraphs 212:11,15 231:9 parameters 6:8 207:5 208:3 290:11 parenteral 23:12 26:16 58:22 145:5,5 211:20 211:22 parenterally 263:12 part 40:12,19 53:18 54:15 59:11,14 65:18 116:22 130:14 149:13 160:21 189:16 279:4 293:19 306:21,21,22 306:22 partially 82:7 particle 49:10 particles 69:13 140:14 particular 20:22 21:4 21:11 22:4 24:3,5 35:22 42:8,9,16 46:13 53:21 54:2 70:13 83:18 84:6 94:3 98:9 99:21 148:8 159:1 176:12,13 182:10 191:15,15 209:12 211:19 218:17 221:8 221:11,11 223:3,11 223:11,18 224:1,1,20 224:20 241:8 261:4 263:11,19 266:18 267:22 269:11 274:9 278:11,20 particularly 63:18 130:12 139:11 149:22 150:19 165:7 168:14 173:4 261:3 264:5 270:8 particulate 140:11 particulates 141:3 parties 15:9 partition 165:14 partitioning 272:20</p>
--	---	---	---	--

<p>party 47:2 52:3,18 53:2 53:14 54:1</p> <p>patent 6:16,17 45:11,15 45:21 46:6,19 68:13 68:15,16,20 69:1,5,9 69:12 70:7 71:14,15 71:16,19,22 72:1,5 73:1,5,8,11 90:11,15 90:16,18,21,22 91:2,5 91:6,8,11,12,14,18,19 94:7,15 97:9,15,16 98:1,5,10,18 99:7,16 100:12,21 101:5,7,9 101:12,14,17,19,22 102:3,8,10,15 103:2,7 103:10,16 104:1 106:8,13,15,21 107:3 107:6,9,12,14,17,21 108:1,8,10,14,16 109:16,19 110:11,17 110:20 111:13,19,22 112:9,11,22 113:22 114:7,10,11,21,22 115:9,11,16,17 116:4 116:5,17,20 118:16 123:21 127:2 129:3 131:10 134:22 145:18 147:6,7 151:5,7 152:13 153:3,6 178:21 179:9 232:12 232:16,17,19,20 233:4,17 234:2,7,9,17 235:1,4,7,11 236:3,9 237:1,11,18 238:1 242:5 243:6,17,20 244:1,6,17,22 245:5,8 245:20 246:1,13,16 246:20,22 247:3,5,13 247:15 248:9,17 249:2,8,18,20 250:2 251:22 254:5,10 314:3,11</p> <p>patents 45:13 90:6 91:22 92:17,17 94:7 97:13 132:12 135:14 136:2 138:10 139:2,3 146:3 148:9 149:1,3 149:21 152:18 177:10 177:22 186:5 203:19 226:22 232:4,7 235:2 237:11 314:2,14</p> <p>patents-in-suit 90:7 91:22 92:3,8,12 93:1 93:9,16,19 94:19 95:2 95:5,8,12 96:7,12,21 97:6 104:12,15,18,22 105:3,14,20 109:9</p>	<p>116:8 117:11 118:2,6 119:15 124:13 125:9 125:16 126:2,15 127:5,7 131:16 132:1 136:5 138:21 139:9 139:15 140:5 142:4 143:5 144:7,10,15 145:7,12,19 146:5,12 147:14,18 148:6,19 149:6,17 150:10,22 151:19 152:1,9 155:14 175:19 176:6 176:18,22 177:9,15 178:4,9,13,20 179:14 186:7,10,14 203:21 204:2,6 226:19 232:5 237:12 247:14,18 248:3 252:14</p> <p>patent-in-suit 104:15</p> <p>patient 25:18 27:16,22 28:7,10 29:1,8,13,20 42:21 43:2,16 108:2 118:7 258:12,16 259:2 268:4</p> <p>patients 73:19</p> <p>PCS 241:13,15</p> <p>pedestrian 150:1 259:6</p> <p>peer-reviewed 239:12 241:17</p> <p>PEG 83:9,12</p> <p>people 150:8,11,11,16 215:16 222:9 241:14 315:17</p> <p>percent 113:9 114:13 121:15 167:22 168:2 229:5,7 230:9,18 231:3 235:20 311:3</p> <p>perfect 235:7</p> <p>perform 41:13 261:21</p> <p>performed 41:5,13 111:16 253:22 255:15</p> <p>period 143:14 219:1</p> <p>periods 240:21</p> <p>permanent 56:7,13</p> <p>permeability 6:10 207:7 208:4 275:16 276:1</p> <p>permissible 250:19</p> <p>permit 221:12 223:12 224:2,21</p> <p>person 21:3 79:22 84:10,22 85:9 86:10 86:21 87:2,10,18 88:14 94:16 95:1 97:21 98:16 99:5,14 100:10,19 101:6,10 101:15 102:1,8</p>	<p>106:14 107:7,15,21 108:14 109:17 110:15 111:11,20 112:9 120:8 121:2,17 122:7 122:14 123:14 125:16 126:2 133:3 137:4 141:20,21 142:3,5,9 143:4,7,16,21 144:4 144:18 145:6,20 146:2,4,11 147:3 151:17,21 152:8 154:17,18 159:5,12 160:10 161:18 162:17 187:2,11 188:9,16 189:2 209:20 210:6 210:14 218:8 220:5 220:19 243:4 246:21 247:4,17 248:2</p> <p>personally 32:11,15,18 41:21 154:12 155:4</p> <p>persons 145:12</p> <p>pertaining 89:4</p> <p>pgs 5:17 7:9,16,21 8:8 8:13,17 9:8,19 10:7 10:14 11:9,16 12:7,13 13:10 17 14:8,16,21</p> <p>pH 50:2 76:11,18 113:13 119:9 124:18 125:4,10,19 126:5 166:7 190:17 226:14 256:21,22 257:2 272:4,21 290:15 309:8,13,21 310:9,19</p> <p>Pharm 6:13 208:6</p> <p>Pharma 1:4 11:16 12:12 62:12</p> <p>pharmaceutical 1:3 7:13 8:12 13:9,16 15:12 21:16 22:13 23:12 24:16,22 27:5 36:21 37:5,8 49:12 52:8,10,13 53:6 55:11 56:4,8,13,17,22 57:7 57:10,16 58:3 59:22 60:5,6 61:4,12,19 64:12,18 67:11,15 68:4,8,18 69:3,6 72:13 73:5,11 89:16 89:22 94:17 143:13 144:19 186:20 187:3 187:4,10,13,19 188:1 188:7,8,11,18 189:4 189:11,20 191:4,9 198:19 200:13 201:22 210:2,7,15 213:12,20 214:20 215:3,8,20 216:13 217:1 222:15</p>	<p>223:6 233:6,18 235:13 253:4 263:9 263:17 277:15 279:3 299:18 311:6</p> <p>pharmaceutically 31:10 233:8 307:12</p> <p>pharmaceuticals 1:9 1:12 144:20 180:22 181:7 182:1</p> <p>pharmaceutics 14:7 89:8,10 258:4</p> <p>pharmacist 25:16 27:10 28:1,5 29:5,9 39:2 55:17</p> <p>pharmacodynamic 164:11 278:12</p> <p>pharmacodynamics 26:9 278:1</p> <p>pharmacokinetic 163:22 164:6 273:13 278:12</p> <p>pharmacokinetics 11:8 25:22 26:6 278:1</p> <p>Pharmacol 6:13 208:6</p> <p>pharmacologically 124:16 129:10 258:7</p> <p>pharmacology 9:18 12:12 25:20</p> <p>Pharmacopeia 37:18 38:2,11,18,21 39:6 51:6,9,12,19 109:1,11 111:6 242:12,15 243:5,8 244:3,8,14,19 245:2,7,22 246:15 247:7 249:10,16 250:4 253:9,10,11,13 253:14,14</p> <p>pharmacy 9:18 25:11 25:13,15 96:2 209:14</p> <p>phase 65:9,18 151:6 169:11 266:10,10 288:20</p> <p>phases 9:8 171:14 266:5 313:5</p> <p>phenylacetate 113:15 118:19 119:4 227:5</p> <p>phenylacetic 119:9 124:8 129:9 155:17</p> <p>phenylbutazone 168:15</p> <p>phosphatidylcholines 293:8</p> <p>phospholipid 293:10 294:1</p> <p>phrase 46:5,18 65:9 74:3,7 102:15 103:2 103:10 104:1,18</p>	<p>139:6 212:17,21 222:5 231:17 242:3</p> <p>phrases 45:20 89:12 105:4 176:7,16,20 177:7,15 179:14 191:9</p> <p>physic 75:4</p> <p>physical 9:7 45:3 49:13 75:9,17 76:22 77:7,8 77:18,19 78:5,6 79:1 79:3 81:22 82:19,21 85:10 87:2 116:8 117:4,11,18 156:10 156:14,16 157:11,22 158:1,13,14,18 159:21 161:19 162:10 162:18 169:1,4 170:4 170:5,15 171:2,3 216:19 224:5,15 225:12,18 226:5,7 296:9 297:2 310:16</p> <p>physicochemical 13:4 74:14 75:5 271:21 272:13,18 278:11 293:9,16 294:13 300:8 302:17,21 303:14</p> <p>physic-chemical 74:4,7 74:11</p> <p>physiochemical 269:6</p> <p>Ph.D 1:16 2:2 5:3,11 16:22 18:11 55:21 94:16 145:3 187:5</p> <p>pick 15:4</p> <p>picture 285:7</p> <p>piece 42:3</p> <p>pKa 159:22 160:2</p> <p>place 15:6 105:4,15,20 261:19 313:22</p> <p>placed 219:5,15</p> <p>places 187:17,20</p> <p>plain 102:14,21 103:1,9 103:20,22 104:11,14 104:17 137:12,21 138:3 147:12,17 176:5,11 244:16,21</p> <p>plaintiffs 1:7 3:4 15:13 16:10,13 17:14 231:16 254:9</p> <p>Plaintiff's 18:13 205:22 208:8 232:13 237:20 240:7 257:13 259:15 262:16 265:9 267:10 279:17 281:1 283:6 285:3 288:5 292:15 295:9 297:19 298:22 304:8 305:18 308:16</p>
--	---	--	---	--

<p>312:4 plastic 119:20 120:1,3 plasticizers 120:6 platform 57:20 please 15:3,5 16:20 17:7,22 18:19 19:21 20:7 24:20 35:4,16 54:18 57:13 81:6,16 83:6 95:20 98:5 99:8 106:7,7 113:1 134:1 140:9 180:10 203:5 205:12 206:9,12 210:10 212:11 236:8 244:20 268:11 271:17 288:15 306:6 312:22 plethora 86:5 266:5 Pluronic 289:16 plus 160:6 point 25:8 107:13 129:22 130:3 131:3 163:8 167:21 203:18 219:6,15 290:18 311:17 316:5 pointed 231:3 pointing 157:20 182:12 points 169:11 polar 308:6 polyether 127:8 128:15 129:11 polyethylene 81:18 127:8 129:12,13 167:6 256:2,5 polyglycerol 296:16 polymer 83:15 128:15 129:12 303:10 polymeric 289:13 294:1 polymers 67:8 81:19 127:8 polyoxyethylene 128:18 255:19 263:10 263:18 296:20 297:6 301:20 303:9 polyoxyl 113:17 227:15 228:20 229:22 230:1 289:18 polypropylene 118:21 119:6,17,19,22 120:6 120:9 121:3,9,19 122:9,13 123:4,10,13 polysorbate 113:18 227:14 228:22 polyvinylpyrrolidone 102:20 poor 140:15 poorly 276:9 299:17 portions 296:4 317:16</p>	<p>position 56:8,13,21 57:3 254:9 positive 167:1,4 173:6 possess 75:11,19 157:12 possible 132:14 161:5 220:11 256:9 259:4 268:21 272:16 278:5 303:4 310:3 possibly 117:4,4 122:22 169:22 post-doctoral 55:21 potency 274:20 potency/selectivity 273:12 potential 50:11 213:22 214:9 268:6,14 278:2 potentially 161:15 223:4 290:6,6 291:21 pounds 60:9 power 261:20 practical 140:19 210:19 299:21 300:3 practice 25:15 27:14 209:14 practiced 25:13 practicing 25:16 27:10 precedence 236:16 precipitate 117:3 precipitating 238:17 Preclinical 268:19 predict 78:15 169:22 216:6 260:11,15,21 261:9 303:5 predictable 307:15 308:1 predicted 77:8,17 78:5 79:3 158:1,12 170:5 170:14 171:1 predicting 160:2 predominantly 35:17 291:4 prefer 317:12 preferable 256:5 preferably 125:12 preferred 110:22 125:19 126:5 preparation 48:9 58:21 62:3,7 65:4 68:1 69:11 80:4 86:2 87:1 98:17 99:6,8,11,15,20 100:11,20 101:4,11 101:16,21 102:2,9 107:8,16,22 108:15 108:19,20,22 109:18 110:16 111:12,21 112:10 113:16,17,18</p>	<p>114:12,15 124:15 125:10 126:16 127:10 128:7 129:8 132:3,18 133:4 151:9 175:9 188:14,19 189:5 211:11,17 218:10 228:20,21,22 242:12 271:5,10 277:4 289:4 289:6,22 290:2 314:7 315:13,21 preparations 23:15 29:6 31:22 39:11,20 40:7,15,22 41:3,9,18 44:2 50:18 51:1 57:21 75:19 87:12,21 88:16 116:10 118:5 125:18 126:4 131:16 132:1 139:11 150:12 159:7,14 160:12 161:6,20 162:19 164:7,12 167:9,13 168:4,20 169:13 171:14 230:17 231:4 241:4 258:19 284:3 284:12 prepare 87:9 108:4 313:14,21 prepared 19:1 38:15 42:11 73:13 118:20 119:5 preparing 73:4 92:16 prerequisite 42:18,19 prescribed 27:15 120:16 presence 50:3 76:11,12 76:15,16 257:4 309:8 309:14,21 310:10,19 present 4:14 76:9 124:14 125:11 126:16 129:8 172:15 236:17 255:19 293:6 presented 304:20 preservative 46:18 110:8 111:5 112:21 117:1,2 124:19,20,21 127:11 131:15,19,22 132:4,13,19 133:2,6 133:12,15,19,21 226:16 242:4 244:2,6 244:17 245:1,5,20 246:14 247:1,6 248:9 248:17 249:1,9 250:3 253:4,6,8,21 preserved 119:7 132:15 pretend 282:10 prevent 181:1 217:2 previous 54:21 55:18</p>	<p>69:18 70:7 136:1 221:18 222:16 255:12 274:3,7,8,16 275:4 280:7 281:12 291:3 296:14 pre-clinical 271:7 pre-formulation 162:4 pre-registration 55:17 pre-term 28:18 pre-weighed 35:21 primary 198:17 247:21 prior 45:10,18 46:3,16 56:16 127:6 138:14 227:21 228:3,4,9 252:13 private 15:5 probably 24:3,5 25:19 32:17,22 73:21 95:15 115:22 204:13 261:17 262:4 270:19,21 287:4,9 316:11 probenecid 233:10 problem 140:15,17,19 170:22 246:10 276:12 problems 50:11 138:13 138:14 139:14,18,20 140:4 141:5 142:10 142:15 275:10,16 problem-solve 142:10 142:14 proceed 17:14 19:21 proceedings 282:17 process 50:6 160:22 162:4 175:4 190:9 214:2 268:3,5 Procter 2:3 3:14 15:19 16:16 produce 110:21 132:15 produced 255:21 product 27:22 28:6,9 28:12,17,19,20,22 29:7,12,18,22 30:5,8 30:10,12 32:2,5 36:21 37:5,8 47:14,16 48:12 48:14,15,22 49:2,5,8 52:4,19 53:2,14 57:10 57:13,15 58:1 61:22 100:16,17,21 160:19 210:3,8,16 213:12,14 213:21 214:20 215:3 215:8,21 production 81:20 296:4 products 28:21 29:4 38:14 47:18,22 48:5 50:9 144:20 216:13 217:2,4 253:5 professional 19:9 20:6</p>	<p>21:14 22:12 program 145:1 programmes 274:20 progress 269:14 276:20 projects 55:20,21,21 60:14 PROLENSA00006182 192:14 PROLENSA00006183 194:1 PROLENSA00006191 203:7 promising 111:1 112:18 promoting 24:15,18 propensity 225:17 226:2,6 proper 151:17,21 152:8 properly 117:6 properties 9:15 12:9 13:5 14:12 49:13 75:10,18 76:22 77:7,9 77:18,20 78:5,7 79:2 79:4 82:1,19,22 84:6 85:11,17 87:3 156:11 156:14,16 157:12,22 158:2,13,14,18 159:2 161:20 162:19 163:22 164:6,11,17 165:2,11 165:22 166:3 169:2,4 169:8,12 170:4,6,15 171:2,3 190:7 226:7 260:11,16 261:2,5,10 269:6 271:22,22 272:14,19 273:13 278:13 280:9 293:9 293:16 294:13 296:10 296:21 297:3 300:10 308:5 310:8,14,17 property 83:15 proportion 36:14 proportions 36:13 proposed 143:4 231:16 proposing 143:7,16,21 144:4 propoxy 300:15,20 301:1,4 302:6 prosecution 135:1 137:7 147:6 152:1,5 152:10 153:3,7,15 178:20,21 179:8,13 186:13 204:5 231:5 251:22 252:2 protective 317:21 protocol 109:13,14,15 121:16 protocols 214:14,19,22</p>
---	--	--	---	---

<p>215:1,5,7 prove 170:2 proven 145:3 provide 47:2,7,10 71:10 72:1 90:5 92:7 124:15 127:7 129:17 129:21 130:1,9,18 131:1,5,7 133:16 171:21 210:1,5,13 214:18 226:14 236:3 236:9 provided 45:18 46:3,16 143:9,18 314:20 315:6 provides 179:4 209:21 237:2 providing 233:1 238:8 291:8 proximity 167:5 public 2:7 23:18 24:18 26:5,8,19 27:6 37:15 39:5,18 44:21 47:7 publication 5:18 6:18 34:15 51:12 66:21 67:1 188:5 206:3 237:18 238:2 publications 34:13 239:12 publish 78:18 260:3 263:4 published 45:5 63:4,14 63:16 64:2,7,10,17 65:2 66:3,7,22 67:9 67:14,21 299:10 311:20 pulled 265:3 purpose 41:15,16 83:18 160:18 purposes 32:8 137:3,13 137:22 227:21 228:10 pursuant 2:2 put 82:12 88:3 121:12 122:4 137:16 141:4 148:1 185:1 193:6 209:6 237:8 239:8 241:22 257:6 259:8 262:8 264:7 267:3 279:8 280:15 282:20 284:17 287:19 292:7 295:1 297:11 298:15 303:22 305:10 307:8 311:9 313:13 putting 43:17 184:18 p.m 204:21 205:5 254:19 255:3 316:15 316:19 318:17,22</p>	<p style="text-align: center;">Q</p> <p>qualifications 22:21 143:14 qualified 45:8 70:6,10 174:10 236:17 qualifies 70:12 qualify 21:10 24:18 70:22 230:18 286:16 quaternary 127:12 question 17:19,20,22 18:1,2 20:1,13 21:5 21:10 24:6 25:9 30:21 32:13 33:14,15 34:21 35:5 40:1 42:2 46:12 59:6 60:4 70:8 75:16 80:8 87:17 92:19,21 93:7 96:5 97:2 99:13 100:18 104:8 115:14 116:14 118:10 120:21 125:21 127:19 132:17 133:9 139:7 140:2 143:15 145:17 148:7 150:5 151:3 152:3 155:2 159:10 170:20 184:13 193:13 195:11 210:10 221:16,17 223:8,21 224:13 236:8 244:20 246:11 248:1 271:15 290:16,17,22 291:1,3 307:18 309:17 313:19 questions 17:15,16 316:22 quick 115:3 235:1 quickly 236:18 quite 79:11,17 81:14 83:4 104:8 114:3 116:11 156:5 157:8 169:21 181:18 184:8 198:5 261:5 286:12 287:1,11 294:10 314:16 quotation 224:14 quote 129:6 224:18,19 quoted 224:14</p> <p style="text-align: center;">R</p> <p>R 3:1 15:1 raft 110:9 111:16 112:5 range 68:7 100:3 108:4 110:7 124:18 125:19 126:5 168:14 226:15 266:17,19 268:13 281:19 ranging 42:14 rat 6:11 207:7 208:5</p>	<p>rate 113:9 114:8 230:18 rated 63:8 241:18 ratio 290:13 291:4 rational 83:17 rationally 83:16 84:8 99:20 reached 248:8,16 reaction 216:14 read 29:9 58:12 92:15 92:16 94:6 96:17 106:1 107:5 123:21 124:4 125:6 126:10 127:2 128:11 129:2 134:2,10 135:14 142:22 153:14 200:1 206:11,20 210:9,21 213:15 216:10 219:10 225:8 231:9 234:6,13 235:2 236:18 238:11 240:15 243:7 246:3 252:2,21 274:2,18 275:5 290:19,22 296:14 299:15 305:4 306:19 314:9,14,16 315:1,2 319:1 readily 120:9 121:3 122:8 reading 94:14 235:1 314:17,17,18 reads 113:8 190:6 233:6 283:19 304:19 ready 96:18 116:13,19 124:5 125:7 126:12 127:3 128:12 134:11 134:12 136:8 143:1 206:13,22 207:1 211:2,3 212:13 213:17 219:11 225:10 231:12 238:12 240:15 245:17,18 253:1,18 291:15 realization 287:16 realize 111:9 200:3 287:3 realized 286:22 287:9 287:10 really 22:2,2 35:2 39:22 42:2 63:17,21 79:20 98:3 104:6,6 105:7 115:2,2 146:15 148:21 149:19 150:16 157:15 164:19 174:17 174:20 191:13 198:8 200:3,14,16 234:7 239:6 259:4 270:12 294:16</p>	<p>reask 116:14 223:9 reason 17:21 18:4 105:8 150:21 190:8 201:1,2 289:19 305:7 reasonable 78:15 153:16 154:1 155:5,8 271:1 272:10 reasons 31:9,11,13,16 43:8,11,14 151:4 160:20 163:9,13,19 269:13 314:15 recall 30:3 38:19 46:1,2 46:22 89:14 317:7 318:5 receive 60:2 61:7 62:6 received 59:20 61:3,11 61:18 62:2 89:3 receiving 85:15 recess 80:21 136:16 205:3 255:1 316:17 recited 250:16 recognized 24:11 recollection 314:22 315:6 record 15:3,10 17:8 18:10 80:20 81:4 136:15,21 170:22 204:15,17 205:2,8,18 207:21 232:11 237:17 240:3 254:15,22 255:6 257:10 259:12 262:12 264:14 267:7 279:12 280:19 283:2 284:21 285:8 288:1 292:11 295:5 297:15 298:19 304:4 305:14 308:13 311:13 316:7 316:13,16,20 317:11 318:20 Recording 15:9 recordkeeping 63:9,10 records 63:21 64:9 reduces 156:6 reducing 283:22 reduction 251:3,16 refer 90:15,21 91:5,11 91:18,21 104:9 105:15,20 124:11 151:11 180:5 184:5 184:15 185:5 186:7 186:11,14 189:9 192:7 195:15 203:1 203:21 204:3,6 207:14 212:6 216:18 232:16 238:1 244:2,6 244:17,22 246:22 247:5 249:9 252:6</p>	<p>reference 132:11 185:2 187:2,11 188:18 189:1,4 192:3,10,13 192:17,21 193:10,16 193:20 194:10,20 195:5,12,16,20 196:16 197:3,4,22 198:1,7 199:12,20 201:18 202:3,5,20 203:2,11,22 204:3,6 206:18,20 207:2 208:12 209:19 212:8 213:2,5,11,19 214:13 214:18 215:1,6,19 216:9 217:15,18 218:16 219:13,18 220:5,19 221:2,7,10 221:22 222:11,19 223:10,22 224:9,19 252:7,10,13,19 253:3 253:7,15,21 311:18 311:20,21 312:15 references 64:15 67:19 127:6 198:17,20 199:16 314:3 referred 166:12 172:16 referring 22:4 136:5 142:15 226:18 307:1 refers 203:12 245:5,20 246:13 reflect 242:14 refresh 314:21 315:5 refreshed 314:11 regarding 22:13 45:19 46:4,17 52:9,13,18 53:2,14 54:1 249:1 254:10 regards 33:20 regime 307:12 Registered 27:9 regulate 118:6,13 258:11,15 259:1 regulations 145:9 regulators 215:14 regulatory 120:15 163:5,8 268:3 reiterate 282:16 relate 95:5,8,12 96:7,12 275:4 related 46:12 47:15 67:6 77:14,15 96:1 147:7 152:13,17 191:1,5 257:3 314:9 relation 6:10 207:6 208:4 relationship 78:13 79:13,14 94:14</p>
--	---	---	--	--

<p>218:19 relative 36:12,12 50:1 235:20 291:6 relatively 139:10 167:14 release 233:7 relevant 19:8 24:3,8,8 138:9 144:9,14 147:8 152:18 232:6 313:21 reliable 219:19 220:7 220:21 reliably 160:3 relied 242:22 243:12 rely 153:2 198:14 249:17 relying 179:22 186:19 192:3,16 195:5,12 196:14 202:14,20 209:13 252:10 remain 224:5 remained 162:9 remaining 113:9 114:8 224:15 230:18 remains 114:14 229:14 229:18 remember 32:21 34:14 56:14 63:17 73:21 102:4 129:4 162:15 168:5 221:20 242:20 243:2,14 249:11 262:3 287:7,15,18 301:14 310:2 311:1 314:4,10 316:2 Remington's 209:13,19 210:1,5,13 removed 288:21 removing 190:9 repeat 19:22 33:13,15 40:18 41:11 59:6 87:16 93:6 115:6 185:10 215:5 236:7 244:20 309:16 rephrase 75:16 100:17 175:3 replacement 255:18 report 68:6 94:12 114:5 130:14 203:18 208:17 252:4 261:18 300:19 reported 281:13 300:10 reporter 2:6 16:1,20 18:8 28:14 84:15 195:10 205:16 207:19 232:9 237:15 240:1 257:8 259:10 262:10 264:9 265:7 267:5 279:10 280:17 282:22</p>	<p>284:19 287:21 290:19 292:9 295:3 297:13 298:17 304:2 305:12 308:11 311:11 Reporters 16:3,5 repositioning 160:18 represent 16:8 17:14 representing 16:4 reproduce 185:10 reproduced 200:12 Reproducibility 73:18 reproducing 184:9 reproduction 230:14 repulsive 291:8 require 251:1,16,17 required 114:8 223:3 256:16 261:22 262:1 296:4 requires 251:3,8,14 273:11,19 research 30:4,9,15,22 32:1,7,10,11,16,19 55:7,20 58:7,9,17,20 59:2,7,13,21 60:15 61:3,11,17,18 62:2,6 89:4 144:22 145:1 276:7 researcher 25:2 39:3 216:1 researchers 215:14 255:16 respect 21:14 22:12 24:21 44:1 111:3 116:20 138:8 141:2 148:5,18 149:5,16 150:10 240:21 241:4 respectively 118:21 119:6 respects 250:11 respiratory 23:14 28:17 respond 231:15 254:9 responsibility 109:13 responsible 57:15 173:15 rest 159:4 210:21 restrict 102:15 103:2 103:10,17 104:1,18 result 175:4 225:19 281:18 resulting 261:2 291:10 results 174:11,15,21 219:19 220:7,21 230:19 231:2 300:20 301:10 reveal 239:15 313:17 reverse 266:11</p>	<p>review 90:11,18 91:2,8 91:14 92:3 104:21 113:4 287:10 314:6 314:13 315:9 reviewed 134:10 175:18 178:19 243:13 243:19 245:13 314:20 Reviews 10:13 14:20 re-publication 312:14 re-published 311:21 re-purposing 160:15 re-read 106:5 177:1 219:9 re-reading 305:6 313:20 rheology 86:16 Richardson 55:15,17 ridiculous 122:18,19 right 22:22 23:4 99:13 116:16 134:7 177:3 183:18 267:13 306:16 306:21 317:8 318:5 318:12 right-hand 183:4,19 195:21 213:9 214:12 218:17 276:22 295:20 306:7 risk 270:10 Road 17:10 Robert 146:20 robot 141:22 142:5 role 28:2,4 56:17 route 160:7 161:11 164:3,21 212:3 277:8 277:10 routine 260:22 routinely 311:6 Royal 21:16 56:17 188:7 rules 84:9 170:10 run 218:22 running 55:20</p>	<p>157:6 161:15 172:15 172:16,19 173:14,16 175:21 176:7,8,13,16 176:20 177:7,16,17 177:21 178:12 179:2 179:3,9,15 181:1,8 182:2,16,17,18,19,20 182:21 184:6,12,16 185:6 186:3 190:3,3 190:12,12 191:4,5,10 191:11 196:3,3 203:12,15,15 207:11 207:14 208:22 290:15 salts 48:3,20 53:17 76:12 172:17 173:20 174:1,12,16 175:5 189:19 190:20 191:6 195:22 196:2 233:8 sample 227:14,15,16 229:14,15,19,20,21 229:21 230:1 satisfied 242:4 satisfies 253:22 satisfy 110:3 242:12 save 270:11 saving 185:9 saying 103:15 130:7 209:3 217:19,19,20 218:5 says 23:10 55:1 69:17 81:9 89:2 90:5 106:3 114:11 118:18 119:2 128:6 137:2 138:8 141:20 153:1,12 155:14 180:20 183:10 183:22 185:18 189:19 190:15 193:8 194:8 196:9,18,20 197:12 199:7 217:9,22 228:17 242:3 245:3 255:14 260:8 273:11 273:17 274:8 275:8 277:2,15 278:1 281:12 288:17 295:21 300:8 306:8 309:5 313:3 scale 123:2 scattering 7:12,15 8:11 24:4,12,14 42:15 63:12 74:15 82:15 science 12:6 24:16,22 144:19 148:3,4 209:14 222:8 sciences 5:17 7:13 11:16 13:9,17 94:18 279:3 scientific 20:5,16 22:11</p>	<p>58:17,20 59:2,7 160:22 scientifically 222:1,4,7 222:18,20 scientist 21:16,18 56:17 277:15 scientists 24:19 scope 153:17 154:2 155:6 screen 112:18 290:20 screening 112:19 search 165:16 247:21 275:8,14 276:17,19 searched 165:19 searching 277:16 second 49:11 68:17 69:12 74:3 81:8 152:21 185:18 190:6 196:20 197:11 204:17 206:11 208:16 209:17 216:9 225:8 239:13 250:15 255:12 258:3 267:22 277:6 283:18 306:21,22 309:4 secondary 202:16 section 58:7 62:22 65:20 134:9 194:16 258:2 259:22 263:1 265:20 267:22 268:18 271:2 272:13 277:22 293:4 sections 278:19 see 23:16 55:3 63:1 64:22 65:22 69:19 74:9,19 81:9 89:6 90:8 92:9 99:10 100:7 113:19 114:10 114:18 119:11 123:22 129:7,15,19 137:9 138:17 139:22 142:1 147:10 151:13 152:7 152:15 153:19 156:1 162:8 166:14 172:2 176:3 177:11 179:13 180:12,15,18 181:3 183:6,10,12,22 184:2 185:16,19 187:7 193:3 194:6,13,18 195:1 196:11,22 197:12,17 199:6 201:14 203:9 206:17 207:8 211:5 214:16 216:15 217:13 218:3 219:8 232:20 233:15 233:19 235:10 238:6 238:20 241:1,5,16 242:8,16 254:2 273:9</p>
---	---	--	--	--

<p>281:20 290:20 300:17 306:14 317:14 seen 234:11 318:15 select 122:15 123:14 160:8 269:22 selection 58:10 268:12 self-assemble 167:15 266:2 289:14 self-assembling 166:20 self-assembly 290:12 self-associate 288:19 313:4 semi-polar 9:16 294:7 semi-solid 86:15 Senju 1:3 15:12 16:10 16:13 sense 153:22 154:9,15 154:16 155:4 sensitive 15:4 256:13 sentence 74:3 81:8 89:2 119:2 125:4 126:14 138:8 141:17,19 152:12,21,22 153:12 155:14 179:12 183:9 187:1 189:18 190:6 190:15 193:8 195:22 206:11 208:15 209:17 210:21,22 217:9 225:8 226:12 227:2 228:16 229:3 230:6 230:16 231:1 240:18 242:10 250:10,15,22 251:7,13 252:22 253:17,20 260:7 265:22 266:9,17 268:13 269:5,11 271:4 272:15 273:7 273:16 274:3 275:4,7 277:1,6,7 278:10 280:6 281:12 283:19 286:4 288:17 293:5 298:7 302:14 304:19 309:5 313:3 sentences 118:15 119:11 172:15 178:19 216:10 218:18 299:15 separate 198:11 201:5 201:6,8,9 separately 233:13 September 1:17 2:5 15:22 80:17 81:1 136:12,18 204:21 205:6 254:19 255:3 318:17 sequester 173:8 sequestering 174:3 180:20 190:10</p>	<p>Sequestrene 185:18,22 186:2 194:17 199:10 199:13,17,21,22 200:5,9,11,12 201:16 201:19 202:1,2,7 series 17:15 77:14,15 281:15 serve 53:10 services 57:7 set 65:12,13 212:16 231:15 249:21 250:1 254:9 315:10 SGA 187:21 shape 123:13,19 shelf-life 43:19 141:6 shipment 214:5 shoot 317:15 shorter 218:22 Shorthand 2:6 show 282:10 showed 73:15 255:22 shown 118:20 119:5 240:20 302:16 side 60:12 side-by-side 201:11 sight 270:11 signature 18:19 significance 137:12,21 significant 142:3 153:3 153:6 255:22 277:9 significantly 293:10,17 294:14 similar 97:1 184:9 185:10 229:13,17 250:10 similarities 293:16 294:9,13 similarity 282:18 294:5 similarly 302:4 simple 132:22 139:10 156:9 219:1 258:9 277:3 simpler 120:21 184:13 simply 154:7 260:9,14 261:7 simulations 14:10 261:16 simultaneously 233:14 single 34:14 79:16 site 159:1 sites 258:11,15 259:1 sitting 29:11 106:2 270:22 315:17 situation 247:22 six 55:5,9,16 243:11 size 42:14 122:13 169:9 171:8 241:4 281:18</p>	<p>sizes 241:13 skill 36:19 79:22 84:10 84:22 85:9 86:21 87:10,18 88:14 94:22 97:21 98:16 99:5,14 99:19 100:10,19 101:6,10,15 102:1,8 106:14 107:7,15,21 108:14 109:17 110:15 111:11,20 112:9 120:8 121:2,17 122:8 122:14 123:14 125:16 126:2 133:3 137:5 138:9,16 141:21 142:4 143:4,8,17,22 144:5 145:6,13,20 146:5,12 151:17,21 152:8 154:17,19 159:5,13 160:10 161:18 162:17 163:17 187:2,12 188:9,16 189:2 209:20 210:6 210:14 218:9 220:5 220:20 243:5 246:21 247:4,17 248:2 skilled 84:18 88:5 99:2 109:10 112:3 138:4 142:9 147:3 153:16 154:1,16 155:6,9 210:20 249:8,14 skills 145:4 Skip 96:16 skipped 265:3 slight 243:15 slightly 92:21 97:2 157:18 311:7 small 140:14 200:3 213:7 296:7,22 302:16 303:7 smaller 123:2 Society 10:13 21:17 22:13 45:6 56:18 188:8 sodium 6:5 33:7 45:20 45:20 89:12,12 102:15,19 103:2,5,10 103:14,16,17 104:1,7 104:18 105:4,5,12 113:14 118:18 119:3 157:1 172:18 173:14 173:15 175:20,21 176:7,7,11 177:6,16 177:16,20,20 178:11 178:12 179:1,2,2,3,4 179:9,10,15,15 180:13,16 181:5,13 182:2,14 184:4,14</p>	<p>185:4,13,22 191:10 191:10,14 194:8,10 194:17,21 196:19 197:4 198:1 200:4,8 200:10,11 201:15 207:4 208:1 217:10 217:11,11,12,16 218:1 227:4 287:12 Soft 7:15 sole 71:16 solubilities 157:4 solubility 44:1,7 156:19 156:21 158:10 159:22 160:9 166:7 168:11 170:1 272:19 273:20 275:16 276:1,9 283:21 284:2,11 286:6 306:9,10 307:2 307:19 308:5 solubility/permeability 275:9 solubilization 9:15 13:4 82:15 83:7 255:17,21 256:6 280:10 281:19 300:9 302:17,21 303:14 solubilize 31:14,15 81:21 83:14 170:1 286:3 299:17 solubilizing 168:7 280:12 282:2,13 307:5,14,22 soluble 157:2 158:10 158:11 286:12 287:1 299:17 solution 9:6 12:11 33:10,16 34:16 44:9 140:10 162:5 166:20 174:4,8 190:9 298:11 solutions 62:14 138:14 291:10 solvent 266:2,13,21 272:8 solvents 160:8 somebody 36:18 38:7 84:18 88:4 94:20,21 101:3 104:9 109:10 110:20 112:2 143:14 145:3,4 154:14 158:7 163:17 184:9 187:20 210:20 262:5 somebody's 270:11 sophisticated 139:11 258:10,14,20,22 259:5 sophistication 138:12 138:20 139:6,8 149:9</p>	<p>sorbitan 128:18 263:10 263:18 sorry 21:15 23:1,3,7 33:13 34:21 35:9 56:15 60:17 72:18 74:4 75:3 78:19 101:13,13 104:7 105:17 106:4 115:2 115:14,21 116:12,15 116:18 117:8,13 118:14 119:13 121:8 122:3 125:22 131:17 132:9 133:13 134:3,5 134:7 146:10 148:12 152:3 161:2 165:7,8 165:17 170:19,19,21 174:14,22 175:1 177:4 182:11 183:13 191:13 193:4,13 195:18 196:15 199:19 200:2 216:16 219:9 221:1 223:7 230:6 238:15 241:12 245:10 246:4,9 247:1 264:18 276:16 278:16,17 290:18,21 303:6 306:15 308:8 315:4 317:5 sort 95:22 157:10 160:20 166:7 168:1 sounds 133:1 sources 247:21 South 4:5 space 185:9 span 212:12 Spanish 287:7 spanning 183:9,13 231:10 spans 183:2,15 196:15 211:1 246:8 spasmodic 243:16 speaking 71:7 special 312:16 specialist 16:4 species 309:9,14,21 310:10,19 specific 86:20 93:6 100:6 102:5 105:9 148:14 157:19 177:21 182:2 227:5 258:11 258:15 259:1 specifically 23:11 61:12 132:2 151:3 235:5 261:1 296:15 317:8 specification 96:22 97:3,7 101:7 104:21 105:3,14,18 111:1</p>
--	--	---	--	--

<p>112:8,16 119:15 121:8 124:13 125:9 125:15 126:1 127:5 135:1 137:7 147:6 151:12,19 153:15 175:19 177:14 186:10 204:2 226:12,18 245:7,22 246:16,20 247:3,13,18 248:3,11 248:14,18 249:7 specifications 135:15 136:2 211:4,7 224:7 224:17 225:3 247:11 specified 99:15 221:12 223:12 224:2,21 specifying 225:4 spectroscopic 42:14 speculate 159:17 speculation 84:14 87:5 98:20 126:7 146:7,14 158:5 159:9,16 160:14 244:10 270:2 294:21 296:12 305:3 307:17 308:3 310:22 speed 138:14 spell 28:14 spent 55:16,19 spherical 266:3 spoke 141:2 spontaneously 266:2 spot 198:21 squeeze 120:4 stable 62:7 stability 11:14 39:10,16 39:19 40:6,14,21 41:2 41:4,8,12,17 42:10,14 42:18,19 43:22 44:9 44:10 68:7 87:11,20 88:7,8,15 89:19,20,20 108:6 110:7,9 111:3,5 112:5,20 113:12 114:5,6,8 116:7,8,9 116:21 117:4,5,12,16 118:2,22 120:14,15 120:17 130:5,8,17,22 140:16 141:2,3,6,7,7 163:10,11 166:6 190:16 209:22 210:2 210:7,15,19 211:10 211:12,17,18 213:12 213:15,20,21 214:10 214:14,19,20,22 215:1,2,5,6,8,20 216:18,21 219:14,19 220:6,21 221:6 222:14 223:4,20 225:4,12,12,13,15,16</p>	<p>225:19 226:2,6 227:3 227:6 230:12 235:19 235:22 241:3 272:6 stabilize 127:9 212:18 212:22 231:18 237:12 238:18,22 stabilized 46:5 stabilizes 31:17,18 stabilizing 80:3,4 216:13,17,20 235:15 stable 43:3,16 46:5 62:3 65:3 67:22 68:6 69:10 86:1,6,22 89:16 89:22 113:15,22 114:12,21 115:10,16 116:4 124:17 125:18 126:4,17 189:21 212:17,21 221:3,13 222:1,12,20 223:13 224:3,22 226:14 228:19 229:6 230:18 231:4,17 232:4 233:6 233:18 234:1,16 235:10 236:3,10 237:2 239:12 240:21 241:9 stage 269:15 stand 61:20 standard 42:11 61:9 74:14 109:5,8 120:13 120:14,15 139:12 153:21 154:8 155:3 189:1 242:4 244:2,7 244:18 245:1,6,21 246:14 247:6 249:9 250:3 251:3 standardized 215:10 215:17 standards 38:21 39:7 242:13,13,15 244:15 250:11,12,16,16 251:1,9,16 stands 29:15 staple 129:14 start 111:2 160:8 204:18 241:12 272:10 started 58:13 276:8 starting 107:13 150:16 starts 125:4 128:6 183:16 195:22 208:16 209:18 273:8 state 17:7 43:13 52:6 75:12 76:9 86:7,8 92:6 119:16 124:14 125:10 126:15 127:6 147:2 148:17 149:4 149:11,13,14,15</p>	<p>150:6,15 162:10 191:9 193:11,16 203:11 213:19 219:13 221:2,7,10,22 222:11 222:13,19 223:10,22 224:9,19 226:13 227:10 229:12,16 253:7 260:13 261:6 268:13,19 269:5,11 271:4 297:9 298:8 302:14 stated 178:22 196:5 294:3 301:13,21 statement 88:4 126:20 127:17,20 128:2 129:18,22 130:4,6,7 130:10,16,19,21 131:2,6,8 139:19 179:3 181:22 190:2 190:11,18 203:14 226:21 227:7,18 229:1,9 230:3,13,21 231:6 250:13,20 251:5,11,19 256:9 263:14 266:6,15 267:1 268:7,15 269:1 269:9,16 270:5 272:22 273:14,21 274:4,7,8,13,16 275:12 277:12,15 278:7,14 280:13 282:4,9,11 285:22 286:8,16 288:22 293:12,21 296:14 298:13 305:1,8 306:12 310:6 313:9 statements 147:7 172:20 275:2,4 277:19 314:19 states 1:1 15:15 51:9,11 181:6 194:10,21 218:19 226:12 227:2 228:18 229:4 230:7,7 232:12 238:17 242:11 253:21 263:8 280:7 293:5 319:3 statistics 37:10,14,16 stay 140:20 stearate 227:15 229:22 230:2 stearate-containing 113:17 228:21 stems 313:5 sterilize 121:12 steroid 156:9 165:7,8 steroids 165:6 168:14 stop 291:9</p>	<p>storage 114:15 214:5 230:10 235:5,18 story 59:15 83:5,5 275:1 STP 11:15 straight 79:16 straightforward 109:2 109:5,7 199:18 strange 66:14 Street 4:5 16:5 stress 312:13 strict 102:19 103:14 268:3 strike 104:16 117:9 119:13 148:15 161:2 176:14 186:5 202:4 203:19 221:8 247:2 string 42:3 struck 273:12 structural 7:4 9:12 14:11 159:2 280:8 293:7,15 294:9,12 296:7 297:1 302:19 303:13 structurally 77:14 structure 75:22 76:2 77:4,10,21 78:8,12 79:5,20 82:11 156:18 158:3,15 170:7,11,13 171:5,21,22 172:8 183:10,22 260:10,11 260:15,16 261:2,8,9 282:19 289:7 290:4 303:3 structures 10:5 80:2 157:18,21 184:9 185:11 266:3,11,18 282:1,13 288:20 290:7,10 291:2 294:3 309:6,12,19 310:2 struggling 101:1 103:13 105:7 122:2 student 55:14 287:7 students 55:22 60:15 60:22 78:21 89:11,15 89:19,21 studies 8:11 82:13,16 163:4 255:15 271:8 280:8 281:12 study 50:13 293:6 studying 59:3,8 subheading 213:14 subject 44:19 138:10 subjected 118:22 submit 163:5 Subscribed 319:9 subsequently 286:22</p>	<p>substances 191:1,6 substantially 124:21 226:16 subtle 184:11 sub-classes 157:16 successful 161:10 273:8 273:11,17 274:10,15 successfully 272:16 sucrose 296:15 sufficient 43:19 132:4 132:19 133:6 212:18 212:22 230:12 231:17 sufficiently 260:9,14 261:7,20 sugar 296:18,19 301:14 suggest 122:17 123:3 171:9 243:4 suggests 179:3 suitable 110:4 111:17 112:6 187:19 264:5 sulfite 217:11,16 218:2 summarize 271:17 summarized 271:1 summer 55:15 Super 262:6 supplement 312:17 support 130:22 143:3 231:4,22 supported 314:16 supporting 130:8 supported 100:8 sure 19:19 34:5 59:7 81:16 105:18 115:15 126:1 141:11,15 149:19 154:6 193:15 221:17 236:9 244:21 306:20 317:7 surface 12:9 74:15 82:13 283:22 Surfaces 14:15 surfactant 7:7,19,20 10:11 11:4,15 13:8 31:12 33:11,17 34:2 34:17 35:11 36:4,9,13 36:15 59:21 60:4 61:10 62:14 72:10,12 72:19 73:12 74:21,22 75:14,14,22 76:3 77:8 77:10,19,20 78:6,8 79:2,4 83:18 84:11 85:2,7,11,22 86:12 87:13,22 88:7,9,17 151:7 155:20 166:13 166:17 167:6 170:7 171:4 227:13 229:14 229:19 260:10,15,17 261:8,10 266:18,20</p>
---	--	---	---	--

<p>286:3,7 288:18 289:6 290:3 291:18 292:3 296:1,4 298:9 300:11 300:21 301:5,19,20 302:7,12,15,18,20,22 303:10,13,15,20 304:21 310:2 surfactants 9:6,14,16 12:11 13:14 52:11,16 61:1,8 62:16 64:3,6,8 65:16,16 66:8,18,20 67:2,5 68:21 74:8,16 74:18 75:1,11,18 76:21 77:4 80:2 81:10,12 82:1,9,10,20 82:22 84:5,20 86:6 166:11,18 167:3 169:21 255:20,22 256:3,5,6 263:9,17 264:4 265:22 280:9 281:16 282:1,12 286:14 289:13,15 293:6,15 294:12,19 296:8 297:1,6 299:16 299:20 300:2 301:15 306:9,11 307:2,4,10 307:11,14 308:1 309:6,11,18 310:4,7 310:16 311:4,5 313:4 surfactant-based 71:4 Surfactant/Water 265:21 surrounding 21:17,19 suspect 146:16 suspected 218:12 suspension 140:13,14 swear 16:20 sworn 17:1 319:9 syndrome 28:18 synonym 185:22 194:11,22 199:13 202:6 synonymous 44:4,6 179:4,10 182:6,8 synonyms 192:21 193:8 193:11,16 199:7 201:3 synthesis 74:20 synthesize 84:11 85:1 synthesized 74:22 81:13 82:2,21 85:12 Synthetic 7:20 9:5 12:10 syrups 258:9 system 7:9 33:11,17 34:3,17 35:11 36:4,9 36:15 61:15 63:8,19</p>	<p>214:3 261:4 285:21 286:7 309:9,14,21 310:10,20 systems 8:10 10:11 11:4 14:19 50:14 58:21 59:3,8,17 62:17 65:10,17 163:15 217:10,17 218:1 256:20 258:10,14,22 286:3 291:18 292:3 S-O-L-U-B-I-L-I-S-E 31:15</p> <hr/> <p style="text-align: center;">T</p> <p>T 5:6 6:1 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 tab 193:7 Table 113:8,9,12 116:1 118:20 119:2,5 214:13 215:19 240:18 240:22 241:3 291:14 292:1 Tables 118:16 tablet 233:12 tablets 233:13 258:9 tabs 192:6 take 17:20 19:4 22:16 54:18 55:5 58:5 62:18 63:13,22 65:19 66:6 68:9 69:15 73:22 80:11 81:7 88:21 90:3 96:15 97:14 102:11 103:6 106:20 108:2,4,7 110:11 116:1,19 118:15 123:20 125:2 126:9 127:1 128:5,21 131:9 132:10 133:22 138:6 141:17 142:12 142:19 146:22 147:22 152:20 153:11 155:11 166:9 171:16 172:11 175:14 177:2 178:16 179:11,20 185:12 186:16 189:8,14 190:21,22 191:22 192:12 195:3,19 196:6 198:22 200:15 201:7 202:9,18 206:20 207:16 208:15 209:8 213:4 214:11 216:8 217:6 218:15 219:10 223:7 225:6 226:9 227:1,9 228:15 229:11 230:5,15 234:13 236:2,15</p>	<p>239:19 240:14 245:12 245:16 249:19 250:8 252:5,18,21 253:17 254:4,5 260:5,10,14 261:7,19 263:6 271:2 272:11 273:6,16 276:21 277:14,21 280:6 281:11 283:16 288:15 291:13,13 292:1 293:3 295:19 298:7 299:12 300:6 302:13 308:8 309:4 310:3 313:1 taken 2:2 15:18 68:17 234:8 274:1 275:2 takes 235:2 236:16 258:5 talk 130:4 145:2 149:21 150:2 152:13 157:16 316:8 317:16 talked 166:10 222:16 242:18 talking 21:11 35:7 71:14 78:3 83:10 170:12 181:11,14,16 181:19 182:11,13 187:15 199:16 258:18 261:1 275:1 296:15 296:18 311:2,4 tape 80:15,18 81:2 136:8,13,19 204:22 205:6 254:16,20 255:4 316:10 318:18 taught 89:11,15,21 106:18 teach 89:8,10 113:22 114:21 115:9,16 116:4 219:18 253:3 256:4 teacher 24:21 teaches 116:22 185:3 221:1 teaching 89:5 101:18 185:7 teachings 101:9,14,22 102:7 106:13 107:6 107:12,14,20 108:13 109:8,16 111:19 220:4,19 team 267:20 278:18 279:4 technique 241:11 techniques 42:13 74:14 86:19 technologies 275:9,15 technology 8:13 138:12 138:20 139:6,8</p>	<p>149:10 Telephone 3:9,20 4:8 telephones 15:6 tell 17:13 22:3 34:19 83:5 116:13,19 218:5 219:11 239:10 245:16 291:15 telling 103:4 105:12 220:3 223:17 tells 223:1 temperature 50:2 76:11,19 219:3,4,6,15 256:20 257:2 272:3 306:10 307:12,13,20 308:7 309:8,13,20 310:9,18 temperatures 216:5 218:21 219:20,20 220:7,8,22,22 307:6 ten 58:16 59:20 60:3 tend 215:13 tenfold 256:1 tension 74:15 82:14 term 34:9,10,10 46:4,5 74:17 75:4 89:15,22 96:2,8 153:13 176:1 178:4,6,10,11,13,15 199:20 201:16 206:15 207:13 208:19 212:17 212:21 216:17,20 221:3,3,22 222:1,4,7 222:11,12,17,19 231:16 232:4 234:1 234:16 236:4,10,10 237:2,3,12 238:22 239:11 terms 20:5,6 90:6 92:8 92:13 93:2,10,20 94:9 94:13 134:20 137:7 150:19 155:1 175:20 176:14 179:6 245:3 test 38:13,16 50:3 108:5,18 109:2,5,6,8 110:2,3,5,8 111:2 113:12 118:22 120:15 120:16,17 133:11 227:4,20 249:20 250:1 253:9,22 294:18 tested 227:11 230:11 250:18 251:9 291:11 testified 17:2 69:17,21 70:2 142:16 249:7 testify 18:4 testimony 47:7,10 123:7 200:17,20 248:21 249:13 261:12</p>	<p>319:3 testing 36:17,20 37:4,7 39:10,19 40:6,14,21 41:2,4,8,12,17 214:19 215:2,7,20 219:14,19 220:6,21 251:18 253:4 268:19 tests 38:9 39:16 41:5,13 41:21 42:1,5,6,8,9,16 68:7 80:9 86:10 110:7,9 111:17 112:5 112:20,21 120:14,14 133:14,21 228:9 tetraborate 179:1 tetrasodium 89:13 102:16 103:3,11 104:2,19 105:5,15,16 105:21,21 172:19 173:20 174:1,12,16 175:5 176:8,8,16,17 176:20,21 177:7,8,17 177:17 178:5,7,10,14 179:16 182:16,21 186:3 190:3,12,19 191:5 196:3,9,15,19 197:2,14,19 203:15 text 58:12 thank 16:19 19:21 32:14 106:22 115:7 157:20 195:15 267:18 312:3 318:13,14 theory 173:5,5 216:1 therapeutic 224:6,16 thereof 124:17,17 129:11 thermodynamic 289:19 thermodynamics 258:6 thing 59:12 61:21 82:6 166:8 181:13 184:3 265:3 317:18 things 49:21 83:11 121:13 156:7 173:8 184:19 211:9 266:8 think 21:9 22:14,22 24:15 54:12 56:15 62:14 76:14,18 82:11 100:1 112:2 116:20 116:21 117:7 127:18 128:3 134:3 139:1,4 141:16 151:20 161:1 163:14,20 174:7,8,9 178:7 181:18 184:7,7 185:7,8,9 187:15 188:3,3,21 200:18 201:1 207:15 223:20 236:14 246:5 254:16</p>
--	---	--	---	---

<p>260:20 261:14 272:4 272:10 275:2 282:8 290:16,17 293:20 294:2 301:9 311:7 312:15 317:4 thiosulfate 217:12 third 187:14,15 193:8 263:7 273:7 Thomas 4:15 16:3 thoroughly 285:21 thought 112:13 115:20 121:7 137:16,18 143:11 147:15 314:10 three 60:21 136:19 205:1 218:18 253:15 301:1 three-dimensional 260:16 261:9 threshold 221:8,11 223:11 224:1,20 time 15:21 17:12 32:12 38:14 41:19 42:12 55:19 56:3,12 73:13 80:14,16,22 103:21 116:19 132:10 136:9 136:10,11,17 137:5 139:3 148:3 150:16 151:4,9 162:8 177:2 198:21 204:9,10,14 204:20 205:5 214:5 219:1,10 234:13 236:18 240:21 254:18 255:2,14 260:21 261:18 267:13 276:12 286:15 287:9,14,15 287:18 305:5 314:14 314:18 316:14,18 318:16 times 3:16 15:19 17:11 138:9 243:11 250:18 time-consuming 262:1 title 213:14 241:3 today 15:11,22 16:1 17:15 18:5 29:11 106:2 166:11 235:9 242:18 243:13 247:12 258:20 270:22 313:15 315:14,22 today's 17:13 314:8 told 40:5,8,13 42:4 89:18 100:5 273:4 top 141:18,20 153:1 183:3,19 194:4,16 195:21 197:11 276:21 total 55:2 73:18 totally 111:4 225:21,22 touch 148:10,12</p>	<p>toxic 43:9 toxicity 269:12,20 270:10,17 toxicological 13:13 164:17 165:2,11 224:6,17 278:12 toxicology 164:22 traditional 289:17 transcript 317:1 319:1 319:2 transferred 303:9 translates 274:21 treat 197:4 198:1 treated 27:18 treating 49:3 155:20 treatment 277:3 trial 37:1,2,3 47:7 trials 268:2 tried 71:19 314:4 triglycerides 65:15,15 trisodium 172:19 197:8 trivial 260:20 true 172:20 226:21 227:7,18 229:1,9 230:3,13,21 231:6 250:13,20 251:5,11 251:19 263:14,16 264:6 266:6,15 267:1 268:7,15 269:1,9,16 272:22 273:14,21 274:4,13 275:12,14 276:5 277:12,19 278:7,14 280:13 285:22 286:8,21,22 288:22 293:12 298:13 305:1,8 306:12 309:11,18 310:6,7,15 313:9 truthfully 17:16 18:5 try 24:7 68:5 102:11 104:16 106:19 117:9 119:14 161:3,9 175:3 176:15 186:6 195:11 202:4 203:19 221:9 247:2,21 249:22 trying 35:20 84:5 139:19 149:20 174:7 174:9 185:1 286:5 turn 15:6 18:19 81:6 94:21 97:9 98:5 106:7,7,18 107:11 112:22 114:4 137:1 180:5,10 193:22 203:5 205:12 206:9 206:19 212:5 233:4 238:11 255:10 258:1 265:19 268:11 285:16</p>	<p>304:18 306:6 Tween 263:11,12,20,20 Tweens 263:11,19 twice 122:22 two 22:14,17 45:10 49:18,22 50:1,2,14 60:21 68:13,15,20 70:16,16,18 80:1 81:2 81:20 87:11,20 88:15 122:21 136:13 141:5 156:19 166:21 172:15 173:9 177:10 178:19 183:9,13,15 187:19 198:11,17 202:17 216:10 294:5 299:15 315:17,18 tyloxapol 28:10 29:1,4 29:7,12 30:10,20,22 31:4 32:18 33:10,16 33:21 34:3,16,20 35:1 35:11,22 47:17,20 53:3 61:4,7,9,12,15 61:16 64:11 67:10 69:2 126:17 128:14 128:18 129:12 155:19 166:11,12,16 167:6,8 167:12 168:4,8,12,19 169:2,5,13 170:5,15 171:2,7,11,12,14 227:16,17 229:6,8,15 229:20,20,21 289:3 289:22 tyloxapol-containing 113:16 228:19 type 61:21 73:17 87:8 87:13,22 88:9 120:1,5 127:8 128:15 129:12 140:17 163:11 211:14 213:7 219:2 227:12 259:7 285:20 301:19 302:12 303:5,6 types 31:2 44:10 119:21 138:13 139:14 139:20 140:4 141:6 225:13,15 typical 151:9 typically 82:12 173:7 198:14 typographic 198:15 243:12 typographical 198:6,8 198:12 200:21 202:10 202:13 242:18 243:1 243:6</p>	<p>UK 17:10 27:10 28:1,4 47:6,12 61:14,16,21 69:22 ultimate 41:6 86:12 268:4 Um 199:5 Um-mm 60:20 118:17 179:7 185:17 191:2 199:3 unambiguously 170:3 uncertain 40:2 unchanged 44:12 unclear 38:5 39:3 78:1 222:12 undergoing 216:13 understand 17:21 69:14 70:8,9,12 85:17 90:16,22 91:6,12,19 92:1 93:15 95:22 97:19 98:14 99:14 101:2 104:8,11 118:9 118:11,14 120:9 121:3 122:8 124:7 137:3 138:4,10 147:2 147:7 150:11 152:17 153:1,12 154:22 155:1 180:7 189:12 192:10 195:17 203:2 212:8 220:6,20 222:3 232:17 238:3 239:7 247:21 252:8 271:20 289:9 293:20 understanding 21:1,6 22:5 34:7 37:14 39:15 44:18,20 45:4 48:7,11,15 79:12 84:8 96:3,5,20 97:5 99:4 103:19 104:7 114:2 137:11,15,17,20 138:6,19 139:1,5,7 144:18 147:12,17,22 148:3,5,17 149:4,11 149:15 150:6,13 153:5 156:10,14,20 163:10,14,21 164:5 164:10,16 165:1,10 165:21 166:5 169:1 169:20 210:6,14 260:8 303:4 understood 18:1 147:3 285:21 299:22 undertaken 30:15 Undoubtedly 29:2,21 unfamiliar 86:11 unfortunate 198:16 unfortunately 198:20 200:22 202:16 299:19</p>	<p>unit 295:22 301:12 United 1:1 15:15 51:9 51:11 232:12 unpredictable 307:15 308:1 unrelated 297:7 unstable 42:21 69:13 218:13 225:21 unsure 84:18 unusual 165:7 261:5 upheld 73:9 upper 169:10 usage 214:6 309:5 use 8:16 10:12 23:13 31:1,4 32:9,15,18 34:11 41:7 43:16,18 44:12,12 50:2 58:22 59:21 61:4,10,12,14 61:19 62:16 64:11,18 67:10,15 68:4 69:2,6 73:5,19 74:3,7,17 82:18 83:14 85:16,19 85:22 86:1,12,18 87:1 96:8 100:11,14,16,16 100:20 101:10,15 106:19 107:12,15,22 108:18 109:17 110:1 110:4 111:12,15,18 111:20 112:7 120:4,9 121:3,19 122:3,3,4,6 141:9 170:10 178:4,6 178:10,11,13,15 180:15,20 206:15 207:13 208:19 215:16 216:7,7,11 218:9 221:5 234:1,16 238:22 241:14 268:4 269:21 270:14,14 286:5 296:6 299:21 300:3 useful 95:10 314:10 uses 84:6 199:20,22 201:15,19 USP 242:13 250:10,15 251:3,8,14 usual 255:18 usually 180:21 181:6 181:22 218:22 U.S. 6:16,17 37:18 38:1 38:10,17 45:13,14,15 90:6,11,15,18,21 91:2 91:5,8,11,14,18 111:6 145:8 178:21 232:16 237:18 238:1 242:12 243:5 253:9,13</p>
U				
<p>uh 111:6</p>				
V				

<p>vacations 55:15 Vadas 212:7 213:2,4,11 213:19 214:12,18 215:1,6,19 216:9 217:15 218:16 219:13 219:18 220:4,19 221:2,7,10,22 222:11 222:19 223:10,22 224:9,18,19 vague 19:13 20:11,19 21:8,22 22:8 24:2 26:1,10,14,21 27:2,8 30:6,21 31:6 33:3,12 33:18,19 34:18 35:12 36:5,10 37:1,12,20 38:4,22 39:9,13,21 41:10 44:3,14 45:1,22 46:8,12,20 50:7 52:5 52:20 53:16 54:3,11 57:11,12,17 58:18 59:5 61:6 62:4 64:4,5 64:13,20 65:5,6 67:3 67:17 68:2 71:1,8,12 72:6 73:2 75:20 77:1 77:11,12,22 78:1,9 79:6,11 80:6 82:3 83:2,21 84:3 85:6,6 85:14 86:4 87:4,15 88:1,19 92:14 93:12 93:21 94:11 95:3,14 96:11 97:18 98:2,3,12 98:19 99:17 100:13 100:22 102:17 103:12 104:3 105:6 106:16 107:10,18 109:3,20 110:18 111:14 112:1 112:12 115:1,12,18 115:21 116:11,20 117:7 118:8 120:12 120:20 121:6,22 125:20 126:6 129:20 132:7,21 133:7,17 134:16 135:4,11,20 138:1 139:16 140:6 144:11,16 146:6,13 147:20 148:13,20 149:7,18 150:14 151:1 154:3,10,20 156:12,13 157:13 158:4,6 159:8,15 161:7,8,22 164:1,2,8 164:13,18 165:4 166:1,4 167:11,17 168:21 169:15 170:8 171:6 174:13,17,18 174:20 175:6 176:9 177:18 178:1 179:17</p>	<p>182:4 184:17 188:20 189:7 191:12 197:6 198:3 209:1 210:17 211:13 215:9,22 217:3 218:11 221:4 221:15 222:2 223:15 224:11 227:22 228:5 228:11 235:12 237:4 243:9 244:9 245:9 246:2,17 247:8 250:5 252:1 256:7 258:17 259:3 261:11 268:8 269:2,18 270:1 271:12 273:1,22 274:5 275:18 276:6 278:8 282:3,7,14,15 284:4,13 286:1,9,10 289:8,12 290:5 291:20 292:5 293:18 294:15,20 296:11 297:4 300:4 301:7 302:10 303:1 305:2 306:13 307:16 308:2 308:4 309:15,22 310:1,12,21 313:10 vaguely 159:18 vagueness 80:8 valid 73:1,12 value 241:8 values 113:10 vaporization 113:11 117:19,22 variation 280:8 variations 9:13 227:12 varied 87:14,22 88:18 262:5 variety 31:2 32:7 42:13 110:21 160:20 168:16 266:3 270:7 288:19 291:18 292:2 313:4 various 59:3,8 171:13 184:12 214:18 278:18 313:6 314:15 vary 77:5,6 82:9 vast 66:17 Vecchio 4:15 16:3 Vehicles 8:6 11:6 12:5 versa 266:14 Versene 185:15 versus 15:13 46:10,10 vesicle 241:4 vesicles 7:19,21 11:5,15 81:20 168:19 240:20 241:8 260:12,21 293:8 Vesicular 7:5 vice 266:14</p>	<p>Vicks 55:16,17 video 15:8 16:4 Videographer 4:15 15:2 16:19 80:16,22 136:11,17 204:20 205:4 254:18 255:2 316:9,14,18 318:16 videotaped 2:1 80:19 81:3 136:14,20 205:1 205:7 254:21 255:5 318:19 view 84:2 137:7 148:5 163:2,8 viewed 312:15 viscometric 86:19 viscosity 74:15 82:14 86:18 169:9 viscous 140:20,21 vital 19:6 8 23:6 54:18 58:9 63:4 65:20 66:3 66:22 68:10,12 89:3 205:21 206:4 240:6 240:12 257:21 259:14 260:1 262:14 263:2 265:14 279:15 280:4 280:22 281:9 283:5 283:14 285:2,14 288:4,13 292:14 293:1 295:8,17 297:18 298:5 299:8 304:7,16 305:17 306:4 309:2 311:16 312:12 vitro 235:16 274:21 volume 6:14 12:13 208:7 229:6,7 vs 1:8</p> <hr/> <p style="text-align: center;">W</p> <hr/> <p>wait 195:10 waived 318:3,7 want 35:17 42:21 44:11 59:18 75:3 81:14 83:5 84:11,19 85:1,8 85:10,16 86:18 96:16 97:3 106:8 122:14 123:1,14,21 152:20 160:11 162:18 185:13 187:17 193:6 231:9 239:14 255:8 256:10 256:12,19 312:13 317:17 wanted 85:22 86:1,14 86:17,22 160:6 161:15 162:4 wants 160:19 warranted 219:7,16</p>	<p>Washington 3:6 16:6 wasn't 130:5 198:7 243:15 317:7 water 33:11,17 34:17 34:20,22 35:18,20,21 36:13,14 75:15 86:6 86:14 100:7 157:1 159:11,22 160:1 165:14 272:19,20 273:19 286:12 288:18 288:21 299:17 313:4 water-based 33:11,17 34:2,6,7,9 35:3,8,18 36:3 water-soluble 33:1,8 189:22 276:10 286:6 way 22:10 25:10 33:7 35:14 43:1,4 57:14 58:22 66:20 76:8 83:7 84:1,21 104:20 106:17 120:16 122:7 128:4,16,16 162:7 174:5 182:15 199:21 201:20 233:14 234:11 286:16 290:1 303:2 310:15 ways 96:5 161:5,9 174:6 204:11 250:17 270:17 276:8 weeks 41:22 113:14 114:16 119:7 230:10 weight 229:5,7 302:18 weighted 220:16 Wellington 17:10 well-established 289:15 298:8 well-known 31:14 172:22 173:7 209:20 well-rated 63:18 went 70:1 278:22 279:2 we're 136:7 187:15 235:9 254:17 258:18 258:19 265:1,1,2 286:19 296:17 311:1 311:4 317:10 we've 84:9 108:20 110:6 162:11 166:10 170:9 whispering 15:5 wide 148:7,11 266:2 288:19 291:17 292:2 309:5 widely 263:8,17 wider 142:17 widespread 299:21 300:3 Williams 146:20</p>	<p>witness 5:2 16:21 19:22 20:5,12 21:9 22:9 26:22 27:3,9 33:4,13 33:19 34:19 36:6,11 37:13,21 38:5 39:1,14 39:22 40:18 41:11 44:4 45:2 46:1,21 49:17 50:8 52:6 53:17 54:4,12 57:12 57:18 59:6,11 61:7 62:5 64:5,14,21 65:6 67:4,18 68:3 71:2,9 71:13 72:7 73:3 75:21 77:12 78:1,11 79:8 80:7 82:5 83:4 83:22 84:4,17 85:6,15 86:5 87:6,16 88:2,20 92:15 93:13,22 94:12 95:4,15 97:19 98:3,13 98:21 99:18 100:14 101:1 102:18 103:13 105:7 106:17 107:11 107:19 109:4,22 110:19 111:15 112:2 112:13 115:2,13,19 118:9 120:13 121:7 122:2 123:18 125:21 126:8 127:15 129:21 132:9,22 133:8 134:20 135:13 138:2 139:17 140:7 144:12 144:17 145:16 146:1 146:8,15 148:21 149:8,19 150:15 151:2 154:12,21 156:13 157:15 158:6 158:21 159:10,17 160:15 161:8 162:2 163:1 164:2,9,14,19 165:5 166:2,5 167:18 168:22 169:16 170:9 171:7 174:14,20 175:8,11 176:10 177:19 178:2 179:18 181:11 182:5 184:18 188:21 191:13 197:7 198:4 200:21 209:2 210:18 211:14 215:10 216:1 217:4 218:12 220:1,11 221:5,16 222:3 223:1,16 224:12 228:2,6,13 234:6 235:13 236:7 236:14 237:6 239:5 239:14,21 243:10 245:10 246:3 247:9 248:14,22 249:6,14</p>
---	--	--	---	--

250:6 252:2,17 256:8 258:18 259:4 260:20 264:2,11 271:19 274:1,6 275:21 276:7 276:19 278:9,16 282:4,8,15 284:5,15 285:6 286:2,10 289:9 289:13 290:6 291:21 292:6 293:19 294:16 294:22 297:5 300:5 301:9 302:11 303:2 305:4 306:14 307:18 308:4 309:16 310:1 310:13 311:1 313:11 313:20 Wood 5:15 word 65:9 90:2 94:1 108:17 122:3 wording 93:6 words 99:10 147:5 176:1,19 177:6 184:18 185:1 243:5 work 22:13 52:2,17 53:1,13,22 55:6 57:2 65:7 68:5,19 159:1 255:12 261:15 287:8 314:16 worked 50:4 55:10,14 55:15 56:3,21 57:18 working 42:17 55:16 56:5 138:11 146:2 165:6 works 61:16 worth 270:9 wouldn't 99:2 105:9 111:15 198:9,11 199:18 249:17 wrapped 254:17 write 52:9,12 230:17 240:20 242:11 250:10 250:15,22 251:7,13 265:22 266:9,17 268:1 272:15 278:10 285:19 286:4 writing 200:3 written 52:7,15 104:20 132:12 137:18,19 278:18,19 286:11 287:10 314:5,5 wrong 134:3 220:2 264:18 265:3 287:6 wrote 286:21	Y Yamashita 6:12 207:3 208:5,11 yeah 79:15 88:13 120:22 128:8 150:9 159:17 175:2,2,11 183:18,21 184:3 204:16 248:7 264:2 286:10 307:21 310:13 317:5 year 32:22 56:6,19 262:3 years 25:19 32:17 58:16 59:20 60:3 69:18 94:17 121:18 299:18 318:15 Yep 74:16 186:1 240:19 yesterday 315:15 York 1:18,18 2:4,4 3:5 3:16,18,18 15:19,20 15:21	Z zwitterionic 81:10 167:4 293:22 310:5 Z-E 31:15	0 0 167:21,22 0.02 227:16 229:5,15 229:19,22 0.03 229:21 0.05 229:20 230:1 0.15 227:14,14,15 229:7 08:10:15 15:2 08:10:16 15:3 08:10:20 15:4 08:10:22 15:5 08:10:25 15:6 08:10:29 15:7 08:10:32 15:8 08:10:34 15:9 08:10:36 15:10 08:10:38 15:11 08:10:42 15:12 08:10:48 15:13 08:10:52 15:14 08:11:00 15:15 08:11:13 15:16 08:11:23 15:17,18 08:11:25 15:19 08:11:30 15:20 08:11:33 15:21 08:11:44 15:22	08:11:53 16:1 08:11:57 16:2 08:12:00 16:3 08:12:04 16:4 08:12:06 16:5 08:12:12 16:6 08:12:17 16:7 08:12:19 16:8 08:12:20 16:9 08:12:21 16:10,11 08:12:25 16:12 08:12:27 16:13 08:12:31 16:14,15 08:12:33 16:16 08:12:36 16:17 08:12:38 16:18 08:12:42 16:19 08:12:43 16:20 08:12:45 16:21 08:12:57 17:4,5 08:13:01 17:6 08:13:02 17:7 08:13:04 17:8,9 08:13:08 17:10 08:13:11 17:11 08:13:14 17:12 08:13:16 17:13 08:13:18 17:14 08:13:20 17:15 08:13:23 17:16 08:13:25 17:17 08:13:26 17:18 08:13:29 17:19 08:13:31 17:20 08:13:34 17:21 08:13:36 17:22 08:13:38 18:1 08:13:40 18:2 08:13:42 18:3,4 08:13:45 18:5 08:13:46 18:6 08:13:49 18:7 08:13:50 18:8 08:13:52 18:9 08:13:53 18:10 08:13:55 18:11 08:13:59 18:12 08:14:30 18:13 08:14:31 18:14 08:14:33 18:15,16 08:14:37 18:17 08:14:45 18:18 08:14:46 18:19 08:14:54 18:20 08:14:57 18:21 08:14:58 18:22 19:1 08:15:00 19:2	08:15:02 19:3 08:15:03 19:4 08:15:13 19:5 08:15:16 19:6 08:15:18 19:7 08:15:19 19:8 08:15:22 19:9 08:15:23 19:10 08:15:24 19:11 08:15:26 19:12 08:15:27 19:13 08:15:30 19:14,15 08:15:32 19:16 08:15:35 19:17 08:15:39 19:18 08:15:40 19:19 08:15:41 19:20 08:15:42 19:21 08:15:43 19:22 08:15:44 20:1,2 08:15:46 20:3 08:15:47 20:4 08:15:49 20:5 08:15:54 20:6 08:15:56 20:7 08:15:58 20:8,9 08:16:01 20:10,11 08:16:06 20:12 08:16:10 20:13 08:16:12 20:14 08:16:15 20:15 08:16:17 20:16 08:16:19 20:17 08:16:20 20:18,19 08:16:21 20:20 08:16:23 20:21 08:16:35 20:22 08:16:36 21:1 08:16:44 21:2,3 08:16:48 21:4 08:16:49 21:5 08:16:51 21:6 08:16:53 21:7 08:16:56 21:8 08:17:06 21:9 08:17:08 21:10 08:17:12 21:11 08:17:15 21:12 08:17:17 21:13 08:17:19 21:14 08:17:27 21:15 08:17:30 21:16 08:17:36 21:17 08:17:43 21:18 08:17:47 21:19 08:17:50 21:20 08:17:56 21:21	08:18:00 21:22 08:18:02 22:1 08:18:06 22:2 08:18:09 22:3 08:18:11 22:4 08:18:13 22:5 08:18:17 22:6 08:18:20 22:7,8 08:18:36 22:9 08:18:38 22:10 08:18:42 22:11 08:18:47 22:12 08:18:54 22:13 08:18:56 22:14 08:19:01 22:15 08:19:02 22:16 08:19:05 22:17 08:19:11 22:18 08:19:13 22:19,20 08:19:16 22:21 08:19:19 22:22 08:19:20 23:1 08:19:21 23:2 08:19:22 23:3 08:19:26 23:4 08:19:28 23:5 08:19:31 23:6,7 08:19:37 23:8 08:19:39 23:9 08:19:40 23:10 08:19:42 23:11 08:19:44 23:12 08:19:48 23:13 08:19:52 23:14 08:19:57 23:15 08:19:58 23:16 08:19:59 23:17,18 08:20:01 23:19 08:20:02 23:20 08:20:03 23:21 08:20:04 23:22 24:1 08:20:06 24:2 08:20:12 24:3 08:20:15 24:4 08:20:20 24:5 08:20:24 24:6 08:20:27 24:7 08:20:31 24:8 08:20:33 24:9 08:20:59 24:10 08:21:02 24:11 08:21:09 24:12 08:21:12 24:13 08:21:15 24:14 08:21:18 24:15 08:21:23 24:16 08:21:25 24:17
X X 1:2,14 5:1,6 6:1 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 319:7						

08:21:27 24:18	08:24:48 27:14	08:27:40 30:9	08:31:07 33:8	08:33:51 36:3
08:21:32 24:19	08:24:53 27:15	08:27:42 30:10	08:31:12 33:9	08:33:53 36:4
08:21:40 24:20	08:24:56 27:16	08:27:45 30:11,12	08:31:13 33:10	08:33:55 36:5
08:21:48 24:21	08:24:58 27:17	08:27:47 30:13	08:31:16 33:11	08:34:00 36:6
08:21:54 24:22	08:24:59 27:18	08:27:52 30:14	08:31:19 33:12	08:34:04 36:7
08:22:00 25:1	08:25:02 27:19	08:27:55 30:15	08:31:23 33:13	08:34:06 36:8
08:22:02 25:2	08:25:06 27:20,21	08:27:59 30:16	08:31:25 33:14,15	08:34:09 36:9
08:22:06 25:3	08:25:11 27:22	08:28:00 30:17	08:31:27 33:16	08:34:11 36:10
08:22:10 25:4	08:25:17 28:1	08:28:01 30:18	08:31:30 33:17	08:34:13 36:11
08:22:14 25:5	08:25:21 28:2	08:28:04 30:19	08:31:34 33:18	08:34:15 36:12
08:22:22 25:6	08:25:22 28:3	08:28:07 30:20	08:31:37 33:19	08:34:16 36:13
08:22:37 25:7	08:25:24 28:4	08:28:11 30:21	08:31:43 33:20	08:34:18 36:14
08:22:40 25:8	08:25:26 28:5	08:28:16 30:22	08:31:45 33:21	08:34:21 36:15
08:22:44 25:9	08:25:27 28:6	08:28:18 31:1	08:31:49 33:22	08:34:24 36:16
08:22:45 25:10	08:25:30 28:7	08:28:20 31:2	08:31:52 34:1,2	08:34:26 36:17
08:22:47 25:11	08:25:32 28:8	08:28:24 31:3	08:31:56 34:3	08:34:33 36:18
08:22:48 25:12	08:25:33 28:9	08:28:25 31:4	08:31:57 34:4	08:34:35 36:19
08:22:49 25:13	08:25:35 28:10	08:28:28 31:5	08:31:59 34:5	08:34:36 36:20
08:22:51 25:14,15	08:25:38 28:11	08:28:30 31:6	08:32:00 34:6	08:34:39 36:21
08:22:53 25:16	08:25:39 28:12	08:28:31 31:7	08:32:01 34:7	08:34:47 36:22
08:22:55 25:17	08:25:40 28:13	08:28:32 31:8	08:32:03 34:8	08:34:54 37:1
08:22:58 25:18,19	08:25:42 28:14	08:28:35 31:9	08:32:06 34:9	08:34:58 37:2
08:23:10 25:20	08:25:45 28:15	08:28:40 31:10	08:32:09 34:10	08:35:00 37:3
08:23:12 25:21,22	08:25:50 28:16	08:28:42 31:11	08:32:12 34:11	08:35:02 37:4
08:23:18 26:1	08:25:52 28:17	08:28:45 31:12	08:32:13 34:12	08:35:05 37:5
08:23:19 26:2	08:25:59 28:18	08:28:51 31:13	08:32:15 34:13	08:35:06 37:6,7
08:23:23 26:3	08:26:03 28:19	08:28:53 31:14	08:32:17 34:14	08:35:09 37:8
08:23:28 26:4	08:26:06 28:20	08:29:05 31:15	08:32:24 34:15	08:35:10 37:9,10
08:23:29 26:5	08:26:08 28:21	08:29:07 31:16	08:32:25 34:16	08:35:12 37:11
08:23:31 26:6	08:26:11 28:22	08:29:09 31:17	08:32:28 34:17	08:35:15 37:12
08:23:33 26:7,8	08:26:16 29:1,2	08:29:26 31:18	08:32:31 34:18	08:35:21 37:13
08:23:36 26:9	08:26:17 29:3	08:29:29 31:19,20	08:32:32 34:19	08:35:23 37:14
08:23:40 26:10	08:26:19 29:4	08:29:31 31:21	08:32:34 34:20	08:35:24 37:15
08:23:41 26:11	08:26:28 29:5	08:29:35 31:22	08:32:37 34:21,22	08:35:26 37:16
08:23:44 26:12	08:26:32 29:6,7	08:29:37 32:1	08:32:39 35:1	08:35:30 37:17
08:23:45 26:13	08:26:36 29:8	08:29:40 32:2	08:32:42 35:2	08:35:31 37:18
08:23:52 26:14	08:26:37 29:9	08:29:45 32:3,4,5	08:32:45 35:3	08:35:35 37:19
08:23:54 26:15	08:26:40 29:10	08:29:48 32:6	08:32:49 35:4	08:35:39 37:20
08:23:57 26:16	08:26:41 29:11	08:29:53 32:7	08:32:51 35:5	08:35:42 37:21
08:24:01 26:17	08:26:43 29:12	08:29:58 32:8,9	08:32:53 35:6,7	08:35:48 37:22
08:24:06 26:18,19	08:26:46 29:13	08:30:02 32:10	08:32:56 35:8	08:35:49 38:1
08:24:09 26:20	08:26:52 29:14	08:30:03 32:11	08:32:58 35:9	08:35:52 38:2
08:24:11 26:21	08:26:53 29:15	08:30:08 32:12	08:33:00 35:10	08:35:56 38:3
08:24:12 26:22	08:26:59 29:16	08:30:14 32:13,14	08:33:03 35:11	08:35:57 38:4
08:24:13 27:1	08:27:02 29:17,18	08:30:16 32:15	08:33:06 35:12	08:35:58 38:5
08:24:17 27:2	08:27:04 29:19	08:30:19 32:16	08:33:09 35:13	08:35:59 38:6
08:24:19 27:3	08:27:11 29:20	08:30:22 32:17	08:33:12 35:14	08:36:02 38:7
08:24:25 27:4	08:27:12 29:21	08:30:37 32:18	08:33:15 35:15	08:36:05 38:8
08:24:27 27:5	08:27:14 29:22	08:30:39 32:19	08:33:16 35:16	08:36:06 38:9
08:24:29 27:6	08:27:15 30:1	08:30:42 32:20	08:33:17 35:17	08:36:09 38:10
08:24:31 27:7	08:27:17 30:2	08:30:45 32:21	08:33:25 35:18	08:36:13 38:11
08:24:34 27:8	08:27:19 30:3	08:30:47 32:22	08:33:28 35:19	08:36:15 38:12
08:24:37 27:9	08:27:21 30:4	08:30:52 33:1	08:33:31 35:20	08:36:16 38:13
08:24:39 27:10	08:27:25 30:5	08:31:00 33:2,3	08:33:42 35:21	08:36:19 38:14
08:24:42 27:11	08:27:27 30:6	08:31:02 33:4,5	08:33:45 35:22	08:36:23 38:15
08:24:43 27:12	08:27:28 30:7	08:31:04 33:6	08:33:48 36:1	08:36:25 38:16
08:24:47 27:13	08:27:38 30:8	08:31:05 33:7	08:33:50 36:2	08:36:28 38:17

08:36:31 38:18	08:39:58 41:12	08:43:49 44:5,6	08:47:25 47:1	08:50:22 49:19
08:36:34 38:19	08:40:04 41:13	08:43:51 44:7	08:47:29 47:2	08:50:23 49:20
08:36:38 38:20	08:40:07 41:14	08:43:57 44:8	08:47:32 47:3	08:50:25 49:21
08:36:42 38:21	08:40:10 41:15	08:44:03 44:9	08:47:33 47:4	08:50:32 49:22
08:36:44 38:22	08:40:13 41:16,17	08:44:12 44:10	08:47:34 47:5	08:50:38 50:1
08:36:48 39:1	08:40:15 41:18	08:44:17 44:11	08:47:37 47:6	08:50:46 50:2
08:36:51 39:2	08:40:19 41:19	08:44:24 44:12	08:47:40 47:7	08:50:55 50:3
08:36:54 39:3	08:40:23 41:20	08:44:34 44:13	08:47:49 47:8,9	08:51:00 50:4
08:36:58 39:4	08:40:33 41:21	08:44:37 44:14	08:47:50 47:10	08:51:04 50:5
08:36:59 39:5	08:40:36 41:22	08:44:38 44:15	08:47:53 47:11	08:51:07 50:6
08:37:02 39:6	08:40:37 42:1	08:44:41 44:16	08:47:54 47:12	08:51:11 50:7
08:37:07 39:7,8	08:40:43 42:2	08:44:43 44:17,18	08:47:57 47:13	08:51:15 50:8
08:37:08 39:9	08:40:51 42:3	08:44:47 44:19	08:48:02 47:14	08:51:18 50:9
08:37:09 39:10	08:40:54 42:4	08:44:50 44:20	08:48:08 47:15	08:51:20 50:10
08:37:12 39:11	08:40:56 42:5,6	08:44:52 44:21	08:48:14 47:16	08:51:32 50:11
08:37:17 39:12,13	08:40:58 42:7	08:44:54 44:22	08:48:21 47:17	08:51:48 50:12
08:37:18 39:14	08:40:59 42:8	08:44:57 45:1	08:48:23 47:18	08:51:49 50:13
08:37:21 39:15	08:41:06 42:9	08:45:00 45:2	08:48:29 47:19,20	08:51:53 50:14
08:37:26 39:16	08:41:09 42:10	08:45:02 45:3	08:48:31 47:21,22	08:51:58 50:15
08:37:28 39:17,18	08:41:18 42:11	08:45:06 45:4	08:48:34 48:1	08:52:01 50:16
08:37:31 39:19	08:41:22 42:12	08:45:13 45:5	08:48:39 48:2	08:52:04 50:17
08:37:34 39:20	08:41:26 42:13	08:45:15 45:6	08:48:43 48:3	08:52:07 50:18
08:37:38 39:21	08:41:30 42:14	08:45:18 45:7,8	08:48:45 48:4	08:52:10 50:19
08:37:52 39:22	08:41:36 42:15	08:45:21 45:9	08:48:47 48:5	08:52:13 50:20,21
08:37:54 40:1	08:41:40 42:16	08:45:28 45:10	08:48:48 48:6	08:52:16 50:22
08:38:00 40:2	08:41:44 42:17	08:45:33 45:11	08:48:51 48:7	08:52:18 51:1
08:38:06 40:3	08:41:48 42:18	08:45:37 45:12,13	08:48:52 48:8,9	08:52:22 51:2
08:38:09 40:4	08:41:53 42:19	08:45:42 45:14	08:48:56 48:10	08:52:30 51:3
08:38:10 40:5	08:41:56 42:20	08:45:44 45:15	08:48:58 48:11,12	08:52:33 51:4
08:38:12 40:6	08:41:59 42:21	08:45:47 45:16	08:49:00 48:13	08:52:35 51:5
08:38:15 40:7	08:42:02 42:22	08:45:48 45:17	08:49:04 48:14	08:52:39 51:6
08:38:18 40:8	08:42:04 43:1	08:45:49 45:18	08:49:06 48:15	08:52:42 51:7
08:38:20 40:9	08:42:06 43:2	08:45:52 45:19	08:49:09 48:16	08:52:43 51:8
08:38:22 40:10	08:42:09 43:3	08:45:55 45:20	08:49:14 48:17	08:52:45 51:9
08:38:26 40:11	08:42:12 43:4	08:46:00 45:21	08:49:17 48:18	08:52:49 51:10,11
08:38:32 40:12	08:42:14 43:5	08:46:06 45:22	08:49:19 48:19	08:52:51 51:12
08:38:35 40:13	08:42:16 43:6	08:46:19 46:1	08:49:23 48:20	08:52:54 51:13
08:38:37 40:14	08:42:17 43:7	08:46:21 46:2	08:49:26 48:21	08:52:55 51:14
08:38:40 40:15	08:42:20 43:8	08:46:23 46:3	08:49:29 48:22	08:52:56 51:15
08:38:44 40:16	08:42:24 43:9	08:46:28 46:4	08:49:33 49:1	08:52:59 51:16,17
08:38:45 40:17	08:42:29 43:10	08:46:30 46:5	08:49:37 49:2	08:53:00 51:18
08:38:50 40:18	08:42:31 43:11	08:46:34 46:6	08:49:39 49:3	08:53:02 51:19
08:38:53 40:19	08:42:33 43:12	08:46:35 46:7	08:49:43 49:4	08:53:06 51:20
08:39:01 40:20	08:42:39 43:13	08:46:36 46:8,9	08:49:47 49:5	08:53:08 51:21
08:39:06 40:21	08:42:42 43:14	08:46:44 46:10	08:49:49 49:6	08:53:10 51:22
08:39:11 40:22	08:42:44 43:15	08:46:49 46:11	08:49:51 49:7	08:53:13 52:1
08:39:20 41:1	08:42:47 43:16	08:46:52 46:12	08:49:52 49:8	08:53:14 52:2
08:39:22 41:2	08:42:53 43:17	08:46:55 46:13	08:49:53 49:9	08:53:16 52:3
08:39:25 41:3	08:42:59 43:18	08:46:58 46:14	08:50:01 49:10	08:53:21 52:4
08:39:28 41:4	08:43:05 43:19	08:47:00 46:15	08:50:03 49:11	08:53:24 52:5
08:39:39 41:5	08:43:14 43:20	08:47:02 46:16	08:50:06 49:12	08:53:25 52:6
08:39:42 41:6	08:43:20 43:21	08:47:05 46:17	08:50:10 49:13	08:53:27 52:7
08:39:47 41:7	08:43:30 43:22	08:47:08 46:18	08:50:12 49:14	08:53:30 52:8
08:39:48 41:8	08:43:32 44:1	08:47:11 46:19	08:50:13 49:15	08:53:33 52:9
08:39:50 41:9	08:43:37 44:2	08:47:13 46:20	08:50:14 49:16	08:53:36 52:10,11
08:39:52 41:10	08:43:39 44:3	08:47:22 46:21	08:50:16 49:17	08:53:40 52:12
08:39:56 41:11	08:43:41 44:4	08:47:24 46:22	08:50:18 49:18	08:53:42 52:13

08:53:46 52:14	08:56:53 55:10	09:00:51 58:4	09:04:08 60:21	09:07:57 63:15,16
08:53:52 52:15	08:56:57 55:11	09:00:52 58:5	09:04:13 60:22	09:08:05 63:17
08:53:56 52:16	08:56:58 55:12,13	09:00:57 58:6	09:04:17 61:1	09:08:08 63:18
08:53:57 52:17	08:57:01 55:14	09:01:01 58:7	09:04:21 61:2	09:08:10 63:19
08:53:59 52:18	08:57:06 55:15	09:01:07 58:8	09:04:23 61:3	09:08:12 63:20
08:54:03 52:19	08:57:10 55:16	09:01:10 58:9	09:04:25 61:4	09:08:16 63:21
08:54:04 52:20	08:57:15 55:17	09:01:11 58:10	09:04:28 61:5	09:08:17 63:22
08:54:06 52:21	08:57:18 55:18	09:01:14 58:11	09:04:30 61:6	09:08:20 64:1
08:54:10 52:22	08:57:22 55:19	09:01:20 58:12	09:04:33 61:7	09:08:21 64:2
08:54:11 53:1	08:57:32 55:20	09:01:24 58:13	09:04:39 61:8	09:08:25 64:3
08:54:13 53:2	08:57:36 55:21	09:01:30 58:14	09:04:43 61:9	09:08:28 64:4
08:54:16 53:3	08:57:42 55:22	09:01:32 58:15	09:04:46 61:10	09:08:31 64:5
08:54:20 53:4	08:57:45 56:1	09:01:33 58:16	09:04:48 61:11	09:08:34 64:6
08:54:23 53:5	08:57:49 56:2	09:01:36 58:17	09:04:50 61:12	09:08:36 64:7
08:54:26 53:6	08:57:51 56:3	09:01:39 58:18	09:04:54 61:13,14	09:08:40 64:8
08:54:28 53:7,8	08:57:53 56:4	09:01:41 58:19	09:04:57 61:15	09:08:43 64:9
08:54:30 53:9	08:58:01 56:5	09:01:49 58:20	09:05:00 61:16	09:08:45 64:10
08:54:31 53:10	08:58:11 56:6	09:01:53 58:21	09:05:04 61:17	09:08:48 64:11
08:54:37 53:11,12	08:58:14 56:7	09:01:58 58:22	09:05:06 61:18	09:08:50 64:12
08:54:40 53:13	08:58:17 56:8	09:02:02 59:1	09:05:08 61:19	09:08:52 64:13
08:54:42 53:14	08:58:19 56:9	09:02:04 59:2	09:05:13 61:20	09:08:59 64:14
08:54:45 53:15	08:58:21 56:10	09:02:07 59:3	09:05:21 61:21	09:09:00 64:15
08:54:50 53:16	08:58:23 56:11	09:02:10 59:4	09:05:26 61:22	09:09:02 64:16
08:54:55 53:17	08:58:24 56:12	09:02:15 59:5	09:05:31 62:1	09:09:03 64:17
08:54:59 53:18	08:58:26 56:13	09:02:19 59:6	09:05:32 62:2	09:09:06 64:18
08:55:04 53:19	08:58:29 56:14	09:02:20 59:7	09:05:34 62:3	09:09:09 64:19
08:55:08 53:20	08:58:50 56:15	09:02:22 59:8	09:05:39 62:4,5	09:09:10 64:20
08:55:11 53:21	08:59:14 56:16	09:02:27 59:9	09:05:40 62:6	09:09:12 64:21
08:55:13 53:22	08:59:17 56:17	09:02:29 59:10	09:05:42 62:7	09:09:19 64:22
08:55:15 54:1	08:59:22 56:18	09:02:30 59:11	09:05:51 62:8	09:09:21 65:1,2
08:55:19 54:2	08:59:26 56:19	09:02:32 59:12,13	09:05:58 62:9	09:09:23 65:3
08:55:26 54:3	08:59:28 56:20	09:02:35 59:14	09:05:59 62:10	09:09:26 65:4
08:55:32 54:4	08:59:30 56:21	09:02:37 59:15,16	09:06:02 62:11	09:09:27 65:5
08:55:34 54:5	08:59:35 56:22	09:02:38 59:17	09:06:05 62:12	09:09:29 65:6
08:55:38 54:6	08:59:38 57:1	09:02:41 59:18	09:06:13 62:13	09:09:39 65:7
08:55:42 54:7	08:59:51 57:2	09:02:43 59:19	09:06:18 62:14	09:09:46 65:8
08:55:46 54:8,9	08:59:54 57:3	09:02:47 59:20	09:06:23 62:15	09:09:52 65:9
08:55:49 54:10	08:59:56 57:4	09:02:50 59:21	09:06:27 62:16	09:09:56 65:10
08:55:52 54:11	08:59:58 57:5	09:02:54 59:22	09:06:31 62:17	09:09:57 65:11
08:55:57 54:12	09:00:00 57:6	09:02:55 60:1	09:06:32 62:18	09:09:59 65:12
08:56:01 54:13	09:00:02 57:7	09:02:56 60:2	09:06:35 62:19	09:10:02 65:13
08:56:05 54:14	09:00:04 57:8	09:02:58 60:3	09:06:36 62:20	09:10:07 65:14
08:56:08 54:15	09:00:05 57:9	09:03:04 60:4	09:06:39 62:21	09:10:15 65:15
08:56:11 54:16	09:00:09 57:10	09:03:08 60:5	09:06:46 62:22	09:10:19 65:16
08:56:13 54:17	09:00:11 57:11	09:03:09 60:6	09:06:47 63:1	09:10:22 65:17
08:56:14 54:18	09:00:14 57:12	09:03:11 60:7	09:06:48 63:2,3	09:10:27 65:18
08:56:19 54:19	09:00:23 57:13	09:03:12 60:8	09:06:51 63:4	09:10:30 65:19
08:56:23 54:20	09:00:24 57:14	09:03:31 60:9	09:07:01 63:5	09:10:35 65:20
08:56:27 54:21	09:00:27 57:15	09:03:34 60:10	09:07:06 63:6	09:10:40 65:21
08:56:33 54:22	09:00:30 57:16	09:03:38 60:11	09:07:27 63:7	09:10:42 65:22
08:56:34 55:1	09:00:32 57:17	09:03:42 60:12	09:07:31 63:8	09:10:43 66:1,2
08:56:38 55:2	09:00:35 57:18	09:03:45 60:13	09:07:34 63:9	09:10:46 66:3
08:56:40 55:3	09:00:38 57:19	09:03:49 60:14	09:07:36 63:10	09:10:48 66:4
08:56:41 55:4,5	09:00:44 57:20	09:03:56 60:15	09:07:40 63:11	09:10:49 66:5
08:56:44 55:6	09:00:47 57:21,22	09:04:03 60:16	09:07:49 63:12	09:10:50 66:6
08:56:48 55:7	09:00:49 58:1,2	09:04:04 60:17,18	09:07:51 63:13	09:10:58 66:7
08:56:51 55:8,9	09:00:50 58:3	09:04:07 60:19,20	09:07:55 63:14	09:11:01 66:8

09:11:04 66:9	09:15:05 68:22	09:18:06 71:15	09:21:34 74:14	09:25:30 77:10
09:11:05 66:10	09:15:06 69:1	09:18:09 71:16	09:21:38 74:15	09:25:33 77:11
09:11:31 66:11	09:15:07 69:2	09:18:14 71:17	09:21:44 74:16	09:25:34 77:12
09:11:33 66:12	09:15:10 69:3	09:18:18 71:18	09:21:51 74:17	09:25:37 77:13
09:11:35 66:13	09:15:14 69:4	09:18:24 71:19	09:21:55 74:18	09:25:41 77:14
09:11:43 66:14	09:15:15 69:5	09:18:27 71:20	09:21:56 74:19,20	09:25:44 77:15
09:11:48 66:15	09:15:17 69:6	09:18:30 71:21	09:21:58 74:21	09:25:52 77:16
09:12:23 66:16	09:15:20 69:7	09:18:34 71:22 72:1	09:22:00 74:22	09:25:54 77:17
09:12:25 66:17	09:15:21 69:8	09:18:36 72:2	09:22:03 75:1	09:25:57 77:18
09:12:30 66:18	09:15:22 69:9	09:18:39 72:3	09:22:06 75:2	09:25:59 77:19
09:12:35 66:19	09:15:24 69:10	09:18:42 72:4	09:22:09 75:3	09:26:02 77:20
09:12:39 66:20	09:15:28 69:11	09:18:44 72:5	09:22:15 75:4	09:26:05 77:21
09:12:42 66:21	09:15:35 69:12	09:18:47 72:6	09:22:21 75:5,6,7	09:26:07 77:22
09:12:45 66:22	09:15:38 69:13	09:18:50 72:7	09:22:22 75:8	09:26:09 78:1
09:12:48 67:1	09:15:42 69:14	09:18:54 72:8	09:22:23 75:9	09:26:23 78:2
09:12:51 67:2	09:15:45 69:15	09:18:56 72:9	09:22:25 75:10	09:26:28 78:3
09:12:59 67:3	09:15:48 69:16	09:19:00 72:10,11	09:22:27 75:11	09:26:32 78:4
09:13:01 67:4	09:15:59 69:17	09:19:04 72:12	09:22:31 75:12	09:26:34 78:5
09:13:10 67:5	09:16:07 69:18	09:19:06 72:13	09:22:37 75:13	09:26:37 78:6
09:13:14 67:6	09:16:09 69:19	09:19:08 72:14,15	09:22:41 75:14	09:26:40 78:7
09:13:17 67:7	09:16:10 69:20	09:19:10 72:16	09:22:45 75:15	09:26:43 78:8
09:13:20 67:8	09:16:11 69:21	09:19:12 72:17	09:22:46 75:16	09:26:47 78:9
09:13:23 67:9	09:16:15 69:22	09:19:13 72:18	09:22:53 75:17	09:26:48 78:10,11
09:13:26 67:10	09:16:17 70:1	09:19:15 72:19	09:22:55 75:18	09:26:51 78:12
09:13:28 67:11	09:16:22 70:2	09:19:20 72:20,21	09:22:59 75:19	09:26:53 78:13
09:13:29 67:12	09:16:26 70:3	09:19:22 72:22	09:23:05 75:20	09:26:59 78:14
09:13:31 67:13	09:16:29 70:4	09:19:30 73:1	09:23:07 75:21	09:27:04 78:15
09:13:33 67:14	09:16:32 70:5	09:19:33 73:2	09:23:09 75:22	09:27:07 78:16
09:13:38 67:15	09:16:33 70:6	09:19:36 73:3	09:23:12 76:1,2	09:27:09 78:17,18
09:13:41 67:16	09:16:36 70:7	09:19:39 73:4	09:23:15 76:3	09:27:13 78:19
09:13:45 67:17	09:16:40 70:8	09:19:45 73:5	09:23:22 76:4	09:27:16 78:20
09:13:47 67:18	09:16:42 70:9	09:19:51 73:6	09:23:30 76:5	09:27:58 78:21
09:13:48 67:19	09:16:45 70:10	09:19:58 73:7	09:23:35 76:6	09:28:00 78:22
09:13:51 67:20	09:16:49 70:11	09:20:01 73:8	09:23:37 76:7	09:28:01 79:1
09:13:52 67:21	09:16:50 70:12	09:20:04 73:9	09:23:42 76:8	09:28:05 79:2
09:13:54 67:22	09:16:53 70:13,14	09:20:05 73:10	09:23:46 76:9	09:28:08 79:3
09:13:57 68:1	09:16:57 70:15,16	09:20:08 73:11	09:23:51 76:10	09:28:10 79:4
09:13:59 68:2	09:16:59 70:17	09:20:13 73:12	09:23:55 76:11	09:28:13 79:5
09:14:05 68:3	09:17:00 70:18	09:20:18 73:13	09:24:05 76:12	09:28:16 79:6
09:14:07 68:4	09:17:02 70:19	09:20:25 73:14	09:24:10 76:13	09:28:18 79:7,8
09:14:11 68:5	09:17:11 70:20	09:20:31 73:15	09:24:15 76:14	09:28:21 79:9
09:14:14 68:6	09:17:14 70:21	09:20:39 73:16	09:24:17 76:15	09:28:22 79:10
09:14:18 68:7	09:17:19 70:22	09:20:40 73:17	09:24:22 76:16	09:28:26 79:11
09:14:20 68:8	09:17:24 71:1	09:20:45 73:18	09:24:27 76:17	09:28:30 79:12
09:14:26 68:9	09:17:27 71:2	09:20:51 73:19	09:24:35 76:18	09:28:33 79:13
09:14:33 68:10	09:17:33 71:3	09:20:57 73:20	09:24:39 76:19	09:28:38 79:14
09:14:35 68:11	09:17:38 71:4	09:20:58 73:21	09:24:48 76:20	09:28:44 79:15
09:14:40 68:12	09:17:41 71:5	09:21:04 73:22	09:24:49 76:21	09:28:49 79:16
09:14:42 68:13	09:17:42 71:6	09:21:08 74:1	09:24:53 76:22	09:28:53 79:17
09:14:44 68:14	09:17:43 71:7	09:21:10 74:2,3	09:24:56 77:1	09:28:59 79:18
09:14:45 68:15	09:17:49 71:8	09:21:15 74:4	09:24:59 77:2	09:29:02 79:19
09:14:47 68:16	09:17:50 71:9	09:21:19 74:5,6,7	09:25:02 77:3	09:29:07 79:20
09:14:49 68:17	09:17:52 71:10	09:21:24 74:8	09:25:06 77:4	09:29:09 79:21
09:14:54 68:18	09:17:54 71:11	09:21:26 74:9,10	09:25:14 77:5	09:29:11 79:22
09:14:57 68:19	09:17:56 71:12	09:21:27 74:11	09:25:20 77:6,7	09:29:13 80:1
09:14:59 68:20	09:17:58 71:13	09:21:29 74:12	09:25:22 77:8	09:29:18 80:2
09:15:03 68:21	09:18:01 71:14	09:21:30 74:13	09:25:26 77:9	09:29:21 80:3

09:29:24 80:4	09:48:22 82:18	09:51:56 85:15	09:55:49 88:7	09:58:46 91:6
09:29:27 80:5	09:48:24 82:19	09:51:58 85:16	09:55:53 88:8	09:58:49 91:7
09:29:31 80:6	09:48:27 82:20	09:52:02 85:17	09:55:54 88:9	09:58:50 91:8
09:29:32 80:7	09:48:31 82:21	09:52:06 85:18	09:55:56 88:10,11	09:58:55 91:9
09:29:34 80:8	09:48:34 82:22	09:52:08 85:19	09:55:57 88:12,13	09:58:57 91:10
09:29:38 80:9	09:48:39 83:1,2	09:52:11 85:20	09:56:00 88:14	09:58:58 91:11
09:29:41 80:10	09:48:42 83:3	09:52:14 85:21	09:56:02 88:15	09:59:03 91:12
09:29:42 80:11	09:48:44 83:4	09:52:17 85:22	09:56:05 88:16	09:59:07 91:13,14
09:29:47 80:12	09:48:46 83:5	09:52:21 86:1	09:56:09 88:17	09:59:09 91:15
09:29:49 80:13	09:48:48 83:6	09:52:24 86:2	09:56:13 88:18	09:59:14 91:16
09:29:50 80:14	09:48:51 83:7	09:52:26 86:3	09:56:15 88:19	09:59:15 91:17,18
09:29:53 80:15	09:49:01 83:8	09:52:28 86:4	09:56:19 88:20	09:59:21 91:19
09:29:57 80:16	09:49:09 83:9	09:52:29 86:5	09:56:23 88:21	09:59:24 91:20
09:29:59 80:17	09:49:14 83:10	09:52:32 86:6	09:56:27 88:22	09:59:25 91:21
09:30:09 80:18	09:49:18 83:11	09:52:38 86:7	09:56:31 89:1	09:59:32 91:22
09:30:12 80:19	09:49:21 83:12	09:52:42 86:8	09:56:32 89:2	09:59:36 92:1
09:30:15 80:20	09:49:25 83:13	09:52:44 86:9	09:56:36 89:3	09:59:37 92:2
09:30:18 80:21	09:49:29 83:14	09:52:49 86:10	09:56:38 89:4	09:59:38 92:3
09:45:18 80:22	09:49:33 83:15	09:52:56 86:11	09:56:41 89:5,6	09:59:40 92:4
09:45:33 81:1	09:49:35 83:16	09:53:00 86:12	09:56:42 89:7,8	09:59:42 92:5
09:45:45 81:2	09:49:38 83:17	09:53:07 86:13	09:56:45 89:9	09:59:43 92:6
09:45:48 81:3	09:49:41 83:18	09:53:09 86:14	09:56:46 89:10	09:59:45 92:7
09:45:50 81:4	09:49:43 83:19	09:53:22 86:15	09:56:48 89:11	09:59:48 92:8
09:45:52 81:5,6	09:49:45 83:20	09:53:33 86:16	09:56:50 89:12	09:59:50 92:9
09:45:55 81:7	09:49:46 83:21	09:53:42 86:17	09:56:55 89:13	09:59:51 92:10,11
09:46:00 81:8	09:49:51 83:22	09:53:46 86:18	09:57:02 89:14	09:59:54 92:12
09:46:05 81:9	09:49:56 84:1	09:53:50 86:19	09:57:03 89:15	09:59:57 92:13
09:46:09 81:10	09:49:59 84:2	09:53:54 86:20	09:57:06 89:16	09:59:58 92:14
09:46:11 81:11	09:50:04 84:3	09:53:57 86:21	09:57:08 89:17	
09:46:13 81:12	09:50:08 84:4	09:54:00 86:22	09:57:11 89:18	I
09:46:17 81:13	09:50:10 84:5	09:54:04 87:1	09:57:16 89:19	1 5:10 9:10 18:9,10,14
09:46:27 81:14	09:50:13 84:6	09:54:09 87:2	09:57:20 89:20	18:16 90:4 97:15,16
09:46:32 81:15	09:50:20 84:7	09:54:11 87:3	09:57:22 89:21	97:22 106:9,15 107:2
09:46:33 81:16	09:50:22 84:8	09:54:14 87:4	09:57:25 89:22	107:2,8,16 108:1,20
09:46:35 81:17	09:50:26 84:9	09:54:15 87:5	09:57:28 90:1	112:14 113:4,5,8,9,12
09:46:39 81:18	09:50:29 84:10	09:54:21 87:6	09:57:30 90:2	113:21 114:20 115:8
09:46:44 81:19	09:50:32 84:11	09:54:24 87:7	09:57:35 90:3	115:15 117:8,10
09:46:49 81:20	09:50:37 84:12,13	09:54:28 87:8	09:57:37 90:4	118:1,16,20 119:16
09:47:00 81:21	09:50:39 84:14,15,16	09:54:32 87:9,10	09:57:46 90:5	120:10 121:4,20
09:47:07 81:22	09:50:43 84:17	09:54:54 87:11	09:57:48 90:6	122:10,15 123:3,15
09:47:09 82:1	09:50:50 84:18	09:54:58 87:12	09:57:53 90:7	155:16 227:3,11,13
09:47:13 82:2	09:50:56 84:19	09:55:01 87:13	09:57:55 90:8,9	227:20 228:8,18
09:47:16 82:3	09:51:00 84:20	09:55:04 87:14	09:57:56 90:10	229:4 230:20 231:2
09:47:21 82:4	09:51:03 84:21	09:55:09 87:15	09:58:01 90:11	235:14 279:13 280:3
09:47:25 82:5	09:51:05 84:22	09:55:10 87:16	09:58:04 90:12	1.2 267:22
09:47:29 82:6	09:51:07 85:1	09:55:11 87:17	09:58:08 90:13,14	1/10 251:3,16
09:47:32 82:7	09:51:11 85:2	09:55:12 87:18	09:58:09 90:15	1/1000 251:2
09:47:36 82:8	09:51:21 85:3,4	09:55:13 87:19	09:58:13 90:16	1:14-CV-00667 15:15
09:47:42 82:9	09:51:22 85:5,6	09:55:16 87:20	09:58:16 90:17,18	1:14-cv-00667-JBS-...
09:47:46 82:10	09:51:26 85:7	09:55:19 87:21	09:58:21 90:19	1:6
09:47:50 82:11	09:51:29 85:8	09:55:22 87:22	09:58:23 90:20	1:14-cv-04149-JBS-...
09:47:54 82:12	09:51:31 85:9	09:55:25 88:1	09:58:24 90:21	1:6
09:47:58 82:13	09:51:34 85:10	09:55:29 88:2	09:58:29 90:22	1:14-cv-05144-JBS-...
09:48:04 82:14	09:51:37 85:11	09:55:31 88:3	09:58:32 91:1,2	1:7
09:48:10 82:15	09:51:41 85:12	09:55:34 88:4	09:58:38 91:3	1:14-cv-06893-JBS-...
09:48:15 82:16	09:51:43 85:13	09:55:44 88:5	09:58:40 91:4	1:12
09:48:18 82:17	09:51:45 85:14	09:55:46 88:6	09:58:41 91:5	1:15-cv-00335-JBS-...

1:7	10:02:11 95:2	10:05:43 97:19	10:09:50 100:14	10:13:30 103:9
1:15-cv-03240-JBS-...	10:02:13 95:3	10:05:45 97:20	10:09:52 100:15,16	10:13:33 103:10
1:13	10:02:23 95:4	10:05:46 97:21	10:10:00 100:17	10:13:37 103:11
1:27 205:3,5	10:02:25 95:5	10:05:48 97:22	10:10:04 100:18	10:13:40 103:12
10 8:10 58:6,8 62:10,11	10:02:28 95:6	10:05:52 98:1	10:10:05 100:19	10:13:43 103:13
65:15 81:7 238:11,14	10:02:30 95:7,8	10:05:56 98:2,3	10:10:07 100:20	10:13:45 103:14
238:16 239:1 246:8	10:02:33 95:9	10:05:59 98:4	10:10:10 100:21	10:13:49 103:15
260:5 264:10,15	10:02:42 95:10	10:06:01 98:5	10:10:28 100:22 101:1	10:13:57 103:16
265:2,8,10,12,17	10:02:47 95:11,12	10:06:24 98:6,7	10:10:30 101:2	10:14:02 103:17
10:00:06 92:15	10:02:50 95:13	10:06:25 98:8	10:10:36 101:3	10:14:05 103:18
10:00:08 92:16	10:02:52 95:14	10:06:29 98:9	10:10:38 101:4	10:14:08 103:19
10:00:12 92:17	10:02:54 95:15	10:06:34 98:10	10:10:44 101:5	10:14:09 103:20
10:00:15 92:18	10:02:56 95:16	10:06:38 98:11	10:10:47 101:6	10:14:11 103:21
10:00:16 92:19,20	10:02:58 95:17	10:06:42 98:12	10:10:50 101:7	10:14:12 103:22
10:00:18 92:21	10:02:59 95:18	10:06:45 98:13	10:10:52 101:8	10:14:15 104:1
10:00:20 92:22	10:03:00 95:19	10:06:48 98:14	10:10:53 101:9	10:14:18 104:2
10:00:22 93:1	10:03:02 95:20	10:06:51 98:15,16	10:10:59 101:10	10:14:21 104:3
10:00:24 93:2	10:03:03 95:21	10:06:54 98:17	10:11:01 101:11	10:14:23 104:4,5
10:00:27 93:3	10:03:10 95:22	10:06:57 98:18	10:11:04 101:12	10:14:27 104:6
10:00:28 93:4	10:03:16 96:1	10:07:01 98:19	10:11:07 101:13	10:14:29 104:7
10:00:29 93:5	10:03:21 96:2	10:07:02 98:20	10:11:09 101:14	10:14:33 104:8
10:00:33 93:6	10:03:25 96:3	10:07:10 98:21	10:11:12 101:15	10:14:36 104:9
10:00:36 93:7	10:03:28 96:4	10:07:14 98:22	10:11:14 101:16	10:14:42 104:10,11
10:00:37 93:8	10:03:30 96:5	10:07:18 99:1	10:11:18 101:17	10:14:44 104:12
10:00:39 93:9	10:03:32 96:6	10:07:21 99:2	10:11:22 101:18	10:14:51 104:13
10:00:43 93:10	10:03:33 96:7	10:07:24 99:3	10:11:30 101:19	10:14:52 104:14
10:00:45 93:11	10:03:35 96:8	10:07:28 99:4	10:11:39 101:20	10:14:54 104:15
10:00:47 93:12	10:03:36 96:9	10:07:30 99:5	10:11:43 101:21,22	10:14:57 104:16
10:00:48 93:13	10:03:37 96:10	10:07:32 99:6	10:11:46 102:1	10:14:59 104:17
10:00:52 93:14	10:03:39 96:11,12	10:07:36 99:7	10:11:50 102:2	10:15:01 104:18
10:00:55 93:15	10:03:43 96:13	10:07:43 99:8	10:11:53 102:3	10:15:04 104:19
10:00:56 93:16	10:03:46 96:14	10:07:46 99:9	10:11:55 102:4	10:15:06 104:20
10:00:58 93:17,18	10:03:47 96:15	10:07:49 99:10	10:12:00 102:5	10:15:09 104:21
10:01:01 93:19	10:03:55 96:16	10:07:51 99:11	10:12:06 102:6	10:15:11 104:22
10:01:04 93:20	10:03:58 96:17	10:07:52 99:12,13	10:12:07 102:7	10:15:13 105:1
10:01:06 93:21	10:04:04 96:18	10:07:56 99:14	10:12:10 102:8	10:15:14 105:2
10:01:09 93:22	10:04:18 96:19,20	10:07:58 99:15	10:12:12 102:9	10:15:15 105:3
10:01:12 94:1	10:04:20 96:21	10:08:02 99:16	10:12:15 102:10	10:15:18 105:4
10:01:16 94:2,3	10:04:22 96:22	10:08:30 99:17	10:12:23 102:11	10:15:22 105:5
10:01:19 94:4	10:04:28 97:1	10:08:34 99:18	10:12:31 102:12	10:15:26 105:6
10:01:22 94:5	10:04:31 97:2	10:08:38 99:19	10:12:34 102:13	10:15:31 105:7
10:01:23 94:6	10:04:34 97:3	10:08:44 99:20	10:12:36 102:14	10:15:35 105:8
10:01:26 94:7	10:04:36 97:4	10:08:47 99:21	10:12:39 102:15	10:15:38 105:9
10:01:29 94:8,9	10:04:37 97:5	10:08:49 99:22	10:12:44 102:16	10:15:42 105:10
10:01:31 94:10	10:04:38 97:6	10:08:50 100:1	10:12:46 102:17	10:15:45 105:11
10:01:33 94:11	10:04:41 97:7	10:08:53 100:2	10:12:56 102:18	10:15:49 105:12
10:01:38 94:12	10:04:45 97:8	10:08:55 100:3	10:12:58 102:19	10:15:51 105:13
10:01:40 94:13	10:04:47 97:9	10:09:03 100:4	10:13:02 102:20	10:15:52 105:14
10:01:44 94:14	10:04:51 97:10	10:09:09 100:5	10:13:05 102:21,22	10:15:54 105:15
10:01:47 94:15	10:04:56 97:11	10:09:14 100:6	10:13:08 103:1	10:16:00 105:16
10:01:48 94:16	10:04:58 97:12	10:09:27 100:7	10:13:11 103:2	10:16:02 105:17
10:01:53 94:17	10:05:00 97:13	10:09:32 100:8	10:13:14 103:3	10:16:04 105:18,19
10:01:55 94:18	10:05:06 97:14	10:09:38 100:9	10:13:16 103:4	10:16:06 105:20
10:01:58 94:19	10:05:11 97:15	10:09:41 100:10	10:13:19 103:5	10:16:09 105:21
10:02:00 94:20	10:05:22 97:16	10:09:43 100:11	10:13:22 103:6	10:16:14 105:22
10:02:05 94:21	10:05:25 97:17	10:09:46 100:12	10:13:26 103:7	10:16:15 106:1
10:02:09 94:22 95:1	10:05:27 97:18	10:09:49 100:13	10:13:29 103:8	10:16:17 106:2

10:16:32 106:4	10:20:47 108:21	10:24:34 111:14	10:28:44 114:6	10:34:20 116:22
10:16:44 106:5	10:20:50 108:22	10:24:39 111:15	10:28:53 114:7	10:34:26 117:1
10:16:46 106:6	10:21:02 109:1	10:24:44 111:16	10:28:57 114:8	10:34:31 117:2
10:16:48 106:7	10:21:08 109:2	10:24:47 111:17	10:29:01 114:9	10:34:35 117:3
10:16:52 106:8	10:21:11 109:3	10:24:50 111:18	10:29:05 114:10	10:34:40 117:4
10:16:56 106:9	10:21:15 109:4	10:24:52 111:19	10:29:11 114:11	10:34:44 117:5
10:17:03 106:10	10:21:17 109:5	10:24:56 111:20	10:29:14 114:12	10:34:48 117:6
10:17:04 106:11	10:21:20 109:6,7	10:24:58 111:21	10:29:17 114:13	10:34:53 117:7
10:17:10 106:12	10:21:22 109:8	10:25:01 111:22	10:29:20 114:14	10:34:56 117:8
10:17:11 106:13	10:21:24 109:9	10:25:04 112:1	10:29:23 114:15	10:34:59 117:9
10:17:14 106:14	10:21:25 109:10	10:25:21 112:2	10:29:27 114:16	10:35:01 117:10
10:17:16 106:15	10:21:30 109:11	10:25:23 112:3	10:29:28 114:17	10:35:05 117:11
10:17:21 106:16	10:21:36 109:12	10:25:29 112:4	10:29:29 114:18	10:35:07 117:12
10:17:52 106:17	10:21:40 109:13	10:25:32 112:5	10:29:31 114:19,20	10:35:15 117:13
10:17:54 106:18	10:21:46 109:14	10:25:39 112:6	10:29:35 114:21	10:35:18 117:14
10:18:00 106:19	10:21:49 109:15	10:25:42 112:7	10:29:38 114:22	10:35:20 117:15
10:18:05 106:20	10:21:51 109:16	10:25:45 112:8	10:29:43 115:1	10:35:24 117:16
10:18:10 106:21	10:21:54 109:17	10:25:48 112:9	10:29:46 115:2	10:35:48 117:17
10:18:15 106:22 107:1	10:21:56 109:18	10:25:51 112:10	10:29:48 115:3,4	10:35:54 117:18
10:18:18 107:2	10:22:00 109:19	10:25:53 112:11	10:29:50 115:5,6	10:36:03 117:19
10:18:25 107:3	10:22:06 109:20	10:25:57 112:12	10:29:51 115:7	10:36:08 117:20
10:18:28 107:4,5	10:22:09 109:21	10:26:05 112:13	10:29:52 115:8	10:36:09 117:21
10:18:30 107:6	10:22:10 109:22	10:26:07 112:14	10:29:54 115:9	10:36:12 117:22
10:18:33 107:7	10:22:26 110:1	10:26:11 112:15	10:29:59 115:10	10:36:17 118:1
10:18:35 107:8	10:22:29 110:2	10:26:15 112:16	10:30:03 115:11	10:36:19 118:2
10:18:39 107:9	10:22:33 110:3	10:26:20 112:17	10:30:09 115:12	10:36:37 118:3
10:18:40 107:10	10:22:35 110:4	10:26:23 112:18	10:31:23 115:13	10:36:38 118:4
10:18:48 107:11	10:22:38 110:5	10:26:25 112:19	10:31:24 115:14	10:36:41 118:5
10:18:49 107:12	10:22:42 110:6	10:26:28 112:20	10:31:26 115:15	10:36:43 118:6
10:18:53 107:13,14	10:22:47 110:7	10:26:31 112:21	10:31:29 115:16	10:36:46 118:7
10:18:56 107:15	10:22:52 110:8	10:26:38 112:22	10:31:33 115:17	10:36:47 118:8
10:18:59 107:16	10:22:58 110:9	10:26:42 113:1	10:31:38 115:18	10:36:53 118:9
10:19:02 107:17	10:23:01 110:10,11	10:26:43 113:2	10:31:43 115:19	10:36:54 118:10
10:19:05 107:18	10:23:05 110:12	10:26:56 113:3	10:31:51 115:20	10:36:55 118:11
10:19:13 107:19	10:23:10 110:13	10:27:01 113:4	10:31:52 115:21	10:36:59 118:12
10:19:15 107:20	10:23:19 110:14	10:27:10 113:5	10:31:59 115:22	10:37:03 118:13
10:19:18 107:21	10:23:20 110:15	10:27:12 113:6,7	10:32:06 116:1	10:37:06 118:14
10:19:21 107:22	10:23:23 110:16	10:27:13 113:8	10:32:11 116:2	10:37:07 118:15
10:19:24 108:1	10:23:26 110:17	10:27:17 113:9	10:32:16 116:3	10:37:17 118:16
10:19:30 108:2	10:23:30 110:18	10:27:21 113:10	10:32:19 116:4	10:37:20 118:17
10:19:38 108:3	10:23:36 110:19	10:27:24 113:11	10:32:23 116:5	10:37:21 118:18
10:19:42 108:4	10:23:39 110:20	10:27:27 113:12	10:32:34 116:6	10:37:24 118:19
10:19:54 108:5	10:23:41 110:21	10:27:31 113:13	10:32:36 116:7	10:37:29 118:20
10:20:00 108:6,7	10:23:46 110:22	10:27:36 113:14	10:32:39 116:8	10:37:32 118:21
10:20:05 108:8	10:23:50 111:1	10:27:45 113:15	10:32:41 116:9	10:37:35 118:22 119:1
10:20:09 108:9	10:23:52 111:2	10:27:47 113:16	10:32:45 116:10	10:37:39 119:2
10:20:13 108:10	10:23:54 111:3	10:27:51 113:17	10:32:51 116:11	10:37:43 119:3
10:20:15 108:11	10:23:57 111:4	10:27:56 113:18	10:32:58 116:12	10:37:46 119:4
10:20:17 108:12	10:24:02 111:5	10:27:59 113:19	10:33:27 116:13	10:37:50 119:5
10:20:18 108:13	10:24:05 111:6	10:28:00 113:20	10:33:29 116:14	10:37:54 119:6
10:20:20 108:14	10:24:10 111:7	10:28:01 113:21	10:33:30 116:15	10:37:57 119:7
10:20:23 108:15	10:24:16 111:8	10:28:04 113:22	10:33:31 116:16	10:38:01 119:8
10:20:26 108:16	10:24:18 111:9	10:28:07 114:1	10:33:32 116:17	10:38:07 119:9
10:20:32 108:17	10:24:21 111:10	10:28:12 114:2	10:33:36 116:18	10:38:09 119:10
10:20:34 108:18	10:24:23 111:11	10:28:18 114:3	10:33:37 116:19	10:38:10 119:11
10:20:38 108:19	10:24:25 111:12	10:28:23 114:4	10:34:11 116:20	10:38:12 119:12,13
10:20:43 108:20	10:24:29 111:13	10:28:40 114:5	10:34:15 116:21	10:38:14 119:14,15

10:38:17 119:16	10:41:40 122:13	10:44:47 125:8	10:49:20 127:22	10:53:42 130:18
10:38:21 119:17	10:41:42 122:14	10:44:48 125:9	10:49:24 128:1	10:53:44 130:19
10:38:24 119:18	10:41:44 122:15	10:44:52 125:10	10:49:27 128:2	10:53:47 130:20
10:38:25 119:19	10:41:48 122:16	10:44:55 125:11	10:49:34 128:3	10:53:48 130:21
10:38:29 119:20	10:41:49 122:17	10:44:59 125:12	10:49:36 128:4	10:53:51 130:22
10:38:36 119:21	10:41:52 122:18	10:45:04 125:13	10:49:39 128:5	10:53:53 131:1
10:38:38 119:22	10:41:58 122:19	10:45:05 125:14	10:49:44 128:6	10:53:55 131:2
10:38:42 120:1	10:42:03 122:20,21	10:45:06 125:15	10:49:52 128:7,8	10:54:00 131:3
10:38:47 120:2	10:42:06 122:22	10:45:07 125:16	10:49:56 128:9	10:54:04 131:4
10:38:52 120:3	10:42:09 123:1	10:45:10 125:17	10:49:58 128:10	10:54:05 131:5
10:38:54 120:4	10:42:11 123:2	10:45:13 125:18	10:49:59 128:11	10:54:07 131:6
10:38:58 120:5	10:42:14 123:3	10:45:15 125:19	10:50:01 128:12	10:54:09 131:7
10:38:59 120:6	10:42:17 123:4	10:45:20 125:20	10:50:10 128:13	10:54:13 131:8,9
10:39:01 120:7,8	10:42:20 123:5	10:45:24 125:21	10:50:11 128:14	10:54:17 131:10
10:39:04 120:9	10:42:23 123:6	10:45:26 125:22 126:1	10:50:16 128:15	10:54:30 131:11
10:39:06 120:10	10:42:24 123:7	10:45:28 126:2	10:50:18 128:16	10:54:33 131:12
10:39:11 120:11	10:42:27 123:8	10:45:30 126:3	10:50:22 128:17	10:54:35 131:13
10:39:16 120:12	10:42:29 123:9	10:45:33 126:4	10:50:23 128:18	10:54:39 131:14
10:39:19 120:13	10:42:32 123:10	10:45:36 126:5	10:50:30 128:19,20	10:54:41 131:15
10:39:20 120:14	10:42:35 123:11	10:45:41 126:6	10:50:31 128:21	10:54:44 131:16
10:39:26 120:15	10:42:38 123:12	10:45:43 126:7	10:50:34 128:22	10:54:48 131:17
10:39:32 120:16	10:42:39 123:13	10:45:55 126:8	10:50:47 129:1	10:54:51 131:18
10:39:36 120:17	10:42:42 123:14	10:45:58 126:9	10:50:48 129:2	10:54:52 131:19
10:39:40 120:18	10:42:44 123:15	10:46:10 126:10	10:50:50 129:3	10:54:55 131:20
10:39:45 120:19	10:42:50 123:16	10:46:13 126:11	10:50:52 129:4	10:54:56 131:21
10:39:49 120:20,21,22	10:42:51 123:17	10:46:15 126:12	10:50:53 129:5,6	10:54:59 131:22
10:39:51 121:1,2	10:42:52 123:18	10:46:43 126:13	10:50:58 129:7	10:55:09 132:1
10:39:53 121:3	10:42:57 123:19	10:46:44 126:14	10:51:02 129:8	10:55:12 132:2
10:39:56 121:4	10:42:59 123:20	10:46:47 126:15	10:51:04 129:9	10:55:17 132:3
10:40:00 121:5,6	10:43:03 123:21	10:46:50 126:16	10:51:09 129:10	10:55:22 132:4
10:40:01 121:7	10:43:18 123:22	10:46:52 126:17	10:51:13 129:11	10:55:25 132:5
10:40:05 121:8	10:43:19 124:1	10:47:01 126:18	10:51:17 129:12	10:55:31 132:6,7
10:40:14 121:9	10:43:22 124:2	10:47:02 126:19	10:51:21 129:13	10:55:47 132:8
10:40:20 121:10	10:43:25 124:3,4	10:47:05 126:20	10:51:25 129:14	10:55:48 132:9
10:40:28 121:11	10:43:31 124:5	10:47:06 126:21	10:51:26 129:15	10:55:55 132:10
10:40:31 121:12	10:43:42 124:6	10:47:10 126:22	10:51:27 129:16,17	10:55:58 132:11
10:40:33 121:13	10:43:43 124:7	10:47:13 127:1	10:51:29 129:18	10:56:37 132:12
10:40:40 121:14	10:43:45 124:8	10:47:19 127:2	10:51:30 129:19	10:56:42 132:13
10:40:42 121:15	10:43:52 124:9	10:47:31 127:3	10:51:37 129:20	10:56:46 132:14
10:40:47 121:16	10:43:55 124:10,11	10:47:49 127:4	10:51:38 129:21	10:56:50 132:15
10:40:48 121:17	10:43:57 124:12	10:47:50 127:5	10:51:40 129:22	10:56:55 132:16,17
10:40:50 121:18	10:43:59 124:13	10:47:54 127:6	10:51:42 130:1	10:56:56 132:18
10:40:54 121:19	10:44:01 124:14	10:47:58 127:7	10:51:44 130:2	10:56:58 132:19
10:40:57 121:20	10:44:04 124:15	10:48:02 127:8	10:51:45 130:3	10:57:01 132:20
10:41:01 121:21,22	10:44:07 124:16	10:48:08 127:9	10:51:49 130:4	10:57:05 132:21
10:41:03 122:1	10:44:11 124:17	10:48:11 127:10	10:51:52 130:5	10:57:07 132:22
10:41:06 122:2	10:44:13 124:18	10:48:15 127:11	10:51:57 130:6	10:57:15 133:1
10:41:09 122:3	10:44:17 124:19	10:48:19 127:12	10:52:00 130:7	10:57:18 133:2
10:41:13 122:4	10:44:21 124:20	10:48:21 127:13	10:52:04 130:8,9	10:57:20 133:3
10:41:19 122:5	10:44:23 124:21	10:48:23 127:14	10:52:06 130:10	10:57:22 133:4
10:41:22 122:6	10:44:26 124:22	10:48:24 127:15	10:52:11 130:11	10:57:25 133:5
10:41:23 122:7	10:44:27 125:1,2	10:48:25 127:16	10:53:26 130:12	10:57:29 133:6
10:41:25 122:8	10:44:32 125:3	10:48:28 127:17	10:53:30 130:13	10:57:32 133:7
10:41:27 122:9	10:44:37 125:4	10:48:29 127:18	10:53:32 130:14	10:57:36 133:8
10:41:31 122:10	10:44:41 125:5	10:49:07 127:19	10:53:35 130:15	10:57:54 133:9
10:41:36 122:11	10:44:42 125:6	10:49:09 127:20	10:53:38 130:16	10:57:58 133:10
10:41:39 122:12	10:44:44 125:7	10:49:16 127:21	10:53:41 130:17	10:58:01 133:11

10:58:04 133:12	11:00:46 135:15	11:22:06 138:7	11:25:24 141:3	11:28:07 143:18
10:58:08 133:13	11:00:48 135:16	11:22:10 138:8	11:25:26 141:4	11:28:10 143:19
10:58:12 133:14	11:00:51 135:17	11:22:12 138:9	11:25:31 141:5	11:28:11 143:20
10:58:17 133:15	11:00:53 135:18	11:22:15 138:10	11:25:34 141:6	11:28:12 143:21
10:58:26 133:16	11:00:54 135:19	11:22:17 138:11	11:25:39 141:7	11:28:14 143:22
10:58:28 133:17	11:00:56 135:20	11:22:20 138:12	11:25:41 141:8	11:28:16 144:1
10:58:35 133:18	11:00:58 135:21	11:22:23 138:13	11:25:44 141:9	11:28:19 144:2
10:58:38 133:19	11:01:02 135:22	11:22:25 138:14	11:25:47 141:10	11:28:21 144:3
10:58:41 133:20	11:01:04 136:1	11:22:28 138:15	11:25:50 141:11	11:28:22 144:4
10:58:44 133:21	11:01:09 136:2	11:22:31 138:16	11:25:53 141:12	11:28:24 144:5
10:58:47 133:22	11:01:13 136:3	11:22:33 138:17,18	11:25:56 141:13	11:28:26 144:6
10:58:50 134:1	11:01:15 136:4	11:22:34 138:19	11:25:57 141:14	11:28:28 144:7
10:59:04 134:2	11:01:17 136:5	11:22:36 138:20	11:26:01 141:15	11:28:38 144:8
10:59:07 134:3	11:01:19 136:6	11:22:38 138:21	11:26:03 141:16	11:28:41 144:9
10:59:09 134:4,5	11:01:22 136:7	11:22:49 138:22	11:26:05 141:17	11:28:42 144:10
10:59:10 134:6,7	11:01:23 136:8	11:22:52 139:1	11:26:09 141:18	11:28:44 144:11
10:59:14 134:8,9	11:01:26 136:9	11:22:55 139:2	11:26:13 141:19	11:29:01 144:12
10:59:17 134:10	11:01:27 136:10	11:23:00 139:3	11:26:16 141:20	11:29:03 144:13,14
10:59:20 134:11	11:01:31 136:11	11:23:01 139:4	11:26:18 141:21	11:29:06 144:15
10:59:34 134:12	11:01:36 136:12	11:23:04 139:5	11:26:20 141:22	11:29:08 144:16
10:59:35 134:13	11:01:45 136:13	11:23:06 139:6	11:26:23 142:1,2	11:29:10 144:17
10:59:37 134:14	11:01:48 136:14	11:23:09 139:7	11:26:24 142:3	11:29:13 144:18
10:59:40 134:15	11:01:51 136:15	11:23:12 139:8	11:26:26 142:4	11:29:17 144:19
10:59:42 134:16	11:01:53 136:16	11:23:13 139:9	11:26:28 142:5	11:29:22 144:20
10:59:44 134:17	11:02 136:12,16	11:23:15 139:10	11:26:32 142:6	11:29:29 144:21
10:59:45 134:18	11:19:18 136:17	11:23:22 139:11	11:26:34 142:7	11:29:32 144:22
10:59:50 134:19	11:19:58 136:18	11:23:25 139:12	11:26:35 142:8	11:29:36 145:1
100,000 60:13	11:20:05 136:19	11:23:31 139:13,14	11:26:37 142:9	11:29:39 145:2
10018 15:21	11:20:08 136:20	11:23:33 139:15	11:26:41 142:10	11:29:43 145:3
10018-1405 2:4 3:18	11:20:11 136:21	11:23:38 139:16	11:26:47 142:11	11:29:47 145:4
102 14:22 66:13 311:14 312:11	11:20:13 136:22 137:1	11:23:40 139:17	11:26:52 142:12	11:29:52 145:5
1049-1070 8:13	11:20:16 137:2	11:23:41 139:18	11:26:57 142:13	11:29:55 145:6
1054 265:19	11:20:21 137:3	11:23:43 139:19	11:26:58 142:14	11:29:59 145:7
108 66:11,21	11:20:23 137:4	11:23:46 139:20	11:27:01 142:15	11:30:01 145:8
11 8:15 60:17 65:16 97:14 172:11 175:15 178:16 267:6,7,11,19 272:12	11:20:25 137:5	11:23:49 139:21	11:27:04 142:16	11:30:04 145:9
11.1 258:3	11:20:28 137:6	11:23:51 139:22	11:27:05 142:17	11:30:05 145:10
11:00:01 134:20	11:20:31 137:7	11:23:53 140:1,2	11:27:07 142:18	11:30:06 145:11
11:00:03 134:21	11:20:34 137:8,9	11:23:56 140:3,4	11:27:08 142:19	11:30:08 145:12
11:00:06 134:22	11:20:35 137:10,11	11:24:00 140:5	11:27:12 142:20	11:30:11 145:13
11:00:08 135:1	11:20:37 137:12	11:24:04 140:6	11:27:14 142:21	11:30:12 145:14
11:00:10 135:2	11:20:40 137:13	11:24:07 140:7	11:27:15 142:22	11:30:14 145:15,16
11:00:13 135:3	11:20:43 137:14	11:24:10 140:8	11:27:23 143:1	11:30:16 145:17
11:00:16 135:4	11:20:44 137:15	11:24:15 140:9	11:27:24 143:2,3	11:30:17 145:18
11:00:18 135:5	11:20:52 137:16	11:24:18 140:10	11:27:27 143:4	11:30:19 145:19
11:00:20 135:6	11:21 136:16,18	11:24:25 140:11	11:27:30 143:5	11:30:22 145:20
11:00:21 135:7	11:21:14 137:17	11:24:30 140:12	11:27:33 143:6	11:30:24 145:21
11:00:24 135:8	11:21:17 137:18	11:24:34 140:13	11:27:34 143:7	11:30:25 145:22
11:00:27 135:9	11:21:21 137:19	11:24:37 140:14	11:27:36 143:8	11:30:29 146:1
11:00:30 135:10	11:21:23 137:20	11:24:42 140:15	11:27:38 143:9	11:30:32 146:2
11:00:33 135:11	11:21:25 137:21	11:24:47 140:16	11:27:41 143:10	11:30:35 146:3
11:00:35 135:12	11:21:28 137:22	11:24:49 140:17	11:27:45 143:11	11:30:37 146:4
11:00:40 135:13	11:21:30 138:1	11:24:52 140:18	11:27:50 143:12	11:30:40 146:5
11:00:43 135:14	11:21:39 138:2	11:24:56 140:19	11:27:56 143:13	11:30:43 146:6
	11:21:50 138:3	11:25:03 140:20	11:27:58 143:14	11:30:45 146:7
	11:21:54 138:4	11:25:08 140:21	11:28:01 143:15	11:30:47 146:8
	11:21:57 138:5	11:25:13 140:22 141:1	11:28:03 143:16	11:30:50 146:9
	11:21:59 138:6	11:25:16 141:2	11:28:05 143:17	11:30:53 146:10

11:30:54 146:11	11:33:50 149:6	11:37:26 151:21	11:39:59 154:16	11:43:01 157:12
11:30:55 146:12	11:33:53 149:7	11:37:28 151:22	11:40:01 154:17	11:43:05 157:13
11:30:58 146:13	11:34:00 149:8	11:37:30 152:1	11:40:03 154:18	11:43:07 157:14
11:31:00 146:14	11:34:02 149:9	11:37:32 152:2	11:40:06 154:19	11:43:08 157:15
11:31:01 146:15	11:34:04 149:10	11:37:36 152:3	11:40:08 154:20	11:43:10 157:16
11:31:04 146:16	11:34:06 149:11	11:37:38 152:4	11:40:10 154:21	11:43:15 157:17
11:31:07 146:17	11:34:08 149:12	11:37:40 152:5,6	11:40:13 154:22	11:43:21 157:18
11:31:10 146:18	11:34:09 149:13	11:37:41 152:7	11:40:15 155:1	11:43:25 157:19
11:31:14 146:19	11:34:16 149:14	11:37:43 152:8	11:40:19 155:2	11:43:27 157:20
11:31:15 146:20	11:34:18 149:15	11:37:45 152:9	11:40:22 155:3	11:43:30 157:21
11:31:19 146:21,22	11:34:21 149:16	11:37:48 152:10	11:40:24 155:4	11:43:32 157:22
11:31:25 147:1	11:34:24 149:17	11:37:50 152:11	11:40:26 155:5	11:43:34 158:1
11:31:28 147:2	11:34:25 149:18	11:37:52 152:12	11:40:29 155:6	11:43:38 158:2
11:31:30 147:3	11:34:54 149:19	11:37:54 152:13	11:40:31 155:7	11:43:41 158:3
11:31:34 147:4	11:34:58 149:20	11:37:58 152:14	11:40:32 155:8	11:43:42 158:4
11:31:37 147:5	11:35:01 149:21	11:37:59 152:15,16	11:40:35 155:9	11:43:43 158:5
11:31:40 147:6	11:35:03 149:22	11:38:00 152:17	11:40:37 155:10,11	11:43:46 158:6
11:31:44 147:7	11:35:07 150:1	11:38:02 152:18	11:40:40 155:12	11:43:50 158:7
11:31:46 147:8	11:35:10 150:2	11:38:05 152:19,20	11:40:42 155:13	11:43:53 158:8
11:31:48 147:9	11:35:13 150:3	11:38:11 152:21	11:40:43 155:14	11:44:00 158:9
11:31:49 147:10,11	11:35:15 150:4,5	11:38:13 152:22	11:40:46 155:15	11:44:03 158:10
11:31:50 147:12	11:35:18 150:6	11:38:16 153:1	11:40:49 155:16	11:44:08 158:11,12
11:31:53 147:13	11:35:19 150:7	11:38:19 153:2	11:40:53 155:17	11:44:10 158:13
11:31:55 147:14	11:35:21 150:8	11:38:23 153:3	11:40:59 155:18,19	11:44:13 158:14
11:31:56 147:15	11:35:24 150:9,10	11:38:26 153:4	11:41:07 155:20	11:44:15 158:15
11:31:59 147:16	11:35:26 150:11	11:38:31 153:5	11:41:10 155:21	11:44:17 158:16
11:32:01 147:17	11:35:28 150:12	11:38:34 153:6	11:41:12 155:22	11:44:19 158:17
11:32:04 147:18	11:35:30 150:13	11:38:36 153:7	11:41:13 156:1	11:44:23 158:18
11:32:07 147:19	11:35:32 150:14	11:38:39 153:8	11:41:14 156:2,3	11:44:25 158:19
11:32:09 147:20	11:35:35 150:15	11:38:40 153:9	11:41:17 156:4	11:44:27 158:20
11:32:10 147:21	11:35:37 150:16	11:38:43 153:10	11:41:22 156:5	11:44:32 158:21
11:32:14 147:22	11:35:40 150:17	11:38:44 153:11	11:41:26 156:6	11:44:41 158:22
11:32:19 148:1	11:35:44 150:18	11:38:50 153:12	11:41:30 156:7	11:44:44 159:1
11:32:23 148:2	11:35:47 150:19	11:38:53 153:13	11:41:35 156:8	11:44:48 159:2
11:32:26 148:3	11:35:52 150:20	11:38:56 153:14	11:41:39 156:9	11:44:53 159:3
11:32:33 148:4	11:35:53 150:21	11:38:59 153:15	11:41:42 156:10	11:44:55 159:4
11:32:35 148:5	11:35:57 150:22	11:39:01 153:16	11:41:44 156:11	11:44:59 159:5
11:32:39 148:6	11:36:01 151:1	11:39:05 153:17	11:41:48 156:12	11:45:01 159:6
11:32:42 148:7	11:36:15 151:2	11:39:08 153:18,19	11:41:50 156:13	11:45:05 159:7
11:32:46 148:8	11:36:17 151:3	11:39:09 153:20	11:41:58 156:14	11:45:06 159:8
11:32:50 148:9	11:36:19 151:4	11:39:10 153:21	11:42:02 156:15,16	11:45:08 159:9
11:32:51 148:10	11:36:22 151:5	11:39:13 153:22	11:42:04 156:17	11:45:11 159:10
11:33:04 148:11	11:36:30 151:6	11:39:17 154:1	11:42:06 156:18	11:45:13 159:11
11:33:08 148:12	11:36:33 151:7	11:39:19 154:2	11:42:11 156:19	11:45:17 159:12
11:33:11 148:13	11:36:39 151:8	11:39:22 154:3	11:42:16 156:20	11:45:19 159:13
11:33:14 148:14,15	11:36:43 151:9	11:39:25 154:4	11:42:18 156:21	11:45:23 159:14
11:33:18 148:16,17	11:36:54 151:10	11:39:28 154:5	11:42:20 156:22	11:45:26 159:15
11:33:21 148:18	11:36:57 151:11	11:39:37 154:6	11:42:23 157:1	11:45:28 159:16
11:33:24 148:19	11:37:02 151:12	11:39:39 154:7	11:42:29 157:2	11:45:29 159:17
11:33:27 148:20	11:37:04 151:13	11:39:41 154:8	11:42:35 157:3	11:45:32 159:18
11:33:34 148:21	11:37:05 151:14	11:39:44 154:9	11:42:39 157:4	11:45:37 159:19
11:33:36 148:22	11:37:07 151:15	11:39:45 154:10	11:42:42 157:5	11:45:40 159:20
11:33:40 149:1	11:37:08 151:16	11:39:46 154:11	11:42:47 157:6,7	11:45:46 159:21
11:33:42 149:2	11:37:10 151:17	11:39:48 154:12	11:42:52 157:8	11:45:50 159:22
11:33:43 149:3	11:37:13 151:18	11:39:49 154:13	11:42:53 157:9	11:45:54 160:1
11:33:46 149:4	11:37:15 151:19	11:39:51 154:14	11:42:55 157:10	11:45:56 160:2
11:33:48 149:5	11:37:23 151:20	11:39:55 154:15	11:42:58 157:11	11:45:59 160:3

11:46:03 160:4	11:49:32 162:19	11:52:08 165:11	11:55:23 168:5	11:58:28 171:1
11:46:07 160:5	11:49:35 162:20	11:52:12 165:12	11:55:25 168:6,7	11:58:30 171:2
11:46:11 160:6	11:49:36 162:21	11:52:13 165:13	11:55:28 168:8	11:58:33 171:3
11:46:16 160:7	11:49:39 162:22	11:52:14 165:14	11:55:32 168:9	11:58:35 171:4
11:46:20 160:8	11:49:42 163:1	11:52:19 165:15	11:55:35 168:10	11:58:38 171:5
11:46:24 160:9,10	11:49:47 163:2	11:52:21 165:16	11:55:38 168:11	11:58:39 171:6
11:46:26 160:11	11:49:52 163:3	11:52:23 165:17	11:55:44 168:12,13	11:58:42 171:7
11:46:29 160:12	11:49:55 163:4	11:52:26 165:18	11:55:46 168:14	11:58:44 171:8
11:46:31 160:13	11:49:58 163:5	11:52:27 165:19	11:55:52 168:15	11:58:48 171:9
11:46:33 160:14	11:50:01 163:6	11:52:28 165:20,21	11:55:55 168:16	11:58:52 171:10
11:46:37 160:15	11:50:03 163:7	11:52:30 165:22	11:55:58 168:17	11:58:56 171:11
11:46:43 160:16	11:50:05 163:8	11:52:35 166:1	11:56:00 168:18	11:58:58 171:12
11:46:45 160:17	11:50:07 163:9	11:52:40 166:2	11:56:01 168:19	11:59:04 171:13
11:46:48 160:18	11:50:10 163:10	11:52:42 166:3	11:56:06 168:20	11:59:07 171:14
11:46:52 160:19	11:50:15 163:11	11:52:53 166:4	11:56:07 168:21	11:59:10 171:15
11:46:55 160:20	11:50:20 163:12	11:52:54 166:5	11:56:12 168:22	11:59:12 171:16
11:46:59 160:21	11:50:23 163:13	11:52:55 166:6	11:56:14 169:1	11:59:16 171:17
11:47:02 160:22	11:50:31 163:14	11:53:02 166:7	11:56:15 169:2	11:59:19 171:18,19
11:47:04 161:1	11:50:33 163:15	11:53:05 166:8	11:56:18 169:3	11:59:23 171:20
11:47:08 161:2	11:50:35 163:16	11:53:07 166:9	11:56:19 169:4	11:59:27 171:21
11:47:12 161:3	11:50:38 163:17	11:53:14 166:10	11:56:21 169:5	11:59:30 171:22 172:1
11:47:13 161:4	11:50:42 163:18	11:53:20 166:11	11:56:25 169:6	11:59:31 172:2,3
11:47:16 161:5	11:50:43 163:19	11:53:24 166:12	11:56:29 169:7	11:59:32 172:4
11:47:19 161:6	11:50:47 163:20	11:53:27 166:13	11:56:31 169:8	11:59:36 172:5
11:47:21 161:7	11:50:49 163:21	11:53:29 166:14	11:56:36 169:9	11:59:37 172:6
11:47:24 161:8	11:50:51 163:22	11:53:30 166:15,16	11:56:40 169:10	11:59:39 172:7
11:47:29 161:9	11:50:56 164:1	11:53:34 166:17	11:56:45 169:11	11:59:42 172:8
11:47:32 161:10	11:50:57 164:2	11:53:36 166:18	11:56:53 169:12	11:59:45 172:9
11:47:42 161:11	11:50:58 164:3	11:53:42 166:19	11:56:58 169:13	11:59:46 172:10
11:47:44 161:12	11:51:00 164:4	11:53:49 166:20	11:57:02 169:14	11:59:48 172:11
11:47:46 161:13	11:51:01 164:5	11:53:54 166:21	11:57:04 169:15,16	11:59:52 172:12,13
11:47:56 161:14	11:51:03 164:6	11:54:00 166:22	11:57:08 169:17	11:59:53 172:14
11:47:58 161:15	11:51:06 164:7	11:54:08 167:1	11:57:10 169:18	11:59:56 172:15
11:48:02 161:16	11:51:09 164:8	11:54:12 167:2	11:57:13 169:19	117 67:5
11:48:07 161:17	11:51:10 164:9	11:54:16 167:3	11:57:16 169:20	12 8:18 9:4 11:11 60:19
11:48:08 161:18	11:51:11 164:10	11:54:22 167:4	11:57:20 169:21	63:22 88:22 107:1
11:48:10 161:19	11:51:12 164:11	11:54:24 167:5	11:57:27 169:22	127:2 179:20 186:17
11:48:13 161:20	11:51:15 164:12	11:54:26 167:6	11:57:35 170:1	267:8,15 279:11,12
11:48:16 161:21	11:51:18 164:13	11:54:31 167:7	11:57:38 170:2	279:18,22 280:2
11:48:19 161:22	11:51:19 164:14	11:54:32 167:8	11:57:41 170:3	288:2,11
11:48:22 162:1	11:51:20 164:15	11:54:36 167:9,10	11:57:43 170:4	12:00:00 172:16
11:48:27 162:2	11:51:21 164:16	11:54:37 167:11	11:57:45 170:5	12:00:03 172:17
11:48:29 162:3	11:51:22 164:17	11:54:38 167:12	11:57:48 170:6	12:00:06 172:18
11:48:31 162:4	11:51:28 164:18	11:54:42 167:13	11:57:51 170:7	12:00:10 172:19
11:48:41 162:5	11:51:34 164:19	11:54:45 167:14	11:57:55 170:8	12:00:15 172:20
11:48:46 162:6	11:51:36 164:20	11:54:48 167:15	11:57:57 170:9	12:00:23 172:21
11:48:48 162:7	11:51:39 164:21	11:54:50 167:16	11:58:01 170:10	12:00:24 172:22
11:48:54 162:8	11:51:42 164:22	11:54:54 167:17	11:58:06 170:11	12:00:29 173:1,2
11:49:00 162:9	11:51:43 165:1	11:54:56 167:18	11:58:12 170:12	12:00:34 173:3
11:49:08 162:10	11:51:45 165:2	11:54:58 167:19	11:58:14 170:13	12:00:36 173:4
11:49:11 162:11	11:51:47 165:3	11:55:02 167:20	11:58:16 170:14	12:00:42 173:5
11:49:16 162:12	11:51:50 165:4	11:55:04 167:21	11:58:18 170:15,16	12:00:48 173:6
11:49:17 162:13	11:51:53 165:5	11:55:09 167:22	11:58:20 170:17	12:00:53 173:7
11:49:20 162:14	11:51:55 165:6	11:55:12 168:1	11:58:21 170:18	12:00:56 173:8
11:49:21 162:15	11:52:00 165:7	11:55:16 168:2	11:58:23 170:19	12:01:00 173:9
11:49:24 162:16,17	11:52:03 165:8	11:55:18 168:3	11:58:26 170:20,21	12:01:01 173:10
11:49:29 162:18	11:52:06 165:9,10	11:55:20 168:4	11:58:27 170:22	12:01:08 173:11

12:01:10 173:12	12:04:12 176:6	12:08:36 178:21	12:11:40 181:19	12:14:23 184:17
12:01:14 173:13	12:04:15 176:7	12:08:39 178:22	12:11:43 181:20	12:14:24 184:18
12:01:15 173:14	12:04:20 176:8	12:08:44 179:1	12:11:50 181:21	12:14:26 184:19
12:01:20 173:15	12:04:24 176:9	12:08:47 179:2	12:11:52 181:22	12:14:32 184:20
12:01:23 173:16	12:04:26 176:10	12:08:51 179:3	12:11:53 182:1	12:14:34 184:21
12:01:27 173:17	12:04:29 176:11	12:08:54 179:4	12:11:57 182:2	12:14:36 184:22
12:01:28 173:18	12:04:34 176:12	12:08:56 179:5	12:12:00 182:3	12:14:37 185:1
12:01:30 173:19	12:04:36 176:13	12:08:59 179:6,7	12:12:01 182:4	12:14:39 185:2
12:01:33 173:20	12:04:38 176:14	12:09:00 179:8	12:12:03 182:5	12:14:41 185:3,4
12:01:37 173:21	12:04:40 176:15	12:09:02 179:9	12:12:05 182:6	12:14:45 185:5
12:01:40 173:22	12:04:41 176:16	12:09:05 179:10	12:12:08 182:7	12:14:48 185:6
12:01:41 174:1	12:04:44 176:17	12:09:11 179:11	12:12:09 182:8	12:14:49 185:7
12:01:44 174:2	12:04:47 176:18	12:09:14 179:12	12:12:11 182:9	12:14:51 185:8
12:01:48 174:3	12:04:49 176:19	12:09:15 179:13	12:12:13 182:10	12:14:52 185:9
12:01:53 174:4	12:04:52 176:20	12:09:18 179:14	12:12:15 182:11	12:14:56 185:10
12:01:55 174:5	12:04:56 176:21	12:09:21 179:15	12:12:17 182:12	12:15:00 185:11,12
12:01:58 174:6	12:04:59 176:22	12:09:25 179:16	12:12:20 182:13	12:15:04 185:13
12:01:59 174:7	12:05:03 177:1	12:09:28 179:17	12:12:24 182:14	12:15:07 185:14,15
12:02:02 174:8	12:05:06 177:2	12:09:32 179:18	12:12:29 182:15	12:15:11 185:16
12:02:06 174:9	12:05:11 177:3	12:09:34 179:19	12:12:32 182:16	12:15:12 185:17,18
12:02:08 174:10	12:05:14 177:4	12:09:36 179:20	12:12:36 182:17	12:15:15 185:19,20,21
12:02:09 174:11	12:05:17 177:5,6	12:09:40 179:21	12:12:38 182:18	12:15:20 185:22
12:02:12 174:12	12:05:21 177:7	12:09:44 179:22	12:12:42 182:19,20	12:15:27 186:1,2
12:02:17 174:13	12:05:26 177:8	12:09:48 180:1	12:12:45 182:21	12:15:32 186:3
12:02:18 174:14	12:05:29 177:9	12:09:49 180:2,3	12:12:48 182:22	12:15:36 186:4
12:02:19 174:15	12:07:01 177:10	12:09:50 180:4	12:12:50 183:1	12:15:39 186:5
12:02:21 174:16,17	12:07:04 177:11	12:09:54 180:5	12:12:53 183:2	12:15:42 186:6,7
12:02:25 174:18	12:07:06 177:12	12:10:00 180:6	12:12:57 183:3	12:15:46 186:8
12:02:26 174:19,20	12:07:09 177:13	12:10:03 180:7	12:13:00 183:4	12:15:47 186:9,10
12:02:27 174:21	12:07:12 177:14	12:10:06 180:8,9	12:13:04 183:5	12:15:50 186:11
12:02:30 174:22	12:07:14 177:15	12:10:07 180:10	12:13:05 183:6	12:15:52 186:12
12:02:31 175:1	12:07:17 177:16	12:10:11 180:11	12:13:06 183:7	12:15:55 186:13
12:02:32 175:2	12:07:23 177:17	12:10:17 180:12	12:13:07 183:8	12:15:56 186:14
12:02:36 175:3	12:07:26 177:18	12:10:24 180:13	12:13:09 183:9	12:15:59 186:15
12:02:37 175:4	12:07:27 177:19	12:10:27 180:14,15	12:13:12 183:10	12:16:00 186:16
12:02:41 175:5	12:07:30 177:20	12:10:40 180:16	12:13:16 183:11	12:16:03 186:17
12:02:45 175:6	12:07:35 177:21	12:10:44 180:17	12:13:17 183:12	12:16:09 186:18
12:02:46 175:7	12:07:37 177:22	12:10:51 180:18	12:13:19 183:13	12:16:20 186:19
12:02:47 175:8	12:07:42 178:1	12:10:52 180:19	12:13:24 183:14,15	12:16:23 186:20
12:02:49 175:9	12:07:45 178:2	12:10:53 180:20	12:13:28 183:16	12:16:26 186:21
12:02:52 175:10	12:07:48 178:3	12:11:02 180:21	12:13:31 183:22	12:16:27 186:22 187:1
12:02:53 175:11	12:07:49 178:4	12:11:06 180:22	12:13:33 184:1	12:16:29 187:2
12:03:02 175:12	12:07:52 178:5	12:11:09 181:1	12:13:35 184:2	12:16:32 187:3
12:03:04 175:13	12:07:53 178:6	12:11:13 181:2	12:13:39 184:3	12:16:35 187:4
12:03:15 175:14	12:07:56 178:7	12:11:14 181:3,4	12:13:41 184:4	12:16:38 187:5
12:03:44 175:15	12:07:58 178:8	12:11:15 181:5	12:13:44 184:5	12:16:41 187:6
12:03:47 175:16	12:07:59 178:9	12:11:20 181:6	12:13:48 184:6	12:16:42 187:7
12:03:48 175:17	12:08:02 178:10	12:11:21 181:7	12:13:51 184:7	12:16:43 187:8,9
12:03:50 175:18	12:08:07 178:11	12:11:24 181:8	12:13:57 184:8	12:16:47 187:10
12:03:54 175:19	12:08:12 178:12	12:11:25 181:9	12:14:00 184:9	12:16:50 187:11
12:03:56 175:20	12:08:14 178:13	12:11:26 181:10	12:14:03 184:10	12:16:52 187:12
12:03:59 175:21	12:08:17 178:14	12:11:27 181:11	12:14:07 184:11	12:16:54 187:13
12:04:02 175:22	12:08:19 178:15	12:11:29 181:12	12:14:10 184:12	12:16:58 187:14
12:04:05 176:1	12:08:23 178:16	12:11:32 181:13	12:14:11 184:13	12:17:03 187:15
12:04:07 176:2	12:08:27 178:17	12:11:34 181:14	12:14:14 184:14	12:17:06 187:16
12:04:08 176:3,4	12:08:29 178:18,19	12:11:36 181:15,16	12:14:17 184:15	12:17:09 187:17
12:04:09 176:5	12:08:33 178:20	12:11:38 181:17,18	12:14:21 184:16	12:17:12 187:18

12:17:16 187:19	12:20:12 190:12	12:23:11 193:5	12:26:41 196:6	12:30:13 199:5,6
12:17:20 187:20	12:20:17 190:13	12:23:16 193:6	12:26:44 196:7	12:30:15 199:7
12:17:31 187:21	12:20:23 190:14	12:23:18 193:7	12:26:50 196:8	12:30:21 199:8
12:17:32 187:22	12:20:24 190:15	12:23:28 193:8	12:26:51 196:9	12:30:22 199:9
12:17:37 188:1	12:20:26 190:16	12:23:34 193:9	12:26:57 196:10	12:30:25 199:10
12:17:39 188:2	12:20:29 190:17	12:23:37 193:10	12:26:58 196:11	12:30:28 199:11,12
12:17:40 188:3	12:20:33 190:18	12:23:39 193:11	12:26:59 196:12	12:30:30 199:13
12:17:43 188:4	12:20:36 190:19	12:23:43 193:12	12:27:01 196:13	12:30:35 199:14
12:17:48 188:5	12:20:39 190:20	12:23:56 193:13	12:27:03 196:14	12:30:38 199:15
12:17:52 188:6	12:20:42 190:21	12:23:58 193:14,15	12:27:06 196:15	12:30:41 199:16
12:17:55 188:7	12:20:47 190:22	12:23:59 193:16	12:27:10 196:16	12:30:44 199:17
12:17:57 188:8	12:20:55 191:1	12:24:03 193:17	12:27:13 196:17	12:30:47 199:18
12:17:59 188:9	12:20:57 191:2	12:24:23 193:18	12:27:14 196:18	12:30:51 199:19
12:18:02 188:10	12:20:59 191:3	12:24:24 193:19	12:27:19 196:19	12:31:00 199:20
12:18:04 188:11,12	12:21:03 191:4	12:24:28 193:20	12:27:25 196:20	12:31:02 199:21
12:18:05 188:13	12:21:05 191:5	12:24:30 193:21,22	12:27:32 196:21,22	12:31:06 199:22
12:18:07 188:14,15	12:21:11 191:6	12:24:33 194:1	12:27:33 197:1,2	12:31:09 200:1
12:18:08 188:16	12:21:16 191:7	12:24:39 194:2	12:27:37 197:3	12:31:13 200:2
12:18:18 188:17	12:21:17 191:8	12:24:40 194:3	12:27:42 197:4	12:31:34 200:3
12:18:21 188:18	12:21:21 191:9	12:24:43 194:4	12:27:46 197:5	12:31:37 200:4
12:18:23 188:19	12:21:22 191:10	12:24:44 194:5	12:27:49 197:6	12:31:41 200:5
12:18:27 188:20	12:21:27 191:11	12:24:45 194:6	12:27:51 197:7	12:31:46 200:6
12:18:29 188:21	12:21:31 191:12	12:24:47 194:7,8	12:27:58 197:8	12:31:48 200:7
12:18:31 188:22	12:21:33 191:13	12:24:49 194:9,10	12:28:06 197:9	12:31:51 200:8
12:18:35 189:1	12:21:35 191:14	12:24:52 194:11,12	12:28:07 197:10	12:31:55 200:9
12:18:37 189:2	12:21:39 191:15	12:24:55 194:13	12:28:09 197:11	12:31:57 200:10
12:18:39 189:3	12:21:41 191:16	12:24:56 194:14	12:28:13 197:12	12:32:00 200:11
12:18:42 189:4	12:21:44 191:17	12:24:57 194:15	12:28:16 197:13,14	12:32:06 200:12
12:18:43 189:5	12:21:47 191:18	12:24:58 194:16	12:28:21 197:15,16	12:32:13 200:13
12:18:45 189:6	12:21:54 191:19	12:25:02 194:17	12:28:22 197:17,18,19	12:32:18 200:14
12:18:47 189:7	12:21:56 191:20	12:25:05 194:18,19	12:28:40 197:20	12:32:24 200:15
12:18:48 189:8	12:22:00 191:21,22	12:25:06 194:20	12:28:42 197:21,22	12:32:29 200:16
12:18:51 189:9	12:22:03 192:1	12:25:08 194:21	12:28:45 198:1	12:32:31 200:17
12:18:56 189:10	12:22:08 192:2	12:25:13 194:22	12:28:50 198:2	12:32:33 200:18,19
12:18:59 189:11	12:22:14 192:3	12:25:15 195:1	12:28:52 198:3	12:32:35 200:20,21
12:19:02 189:12	12:22:16 192:4	12:25:16 195:2,3	12:28:53 198:4	12:32:37 200:22 201:1
12:19:03 189:13	12:22:18 192:5	12:25:19 195:4	12:28:56 198:5	12:32:41 201:2
12:19:05 189:14	12:22:19 192:6	12:25:31 195:5	12:28:58 198:6	12:32:42 201:3
12:19:09 189:15	12:22:29 192:7	12:25:34 195:6,7	12:29:01 198:7	12:32:46 201:4
12:19:15 189:16	12:22:30 192:8	12:25:36 195:8,9	12:29:03 198:8	12:32:48 201:5
12:19:19 189:17	12:22:31 192:9	12:25:38 195:10	12:29:06 198:9	12:32:50 201:6
12:19:21 189:18	12:22:33 192:10	12:25:42 195:11	12:29:10 198:10	12:32:52 201:7
12:19:25 189:19	12:22:35 192:11	12:25:43 195:12	12:29:13 198:11	12:32:53 201:8
12:19:29 189:20	12:22:36 192:12	12:25:45 195:13	12:29:15 198:12	12:32:55 201:9
12:19:33 189:21	12:22:40 192:13	12:25:47 195:14,15	12:29:18 198:13,14	12:32:58 201:10,11
12:19:36 189:22	12:22:44 192:14	12:25:52 195:16	12:29:20 198:15	12:33:00 201:12
12:19:41 190:1	12:22:48 192:15	12:25:53 195:17	12:29:22 198:16	12:33:02 201:13
12:19:44 190:2	12:22:49 192:16	12:25:55 195:18	12:29:29 198:17	12:33:03 201:14
12:19:46 190:3	12:22:55 192:17	12:26:03 195:19	12:29:35 198:18	12:33:11 201:15
12:19:51 190:4	12:22:57 192:18	12:26:14 195:20	12:29:39 198:19	12:33:16 201:16
12:19:52 190:5	12:22:58 192:19	12:26:20 195:21	12:29:43 198:20	12:33:18 201:17
12:19:53 190:6	12:22:59 192:20	12:26:23 195:22	12:29:46 198:21	12:33:19 201:18
12:19:56 190:7	12:23:03 192:21	12:26:27 196:1	12:29:48 198:22	12:33:24 201:19
12:20:00 190:8	12:23:06 192:22 193:1	12:26:29 196:2	12:29:50 199:1	12:33:28 201:20
12:20:04 190:9	193:2	12:26:32 196:3	12:29:53 199:2	12:33:32 201:21
12:20:08 190:10	12:23:07 193:3	12:26:36 196:4	12:29:54 199:3	12:33:35 201:22
12:20:10 190:11	12:23:10 193:4	12:26:39 196:5	12:30:05 199:4	12:33:39 202:1

12:33:46 202:2	12:36:39 205:1	13:29:05 207:15	13:32:50 210:15	13:39:43 213:7
12:33:48 202:3	12:36:42 205:2	13:29:07 207:16	13:32:53 210:16	13:39:51 213:8
12:33:52 202:4	12:36:44 205:3	13:29:09 207:17	13:32:55 210:17	13:39:53 213:9
12:33:55 202:5	12:37 204:21 205:3	13:29:19 207:18	13:32:59 210:18	13:39:54 213:10
12:33:57 202:6	120 8:17	13:29:20 207:19	13:33:04 210:19	13:39:55 213:11
12:34:02 202:7	125-171 8:8	13:29:22 207:20,21	13:33:08 210:20	13:40:00 213:12
12:34:04 202:8	13 9:12 98:8 106:21	13:29:24 207:22	13:33:10 210:21	13:40:05 213:13,14
12:34:07 202:9	195:4 202:18 243:18	13:29:27 208:1	13:33:12 210:22	13:40:09 213:15
12:34:10 202:10	267:22 280:18,19	13:29:30 208:2	13:33:16 211:1	13:40:11 213:16
12:34:13 202:11	281:2,5,7	13:29:34 208:3	13:33:21 211:2	13:40:13 213:17
12:34:17 202:12,13	13:25:53 205:4	13:29:37 208:4	13:33:31 211:3	13:40:27 213:18
12:34:20 202:14	13:25:55 205:5	13:29:40 208:5	13:33:32 211:4	13:40:28 213:19
12:34:22 202:15,16	13:26:05 205:6	13:29:45 208:6	13:33:35 211:5,6	13:40:31 213:20
12:34:25 202:17	13:26:07 205:7	13:29:48 208:7	13:33:36 211:7	13:40:34 213:21
12:34:27 202:18	13:26:10 205:8	13:30:13 208:8,9	13:33:41 211:8	13:40:36 213:22
12:34:32 202:19	13:26:12 205:9,10	13:30:14 208:10,11	13:33:44 211:9	13:40:40 214:1
12:34:44 202:20	13:26:13 205:11	13:30:18 208:12	13:33:45 211:10	13:40:44 214:2
12:34:47 202:21	13:26:14 205:12	13:30:21 208:13	13:33:48 211:11	13:40:48 214:3
12:34:48 202:22	13:26:17 205:13	13:30:22 208:14	13:33:51 211:12	13:40:51 214:4
12:34:49 203:1	13:26:22 205:14	13:30:23 208:15	13:33:52 211:13	13:40:54 214:5
12:34:52 203:2	13:26:27 205:15	13:30:30 208:16	13:33:54 211:14	13:40:57 214:6
12:34:55 203:3,4	13:26:29 205:16	13:30:34 208:17	13:33:56 211:15	13:41:00 214:7
12:34:56 203:5	13:26:31 205:17	13:30:41 208:18	13:33:58 211:16	13:41:01 214:8
12:35:02 203:6	13:26:32 205:18	13:30:42 208:19	13:34:00 211:17	13:41:04 214:9
12:35:06 203:7	13:26:34 205:19	13:30:47 208:20	13:34:05 211:18	13:41:08 214:10
12:35:14 203:8	13:26:40 205:20	13:30:50 208:21	13:34:10 211:19	13:41:09 214:11
12:35:18 203:9	13:26:41 205:21,22	13:30:54 208:22	13:34:14 211:20	13:41:11 214:12
12:35:19 203:10	13:27:04 206:1	13:30:56 209:1	13:34:18 211:21	13:41:16 214:13
12:35:20 203:11	13:27:05 206:2,3	13:31:03 209:2	13:34:19 211:22	13:41:19 214:14
12:35:22 203:12	13:27:09 206:4	13:31:05 209:3	13:34:21 212:1	13:41:22 214:15,16
12:35:27 203:13	13:27:12 206:5,6	13:31:08 209:4	13:34:22 212:2	13:41:23 214:17
12:35:28 203:14	13:27:16 206:7	13:31:12 209:5,6	13:34:25 212:3	13:41:24 214:18
12:35:32 203:15	13:27:17 206:8,9	13:31:15 209:7,8	13:34:30 212:4	13:41:27 214:19
12:35:33 203:16	13:27:26 206:10	13:31:18 209:9	13:34:34 212:5	13:41:29 214:20
12:35:34 203:17	13:27:30 206:11	13:31:23 209:10	13:34:39 212:6	13:41:32 214:21
12:35:36 203:18	13:27:36 206:12	13:31:25 209:11	13:34:50 212:7	13:41:33 214:22
12:35:39 203:19	13:27:37 206:13	13:31:26 209:12	13:34:53 212:8	13:41:37 215:1
12:35:42 203:20,21	13:27:51 206:14	13:31:33 209:13	13:34:55 212:9	13:41:39 215:2,3,4
12:35:45 203:22	13:27:52 206:15	13:31:38 209:14	13:34:56 212:10	13:41:50 215:5,6
12:35:46 204:1	13:27:57 206:16	13:31:40 209:15	13:35:00 212:11	13:41:51 215:7
12:35:47 204:2	13:27:59 206:17	13:31:42 209:16	13:35:04 212:12	13:41:54 215:8
12:35:49 204:3	13:28:00 206:18	13:31:43 209:17	13:35:18 212:13	13:41:57 215:9
12:35:51 204:4,5	13:28:03 206:19	13:31:47 209:18	13:38:42 212:14	13:42:00 215:10
12:35:53 204:6	13:28:08 206:20	13:31:50 209:19	13:38:43 212:15	13:42:07 215:11
12:35:55 204:7	13:28:14 206:21	13:31:53 209:20	13:38:47 212:16	13:42:09 215:12
12:36:01 204:8	13:28:17 206:22 207:1	13:31:56 209:21	13:38:50 212:17	13:42:12 215:13
12:36:02 204:9	13:28:19 207:2	13:31:59 209:22	13:38:54 212:18	13:42:15 215:14
12:36:06 204:10	13:28:26 207:3	13:32:00 210:1	13:38:58 212:19	13:42:18 215:15
12:36:09 204:11	13:28:31 207:4	13:32:03 210:2	13:38:59 212:20	13:42:21 215:16
12:36:11 204:12	13:28:34 207:5	13:32:06 210:3	13:39:01 212:21	13:42:24 215:17
12:36:12 204:13	13:28:39 207:6	13:32:09 210:4,5	13:39:04 212:22	13:42:26 215:18
12:36:13 204:14,15	13:28:43 207:7	13:32:13 210:6	13:39:07 213:1	13:42:30 215:19
12:36:17 204:16,17	13:28:49 207:8,9,10	13:32:15 210:7	13:39:11 213:2	13:42:35 215:20
12:36:18 204:18	13:28:54 207:11	13:32:18 210:8,9	13:39:21 213:3	13:42:38 215:21,22
12:36:21 204:19,20	13:28:57 207:12	13:32:44 210:10,11,12	13:39:25 213:4	13:42:40 216:1
12:36:24 204:21	13:28:58 207:13	210:13	13:39:29 213:5	13:42:45 216:2
12:36:32 204:22	13:29:01 207:14	13:32:47 210:14	13:39:32 213:6	13:42:49 216:3

13:42:54 216:4	13:46:08 218:22	13:49:00 221:14	13:52:29 224:9	13:57:15 227:3
13:42:56 216:5	13:46:11 219:1	13:49:02 221:15	13:52:31 224:10	13:57:19 227:4
13:43:00 216:6	13:46:17 219:2	13:49:22 221:16	13:52:33 224:11	13:57:26 227:5
13:43:04 216:7	13:46:20 219:3	13:49:23 221:17	13:54:00 224:12	13:57:28 227:6
13:43:05 216:8	13:46:24 219:4	13:49:25 221:18	13:54:04 224:13	13:57:30 227:7
13:43:10 216:9	13:46:27 219:5	13:49:30 221:19	13:54:10 224:14	13:57:33 227:8
13:43:22 216:10	13:46:30 219:6	13:49:33 221:20,21	13:54:14 224:15	13:57:34 227:9
13:43:25 216:11	13:46:34 219:7,8	13:49:34 221:22	13:54:18 224:16	13:57:38 227:10
13:43:28 216:12	13:46:38 219:9	13:49:38 222:1	13:54:21 224:17	13:57:47 227:11
13:43:32 216:13	13:46:41 219:10	13:49:45 222:2,3	13:54:25 224:18	13:57:49 227:12
13:43:35 216:14	13:46:44 219:11	13:49:48 222:4	13:54:29 224:19	13:57:53 227:13
13:43:38 216:15	13:46:57 219:12	13:49:50 222:5	13:54:32 224:20	13:57:58 227:14
13:43:39 216:16	13:46:58 219:13	13:49:53 222:6	13:54:34 224:21	13:58:03 227:15
13:43:41 216:17	13:47:01 219:14	13:49:57 222:7	13:54:37 224:22	13:58:10 227:16
13:43:44 216:18	13:47:04 219:15	13:50:22 222:8	13:54:40 225:1	13:58:14 227:17
13:43:51 216:19	13:47:06 219:16	13:50:25 222:9	13:54:43 225:2	13:58:16 227:18
13:43:53 216:20	13:47:08 219:17	13:50:28 222:10	13:54:46 225:3	13:58:20 227:19,20
13:43:56 216:21	13:47:12 219:18	13:50:29 222:11	13:54:52 225:4	13:58:23 227:21
13:43:58 216:22	13:47:14 219:19	13:50:33 222:12	13:54:57 225:5	13:58:26 227:22
13:44:00 217:1	13:47:18 219:20	13:50:38 222:13	13:55:01 225:6	13:58:29 228:1
13:44:03 217:2	13:47:22 219:21	13:50:41 222:14	13:55:04 225:7	13:58:33 228:2
13:44:08 217:3	13:47:23 219:22	13:50:44 222:15	13:55:10 225:8	13:58:35 228:3
13:44:10 217:4	13:47:24 220:1	13:50:47 222:16	13:55:15 225:9	13:58:37 228:4
13:44:12 217:5,6	13:47:29 220:2	13:50:50 222:17	13:55:18 225:10	13:58:40 228:5
13:44:17 217:7,8	13:47:32 220:3	13:50:53 222:18	13:55:30 225:11,12	13:58:44 228:6
13:44:18 217:9	13:47:35 220:4	13:50:55 222:19	13:55:33 225:13	13:58:46 228:7
13:44:21 217:10	13:47:37 220:5	13:50:57 222:20	13:55:40 225:14	13:58:48 228:8
13:44:25 217:11	13:47:39 220:6	13:51:02 222:21	13:55:44 225:15,16	13:58:51 228:9
13:44:30 217:12	13:47:42 220:7	13:51:04 222:22	13:55:46 225:17	13:58:54 228:10
13:44:36 217:13,14	13:47:45 220:8	13:51:05 223:1	13:55:55 225:18	13:58:55 228:11
13:44:37 217:15	13:47:48 220:9	13:51:07 223:2	13:56:00 225:19	13:58:56 228:12
13:44:39 217:16	13:47:49 220:10	13:51:13 223:3	13:56:03 225:20	13:59:00 228:13
13:44:43 217:17	13:47:50 220:11	13:51:15 223:4	13:56:07 225:21	13:59:01 228:14
13:44:48 217:18	13:47:54 220:12	13:51:20 223:5	13:56:12 225:22 226:1	13:59:04 228:15
13:44:51 217:19	13:48:00 220:13	13:51:23 223:6	13:56:15 226:2	13:59:09 228:16
13:44:53 217:20	13:48:04 220:14	13:51:25 223:7	13:56:17 226:3	13:59:13 228:17
13:44:58 217:21	13:48:07 220:15	13:51:30 223:8	13:56:18 226:4	13:59:17 228:18
13:44:59 217:22	13:48:10 220:16	13:51:33 223:9	13:56:19 226:5	13:59:20 228:19
13:45:01 218:1,2	13:48:13 220:17	13:51:35 223:10	13:56:21 226:6	13:59:24 228:20
13:45:05 218:3,4	13:48:15 220:18	13:51:38 223:11	13:56:25 226:7	13:59:27 228:21
13:45:08 218:5	13:48:17 220:19	13:51:41 223:12	13:56:27 226:8	13:59:29 228:22
13:45:11 218:6	13:48:20 220:20	13:51:46 223:13	13:56:28 226:9	13:59:32 229:1
13:45:14 218:7	13:48:22 220:21	13:51:48 223:14	13:56:32 226:10	13:59:34 229:2
13:45:15 218:8	13:48:25 220:22	13:51:50 223:15	13:56:36 226:11	13:59:35 229:3
13:45:18 218:9	13:48:27 221:1	13:51:53 223:16	13:56:37 226:12	13:59:37 229:4
13:45:23 218:10	13:48:29 221:2	13:51:55 223:17	13:56:40 226:13	13:59:40 229:5
13:45:27 218:11	13:48:32 221:3	13:51:58 223:18	13:56:45 226:14	13:59:44 229:6
13:45:31 218:12	13:48:36 221:4	13:52:02 223:19	13:56:49 226:15	13:59:47 229:7
13:45:34 218:13	13:48:40 221:5	13:52:05 223:20	13:56:52 226:16	13:59:51 229:8
13:45:39 218:14	13:48:41 221:6	13:52:09 223:21,22	13:56:54 226:17	13:59:52 229:9
13:45:40 218:15	13:48:43 221:7	13:52:12 224:1	13:56:57 226:18	13:59:53 229:10
13:45:46 218:16	13:48:45 221:8	13:52:15 224:2	13:56:58 226:19	13:59:54 229:11
13:45:50 218:17	13:48:49 221:9	13:52:17 224:3	13:56:59 226:20	13:59:57 229:12
13:45:53 218:18	13:48:50 221:10	13:52:20 224:4,5	13:57:00 226:21	131 91:6,21 110:11,17
13:45:58 218:19	13:48:51 221:11	13:52:23 224:6	13:57:03 226:22	111:13,19,22 112:8
13:46:01 218:20	13:48:54 221:12	13:52:26 224:7	13:57:06 227:1	112:11 242:5 243:6
13:46:04 218:21	13:48:58 221:13	13:52:28 224:8	13:57:12 227:2	247:15 248:9,17

249:2,20 250:2 251:22 254:4,10 137 263:6 14 8:9 10:4 108:7 110:13 192:1 212:12 251:15,17 262:13 263:1 268:11 271:2 283:1,2,7,10,12 14:00:02 229:13 14:00:05 229:14 14:00:08 229:15 14:00:21 229:16 14:00:25 229:17 14:00:29 229:18 14:00:33 229:19 14:00:39 229:20 14:00:47 229:21 14:00:52 229:22 14:00:59 230:1 14:01:05 230:2,3 14:01:07 230:4 14:01:08 230:5 14:01:12 230:6 14:01:16 230:7 14:01:20 230:8 14:01:24 230:9 14:01:28 230:10 14:01:33 230:11 14:01:35 230:12 14:01:38 230:13 14:01:42 230:14 14:01:46 230:15 14:01:50 230:16 14:01:54 230:17 14:01:57 230:18 14:02:01 230:19 14:02:04 230:20 14:02:06 230:21 14:02:12 230:22 14:02:14 231:1 14:02:17 231:2 14:02:20 231:3 14:02:23 231:4 14:02:26 231:5 14:02:27 231:6 14:02:29 231:7 14:02:30 231:8 14:02:36 231:9 14:02:41 231:10 14:02:44 231:11 14:02:45 231:12 14:04:33 231:13 14:04:34 231:14 14:04:38 231:15 14:04:41 231:16 14:04:45 231:17 14:04:48 231:18	14:04:51 231:19,20 14:04:54 231:21 14:04:58 231:22 14:05:05 232:1 14:05:07 232:2 14:05:08 232:3 14:05:12 232:4 14:05:14 232:5 14:05:18 232:6 14:05:21 232:7 14:05:24 232:8 14:05:26 232:9 14:05:29 232:10 14:05:31 232:11 14:05:33 232:12 14:05:59 232:13,14 14:06:01 232:15,16 14:06:08 232:17 14:06:11 232:18 14:06:12 232:19 14:06:15 232:20 14:06:19 232:21 14:06:20 232:22 233:1 14:06:23 233:2 14:06:24 233:3 14:06:25 233:4 14:06:31 233:5 14:06:39 233:6 14:06:42 233:7 14:06:47 233:8 14:06:51 233:9 14:06:56 233:10 14:07:02 233:11 14:07:07 233:12 14:07:10 233:13 14:07:15 233:14 14:07:17 233:15 14:07:18 233:16,17 14:07:22 233:18 14:07:25 233:19 14:07:26 233:20 14:07:29 233:21 14:07:30 233:22 234:1 14:07:33 234:2 14:07:37 234:3 14:07:38 234:4 14:07:40 234:5 14:07:42 234:6 14:07:44 234:7 14:07:47 234:8 14:07:52 234:9 14:07:55 234:10 14:07:57 234:11 14:08:00 234:12,13 14:08:02 234:14 14:08:03 234:15 14:13:48 234:16	14:13:53 234:17 14:13:58 234:18 14:13:59 234:19 14:14:01 234:20 14:14:05 234:21 14:14:08 234:22 14:14:13 235:1 14:14:18 235:2 14:14:21 235:3 14:14:27 235:4 14:14:31 235:5 14:14:39 235:6 14:14:42 235:7 14:14:46 235:8 14:14:51 235:9 14:14:53 235:10 14:14:56 235:11 14:14:57 235:12 14:15:08 235:13 14:15:12 235:14 14:15:15 235:15 14:15:19 235:16 14:15:29 235:17 14:15:34 235:18 14:15:38 235:19 14:15:43 235:20 14:15:46 235:21 14:15:51 235:22 14:15:53 236:1 14:15:54 236:2 14:15:59 236:3 14:16:03 236:4 14:16:07 236:5 14:16:08 236:6 14:16:11 236:7 14:16:13 236:8 14:16:14 236:9 14:16:18 236:10 14:16:21 236:11 14:16:23 236:12 14:16:24 236:13 14:16:50 236:14 14:16:53 236:15 14:17:00 236:16 14:17:03 236:17 14:17:06 236:18 14:17:09 236:19 14:17:11 236:20 14:17:13 236:21,22 14:17:14 237:1 14:17:18 237:2 14:17:20 237:3 14:17:23 237:4 14:17:30 237:5 14:17:31 237:6 14:17:35 237:7 14:17:37 237:8	14:17:39 237:9 14:17:40 237:10 14:17:43 237:11 14:17:46 237:12 14:17:49 237:13 14:18:04 237:14 14:18:05 237:15 14:18:07 237:16 14:18:08 237:17 14:18:10 237:18 14:18:14 237:19 14:18:45 237:20 14:18:46 237:21 14:18:47 237:22 238:1 14:18:52 238:2 14:19:00 238:3 14:19:02 238:4 14:19:03 238:5 14:19:07 238:6 14:19:10 238:7,8 14:19:13 238:9 14:19:14 238:10 14:19:16 238:11 14:19:32 238:12 14:19:51 238:13,14 14:19:53 238:15 14:20:21 238:16 14:20:26 238:17 14:20:29 238:18 14:20:32 238:19 14:20:33 238:20 14:20:34 238:21,22 14:20:38 239:1 14:20:41 239:2 14:20:44 239:3 14:20:45 239:4 14:20:48 239:5 14:20:50 239:6 14:20:54 239:7 14:20:55 239:8 14:20:57 239:9 14:21:02 239:10 14:21:05 239:11 14:21:08 239:12 14:21:12 239:13 14:21:14 239:14 14:21:16 239:15 14:21:18 239:16,17 14:21:20 239:18,19 14:21:21 239:20 14:21:26 239:21 14:21:49 239:22 14:21:52 240:1 14:21:55 240:2 14:21:56 240:3 14:21:57 240:4 14:22:01 240:5	14:22:03 240:6 14:22:16 240:7 14:22:17 240:8 14:22:44 240:9,10 14:22:47 240:11 14:22:52 240:12 14:22:54 240:13 14:22:55 240:14 14:23:16 240:15 14:24:15 240:16 14:24:16 240:17 14:24:19 240:18 14:24:20 240:19 14:24:21 240:20 14:24:25 240:21 14:24:29 240:22 14:24:31 241:1 14:24:32 241:2,3 14:24:37 241:4 14:24:40 241:5 14:24:41 241:6,7 14:24:45 241:8 14:24:49 241:9 14:24:51 241:10 14:24:54 241:11 14:24:58 241:12 14:25:14 241:13 14:25:20 241:14 14:25:24 241:15 14:25:30 241:16 14:25:39 241:17 14:25:43 241:18 14:25:48 241:19,20 14:25:54 241:21 14:25:55 241:22 14:25:57 242:1 14:26:01 242:2,3 14:26:10 242:4 14:26:13 242:5 14:26:17 242:6 14:26:21 242:7 14:26:22 242:8 14:26:23 242:9 14:26:24 242:10 14:26:27 242:11 14:26:29 242:12 14:26:33 242:13 14:26:36 242:14 14:26:39 242:15 14:26:43 242:16 14:26:44 242:17 14:26:45 242:18 14:26:47 242:19 14:26:48 242:20 14:26:49 242:21,22 14:26:52 243:1 14:26:54 243:2
---	---	--	---	---

14:26:55 243:3,4	14:30:57 245:19	14:34:20 248:12	14:37:55 251:7	14:41:54 254:1
14:26:58 243:5	14:31:01 245:20	14:34:21 248:13	14:37:57 251:8	14:41:57 254:2,3
14:27:01 243:6	14:31:03 245:21	14:34:29 248:14	14:38:01 251:9	14:41:58 254:4
14:27:05 243:7	14:31:08 245:22	14:34:34 248:15	14:38:04 251:10	14:42:03 254:5
14:27:10 243:8	14:31:11 246:1	14:34:39 248:16	14:38:05 251:11	14:42:12 254:6
14:27:13 243:9	14:31:13 246:2	14:34:41 248:17	14:38:06 251:12	14:42:24 254:7
14:27:22 243:10	14:31:27 246:3	14:34:45 248:18	14:38:07 251:13	14:42:30 254:8
14:28:03 243:11	14:31:31 246:4	14:34:48 248:19,20	14:38:09 251:14	14:42:33 254:9
14:28:05 243:12	14:31:39 246:5	14:34:49 248:21	14:38:13 251:15	14:42:36 254:10
14:28:09 243:13	14:31:41 246:6	14:34:53 248:22	14:38:18 251:16	14:42:40 254:11
14:28:11 243:14,15	14:31:44 246:7	14:34:56 249:1	14:38:21 251:17	14:42:41 254:12
14:28:14 243:16	14:31:47 246:8	14:34:59 249:2	14:38:25 251:18	14:42:43 254:13
14:28:17 243:17	14:31:50 246:9	14:35:03 249:3	14:38:26 251:19	14:42:52 254:14
14:28:21 243:18	14:31:51 246:10,11	14:35:06 249:4	14:38:27 251:20	14:42:53 254:15
14:28:24 243:19	14:31:53 246:12	14:35:07 249:5	14:38:30 251:21	14:42:54 254:16
14:28:38 243:20	14:31:56 246:13	14:35:08 249:6	14:38:34 251:22	14:42:57 254:17
14:28:41 243:21	14:32:00 246:14	14:35:09 249:7	14:38:40 252:1	14:43:00 254:18
14:28:49 243:22	14:32:04 246:15	14:35:14 249:8	14:38:49 252:2	14:43:02 254:19
14:28:50 244:1	14:32:08 246:16	14:35:18 249:9	14:38:52 252:3	14:43:11 254:20
14:28:53 244:2	14:32:11 246:17	14:35:21 249:10	14:38:56 252:4	14:43:15 254:21
14:28:57 244:3	14:32:13 246:18	14:35:24 249:11	14:38:57 252:5	14:43:18 254:22
14:29:01 244:4,5	14:32:17 246:19	14:35:25 249:12	14:39:06 252:6	14:43:20 255:1
14:29:05 244:6	14:32:18 246:20	14:35:26 249:13	14:39:39 252:7	14:58:44 255:2
14:29:08 244:7	14:32:20 246:21	14:35:28 249:14	14:39:42 252:8	14:59:22 255:3
14:29:12 244:8	14:32:24 246:22	14:35:29 249:15	14:39:43 252:9,10	14:59:28 255:4
14:29:14 244:9	14:32:28 247:1	14:35:35 249:16	14:39:46 252:11	14:59:32 255:5
14:29:16 244:10	14:32:32 247:2,3	14:35:39 249:17	14:39:47 252:12	14:59:35 255:6
14:29:17 244:11	14:32:37 247:4	14:35:53 249:18	14:39:48 252:13	14:59:36 255:7,8
14:29:22 244:12	14:32:41 247:5	14:35:56 249:19	14:39:50 252:14	14:59:39 255:9
14:29:29 244:13	14:32:44 247:6	14:35:59 249:20	14:39:54 252:15	14:59:43 255:10
14:29:31 244:14	14:32:49 247:7	14:36:24 249:21,22	14:39:56 252:16	14:59:47 255:11
14:29:34 244:15	14:32:54 247:8	14:36:31 250:1	14:39:58 252:17	14:59:50 255:12
14:29:35 244:16	14:32:57 247:9	14:36:35 250:2	14:39:59 252:18	14:59:58 255:13
14:29:39 244:17	14:32:59 247:10	14:36:42 250:3	14:40:05 252:19	14:59:59 255:14
14:29:42 244:18	14:33:03 247:11	14:36:46 250:4	14:40:11 252:20	147-172 5:17
14:29:48 244:19	14:33:04 247:12	14:36:49 250:5	14:40:13 252:21	15 8:14 10:11 65:12
14:29:51 244:20	14:33:07 247:13	14:36:53 250:6	14:40:17 252:22	168:1 209:10 211:1
14:29:52 244:21	14:33:10 247:14	14:36:55 250:7	14:40:20 253:1	264:15,19 265:13
14:29:57 244:22	14:33:13 247:15	14:36:56 250:8	14:40:55 253:2	284:20,21 285:4,10
14:30:00 245:1	14:33:16 247:16	14:37:01 250:9	14:40:56 253:3	285:12 286:17,18
14:30:04 245:2	14:33:18 247:17	14:37:16 250:10	14:40:59 253:4	287:19
14:30:08 245:3	14:33:20 247:18	14:37:19 250:11	14:41:02 253:5	15:00:02 255:15
14:30:11 245:4	14:33:23 247:19	14:37:21 250:12,13	14:41:07 253:6	15:00:06 255:16
14:30:14 245:5	14:33:27 247:20	14:37:22 250:14	14:41:10 253:7	15:00:09 255:17
14:30:18 245:6	14:33:33 247:21	14:37:23 250:15	14:41:12 253:8	15:00:13 255:18
14:30:22 245:7	14:33:37 247:22	14:37:25 250:16	14:41:16 253:9	15:00:16 255:19
14:30:24 245:8	14:33:39 248:1	14:37:28 250:17	14:41:20 253:10	15:00:22 255:20
14:30:27 245:9	14:33:41 248:2	14:37:32 250:18	14:41:23 253:11	15:00:28 255:21
14:30:30 245:10	14:33:43 248:3	14:37:35 250:19	14:41:24 253:12,13	15:00:32 255:22
14:30:37 245:11	14:33:46 248:4	14:37:37 250:20	14:41:27 253:14	15:00:37 256:1
14:30:39 245:12	14:33:56 248:5	14:37:38 250:21,22	14:41:31 253:15	15:00:42 256:2
14:30:43 245:13	14:33:59 248:6	14:37:40 251:1	14:41:36 253:16,17	15:00:45 256:3
14:30:46 245:14	14:34:08 248:7	14:37:43 251:2	14:41:39 253:18	15:00:49 256:4
14:30:48 245:15	14:34:10 248:8	14:37:48 251:3	14:41:44 253:19	15:00:52 256:5
14:30:49 245:16	14:34:12 248:9	14:37:52 251:4	14:41:45 253:20	15:00:55 256:6
14:30:53 245:17	14:34:16 248:10	14:37:53 251:5	14:41:47 253:21	15:00:59 256:7
14:30:56 245:18	14:34:19 248:11	14:37:54 251:6	14:41:50 253:22	15:01:03 256:8

15:01:06 256:9	15:04:34 259:3	15:07:58 261:19	15:11:48 264:16	15:15:12 267:15
15:01:09 256:10	15:04:36 259:4	15:08:04 261:20	15:11:51 264:17	15:15:13 267:16
15:01:12 256:11,12	15:04:38 259:5	15:08:08 261:21	15:11:52 264:18	15:15:14 267:17
15:01:15 256:13	15:04:42 259:6	15:08:10 261:22	15:11:54 264:19	15:15:15 267:18
15:01:19 256:14	15:04:46 259:7	15:08:15 262:1	15:11:57 264:20	15:15:17 267:19
15:01:24 256:15	15:04:48 259:8	15:08:19 262:2,3	15:12:00 264:21	15:15:20 267:20
15:01:28 256:16	15:05:01 259:9	15:08:23 262:4	15:12:02 264:22 265:1	15:15:23 267:21
15:01:31 256:17	15:05:02 259:10	15:08:28 262:5	15:12:12 265:2	15:15:28 267:22
15:01:32 256:18	15:05:03 259:11	15:08:31 262:6	15:12:17 265:3	15:15:38 268:1
15:01:35 256:19	15:05:04 259:12	15:08:33 262:7	15:12:27 265:4	15:15:43 268:2
15:01:38 256:20	15:05:06 259:13	15:08:36 262:8	15:12:28 265:5	15:15:47 268:3
15:01:42 256:21	15:05:09 259:14	15:09:00 262:9	15:12:30 265:6	15:15:50 268:4
15:01:45 256:22	15:05:31 259:15	15:09:01 262:10	15:12:31 265:7	15:15:54 268:5
15:01:48 257:1	15:05:32 259:16,17,18	15:09:02 262:11	15:12:33 265:8,9	15:15:58 268:6
15:01:50 257:2	15:05:35 259:19	15:09:03 262:12	15:12:42 265:10,11,12	15:16:01 268:7
15:01:51 257:3	15:05:36 259:20,21	15:09:05 262:13	15:12:45 265:13	15:16:03 268:8
15:02:04 257:4	15:05:39 259:22	15:09:09 262:14	15:12:49 265:14,15	15:16:04 268:9
15:02:07 257:5	15:05:42 260:1	15:09:32 262:15,16	15:12:50 265:16	15:16:05 268:10
15:02:10 257:6	15:05:43 260:2	15:09:33 262:17	15:13:00 265:17	15:16:06 268:11
15:02:21 257:7	15:05:44 260:3	15:09:34 262:18,19	15:13:02 265:18	15:16:12 268:12
15:02:23 257:8	15:05:48 260:4	15:09:37 262:20	15:13:05 265:19	15:16:15 268:13
15:02:24 257:9	15:05:49 260:5	15:09:38 262:21	15:13:18 265:20	15:16:18 268:14
15:02:26 257:10	15:05:53 260:6	15:09:39 262:22	15:13:23 265:21	15:16:20 268:15
15:02:28 257:11	15:05:58 260:7	15:09:41 263:1	15:13:28 265:22	15:16:22 268:16
15:02:31 257:12	15:06:01 260:8	15:09:45 263:2	15:13:30 266:1	15:16:23 268:17
15:02:51 257:13	15:06:04 260:9	15:09:46 263:3	15:13:34 266:2	15:16:26 268:18
15:02:52 257:14	15:06:07 260:10	15:09:47 263:4	15:13:38 266:3	15:16:28 268:19
15:02:53 257:15,16	15:06:11 260:11	15:09:50 263:5	15:13:41 266:4	15:16:33 268:20
15:03:00 257:17	15:06:15 260:12	15:09:52 263:6	15:13:46 266:5	15:16:36 268:21
15:03:01 257:18	15:06:17 260:13	15:09:59 263:7	15:13:48 266:6	15:16:38 268:22
15:03:02 257:19	15:06:19 260:14	15:10:05 263:8	15:13:51 266:7	15:16:41 269:1
15:03:04 257:20	15:06:22 260:15	15:10:08 263:9	15:13:54 266:8	15:16:44 269:2
15:03:09 257:21,22	15:06:26 260:16	15:10:12 263:10	15:13:56 266:9	15:16:45 269:3
15:03:10 258:1	15:06:28 260:17	15:10:18 263:11	15:13:58 266:10	15:16:47 269:4
15:03:13 258:2	15:06:29 260:18	15:10:23 263:12	15:14:02 266:11	15:16:48 269:5
15:03:18 258:3	15:06:30 260:19	15:10:28 263:13	15:14:05 266:12	15:16:50 269:6
15:03:26 258:4	15:06:32 260:20	15:10:29 263:14	15:14:08 266:13	15:16:55 269:7
15:03:30 258:5	15:06:35 260:21	15:10:34 263:15	15:14:13 266:14	15:16:58 269:8,9
15:03:34 258:6	15:06:40 260:22	15:10:35 263:16	15:14:15 266:15	15:16:59 269:10
15:03:39 258:7	15:06:44 261:1	15:10:38 263:17	15:14:16 266:16	15:17:00 269:11
15:03:43 258:8	15:06:47 261:2	15:10:43 263:18	15:14:17 266:17	15:17:02 269:12
15:03:46 258:9	15:06:49 261:3	15:10:47 263:19	15:14:19 266:18	15:17:05 269:13
15:03:49 258:10	15:06:53 261:4	15:10:50 263:20	15:14:21 266:19	15:17:09 269:14
15:03:53 258:11	15:06:57 261:5	15:10:51 263:21,22	15:14:25 266:20	15:17:12 269:15,16
15:03:57 258:12	15:06:58 261:6	15:10:52 264:1	15:14:28 266:21	15:17:14 269:17,18
15:04:00 258:13	15:07:01 261:7	15:10:53 264:2	15:14:31 266:22	15:17:15 269:19
15:04:03 258:14	15:07:04 261:8	15:10:55 264:3	15:14:32 267:1,2	15:17:18 269:20
15:04:07 258:15	15:07:07 261:9	15:10:59 264:4	15:14:33 267:3	15:17:21 269:21
15:04:10 258:16	15:07:11 261:10	15:11:02 264:5	15:14:41 267:4	15:17:24 269:22
15:04:11 258:17	15:07:13 261:11	15:11:05 264:6,7	15:14:43 267:5	15:17:27 270:1
15:04:13 258:18	15:07:25 261:12	15:11:31 264:8	15:14:45 267:6	15:17:28 270:2
15:04:15 258:19	15:07:27 261:13	15:11:33 264:9	15:14:46 267:7	15:17:30 270:3
15:04:19 258:20	15:07:30 261:14	15:11:34 264:10	15:14:48 267:8	15:17:32 270:4
15:04:22 258:21	15:07:35 261:15	15:11:36 264:11	15:14:51 267:9	15:17:36 270:5
15:04:26 258:22	15:07:40 261:16	15:11:39 264:12,13	15:15:08 267:10	15:17:37 270:6
15:04:29 259:1	15:07:45 261:17	15:11:40 264:14	15:15:09 267:11	15:17:39 270:7
15:04:32 259:2	15:07:53 261:18	15:11:42 264:15	15:15:10 267:12,13,14	15:17:45 270:8

15:17:49 270:9	15:20:57 273:2	15:23:36 275:17	15:26:41 278:12	15:29:59 281:14
15:17:54 270:10	15:20:59 273:3	15:23:39 275:18	15:26:46 278:13	15:30:00 281:15
15:17:58 270:11	15:21:02 273:4	15:23:40 275:19	15:26:47 278:14	15:30:06 281:16
15:18:01 270:12	15:21:09 273:5	15:23:41 275:20	15:26:49 278:15,16	15:30:13 281:17
15:18:03 270:13	15:21:15 273:6	15:23:44 275:21	15:26:52 278:17	15:30:17 281:18
15:18:07 270:14	15:21:22 273:7	15:23:47 275:22	15:26:54 278:18	15:30:20 281:19
15:18:14 270:15	15:21:24 273:8	15:23:52 276:1	15:26:58 278:19	15:30:23 281:20
15:18:21 270:16	15:21:26 273:9	15:23:55 276:2	15:27:01 278:20	15:30:24 281:21,22
15:18:26 270:17	15:21:30 273:10	15:23:59 276:3	15:27:04 278:21	15:30:27 282:1
15:18:31 270:18	15:21:31 273:11	15:24:02 276:4	15:27:05 278:22	15:30:31 282:2
15:18:33 270:19,20	15:21:33 273:12	15:24:03 276:5	15:27:08 279:1,2	15:30:34 282:3
15:18:35 270:21	15:21:37 273:13	15:24:07 276:6	15:27:14 279:3	15:30:36 282:4
15:18:38 270:22 271:1	15:21:40 273:14	15:24:09 276:7	15:27:16 279:4	15:30:37 282:5
15:18:41 271:2	15:21:41 273:15	15:24:13 276:8	15:27:17 279:5	15:30:39 282:6
15:18:44 271:3	15:21:42 273:16	15:24:16 276:9	15:27:19 279:6,7	15:30:41 282:7
15:18:48 271:4	15:21:45 273:17	15:24:29 276:10	15:27:20 279:8	15:30:45 282:8
15:18:49 271:5	15:21:49 273:18	15:24:32 276:11	15:27:46 279:9	15:30:48 282:9
15:18:52 271:6	15:21:52 273:19	15:24:40 276:12	15:27:47 279:10	15:30:50 282:10
15:18:55 271:7	15:21:55 273:20	15:24:41 276:13	15:27:49 279:11	15:30:53 282:11
15:18:58 271:8	15:21:56 273:21	15:24:44 276:14,15,16	15:27:51 279:12	15:30:57 282:12
15:19:02 271:9	15:21:58 273:22	15:24:45 276:17	15:27:55 279:13	15:30:58 282:13
15:19:05 271:10	15:22:00 274:1	15:24:47 276:18,19	15:27:59 279:14	15:31:02 282:14
15:19:08 271:11	15:22:03 274:2	15:24:48 276:20	15:28:01 279:15	15:31:03 282:15
15:19:10 271:12	15:22:04 274:3	15:24:49 276:21	15:28:14 279:16,17	15:31:06 282:16
15:19:12 271:13	15:22:05 274:4	15:24:53 276:22	15:28:15 279:18,19	15:31:08 282:17
15:19:14 271:14	15:22:07 274:5	15:25:00 277:1	15:28:16 279:20,21	15:31:13 282:18
15:19:15 271:15	15:22:08 274:6	15:25:04 277:2	15:28:19 279:22	15:31:15 282:19
15:19:17 271:16	15:22:10 274:7	15:25:09 277:3	15:28:20 280:1,2	15:31:16 282:20
15:19:18 271:17	15:22:15 274:8	15:25:11 277:4	15:28:22 280:3	15:31:32 282:21
15:19:22 271:18	15:22:20 274:9	15:25:14 277:5	15:28:26 280:4	15:31:33 282:22
15:19:27 271:19	15:22:22 274:10	15:25:17 277:6	15:28:27 280:5	15:31:34 283:1
15:19:31 271:20	15:22:25 274:11	15:25:18 277:7	15:28:28 280:6	15:31:35 283:2
15:19:32 271:21	15:22:28 274:12	15:25:20 277:8	15:28:32 280:7	15:31:37 283:3
15:19:41 271:22	15:22:29 274:13	15:25:24 277:9	15:28:35 280:8	15:31:41 283:4
15:19:44 272:1	15:22:30 274:14	15:25:26 277:10	15:28:38 280:9	15:31:44 283:5
15:19:48 272:2	15:22:33 274:15	15:25:29 277:11	15:28:42 280:10	15:32:09 283:6,7
15:19:50 272:3	15:22:37 274:16	15:25:32 277:12	15:28:46 280:11	15:32:10 283:8,9
15:19:53 272:4	15:22:39 274:17,18	15:25:35 277:13	15:28:49 280:12	15:32:13 283:10
15:19:58 272:5	15:22:41 274:19	15:25:36 277:14	15:28:51 280:13	15:32:15 283:11,12
15:20:02 272:6	15:22:44 274:20	15:25:51 277:15	15:28:52 280:14	15:32:18 283:13
15:20:04 272:7	15:22:48 274:21	15:25:53 277:16	15:28:53 280:15	15:32:22 283:14
15:20:07 272:8	15:22:52 274:22	15:25:56 277:17	15:29:05 280:16	15:32:23 283:15
15:20:10 272:9	15:22:54 275:1	15:25:59 277:18	15:29:07 280:17	15:32:24 283:16
15:20:12 272:10	15:22:57 275:2	15:26:02 277:19	15:29:09 280:18,19	15:32:26 283:17
15:20:15 272:11	15:23:00 275:3	15:26:04 277:20,21	15:29:11 280:20	15:32:27 283:18
15:20:18 272:12	15:23:04 275:4	15:26:10 277:22	15:29:14 280:21	15:32:29 283:19
15:20:27 272:13	15:23:06 275:5	15:26:13 278:1	15:29:16 280:22	15:32:33 283:20
15:20:30 272:14	15:23:08 275:6	15:26:17 278:2	15:29:35 281:1,2	15:32:37 283:21
15:20:34 272:15	15:23:11 275:7	15:26:19 278:3	15:29:36 281:3,4	15:32:40 283:22
15:20:36 272:16	15:23:14 275:8	15:26:22 278:4	15:29:39 281:5	15:32:44 284:1
15:20:38 272:17	15:23:17 275:9	15:26:25 278:5	15:29:40 281:6,7	15:32:47 284:2
15:20:41 272:18	15:23:21 275:10	15:26:28 278:6	15:29:42 281:8	15:32:49 284:3
15:20:46 272:19	15:23:23 275:11	15:26:30 278:7	15:29:46 281:9	15:32:53 284:4
15:20:48 272:20	15:23:24 275:12	15:26:31 278:8	15:29:47 281:10	15:32:55 284:5
15:20:51 272:21	15:23:25 275:13,14	15:26:35 278:9	15:29:48 281:11	15:32:58 284:6
15:20:53 272:22	15:23:29 275:15	15:26:36 278:10	15:29:51 281:12	15:33:02 284:7
15:20:55 273:1	15:23:32 275:16	15:26:38 278:11	15:29:53 281:13	15:33:06 284:8

15:33:11 284:9	15:36:41 287:7	15:40:06 290:2	15:43:44 292:21	15:47:43 295:14
15:33:13 284:10	15:36:45 287:8	15:40:10 290:3	15:43:47 292:22	15:47:44 295:15
15:33:16 284:11	15:36:48 287:9	15:40:13 290:4	15:43:51 293:1	15:47:47 295:16
15:33:20 284:12	15:36:51 287:10	15:40:14 290:5	15:43:52 293:2	15:47:50 295:17
15:33:22 284:13	15:36:55 287:11	15:40:16 290:6	15:43:53 293:3	15:47:51 295:18
15:33:23 284:14	15:36:59 287:12	15:40:18 290:7	15:44:02 293:4	15:47:52 295:19
15:33:26 284:15	15:37:02 287:13	15:40:21 290:8	15:44:06 293:5	15:47:58 295:20
15:33:29 284:16	15:37:05 287:14	15:40:22 290:9 291:1	15:44:17 293:6	15:48:02 295:21
15:33:32 284:17	15:37:06 287:15	15:40:24 290:10 291:2	15:44:20 293:7	15:48:04 295:22
15:33:42 284:18	15:37:07 287:16	291:3	15:44:22 293:8	15:48:08 296:1
15:33:43 284:19	15:37:09 287:17	15:40:25 290:11	15:44:26 293:9	15:48:12 296:2
15:33:45 284:20	15:37:11 287:18	15:40:31 290:12	15:44:30 293:10	15:48:15 296:3
15:33:46 284:21	15:37:13 287:19	15:40:39 290:13	15:44:34 293:11,12	15:48:20 296:4
15:33:48 284:22	15:37:29 287:20	15:40:44 290:14	15:44:36 293:13	15:48:22 296:5
15:33:53 285:1	15:37:30 287:21	15:40:50 290:15	15:44:40 293:14	15:48:26 296:6
15:33:54 285:2	15:37:32 287:22	15:40:53 290:16	15:44:43 293:15	15:48:30 296:7
15:34:31 285:3,4,5,6,7	15:37:33 288:1	15:40:54 290:17	15:44:46 293:16	15:48:33 296:8
15:34:32 285:8,9	15:37:36 288:2	15:40:57 290:18	15:44:49 293:17	15:48:37 296:9
15:34:40 285:10	15:37:41 288:3	15:40:58 290:19	15:44:51 293:18	15:48:40 296:10
15:34:41 285:11,12	15:37:42 288:4	15:41:00 290:20,21,22	15:44:54 293:19	15:48:41 296:11
15:34:44 285:13	15:38:14 288:5,6	15:41:16 291:4	15:45:14 293:20	15:48:42 296:12
15:34:47 285:14	15:38:15 288:7,8	15:41:19 291:5	15:45:18 293:21	15:48:44 296:13,14
15:34:48 285:15	15:38:31 288:9,10	15:41:24 291:6	15:45:19 293:22	15:48:47 296:15
15:34:49 285:16	15:38:32 288:11	15:41:28 291:7	15:45:24 294:1	15:48:58 296:16
15:34:52 285:17	15:38:35 288:12	15:41:31 291:8	15:45:27 294:2	15:49:04 296:17
15:34:58 285:18	15:38:37 288:13	15:41:40 291:9	15:45:30 294:3	15:49:09 296:18
15:35:00 285:19	15:38:38 288:14,15	15:41:43 291:10	15:45:35 294:4	15:49:14 296:19
15:35:03 285:20	15:38:43 288:16	15:41:46 291:11	15:45:38 294:5	15:49:18 296:20
15:35:07 285:21	15:38:46 288:17	15:41:49 291:12	15:45:42 294:6	15:49:20 296:21
15:35:09 285:22	15:38:49 288:18	15:41:50 291:13	15:45:45 294:7	15:49:23 296:22
15:35:10 286:1	15:38:52 288:19	15:41:55 291:14	15:45:51 294:8	15:49:27 297:1
15:35:13 286:2	15:38:57 288:20	15:42:01 291:15	15:45:55 294:9	15:49:30 297:2
15:35:15 286:3	15:39:00 288:21	15:42:10 291:16	15:45:57 294:10	15:49:33 297:3
15:35:19 286:4	15:39:02 288:22	15:42:11 291:17	15:45:59 294:11	15:49:34 297:4
15:35:21 286:5	15:39:03 289:1	15:42:14 291:18	15:46:03 294:12	15:49:35 297:5
15:35:24 286:6	15:39:04 289:2	15:42:18 291:19	15:46:07 294:13	15:49:37 297:6
15:35:29 286:7	15:39:06 289:3	15:42:22 291:20	15:46:10 294:14	15:49:42 297:7
15:35:31 286:8	15:39:10 289:4	15:42:26 291:21	15:46:12 294:15	15:49:45 297:8
15:35:33 286:9	15:39:12 289:5	15:42:27 291:22 292:1	15:46:14 294:16	15:49:48 297:9
15:35:34 286:10	15:39:15 289:6	15:42:31 292:2	15:46:18 294:17	15:49:50 297:10
15:35:37 286:11	15:39:18 289:7	15:42:34 292:3	15:46:20 294:18	15:49:52 297:11
15:35:39 286:12	15:39:21 289:8	15:42:37 292:4	15:46:22 294:19	15:50:16 297:12
15:35:40 286:13	15:39:22 289:9	15:42:41 292:5	15:46:24 294:20	15:50:18 297:13
15:35:43 286:14	15:39:23 289:10	15:42:43 292:6	15:46:25 294:21	15:50:20 297:14
15:35:45 286:15,16	15:39:24 289:11	15:42:44 292:7	15:46:27 294:22	15:50:21 297:15
15:35:48 286:17	15:39:28 289:12	15:42:57 292:8	15:46:28 295:1	15:50:23 297:16
15:35:50 286:18	15:39:31 289:13	15:42:58 292:9	15:46:44 295:2	15:50:27 297:17
15:35:53 286:19	15:39:33 289:14	15:43:00 292:10	15:46:46 295:3	15:50:28 297:18
15:35:55 286:20	15:39:37 289:15	15:43:01 292:11	15:46:47 295:4	15:50:53 297:19,20
15:35:57 286:21	15:39:39 289:16	15:43:04 292:12	15:46:48 295:5	15:50:54 297:21,22
15:36:01 286:22	15:39:47 289:17	15:43:08 292:13	15:46:50 295:6	15:50:57 298:1
15:36:04 287:1	15:39:51 289:18	15:43:10 292:14	15:46:54 295:7	15:50:59 298:2,3
15:36:09 287:2	15:39:54 289:19	15:43:35 292:15	15:46:55 295:8	15:51:02 298:4
15:36:10 287:3	15:39:56 289:20	15:43:36 292:16	15:47:18 295:9	15:51:06 298:5
15:36:12 287:4	15:39:57 289:21	15:43:37 292:17,18	15:47:19 295:10	15:51:07 298:6
15:36:19 287:5	15:39:59 289:22	15:43:41 292:19	15:47:20 295:11,12	15:51:08 298:7
15:36:38 287:6	15:40:03 290:1	15:43:43 292:20	15:47:42 295:13	15:51:11 298:8

15:51:14 298:9	15:54:37 301:7	15:57:40 304:5	16:00:35 306:12	16:03:58 309:9
15:51:17 298:10	15:54:42 301:8,9	15:57:43 304:6	16:00:37 306:13	16:04:02 309:10,11
15:51:20 298:11	15:54:44 301:10	15:57:45 304:7	16:00:39 306:14	16:04:06 309:12
15:51:24 298:12	15:54:46 301:11	15:58:09 304:8	16:00:41 306:15,16	16:04:09 309:13
15:51:25 298:13	15:54:52 301:12	15:58:10 304:9	16:00:45 306:17	16:04:11 309:14
15:51:26 298:14,15	15:54:56 301:13	15:58:11 304:10,11	16:00:47 306:18	16:04:14 309:15
15:51:33 298:16	15:55:00 301:14	15:58:14 304:12	16:00:48 306:19	16:04:16 309:16
15:51:34 298:17	15:55:03 301:15	15:58:15 304:13,14	16:01:02 306:20	16:04:18 309:17,18
15:51:37 298:18	15:55:11 301:16	15:58:18 304:15	16:01:04 306:21	16:04:21 309:19
15:51:38 298:19	15:55:13 301:17	15:58:21 304:16	16:01:07 306:22	16:04:24 309:20
15:51:39 298:20	15:55:15 301:18	15:58:22 304:17	16:01:09 307:1,2	16:04:27 309:21
15:51:42 298:21	15:55:18 301:19	15:58:23 304:18	16:01:12 307:3	16:04:31 309:22
15:52:08 298:22 299:1	15:55:21 301:20	15:58:30 304:19	16:01:14 307:4	16:04:33 310:1
15:52:09 299:2,3	15:55:26 301:21	15:58:35 304:20	16:01:17 307:5	16:04:37 310:2
15:52:13 299:4	15:55:27 301:22 302:1	15:58:38 304:21	16:01:20 307:6	16:04:41 310:3
15:52:14 299:5,6	15:55:29 302:2	15:58:41 304:22	16:01:21 307:7	16:04:46 310:4
15:52:17 299:7	15:55:33 302:3	15:58:44 305:1	16:01:23 307:8	16:04:54 310:5
15:52:20 299:8	15:55:35 302:4	15:58:46 305:2	16:01:26 307:9	16:05:12 310:6
15:52:21 299:9	15:55:39 302:5	15:58:47 305:3	16:01:30 307:10	16:05:14 310:7
15:52:22 299:10	15:55:40 302:6	15:58:50 305:4	16:01:35 307:11	16:05:19 310:8
15:52:26 299:11	15:55:43 302:7	15:58:52 305:5	16:01:36 307:12	16:05:22 310:9
15:52:27 299:12	15:55:47 302:8,9	15:58:57 305:6	16:01:46 307:13	16:05:25 310:10
15:52:30 299:13,14	15:55:49 302:10,11	15:58:58 305:7	16:01:50 307:14	16:05:27 310:11,12
15:52:31 299:15	15:55:51 302:12	15:59:01 305:8	16:01:54 307:15	16:05:29 310:13
15:52:35 299:16	15:55:53 302:13	15:59:02 305:9	16:01:57 307:16	16:05:30 310:14
15:52:37 299:17	15:55:58 302:14	15:59:03 305:10	16:01:58 307:17	16:05:31 310:15
15:52:40 299:18	15:56:01 302:15	15:59:15 305:11	16:02:00 307:18	16:05:33 310:16
15:52:43 299:19	15:56:04 302:16	15:59:17 305:12	16:02:01 307:19	16:05:36 310:17
15:52:46 299:20	15:56:07 302:17	15:59:19 305:13	16:02:02 307:20,21	16:05:39 310:18
15:52:50 299:21	15:56:10 302:18	15:59:20 305:14	16:02:04 307:22	16:05:42 310:19
15:52:53 299:22	15:56:13 302:19	15:59:22 305:15	16:02:06 308:1	16:05:46 310:20
15:52:56 300:1	15:56:16 302:20	15:59:27 305:16	16:02:09 308:2	16:05:47 310:21
15:52:59 300:2	15:56:19 302:21	15:59:28 305:17	16:02:10 308:3	16:05:48 310:22
15:53:02 300:3	15:56:22 302:22	15:59:52 305:18	16:02:11 308:4	16:05:49 311:1
15:53:05 300:4	15:56:23 303:1	15:59:53 305:19	16:02:14 308:5	16:05:51 311:2
15:53:10 300:5	15:56:25 303:2	15:59:54 305:20,21	16:02:15 308:6	16:05:55 311:3
15:53:13 300:6	15:56:27 303:3	15:59:57 305:22	16:02:18 308:7	16:05:58 311:4
15:53:18 300:7	15:56:31 303:4	15:59:58 306:1	16:02:21 308:8	16:06:00 311:5
15:53:27 300:8	15:56:33 303:5	15:59:59 306:2	16:02:36 308:9	16:06:03 311:6
15:53:30 300:9	15:56:37 303:6	154 206:9	16:02:41 308:10	16:06:06 311:7
15:53:34 300:10	15:56:42 303:7	16 11:4,18 97:10	16:02:43 308:11	16:06:07 311:8
15:53:38 300:11	15:56:44 303:8	123:21 124:2 128:22	16:02:45 308:12	16:06:09 311:9
15:53:43 300:12	15:56:47 303:9	211:1 225:7 233:5,5	16:02:46 308:13	16:06:18 311:10
15:53:47 300:13	15:56:49 303:10	233:17,20 234:2,17	16:02:50 308:14	16:06:20 311:11
15:53:51 300:14	15:56:51 303:11	236:2,4,11 237:3	16:02:55 308:15	16:06:22 311:12
15:53:58 300:15	15:56:53 303:12	281:17 287:22 288:1	16:03:22 308:16,17	16:06:23 311:13
15:54:02 300:16	15:56:55 303:13	288:6,9 291:15	16:03:23 308:18,19	16:06:25 311:14
15:54:05 300:17	15:56:58 303:14	292:12,22	16:03:30 308:20	16:06:31 311:15
15:54:07 300:18,19	15:57:02 303:15	16th 4:5	16:03:32 308:21	16:06:32 311:16
15:54:10 300:20	15:57:03 303:16,17	16:00:04 306:3	16:03:33 308:22	16:06:33 311:17
15:54:14 300:21	15:57:04 303:18,19	16:00:08 306:4	16:03:37 309:1	16:06:37 311:18
15:54:16 300:22	15:57:05 303:20	16:00:10 306:5,6	16:03:40 309:2	16:06:38 311:19
15:54:18 301:1	15:57:08 303:21,22	16:00:19 306:7	16:03:42 309:3,4	16:06:39 311:20
15:54:21 301:2	15:57:33 304:1	16:00:23 306:8	16:03:45 309:5	16:06:45 311:21
15:54:27 301:3,4	15:57:34 304:2	16:00:25 306:9	16:03:49 309:6	16:06:50 311:22
15:54:30 301:5	15:57:36 304:3	16:00:30 306:10	16:03:53 309:7	16:06:55 312:1,2
15:54:34 301:6	15:57:37 304:4	16:00:32 306:11	16:03:56 309:8	16:07:33 312:3,4

16:07:34 312:5,6,7	16:10:41 314:21	16:18:23 317:22 318:1	206:10,15,19 207:2	306:2
16:07:37 312:8	16:10:43 314:22	16:18:25 318:2	207:13 208:13 227:3	226 252:18
16:07:38 312:9,10	16:10:45 315:1	16:18:27 318:3,4	229:13,17 230:7	23 14:10 124:2 147:1,2
16:07:41 312:11	16:10:48 315:2	16:18:30 318:5	280:20 281:8 291:14	151:11,14,15,16
16:07:45 312:12	16:10:50 315:3	16:18:31 318:6	2-amino-3 113:14	152:7 250:8 308:12
16:07:46 312:13	16:10:51 315:4	16:18:33 318:7	118:19 119:3,8 124:8	308:13,17,20,22
16:07:49 312:14	16:10:52 315:5	16:18:34 318:8,9	129:9 155:17 227:4	232 6:16
16:07:54 312:15	16:10:55 315:6	16:18:36 318:10,11	2.1 255:12	237 6:18
16:07:59 312:16	16:10:57 315:7	16:18:39 318:12,13	2.4 277:22	24 14:18 152:20 254:6
16:08:03 312:17	16:10:59 315:8	16:18:40 318:14	2:44 254:19 255:1	311:12,13 312:5,8,10
16:08:06 312:18	16:11:02 315:9	16:18:45 318:15	20 12:15 13:4 25:19	240 7:10
16:08:11 312:19	16:11:05 315:10	16:18:47 318:16	62:19 63:3,13 65:19	25 18:19,20 110:13,16
16:08:13 312:20	16:11:08 315:11	16:18:52 318:17	66:2 142:20 157:10	111:12,21 112:10
16:08:14 312:21	16:11:14 315:12	16:19:00 318:18	168:1 205:12 230:15	153:11 242:5,6,7
16:08:15 312:22	16:11:16 315:13	16:19:03 318:19	231:8 263:11,20	243:6 249:20 250:1
16:08:17 313:1	16:11:18 315:14	16:19:06 318:20	297:16 298:4,18,19	251:21 254:10
16:08:20 313:2	16:11:20 315:15	1625 16:5	299:1,4,6,10 300:19	257 7:17
16:08:22 313:3	16:11:22 315:16	167 206:19	2000 186:19 187:9,22	257-269 11:9
16:08:27 313:4	16:11:25 315:17	17 5:4 11:13 63:13 64:5	189:10 191:3,8	258 288:15 291:14
16:08:31 313:5	16:11:27 315:18	65:11 134:1,9 226:9	209:13,18 210:1,5,13	259 7:22
16:08:34 313:6	16:11:29 315:19,20	292:10,11,16,19,21	260:3,13 299:10,22	26 108:9,10,15 109:18
16:08:38 313:7	16:11:34 315:21	17,000 60:9	312:1,2	243:19 244:1,16,21
16:08:42 313:8	16:11:36 315:22 316:1	175-193 14:21	2001-4413 3:6	245:4,19 246:13,22
16:08:43 313:9	16:11:37 316:2	176 313:1	2006 16:6	247:5
16:08:45 313:10	16:11:39 316:3	18 5:12 12:4,8 98:9,10	2001 179:22 180:7,10	26th 2:4
16:08:52 313:11	16:11:46 316:4	98:17 99:6,16 100:11	180:13,17 181:5	262 8:9
16:08:53 313:12	16:11:47 316:5	100:20 101:5,11,16	183:2 184:5,15 185:5	265 8:14
16:08:54 313:13	16:11:50 316:6	102:2,9,14 103:1	185:21 186:2	267 8:18
16:08:59 313:14	16:11:52 316:7	137:2 191:1 227:10	2002 64:2 311:20	27 283:16
16:09:00 313:15	16:11:53 316:8,9,10,11	228:15 295:4,5,6,10	2003 145:6 148:5,15,18	27-36 10:7
16:09:05 313:16	316:12	295:13,15,16 297:11	149:5,16 150:7 188:9	279 9:10
16:09:07 313:17	16:11:55 316:13,14	19 12:9 62:18 63:3	188:16 189:2 263:16	28 65:19 66:2 68:9,12
16:09:09 313:18	16:12:03 316:15	138:7 139:20 141:19	275:14 276:5,13	251:15
16:09:11 313:19	16:12:09 316:16	229:11 230:5,6	2005 58:13	281 9:20
16:09:13 313:20	16:16:59 316:17,18	240:11 297:14,15,20	2006 70:1 263:4,14	283 10:9
16:09:17 313:21	16:17:37 316:19	298:1,3	2007 56:20	285 10:15
16:09:22 313:22	16:17:41 316:20	1903 280:6	2008 63:14,16 64:7	288 11:11
16:09:24 314:1	16:17:42 316:21	1903-1910 9:8	66:7	29 242:5 243:6 244:5
16:09:26 314:2	16:17:45 316:22	191 189:14	2009 70:1,3	249:20,21,21 250:2
16:09:30 314:3	16:17:48 317:1	192 190:21	2013 66:22	251:21 254:10
16:09:33 314:4	16:17:50 317:2	1987 6:14 207:2 208:6	2013/0210878 6:18	290 90:22 91:21 106:20
16:09:41 314:5	16:17:51 317:3	208:11	237:19 238:2	107:2,6,9,14,17,21
16:09:43 314:6	16:17:53 317:4	1991 5:16	2014 319:10	108:1,8,10,13,16
16:09:45 314:7	16:17:54 317:5	1993 55:6,10	2015 1:17 2:5 15:22	109:16,19 112:22
16:09:49 314:8	16:17:55 317:6	1994 11:9	80:18 81:2 136:13,19	113:21 114:10,11,20
16:09:51 314:9	16:17:57 317:7	1997 12:13	204:22 205:6 254:20	114:22 115:9,10,16
16:09:57 314:10	16:18:00 317:8		255:4 318:18	115:17 116:3,5
16:10:02 314:11	16:18:02 317:9,10	2	202 3:9,10	118:16 123:20 127:1
16:10:07 314:12	16:18:04 317:11	2 5:14 9:20 22:19 23:8	206 5:18	129:3 131:10 243:17
16:10:08 314:13	16:18:07 317:12	23:9 69:17 90:4 92:6	208 6:14	243:20 244:1,6,17,22
16:10:11 314:14	16:18:10 317:13	96:17 116:1,2,3	21 13:13 212:13 231:10	245:5,8,20 246:1,13
16:10:24 314:15	16:18:13 317:14	117:11 118:1,16	233:4 304:3,4,9,12,14	246:16,20,22 247:3,5
16:10:29 314:16	16:18:14 317:15	119:2,5,16 120:11	212 3:20,21	247:13
16:10:33 314:17	16:18:16 317:16	121:5,21 122:10,16	213 4:8,9	292 11:18
16:10:35 314:18	16:18:18 317:17	123:3,15,21 127:2	215 180:21	295 12:8
16:10:38 314:19	16:18:20 317:18,19	128:6 155:19 180:4,6	22 14:4 151:14 242:1	297 12:15
16:10:39 314:20	16:18:21 317:20,21	205:17,18 206:1,3,7	305:13,14,19,22	299 13:11

<p style="text-align: center;">3</p> <p>3 6:5 11:9 80:11 81:6 128:6 131:10,11,14 131:17,21 189:8,9 207:20,21 208:9,11 208:19 240:18,22 241:3 245:12,13 246:4,6,6,7 292:1</p> <p>3D 260:11</p> <p>3-D 261:1 262:1</p> <p>3-Dodecylcarbonylo... 13:6</p> <p>3:00 255:1,3</p> <p>30 157:10 198:10 243:19 244:1,17,22 245:4,19 246:13,22 247:5</p> <p>304 13:18</p> <p>305 14:9</p> <p>308 14:17</p> <p>31 272:11</p> <p>312 14:22</p> <p>32 155:12 166:9,12 273:6 276:22</p> <p>325 258:1</p> <p>325-356 7:16</p> <p>33 13:11 298:20 299:7</p> <p>333 4:5</p> <p>35 171:17 172:8 277:14</p> <p>3541 201:14</p> <p>3542 182:14</p> <p>3543 183:5,15</p> <p>3544 180:12,16 182:2 182:14 185:12 201:15</p> <p>355-3333 3:21</p> <p>36 244:5</p> <p>38 125:3</p> <p>39 6:14 208:7 277:21 311:21 312:15</p> <hr/> <p style="text-align: center;">4</p> <p>4 1:17 2:5 6:16 15:22 69:17 80:17 81:1 88:21 119:3 136:13 136:19 195:15 205:6 232:10,11,14 254:19 255:3 318:17</p> <p>4th 204:22</p> <p>4-bromobenzoyl 113:14 118:19 119:8 124:8 129:9 155:17 227:4</p> <p>4:13 316:15,17</p> <p>4:18 316:17,19</p> <p>4:19 318:17,22</p> <p>40 113:17 125:3 227:15</p>	<p>228:20 229:22 230:1 235:19</p> <p>408-4000 3:9</p> <p>408-4400 3:10</p> <p>417-424 10:14</p> <p>42 172:14 203:18</p> <p>423 285:16</p> <p>43 175:15</p> <p>431 90:16 91:21 98:5 98:10,18 99:6,16 100:12,21 101:5,9,12 101:14,17,22 102:3,7 102:10,15 103:2,7,10 104:1 179:8</p> <p>438 203:6</p> <p>44 178:17</p> <p>45 179:21</p> <p>47 13:18 186:18 206:16 206:18,20 207:2 208:12 304:5,15</p> <p>48 195:4</p> <p>49 12:13 14:9 202:19 305:15 306:3</p> <p>49-60 11:16</p> <hr/> <p style="text-align: center;">5</p> <p>5 5:18 6:17 22:16,21 23:3,7,8 65:13,14 134:1,6 137:1 205:13 205:19 206:3 237:16 237:17,21 252:5,6</p> <p>50 192:2 193:5,7</p> <p>52-1 214:14 215:19</p> <p>53 212:11,15</p> <p>546-553 14:16</p> <p>576-1000 4:8</p> <p>576-1100 4:9</p> <p>58 209:12,17 210:22 293:3</p> <p>585-589 9:19</p> <p>59 225:7</p> <p>594-600 12:13</p> <hr/> <p style="text-align: center;">6</p> <p>6 7:4,10 55:2 73:22 125:3,3,11 127:2 141:19,20 142:19 146:22 151:10 203:1 238:11,13,15 240:2,3 240:4,8,10,11,14 241:7,20 255:9,9</p> <p>60 113:13 114:15 118:22 119:7 128:22 129:6 230:10</p> <p>606 91:19,22 97:9,15 97:16,22 106:8,10,11 106:13,15</p>	<p>61 226:10</p> <p>62 17:9 128:9 227:1</p> <p>620 2:3 3:17 15:20 180:10 183:4</p> <p>621 6:14 208:7</p> <p>626 6:14 208:7</p> <p>63 128:5 227:9</p> <p>64 128:5,9 228:16</p> <p>65 229:12,16</p> <p>65-76 7:9</p> <p>65-83 14:8</p> <p>66 230:6 255:11</p> <p>67 230:16</p> <p>69 231:8,9,14,20</p> <hr/> <p style="text-align: center;">7</p> <p>7 7:12,17 113:3 117:14 117:14,15 125:12 153:1,11 189:16 192:6,7 251:2,4,15 257:9,10,11,14,17,19 257:20 258:2</p> <p>7.0 113:13</p> <p>7.5 125:12,19 126:5</p> <p>70 231:9</p> <p>71 231:10,14,20</p> <p>72 212:12,15</p> <p>73 66:6</p> <p>74 240:14 242:3</p> <p>75 235:19 242:11</p> <p>755 232:17,19,20 233:4 233:17 234:2,17 236:3,9 237:1</p> <p>76 250:9</p> <p>78 254:7,8,12</p> <p>798-806 13:10</p> <p>799 300:7</p> <hr/> <p style="text-align: center;">8</p> <p>8 7:18,22 10:9 96:15 103:6,9,22 114:9,10 114:22 115:10,17 116:5 117:15 155:11 166:10 212:5,7 246:8 259:11,12,13,16,19 259:21,22 260:3,6 283:3,13</p> <p>8,129,431 90:12,15 178:22</p> <p>8,192,755 6:16 232:12 232:16</p> <p>8,669,290 90:18,21</p> <p>8,754,131 91:2,5</p> <p>8,871,813 91:8,11</p> <p>8,927,606 91:15,18</p> <p>8.5 125:13,19 126:5</p> <p>8:00 2:5</p>	<p>8:12 15:21</p> <p>80 227:14 263:12,20</p> <p>80-containing 113:18 228:22</p> <p>813 91:12,21</p> <p>813-8800 3:20</p> <p>82 66:15 306:6</p> <p>826-832 12:7</p> <p>827 295:19</p> <p>83 66:15</p> <p>84 66:15</p> <p>859-868 13:17</p> <p>866 304:18</p> <p>87 14:17 308:14 309:1</p> <p>878 238:2,5,16 239:1</p> <p>89 66:15</p> <hr/> <p style="text-align: center;">9</p> <p>9 8:4 10:15 58:5,8 65:15 125:12,12 171:17 262:11,12,17 262:20,22 263:4 284:22 285:13</p> <p>9-23 7:21</p> <p>9:31 80:17,21</p> <p>9:46 80:21 81:1</p> <p>90 114:13 230:9,17 231:2</p> <p>90071 4:6</p> <p>901 3:5</p> <p>916 192:12</p> <p>917 193:22 194:16</p> <p>93 66:15</p> <p>95 195:19 196:15</p> <p>96 196:7,16,18 197:3 197:20 199:4 201:18 202:3,5</p> <p>97 196:16,20 197:3,11 197:20</p> <p>987 213:6 214:12</p> <p>990 216:8</p> <p>992 218:15</p>
---	---	--	---

PLEASE ATTACH TO THE DEPOSITION OF DR. JAYNE LAWRENCE

DATE TAKEN: September 4, 2015

CASE CAPTION: Senju Pharmaceutical Co., Ltd. v. Lupin Ltd. And Lupin Pharmaceuticals, Inc.

ERRATA SHEET

PAGE	LINE	CHANGE	REASON
61	1	"or using" should be "non-ionic"	transcription error
84	12	"it" should be "I"	transcription error
167	1	"positive and negative" should be "positively or negatively"	transcription error
167	4	"they're" should be "their"	transcription error
187	21	"SGA" should be "FDA"	transcription error
217	19	frequent" should be "frequently"	transcription error
301	15	"non" should be "amine"	transcription error

I have read the foregoing transcript of my deposition and except for any corrections or changes noted above, I hereby subscribe to the transcript as an accurate record of the statements made by me.

Executed this 8th day of October, 2015.



1 I HEREBY CERTIFY that I have read this transcript of
2 my deposition and that this transcript accurately
3 states the testimony given by me, with the changes
4 of corrections, if an, as noted.

5

6



7

X

8

9

Subscribed and sworn to be before this _8th_ day of

10

October, 2015

11

12

13

14

15

16

17

18

19

20

21

22